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ABSTRACT
Prostate cancer is the leading invasive malignancy and the second most common
cause of cancer death among American men. Despite compelling evidence that oxidative
stress, ineffective DNA damage repair, and habitually low antioxidants intake may act in
tandem to influence prostate carcinogenesis, few studies have examined gene-diet
interactions involving these risk factors. Even fewer studies have examined such
interactions in relation to prostate cancer aggressiveness. This study investigated whether
single nucleotide polymorphisms (SNPs) in DNA repair- and oxidative stress-related
genes modulated associations between antioxidant intake and prostate cancer
aggressiveness. We utilized data from the North Carolina-Louisiana Prostate Cancer
Project (PCaP) among African-American (n = 948) and European-American (n = 1,016)
men. Antioxidant intake was assessed using a food frequency questionnaire, and
genotypes of 30 germline SNPs were examined.

Effect modification by certain polymorphic variants were observed with some
variations by race, including variants in XRCC1 (rs2854508, T > A), XPA (rs3176644, G >
T), NOS3 (rs1799983, G > T), OGG1 (rs1805373, G > A) and NQO1 (rs689453, C > T). For
example, significant interaction was observed between XRCC1 (rs2854508) genotype and

α-tocopherol intake among African Americans and European Americans, such that
among those with the TT genotype, higher α-tocopherol intake was inversely related to
prostate cancer aggressiveness, while higher α-tocopherol intake was positively related to
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high aggressive prostate cancer among those who harbor the AA or AT genotype. A
similar pattern of effect modification by XRCC1 (rs2854508) was observed for the
association between γ-tocopherol and prostate cancer aggressiveness, but only among
African Americans. Lower odds of high aggressive prostate cancer was observed among
European Americans who possess the CT or TT genotype of NQO1 (rs689453) and had
higher lycopene intake, but not European Americans with the CC genotype, and there
was no evidence of effect modification among African Americans.
Reduced odds and increased odds of high aggressive prostate cancer were
observed with higher intakes of certain antioxidants (i.e., α-tocopherol, γ-tocopherol and
lycopene) dependent on genotype, indicating potentially differential dietary
recommendations based on genetic susceptibility. Because germline genotype is
unalterable, these findings underscore the importance of considering genetic risk
variability as part of dietary intervention strategies to identify the subgroup of men who
are likely to benefit from such interventions.
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CHAPTER 1
INTRODUCTION/BACKGROUND
1.1

INTRODUCTION
Prostate cancer (PCa) is the most prevalent invasive cancer and a leading cause of

death in American men [1]. It is estimated that about 2.8 million American men are living
with PCa with an estimated 241,740 new cases of PCa diagnosed in the U.S. in 2012 [1,
2]. Due to improved early detection methods, particularly with the advent and subsequent
widespread use of prostate-specific antigen (PSA) test for PCa screening and
improvements in cancer treatment, the majority of men diagnosed with PCa die with,
rather than of, the disease. Thus, PCa is often regarded as an indolent disease of aging
[3]. However, aggressive forms of PCa are very lethal. PCa aggressiveness generally
refers to the extent of cancer invasiveness and migration, and often is defined based on
tumor grade (Gleason score), cancer stage, and PSA level at diagnosis [4, 5]. Men with
high aggressive PCa have been reported to have as much as a 14-fold increased risk of
dying from the disease when compared to those with less aggressive PCa [5]. It is also
estimated that about 30% of prostate tumors progress aggressively [6]. Given the
prevalence and magnitude of fatalities associated with aggressive PCa, much research has
been devoted to identifying biomarkers that distinguish indolent disease from aggressive
disease [7, 8]. On the contrary, less research has been dedicated to understanding the
interplay between genetic susceptibility and environmental factors that influence PCa
aggressiveness. Specifically, less attention has been given to interactions between single
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nucleotide polymorphisms (SNPs) within coding regions of genes that have been
implicated in carcinogenesis and dietary micronutrients such as antioxidants, which may
offer new insights for preventing or reversing PCa aggressiveness.
Similarly, researchers have, until recently, paid very little attention to the potential
salutary effects of antioxidant-rich diet on PCa progression in men with biochemical
recurrence of PCa. Biochemical recurrence of PCa is determined by the rising level of
PSA after post-treatment nadir (lowest detectible level of PSA after treatment), and often
an indicator of metastasis [9-12]. Men with biochemically recurrent PCa are traditionally
treated with androgen ablation therapy (medical or surgical) to slow the disease
progression and delay time to metastasis [9, 11-13]. However, androgen ablation is not a
cure for PCa, does not always slow the disease progression, and it has been associated
with life-altering side effects including erectile dysfunction, loss of bone density and
cognitive decline; and long-term use of androgen ablation has also been associated with
obesity, diabetes and cardiovascular disease [14-16]. Widespread recognition of these
side effects has brought to the fore the need for new treatment options that could prevent,
delay or reverse PCa progression in men with rising PSA levels after curative treatment
for PCa without the side effects of androgen ablation. Epidemiologic studies suggest that
diet is one of the important environmental factors that influence PCa initiation and
progression [17]. Diets rich in antioxidants have also been shown to have
chemopreventive effects [18]. Although promising, there is conflicting evidence on
whether a plant-based, antioxidant-rich diet can halt PCa progression in men with
biochemically defined PCa recurrence [9, 19-21]. However, these studies were limited by
their inability to evaluate effects of bioactive antioxidants status (as markers of
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antioxidant intake) on PCa progression. Thus, there is a need for well-designed,
randomized clinical trials to examine effects of changes in bioactive levels of dietary
antioxidant on PCa progression.

1.2

EPIDEMIOLOGY OF PROSTATE CANCER
PCa is the most commonly diagnosed invasive cancer and the second most

virulent cancer in American men [1]. In 2012, PCa accounted for an estimated 29%
(241,740) of all newly diagnosed cancers and 9% (28,170) of cancer deaths in American
men [1]. At present, American men have an estimated 16% (one in six) risk of
developing PCa during their lifetime, and a 3% (one in 36) risk of dying from the disease
[22]. The introduction of PSA screening test in the late 1980’s, and subsequent
widespread use of PSA testing for PCa diagnosis led to about a 10% rise in the number of
reported cases of PCa each year in the U.S. from 1986 until 1992, when the incidence
rate peaked at 237 new cases per 100,000 men [23]. Since 1992, the number of newly
diagnosed cases of PCa has been declining, which suggests that the screening effect is
diminishing as the pool of men with previously undiagnosed latent disease who were
captured with the advent of the PSA screening test may have been exhausted [24-26].
Even with the decline in PCa incidence rate, the disease remains the most frequent
malignancy in American men, with the exception of superficial skin cancer [27]. This has
been attributed to a multiplicity of factors including increasing life-expectancy, increased
prevalence of environmental carcinogens, and improved diagnostic technology,
particularly in the area of transurethral ultrasonography and biopsy technology [26, 28].
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PCa is a multifactorial disease with etiology involving both genetic and
environmental components. The well-established risk factors for PCa are aging,
race/ethnicity and family history. Other less-established, but “highly probable” risk
factors (due to reasonably consistent evidence of their involvement in PCa) include
androgens, inflammation, diet, physical activity/obesity, and tobacco use. Purported risk
factors such as vasectomy, sexually transmitted diseases, benign prostatic hyperplasia
(BPH), and human papilloma virus (HPV) infections are a subject of both persistent
controversy and active research (reviewed in [26, 28, 29]).
Perhaps the most distinguishable feature of PCa is its inseparable association with
aging. PCa risk increases much faster with age than does other types of cancer [26]. In
the U.S., the average age of prostate cancer diagnosis is 67 years. It is rarely diagnosed in
men younger than age 50 years (3%); however, after this age the incidence increases
exponentially with about 97% of the cases diagnosed in men ≥ 50 years old, and 60%
diagnosed in men ≥ 65 years old [1]. The probability of developing PCa for men ≤ 39
years old is one in 8,499. This increases to one in 38 for men 40-50 years old, one in 15
for men 60-69 years old, and one in eight for men ≥ 70 years of age. The risk of death
from PCa also increases substantially with aging, with men ≥ 70 years old having the
highest proportion of death from the disease [1]. Indeed, autopsy reports have shown that
about 70% of men who die by age 80 or older have histological evidence of latent PCa
[30, 31].
African ancestry is an established risk factor for PCa incidence, aggressiveness
and mortality from the disease [1]. Men of African descent are more likely to be
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diagnosed with PCa at an early age [1, 27], present with advance-staged disease [32, 33],
higher PSA levels [34, 35], poorly differentiated tumors [36, 37], and are more likely to
die from PCa as compared to men of European ancestry [38, 39]. In two recent studies of
PCa mortality-to-incidence ratio in South Carolina and Georgia, African-American men
were found to have 58% and 55% higher PCa specific mortality given incidence,
respectively, when compared to European Americans [20, 40]. Reasons behind these
marked racial differences remain unclear; however, plausible explanations include
inherited genetic susceptibility along racial lines, as well as differences in environmental
and socioeconomic factors [41].
The hereditary component of PCa is also well-documented. Men with family
history of PCa, especially among first-degree relatives (father or brother) have about a
three-fold increased risk of developing the disease regardless of race/ethnicity [42, 43].
First-degree male relatives of a PCa patient also tend to be diagnosed with PCa an
average of 6 to 7 years earlier than those without family history of PCa [44]. Family
history of PCa is also a risk for developing the more aggressive forms of the disease [45,
46]. Additionally, familial clustering for PCa has also been found to be stronger than that
of breast cancer and colon cancer, two malignancies that are well-recognized for their
familial aggregation [47]. Also, several studies have reported significant associations
between having a first-degree female relative (mother or a sister) with history of breast
cancer and risk of PCa, as well as an increased risk for aggressive PCa [48-50].
PCa is often described as an androgen-dependent disease. This is largely
attributable to the Nobel Prize winning study of urologist Charles Huggins, which led to
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the use of androgen deprivation therapy for treatment of advanced PCa [51]. While the
evidence remains inconclusive, androgens, particularly testosterone, have been
implicated in the initiation and progression of PCa [52]. As is the case with normal
prostate growth and function, the induction and progression of PCa largely depends on
androgens and androgen receptor signaling [53]. Experimental studies suggest that the
enzyme 5 alpha-reductase which is found in the prostate gland converts testosterone into
dihydrotestosterone (DHT), a more active androgen which binds to genomic
deoxyribonucleic acid (DNA) and regulates the expression of oncogenes that cause PCa
[54]. The role of androgens in prostate carcinogenesis is also supported by
epidemiological studies that have found that eunuchs (i.e., males who are castrated before
puberty) do not develop PCa, primarily because the main source of androgens has been
removed from the body [26, 28]. It is, however, important to note that recent studies have
reported conflicting evidence on the role of androgens in PCa, and its aggressiveness [55,
56]. Similarly, the definitive role of specific androgens, timing of their effect, and their
underlying mechanisms remains unclear [56].
Chronic inflammation has been implicated in the etiology of malignancy in
several organs including the esophagus, lungs, pancreas, liver, stomach, colon, and
urinary bladder [57]. Emerging evidence suggests that chronic inflammation may play a
role in the neoplastic transformation of the prostate, and in PCa aggressiveness [10, 58].
The suggested mechanisms of inflammatory effect on prostate carcinogenesis include
induction of oxidative stress-induced DNA damage, rapid cellular turnover and
angiogenesis [58, 59]. Molecular and genetic studies also suggest that the sequelae of
inflammatory effect on PCa involves formation of proliferative inflammatory atrophy
6

(PIA) in the prostate epithelium, which transitions into prostate intraepithelial neoplasia
(PIN), a known precursor lesion of PCa [60]. Epidemiological studies have also reported
associations between chronic prostatitis (inflammation of the prostate) and PCa [61, 62].
Several parallels have been drawn between dietary patterns and PCa; however, the
evidence can, at best, be described as probable, rather than conclusive. A litany of
epidemiological studies have found that excessive intake of energy (calories), calcium
and dairy products (e.g., milk, cheese, cream, butter, etc.), animal fat and red meat
increases risk for PCa and PCa aggressiveness (reviewed [17, 63, 64]). On the other hand,
a diet rich in whole-grains, fruits, vegetables, isoflavones, nuts, seeds and berries appear
to offer protection against PCa incidence [65, 66] and aggressiveness [67-69]. These
protective effects are often attributed to the antioxidant micronutrients found in these
diets. Antioxidants appear to modulate PCa incidence and aggressiveness by reducing
oxidative DNA damage and gene mutations [70, 71]. However, the three largest
randomized controlled trials conducted to examine associations between specific
antioxidants and PCa (i.e., ATBC trial, the SELECT study, the Physicians’ Health Study
II) failed to establish definitive chemopreventive effects of antioxidants on prostate
carcinogenesis [72-74]. Notwithstanding, a number of studies have reported significant
associations between dietary antioxidants, particularly vitamin E, β-carotene, vitamin C,
lycopene, and selenium, and PCa incidence [75-77] and aggressiveness [67, 78, 79].
Nonetheless, the association between dietary antioxidants and PCa remain an issue of
intense scrutiny and ongoing research.
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Despite biologically plausible relations, there are inconsistent findings on whether
physical activity reduces PCa risk (reviewed in [80, 81]). It has been postulated that
regular physical activity modulates prostate carcinogenesis by reducing serum
testosterone levels, mitigating oxidative DNA damage, and enhancing immune defenses
against genomic alterations [82]. There has also been increasing evidence that regular,
moderate-to-vigorous physical activity may reduce the risk of developing aggressive PCa
[83-85]. Several studies have also reported associations between obesity and prostate
cancer risk [86, 87] and aggressiveness [88, 89]. However, the evidence remains
inconclusive.
Tobacco smoke is a known carcinogen which is traditionally associated with lung
cancer, but has also been associated with other malignancies, including cancers of the
bladder, pancreas, esophagus, stomach, colon, and breast [90]. In recent years, there has
been growing evidence that tobacco smoke is not only associated with PCa risk [91], but
also PCa aggressiveness [92-94], recurrence [95, 96], and PCa specific mortality [38, 97].
The timing of the effect of tobacco smoke on PCa likely spans decades, and may be
modulated by genetic susceptibility and/or gene-environment interaction. Nonetheless, at
present, the epidemiological evidence on the association between tobacco smoke and PCa
is not consistent (reviewed in [91, 92]).

1.3

STUDY RATIONAL AND SIGNIFICANCE

Dietary Antioxidant Intake and Prostate Cancer Progression
Primary management of PCa involves radical prostatectomy or radiation
treatment, with curative intent [98, 99]. Unfortunately, about one in three men treated
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with radiation or prostatectomy will experience PCa recurrence within 10 years of
treatment. This increases to one in two men after 15 years of definitive therapy [100]. A
rising level of serum PSA is the earliest sign of PCa recurrence, and often referred to as
biochemical recurrence of PCa [100, 101]. Although the definition of biochemical
recurrence of PCa has been a subject of debate, it is generally defined as having three or
more successive rises in PSA above 0.2-0.4 ng/ml from the lowest detectable level after
definitive therapy [101-103]. Sustained rise in PSA level after definitive therapy is also
an early sign of metastatic disease and poorer prognosis [9, 104]. Biochemical recurrence
of PCa is often treated with androgen ablation to delay time to metastasis [99, 105].
However, androgen ablation is not a cure for PCa, is not always effective, and often
inflicts severe side effects including erectile dysfunction, osteoporosis, gynecomastia,
cognitive decline, weight gain, diabetes, and cardiovascular disease [14-16]. Thus, there
is considerable interest in a search for novel biomarker-driven treatment options that
would halt PCa progression and prevent metastases without the side effects of androgen
ablation.
There is ample evidence that a plant-based, antioxidant-rich diet, including a diet
rich in fruits, vegetable, whole grains, soy and soy products may halt PCa progression in
men with established disease [106]. Suggested mechanisms of dietary antioxidants’ effect
on PCa progression include mitigation of oxidative DNA damage and suppression of
LNCaP cell growth by down-regulating male sex hormones [18, 70]. While serum PSA
level remains a controversial diagnostic test for PCa since a rising level of PSA is not
exclusive to prostate carcinoma, but also common with benign prostatic hyperplasia
(BPH) and prostatitis [107], sustained rise in PSA level is an established biomarker of
9

PCa progression [108]. Findings from recent studies suggest that antioxidant-rich dietary
interventions may benefit men with PCa recurrence, as evidenced by a decline in serum
PSA level [9, 19, 109, 110]. However, the evidence remains inconclusive thus far, with a
number of studies reporting null associations [13, 111-113]. Perhaps these inconsistent
findings may be due to the inability of these studies to measure and evaluate the
therapeutic effects of bioavailable antioxidants as markers of antioxidant intake. Thus,
there is a need for well-designed randomized trials to evaluate the effects of biomarkers
of antioxidants intake such as serum carotenoids and tocopherols on PSA dynamics, and
by extension, PCa progression.

Oxidative Stress, Antioxidant Defense, and DNA Repair Pathways
Oxidative DNA damage is a major focus of ongoing etiologic PCa research.
Oxidative stress refers to a state of imbalance in intracellular levels of reactive oxygen
species (ROS), and biochemical antioxidants, in favor of ROS [71]. While oxygen is
essential for normal cell growth and function, molecular oxygen-overload often results in
excessive production of ROS, which causes damage to cellular components of genetic
material particularly, protein, lipids, and nucleic acid [71, 114, 115]. Under normal
physiological conditions, excess molecular oxygen is reduced to water (H2O) through an
elaborate system of electron transport involving series of oxygen-reduction reactions
(redox) [70]. However, incomplete or partial reduction of oxygen results in the
production of singlet oxygen (1O2), hydroxyl radical (.HO), superoxide anion radical (O2-)
and hydrogen peroxide (H2O2), collectively referred to as oxygen free radicals or reactive
oxygen species (ROS) [70, 71, 116].
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It is estimated that about 5% of molecular oxygen load are eventually converted
to ROS during normal mitochondrial oxygen metabolism [70]. High levels of ROS are
often produced as a result of endogenous processes such as chronic inflammation and
oxidative phosphorylation, or through exposure to exogenous substances such as ionizing
radiation, environmental toxins and pharmaceuticals [70, 117]. To counterbalance
elevated levels of ROS, antioxidant enzymes (e.g., superoxide dismutase, catalase, and
glutathione peroxidase) and non-enzymatic antioxidants (such as dietary sources of αtocopherol, β-carotene, β-cryptoxanthin, lycopene, lutein, zeaxanthin, etc.), break down
ROS to restore intracellular redox homeostasis [70]. Oxidative stress occurs when
intracellular ROS levels exceed antioxidant defense capacity, resulting in oxidative DNA
damage, altered gene expression, and cell death [70, 71]. Oxidative stress has been
implicated in the etiology of several chronic diseases including cancer, neurodegenerative
disorders, diabetes, arteriosclerosis, and pulmonary diseases [118].
Oxidative stress has been linked to PCa through its intimate association with
known or potential risk factors for PCa, such as aging, androgens, and inflammation.
Aging is the strongest risk factor for PCa, and is associated with inexorable decline in
body functions including decline in antioxidant defense capacity [119]. Elevated levels of
ROS and consequential oxidative DNA damage has been observed in aging tissues,
including the prostate [117, 120]. Similarly, elevated levels of androgens can alter
intracellular redox status in favor of ROS [70, 71]. This is also supported by findings
from studies that show that androgen deprivation therapy reduces ROS levels in PCa cells
(LNCaP), resulting in delayed disease progression [121, 122]. Likewise, chronic
inflammation, particularly inflammation of the prostate (i.e., prostatitis), also appears to
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increase ROS production through activation of phagocytes, such as neutrophils and
macrophages, resulting in increased oxygen-uptake which, in turn, increases ROS
production in prostate epithelial cells [70, 117]. It has also been clearly demonstrated that
oxidative stress in PCa cells is essential for their aggressiveness (i.e., invasion and
migration), with aggressive forms of PCa displaying higher degree of oxidative stress
than do less aggressive forms [123].
Oxidative DNA damage is marked by the formation of oxidized base lesions or
adducts which, if unrepaired, can result in mutation, altered gene expression, and
transformation of normal cells into malignancy [8, 70]. Cellular response to oxidative
DNA damage involves activation of several oxidative stress-mediating genes/pathways,
including DNA repair pathways and antioxidant enzymes, in order to prevent further
DNA damage, recover from mutagenesis, and restore genomic stability [124, 125]. Four
categories of DNA repair pathways are known to operate on different types of DNA
damage by reversing and/or removing damaged elements: (1) base excision repair (BER),
which repairs small lesions such as oxidized DNA bases and nonbulky adducts; (2)
nucleotide excision repair (NER), which removes bulky lesions and damaged singlestranded fragments from environmental and oxidative stress-induced damage; (3)
mismatch repair (MMR) that corrects DNA replication errors, specifically mispaired
DNA bases; and (4) double-stranded breaks, which are repaired through complex
pathways involving homologous recombination and end-joining DNA repair mechanisms
[124-126].
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Single nucleotide polymorphisms (SNPs) in genes involved in oxidative stress
and DNA repair pathways may influence susceptibility to PCa [8, 10]. Several studies
have reported associations between SNPs in DNA repair and oxidative stress genes, and
overall risk of PCa (summarized in a recent meta-analysis [127]). Existing evidence also
suggests that associations between these SNPs and overall PCa risk may be modulated by
dietary antioxidants [128-130]. Similarly, there is growing evidence that some of the
SNPs in DNA repair and oxidative stress genes confer greater risk for developing
aggressive PCa [131, 132]. However, just a handful of studies have investigated joint
effects of these SNPs and antioxidant status in relations to PCa aggressiveness, with
mixed findings [133-135]. These studies were limited by small sample size, lack of racial
diversity, and inability to control for multiple potential confounders such as body mass
index (BMI), physical activity, dietary factors including calcium and energy (calorie)
intake. Thus, there is a need for a large, racially diverse, population-based study, with
detailed data on demographics, personal and family health history, lifestyle, dietary
patterns, PCa screening history, and clinical attributes of PCa.

1.4

OBJECTIVES AND HYPOTHESES

OBJECTIVE 1: To examine whether changes in dietary antioxidant intake (baseline to 3months) as measured by plasma concentrations of carotenoids and tocopherols are
associated with PCa progression (assessed by changes in serum PSA level as an
intermediate prognostic marker of disease progression) in African-American and
European-American men with biochemically defined PCa recurrence after
definitive therapy.
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Hypotheses:
i. Higher levels of plasma carotenoids and tocopherols at baseline will be
associated with lower serum PSA levels at baseline.
ii. Higher post-intervention plasma carotenoids and tocopherol levels (at 3
months) will be associated with lower post-intervention PSA levels (at 3
months, and at 6 months), after adjusting for baseline PSA level.
iii. Change in plasma carotenoids and tocopherol levels (baseline to 3 months)
will inversely correlate with serum PSA levels at 3 months and at 6 months.

OBJECTIVE 2: To examine associations between antioxidant levels in adipose tissue,
plasma and diet, and PCa aggressiveness among African American and EuropeanAmerican men.
Hypothesis: Lower levels of antioxidants in adipose tissue, plasma and diet are associated
with high aggressive PCa, and these associations do not vary by race.

OBJECTIVE 3: To examine whether SNPs in DNA repair and oxidative stress genes
modulate associations between antioxidants in adipose tissue, plasma and diet,
and PCa aggressiveness among African-American and European-American men.
Hypothesis: SNPs in DNA repair and oxidative stress genes modify associations between
antioxidants in adipose tissue, plasma and diet, and PCa aggressiveness, and the
degree of the effect modification vary by race.
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CHAPTER 2
LITERATURE REVIEW
2.1

DIETARY INTERVENTION TRIALS FOR RECURRENT PROSTATE CANCER AFTER
DEFINITIVE

Clinically localized PCa is traditionally managed with definitive therapy which
consists of prostatectomy or radiation therapy, or prostatectomy followed by radiation
therapy [9, 12, 100]. However, over a third of PCa patients treated with definitive therapy
develop biochemically defined disease recurrence within 10 years of treatment [100].
Biochemical recurrence of PCa is marked by sustained rise in PSA after post-treatment
nadir (lowest detectable level of PSA after treatment) [100-102]. A rising level of PSA is
also a surrogate serum marker of PCa progression [9]. Men with biochemically recurrent
PCa and rising level of PSA are often treated with androgen ablation with the hope of
delaying the disease progression. Nonetheless, there is little evidence supporting the
efficacy of androgen ablation in this population of men [136-138]. Androgen ablation has
also been associated with severe, life-altering side effects [14, 15]. These reasons have
motivated the search for new and innovative treatment strategies that could halt or delay
the progression of recurrent PCa without the side effects of androgen ablation [9].
There is growing evidence that recurrent PCa may be a diet-sensitive disease
stage because a number of dietary intervention trials have found inverse associations
between increased consumption of a plant-based, antioxidant-rich diet and serum PSA
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levels [18, 19, 109, 139]. This suggests that plant-based diets that are rich in antioxidants
may offer an alternate treatment option for recurrent PCa. However, the current evidence
is limited and inconclusive, as other dietary intervention studies including well-designed
randomized clinical trials have also found null associations between antioxidant-rich
dietary interventions and PCa progression in men with biochemically defined recurrence
([13, 112, 113], also reviewed in [111]). Thus, the exact role of dietary antioxidants in
relations to PCa progression remains unclear.
In a recent dietary intervention trial of men with biochemically defined PCa
recurrence and rising PSA levels, Saxe et al. [9] investigated the effect of dietary
modification involving a plant-based, antioxidant-rich diet, together with stress
management training, on PCa progression. The study consisted of 13 men (supported by
their spouses) who opted not to use conventional therapy for treatment of recurrent
disease. The study participants were recruited through the Veterans Affairs hospitals in
San Diego, California and followed over a 6-month period. The investigators utilized a
pre-post design with each participant serving as his own control. The intervention in this
study consisted of increased intake of whole grains, fruits, vegetables, and legumes, along
with lessons on how to shop for, and cook the study-compliant diet. Study participants in
the intervention group were also offered individual dietary counseling, instructional
materials, and a series of group meetings to help reinforce the intervention. Stress
management training was also offered to the intervention group to help relieve any form
of stress that may have been associated with change in diet palatability and culinary
habits. Pre-intervention PSA values were obtained from participants' medical records,
and rates of pre-intervention PSA rise were calculated based on these PSA values,
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including the initial PSA values used to establish biochemical recurrence of the disease
(i.e., three successive PSA values, at least 1 month apart) and all documented PSA values
thereafter, until the start of intervention. The intervention rate of PSA rise was estimated
based on PSA values measured at baseline, at 3-months, and at 6-months. The preintervention and intervention rates of PSA rise, and PSA doubling time were estimated
for each patient as the natural log of PSA by time (months) and natural log of two divided
by the rate of change in PSA, respectively, using linear regression analyses. Results of
the study show a significant decline in rates of PSA rise during intervention when
compared with the pre-intervention rates of PSA rise (p< 0.01). Additionally, significant
improvements were made in PSA doubling time during the intervention, which increased
from a median doubling time of 11.9 months (pre-intervention) to 112.3 months over the
6-month intervention period. This study suggests that plant-based, antioxidant-rich
dietary modification combined with stress reduction may slow the progression of PCa as
evidenced by decline in rates of PSA rise and prolonged PSA doubling time.
Carmody et al. [21] also investigated whether men with recurrent PCa and rising
level of PSA can make sustainable dietary changes after attending series of cooking
lessons integrated with mindfulness training, and whether these dietary changes can
influence quality of life and PCa progression. The study population consisted of 36 male
residents of Massachusetts with biochemically defined PCa recurrence after receiving
definitive therapy who had not received any disease-directed therapy after PCa
recurrence. The study participants were randomized into intervention (n=17) and control
(n =19) groups, and followed over a 3-month period. Participants in the intervention
group (supported by spouses or partner of choice to help with dietary change) were
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offered 11 weekly diet and cooking lessons which emphasized increased intake of plantbased diets that are rich in antioxidants, particularly foods that are rich in carotenoids,
soy, and isoflavones; including vegetables, whole grains, and soybean and soybean
products. The intervention also encouraged consumption of fish, especially salmon due to
its ω-3 fatty acids content, and discouraged intake of poultry and dairy products
(including meat) because of saturated fat and calcium contents, which have been
associated with PCa incidence, aggressiveness, and progression [17]. Since dietary
changes can be onerous and often difficult to adhere to, mindfulness training was offered
as part of the intervention to help promote participants’ sense of control over change in
dietary patterns. The intervention group was compared to a “wait-list” control group, who
were offered an opportunity for the intervention at the end of the study. Diet assessment
in both arms of the study was done using 24-hour diet recall interviews which provided
estimates of nutrient intake including antioxidants, fat, protein, calcium and fiber at
baseline, after 11 weeks of intervention, and at the end of the intervention (3 months).
Change in quality of life was assessed using functional assessment questionnaires
eliciting information on physical/functional status at the three study time points (baseline,
11 weeks, and 3-months). Pre-intervention PSA values were obtained from participants’
medical records, and three additional PSA values were measured at the three study time
points. The investigators calculated average pre-intervention PSA slopes for the
intervention and control groups separately based on the two most current PSA values in
participant’s medical records. Similarly, they estimated the average intervention PSA
slopes between the two groups based on PSA assays measured at the three study time
points. PSA velocity was also calculated as the natural log of PSA by time. Results of the
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study show that the intervention group was able make positive dietary changes including
increased intake of antioxidants, particularly lycopene (p = 0.05), carotenoids (p = 0.05),
and decreased intake of animal protein (p = 0.03), saturated fat (p <0.01) and calcium (p
= 0.01). Additionally, the intervention group had significant improvements in quality of
life when compared with the control group (p = 0.02). However, there were no
differences in change in PSA slope between the two study groups (p = 0.28).
Nonetheless, the average PSA doubling time was significantly prolonged for the
treatment group by about 172% (from 21.5 months at baseline to 58.5 months at 3months), while that of the control group only increased by 1.6% (from 18.4 months at
baseline to 18.7 months at 3-months). These findings suggest that men with recurrent
PCa and rising PSA levels can make beneficial dietary changes involving antioxidants,
and when integrated with mindfulness practice and partner support, these dietary
modifications may improve quality of life and delay the progression of PCa.
Hébert et al. [13] also investigated the efficacy of plant-based, antioxidant-rich
dietary intervention, integrated with physical activity and stress reduction, on PCa
progression in men with biochemically defined recurrence. This study (EASE Study) was
conducted in South Carolina and consisted of 47 men who had been previously treated
with definitive therapy for histologically confirmed adenocarcinoma of the prostate. The
study participants were randomized into intervention (n = 26) and control (n = 21), and
followed over a 6 month period. Participants in the intervention group were enrolled in
the study along with a spouse or partner-of-choice to offer support in the process of
lifestyle change. Those in the control arm of the study had the usual care with an
opportunity for the intervention at the end of the study. The intervention consisted of
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individual diet and physical activity counseling sessions, as well as group sessions
involving discussions on how to shop for, and cook study-compliant meals, physical
activity goals, and practice of meditation that cultivates mindfulness. The diet aspect of
the intervention emphasized increased intake of plant-based foods such as whole grains,
fruits, vegetables, and legumes (particularly soybeans and soybean products), all of which
are rich in antioxidant micronutrients. The intervention also emphasized reduced intake
of meat and dairy products. The investigators integrated meditation and physical activity
as part of the intervention to help reduce stress associated with comprehensive dietary
change and to promote the overall well-being of the participants. Diet assessment was
done using 24-hour diet recall interviews at baseline, and at 3 months and 6 months.
Physical activity questionnaires were also used to ascertain activity levels and serum PSA
assays were measured at each of the study time points (baseline, and at 3 months and 6
months). Effectiveness of the intervention on serum PSA levels was evaluated using an
intent-to-treat, mixed-effects model with repeated measures analysis of variance. Post
hoc analyses were also performed using signal detection (i.e., decision tree) methods to
examine effects of individual dietary components on serum PSA level. Results of the
study show that there were no significant differences in change in serum PSA levels
between the intervention and control groups (p = 0.45). However, the intervention group
made positive dietary modifications including increased intake of fruits, vegetables, and
fiber (albeit, statistically non-significant); and decreased intake of calories (p = 0.01),
total fat (p = 0.02), and saturated fat (p <.01). Results from the signal detection analyses
also show that irrespective of intervention status, 56% of men who increased fruit intake
had no rise in serum PSA levels compared to 29% of men who did not increase fruit
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intake. Similarly, 56% of men who increased fruit and fiber intake and decreased
saturated fat intake had no rise in serum PSA levels compared to 44% of men who did
not. Thus, this study provides suggestive evidence that increased consumption of fruits
and fiber, along with decreased intake of saturated fat, may offer protection against PCa
progression.
Over the last two decades, a total of ten papers have been published defined by
the authors as plant-based dietary interventional studies in relations to PCa progression
[9, 11, 13, 18, 21, 112, 139-142], representing eight independent studies on plant-based
diet intervention trials that have been conducted in the last 20 years. Five of these eight
studies reported potential inhibitory effect of dietary modification on PCa progression as
measured by change in serum PSA level [9, 11, 18, 21, 141]. Three of these studies found
no effect of dietary modifications on PCa progression [13, 112, 140]. These mixed
findings can be attributed to multiple factors, including the fact that conventional dietary
interventions such as those described above are multifaceted, involving different
combinations of diet, stress reduction, and physical activity which make it difficult to
evaluate the independent effect of the prescribed diet. Secondly, diets used in dietary
intervention trials usually have several components, such as increasing fruits, vegetables,
and fiber intake, while decreasing consumption of meat and dairy products at the same
time, which makes it difficult to evaluate independent effects of specific food
constituents, including micronutrients such as antioxidants. There is also the possibility
of treatment “contamination” between the intervention group and the control group,
where health-conscious persons in the control group may have knowingly or
inadvertently adopted the behavior change prescribed for the intervention group. These
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limitations provide justification for further high-impact translational research involving
biomarkers of dietary antioxidant intake and predictive markers of PCa progression to
help establish potential etiologic relationship. Such research would provide more
definitive evidence on the efficacy of dietary intervention on PCa progression.
Additionally, this could provide valuable information to clinicians that can facilitate the
development of structured and monitored dietary intervention strategies as a costeffective treatment alternative for men with biochemically recurrent disease.
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Table 2.1 Summary of findings from plant-based, dietary intervention trials in relation to prostate cancer progression among
men with biochemically defined prostate cancer recurrence (PSA endpoint studies)
Author

Intervention

Subjects and design

Results

Randomized trials
Hébert et al., 2012

Diet,
Physical activity &
Stress reduction

A six month follow-up study: 2.5-hr weekly
sessions over 3 months, monthly booster
sessions continued for another 3 months.

No difference in change in PSA
level between the intervention
and control group (p = 0.45)

Intervention (n = 26)
Control (n = 21)

Mean PSA at 3-months:
Intervention : 1.09 (0.54-2.18)
Control
: 0.77 (0.36-1.68)
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Intervention emphasized increased intake of
antioxidant-rich diet such as whole grains,
fruits, vegetables, and legumes (particularly
soybeans and soybean products).
Carmody et al.,
2008

Diet,
Stress reduction

A 23-week follow-up study of 36 male
residents of Massachusetts randomized into
intervention (n = 17) and control (19).

Mean PSA at 6-months:
Intervention : 0.78 (0.36-1.70)
Control
: 0.84 (0.42-1.68)
No difference in change in PSA
slope (p = 0.28)
PSA doubling time:

Active intervention: 11weekly 2.5-hr sessions,
and followed for additional 12 weeks.
Intervention emphasized increased intake of
carotenoids, soy, and isoflavones; including
vegetables, whole grains, soybean, soybean
products and fish (particularly salmon).

Intervention: ↑ from 21.5 months
(pre-study) to 58.5 months
(during intervention)
Controls: ↑ from 18.4 (pre-study)
to 18.7 months (during study
period)

Table 2.2 (continued): Summary of findings from plant-based, dietary intervention trials in relation to prostate cancer progression
among men with biochemically defined prostate cancer recurrence (PSA endpoint studies)
Author

Intervention

Subjects and design

Results

Non-randomized trials (no controls)
Saxe et al., 2001

Diet,
Stress
reduction

Ten Massachusetts male residents followed over 4
months.

Rate of PSA rise decreased in 8 of 10
men.

Twelve weekly intervention of 3-4 hrs each

Median PSA doubling time increased
by 2.7 folds [from 6.5 months (prestudy) to 17.7 months]

Intervention emphasized increased intake of whole
grains, legumes, fresh green and yellow vegetables,
seeds, legumes, soy products and fruit.
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Saxe et al., 2006

Diet,
Stress
reduction

Thirteen men from VA hospitals in San Diego, CA
Ten 3 hour meetings over 6-months:
Once per week for first month
Once per month for month 2 to 5
Two in month 6
Intervention emphasized same diets as Saxe et al.,
2001.

Nguyen et al.,
2006

Diet,
Stress
reduction

Same population as Saxe et al., 2006

Examined rates of PSA rise at different intervals

Rate of PSA rise decline during
intervention compared with the preintervention rates of PSA rise (p <
0.01).
Median PSA doubling time increased
by 9.4 folds [from 11.9 months (prestudy) to 112.3 months]
Rate of PSA rise decreased when
comparing pre-study (0.06) to 0- to 3months (–0.002, P < .01).
However, the rate of PSA rise
increased when comparing the interval
0- to 3-months (-0.002) with 3- to 6months (0.03, P = .43).

2.2

ASSOCIATIONS OF ANTIOXIDANTS AND PROSTATE CANCER RISK AND
AGGRESSIVENESS

Extensive research on carcinogenesis and chemoprevention (i.e., the use of diet,
nutritional supplements and/or medications to prevent cancer) has led to a firm
conclusion that one of the mechanisms by which diet modifies PCa risk and
aggressiveness is through the consumption of antioxidant micronutrients, which are
found in many foods including fruits, vegetables, and legumes [17, 18, 117, 123]. It has
been clearly established that antioxidants protect cellular DNA from damage by oxidative
stress through the elimination of intracellular reactive oxygen species (ROS) [8, 70].
Sustained oxidative stress (i.e., prolonged period of elevated levels of ROS beyond
antioxidant repair capacity) can lead to changes to the prostatic microenvironment,
including DNA base damage, DNA strand breaks, altered gene expression, and
ultimately, PCa [70, 117]. Although numerous studies have examined associations
between dietary antioxidants and PCa with some promising results, there is a lack of
consistency in the outcome of these studies (reviewed in [64, 76, 143-149]). These
inconsistencies emphasize the need for well-designed and well-executed studies to help
delineate the role of individual antioxidants in PCa and PCa aggressiveness before
widespread use of antioxidants for chemoprevention is encouraged. This summary
includes reviews of benchmark studies and the current state of the science on
relationships between antioxidants and PCa, with special emphasis on PCa
aggressiveness.
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Vitamin E
Vitamin E is thought to play an important role in PCa prevention because of its
antioxidant effect. Vitamin E is a complex fat-soluble compound occurring in eight
different chemical forms; four tocopherols [alpha (α), beta (β), gamma (γ), and delta (δ)]
and four tocotrienols (α-, β-, γ-, and δ-tocotrienols) with varying levels of bioavailability
and biologic significance [150]. The most bioactive form of vitamin E in human serum
and tissues is α-tocopherol, which is also the most extensively researched form of
vitamin E in relation to PCa [150-152]. The most common form of vitamin E in
American diet is γ- tocopherol, while α-tocopherol is the most common type found in
nutritional supplements [150, 153, 154]. Vitamin E is found in the human diet in various
plant seeds, nuts, and oils [154]. Consumption of vitamin E from diet and nutritional
supplements as well as serum and tissue levels of individual tocopherols and tocotrienols
have been associated with PCa and PCa aggressiveness (reviewed in [64, 76, 154-158]).
Unfortunately, the evidence is conflicting and often difficult to reconcile.
Several clinical trials have examined antioxidant supplementation in relation to
prostate cancer incidence. The Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer
Prevention Trial is one of the benchmark studies in this area of research. The ATBC trial
a randomized, double-blinded, placebo-controlled trial conducted among 29,133 Finish
male smokers, aged 50-69 years, with a primary aim of exploring chemoprevention of
lung cancer. The study participants were randomized into four treatment groups; (1) αtocopherol 50mg/daily; (2) β-carotene 20 mg/daily; (3) α-tocopherol 50mg/daily and βcarotene 20 mg/daily; and (4) placebo. Although the primary end-point was lung cancer,
the investigators observed that after 5 to 8 years of follow-up, smokers assigned to the
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α−tocopherol group had a 32% (95% confidence interval [CI] = −47% to −12%) reduced
risk of PCa incidence and 41% (95% CI = −65% to −1%) lower risk of death from PCa
when compared to the placebo group [159]. Analysis of a 6-year post-intervention
follow-up of this study showed that the protective effect in the α−tocopherol group
reduced from 36% (RR = 66; 95% CI = 0.51-1.04) during the trial to 27% (RR = 0.73;
95% CI = 0.51 – 1.04) 3 years post-trial, and finally to 6% (RR = 0.96; 95% CI = 0.72 –
1.24) 6 years post-trial. This observation led to the conclusion that the beneficial effects
of α−tocopherol against PCa require long-term use [160]. In a recent analysis of the
ATBC trial with 19-year follow-up data, using biomarkers of antioxidant intake,
Weinstein et al. [79] observed that higher levels of serum α−tocopherol reduced the risk
of PCa by 20% (RR = 0.80; 95% CI = 0.66 - 0.96; highest vs. lowest quintile; Ptrend =
0.03). Higher levels of serum α−tocopherol were also found to reduce the risk of
advanced PCa by 44% (RR = 0.56; 95% CI, 0.36-0.85; Ptrend = 0.002). Other studies have
also provided evidence on the beneficial effects of vitamin E on PCa [74, 161, 162]. For
example, in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO),
Kirsh et al. [68] observed that among current and former smokers, daily intake of 400 IU
of vitamin E was associated with a 71% (RR = 0.29; 95% CI = 0.12 to 0.68; Ptrend = .01)
decreased risk of advanced PCa (i.e., Gleason score ≥ 7 or cancer stage II/IV) compared
to a placebo group. Similarly, in a case-control study nested within the Physicians’
Health Study, male physicians with the highest levels of serum α−tocopherol were found
to have a 36% lower risk of aggressive PCa, albeit, statistically non-significant (OR =
0.64; 95% CI = 0.38 - 1.07). A subgroup analysis showed that the inverse association for
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aggressive PCa was stronger and statistically significant for current/former smokers (OR
= 0.51; 95% CI = 0.26 - 0.98; highest vs. lowest quintile) [163].
However, these findings are contradicted by results from the Selenium and
Vitamin E Cancer Prevention Trial (SELECT), which was established based on the
promising results of the ATBC trial [73]. SELECT recruited 35,533 male residents of the
US, Canada, and Puerto Rico, aged ≥ 50 years, who were randomized into selenium (200
µg/day) only, vitamin E (α−tocopherol, 400 IU/day) only, a combination of selenium
(200 µg/day) and vitamin E (α−tocopherol, 400 IU/day) or placebo. This trial was
designed to span a minimum of seven years and maximum of 12 years, but did not
continue after the initial phase of seven years due to a suspicion that the intervention with
α-tocopherol may have been putting the study participants at risk for developing PCa
[73]. After the 7-year follow-up period, those taking vitamin E alone had a 13% increased
risk of PCa, albeit statistically non-significant (HR = 1.13; 99% CI = 0.95 -1.35) [73].
Analysis of data from additional 1.5 years of follow-up of SELECT showed a stronger
and statistically significant increased risk of PCa in the study participants who received
vitamin E alone (HR = 1.17; 95% CI = 1.004 - 1.36, Ptrend = 0.008) [164]. However, in
another large randomized, placebo-controlled trial (The Physicians’ Health Study II),
supplemental vitamin E (400 IU) taken every other day over a 10-year period did not
have an effect on PCa incidence (HR = 0.97; 95% CI = 0.85-1.09) or PCa-specific
mortality (HR = 1.01; 95% CI = 0.64-1.58) in US male physicians [74]. Additionally,
analysis of data from the Nutritional Cohort of the Cancer Prevention Study II showed
that daily intake of supplemental vitamin E (≥ 400 IU) does not have an effect on overall
risk of PCa (RR = 0.98; 95% CI = 0.89-1.08) or risk of advanced-stage disease (RR =
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0.97; 95% CI = 0.74 – 1.26) [165]. A number of observational studies, particularly casecontrol and cohort studies have also examined associations of vitamin E and PCa
incidence [78, 152, 166-168] and advanced/aggressive PCa [169-171] with mixed
findings. However, it is important to note that after reviewing evidence from cohort, casecontrol, and ecological studies involving serum/plasma-based, questionnaire-based, and
aggregate data, the World Cancer Research Fund and the American Institute for Cancer
Research (WCRF/AICR) expert panel concluded in 2007 that although the evidence
remains inconsistent, it is “probable” that vitamin E protects against PCa [172].

Carotenoids
It has been suggested that carotenoids may decrease the risk and aggressiveness of
PCa by neutralizing ROS, which play a role in PCa through oxidative DNA damage [117,
123]. The most common carotenoids in the Western diet are α-carotene, β-carotene, βcryptoxanthin, lycopene, lutein, zeaxanthin, and retinol (vitamin A), all of which are
found in a variety of foods [173, 174]. Carrots, pumpkin, and winter squash are the
primary sources of α-carotene; while β-carotene, β-cryptoxanthin, lutein and zeaxanthin
are most abundant in deep-yellow/orange fruits such as apricots, cantaloupes, and
mangoes, as well as in dark-green leafy vegetables, such as spinach, kale, broccoli,
Brussels sprouts, green beans, peas, and zucchini. Lycopene is primarily found in
tomatoes and tomato-based products, particularly processed tomatoes [173, 174]. Several
studies have examined associations between carotenoids and PCa. However, the evidence
remains inconsistent, emphasizing the need for high-impact research to help delineate
relationships between individual carotenoids and PCa; especially PCa aggressiveness,
which has received very little attention in the literature.
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The US Physicians’ Health Study is one of the longest prospective studies
conducted to examine associations between plasma concentrations of all the major
carotenoids and PCa risk. Gann et al. [163] conducted a case-control study nested within
the Physicians’ Health Study, involving 578 men with PCa who were age-matched to
1294 controls. The investigators examined associations between plasma levels of αcarotene, β-carotene, β-cryptoxanthin, lycopene, lutein and retinol, and PCa risk and
observed that none of these carotenoids were associated with overall risk of PCa.
However, lycopene was strongly and inversely associated with PCa aggressiveness (OR =
0.56; 95% CI = 0.34 - 0.92, p = 0.02; highest vs. lowest quintile). Similarly, in a recent
population-based, case-control study, Zhang et al. [175] investigated associations
between plasma concentrations of α-carotene, β-carotene, β-cryptoxanthin, lycopene, and
lutein/zeaxanthin and PCa, and found that only plasma lycopene was inversely and
significantly associated with PCa risk (OR = 0.45; 95% CI = 0.24 - 0.85; highest vs.
lowest quartile; Ptrend = 0.042).
Lycopene is considered a potent antioxidant, which in addition to its ability to
neutralize ROS, is also thought to protect against PCa through the inhibition of IGFmediated cell proliferation and suppression malignant prostate cell growth [176, 177].
Lycopene consumption has been inversely associated with PCa in both serum-based and
questionnaire-based studies; however, the evidence remains mixed (reviewed in [64, 143,
145, 178]). In a meta-analysis of 10 cohort studies and 11 case-control studies, lycopene
consumption appeared to offer protection against PCa. In the cohort studies, cooked
tomato products were associated with a 19% (RR = 0.81; 95% CI = 0.71 - 0.92) reduced
risk of PCa cancer, and consumption of raw tomatoes (200g/day) was associated with a
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22% (RR = 0.78; 95% CI = 0.66 - 0.92) lower risk of PCa in the case-control studies.
Other sources of lycopene were not associated with PCa [179]. In addition, a fairly recent
prospective study, lycopene consumption was found to reduce the risk of PCa in men
with a family history of the disease (Ptrend = 0.04) [180]. In the European Prospective
Investigation into Cancer and Nutrition (EPIC), plasma lycopene was inversely
associated with advance-staged PCa (RR = 0.40; 95% CI = 0.19 - 0.88, highest vs. lowest
quintile), but not localized disease (RR = 1.40; 95% CI = 0.89 - 2.21; lowest vs. highest
quintile) [181]. Similarly, in the Third National Health and Nutrition Examination Survey
(NHANES III), serum lycopene was associated with a 63% lower risk of aggressive PCa
(RR = 0.37; 95% CI = 0.15–0.94; highest vs. lowest quartile; Ptrend = 0.04), but not
overall PCa risk (RR = 0.65; 95% CI = 0.36–1.15; highest vs. lowest quartile; Ptrend =
0.09) [182]. However, in a case-control study nested within the PLCO trial, serum
lycopene status had no association with PCa risk (Ptrend = 0.28) or PCa aggressiveness
(Ptrend = 0.43) [183]. Other studies have also reported null associations between
serum/plasma- and questionnaire-based studies on lycopene level and PCa risk and
aggressiveness [184-187]. Together, the weight of the evidence suggests that lycopene
likely offers protection against PCa and may have greater influence on PCa
aggressiveness; however, more research is needed for definitive conclusion.
Perhaps the most puzzling association between individual carotenoids and PCa is
that of β-carotene and PCa risk. In the ATBC trial, β-carotene was associated with a 23%
(95% CI = −4% to −59%) increased risk of PCa and a 15% (95% CI = −30% to −89%)
increased risk of death from PCa [159]. Also, in a nested case-control study using data
from the PLCO trial, higher levels of serum β-carotene was associated with a 67% (OR =
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1.67; 95% CI = 1.03 - 2.72, highest vs. lowest quintile) increased risk of aggressive PCa
(Gleason sum ≥ 7 or stage III or IV). This increased risk was much higher for advancedstage (stage III or IV) disease (OR = 3.16; 95% CI = 1.37 - 7.31, highest vs. lowest
quintile) [183]. In another prospective study, high serum level of β-carotene was
associated with a 2.3 fold increased risk of PCa (RR = 2.3; 95% CI = 1.12 - 4.66, highest
vs. lowest tertile, Ptrend = 0.023) [187]. While assessing PCa as a secondary aim in the
Carotene and Retinol Efficiency Trial (CARET) it was observed that daily
supplementations of 30mg of β-carotene plus 25,000 IU of retinyl palmitate was
associated with a 52% increased risk of aggressive PCa (RR = 1.52; 95% CI = 1.03 2.24) [188]. Interestingly, other studies have reported inverse associations between βcarotene and PCa. Kirsh et al. [68] observed that supplemental β-carotene of at least 2000
µg/day was associated with a 48% lower risk of PCa in men with low dietary β-carotene
intake (RR = 0.52; 95% CI = 0.33 - 0.81). In addition, a nested case-control study, high
plasma β-carotene was also associated with a 69% PCa risk reduction (OR = 0.31; 95%
CI = 0.15 – 62; higher than median vs. lower than median) [189]. However, in a recent
meta-analysis, β-carotene was not associated with PCa incidence (RR = 0.99, 95% CI =
0.91 - 1.07) [190]. Similarly, there is conflicting evidence on associations between
serum/plasma levels and dietary intake of α-carotene, β-carotene, β-cryptoxanthin,
lutein/zeaxanthin, and retinol on PCa risk and aggressiveness [17, 76, 190]. For example,
Lu et al. [191] reported a 70% to 80% PCa risk reduction in men with higher plasma
levels of β-cryptoxanthin, lutein and zeaxanthin, but retinol, α- and β-carotene were not
associated with PCa risk. However, in a prospective cohort study, dietary intake of βcryptoxanthin was associated with an increased risk of PCa in a dose-response fashion
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(Ptrend < 0.01). There were no discernible associations between retinol, α- and β-carotene,
lutein/zeaxanthin and PCa [171]. These apparent discrepancies may be explained by
baseline antioxidant status of the studied populations. That is, antioxidant
supplementation in a population that is nutritionally replete may not have a beneficial
effect, whereas supplementing a population that is nutritionally deficient might have
substantial health benefits [192-195].

Selenium
Selenium is an essential micronutrient found in many food items, particularly
plant-based foods such as bread and cereal (depending on soil concentrations), and in
meat and fish products as well as nutritional supplements [17, 158]. It has been suggested
that selenium may protect against PCa by inducing the antioxidant enzyme glutathione
peroxidase, which neutralizes the free radical superoxide anion (.O2-) and also by
inhibiting PCa cell proliferation through the suppression of angiogenesis [158, 196].
Dong et al. [197] have also demonstrated a dose dependent effect of selenium on PCa cell
growth inhibition and apoptosis. Nonetheless, the role of selenium in prostate
carcinogenesis remains a subject of ongoing debate.
Interest in the role of selenium in the prevention of PCa was stimulated by the
National Prevention of Cancer (NPC) trial, which was primarily designed to investigate
the effect of selenium on the recurrence of nonmelanoma skin cancer [198]. In this
double-blinded, randomized, placebo-controlled trial, 1,312 patients recruited from
dermatology clinics located in the eastern seaboard of the US were randomized into
treatment (200µg of selenium daily) and placebo. After 13 years of follow-up, it was
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observed that selenium did not have any effect on skin cancer recurrence; however,
selenium was inversely associated with overall risk of PCa (RR = 0.51; 95% CI = 0.29 0.87). Nonetheless, results from a subgroup analysis showed that the PCa risk reduction
was only in men with baseline PSA level ≤ 4 ng/ml (RR = 0.33; 95% CI = 0.14 - 0.79),
but not those with baseline PSA ≥ 4 ng/ml (RR = 0.95; 95% CI = 0.42 – 2.14). In a
matched case-control study, Yoshizawa et al. [199] observed inverse associations
between toenail levels of selenium and advanced-stage PCa (OR = 0.35, 95% CI = 0.16 0.78, highest vs. lowest quintile, Ptrend = 0.03). Van den Brandt et al. [200] also examined
association between toenail level of selenium and PCa risk in a cohort of 1,211 men and
found that elevated toenail levels of selenium was protective against PCa (RR = 0.69,
95% CI = 0.48 - 0.99, highest vs. lowest quintile, Ptrend = 0.008). However, subgroup
analysis in this study also showed that the protective effect was only evident in former
smokers (Ptrend = 0.003), and not current (Ptrend = 0.383) or non-smokers (Ptrend = 0.412).
Three recent meta-analysis involving serum/plasma-, toenail- and questionnaire-based
studies indicated that men with high intake of selenium have lower risk of developing
PCa [144, 146, 201]. However, it is important to note that assessment of selenium intake
in epidemiological studies is fraught with problems arising from the way food is
prepared, digested and absorbed.
In the SELECT trial (described above), daily supplementation of 200 µg selenium
did not have an effect on PCa risk (HR = 1.09; 99% CI = 0.93 - 1.27, Ptrend = 0.18),
neither did daily intake of 200 µg of selenium in combination with 400 IU of vitamin E in
supplement form (HR = 1.05; 99% CI = 0.89 - 1.22, Ptrend = 0.46) [164]. In another
randomized, placebo-controlled trial, Marshall et al. [202] investigated the effect of daily
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intake of 200 µg of selenium on high-grade prostatic intraepithelial neoplasia (HGPIN), a
premalignant lesion of PCa. After a 3-year follow-up, it was observed that while
selenium appears to be protective against PCa, the effect was not statistically significant
(RR = 0.82; 95% CI = 0.40 - 1.69). In a nested case-control study conducted within the
EPIC study, no associations were found between plasma selenium levels and PCa risk
(RR = 0.96; 99% CI = 0.70 - 1.31, highest vs. lowest quintile, Ptrend = 0.25) [203]. Chan et
al. also examined associations between plasma selenium level, SOD2 gene variants, and
PCa aggressiveness in men with localized and locally advanced PCa, and found that
selenium appears to increase the risk of developing aggressive PCa (RR = 1.35, 95% CI
= 0.99 – 1.84) [134]. After reviewing the evidence from randomized controlled trails,
Klein et al. [204] concluded that selenium does not appear to have any effect on PCa risk.
However, in another review of the evidence from clinical and observational studies,
Richman and Chan [147] concluded that while the relationship between selenium and
PCa remain inconsistent, selenium is likely more relevant to the etiology of aggressive or
advanced-stage PCa. Nevertheless, research on selenium intake and PCa aggressiveness
is very limited, which emphasizes the need for more well-designed studies in this area
involving the use of validated biomarkers that reflect long-term selenium intake.

Vitamin C
Vitamin C (ascorbic acid) is a water-soluble vitamin and a potent antioxidant that
may confer protection against PCa by preventing oxidative DNA damage through the
scavenging of ROS [205, 206]. In vitro and in vivo studies have also demonstrated dose
and time dependent effects of vitamin C on PCa through the inhibition of PCa cell lines
(i.e., LNCaP and PC-3) [207, 208]. Vitamin C is abundantly found in many plant and
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animal foods such as fruits (e.g., citrus, cantaloupe, pineapple, kiwi, and berries),
vegetables (e.g., broccoli, brussels sprouts, potatoes, tomatoes, winter squash, and
cauliflower) and organ meat (e.g., liver and kidney) [206, 209]. Although vitamin C has
been associated with reduced risk of other cancers [206], the role of vitamin C in PCa is
controversial because of conflicting findings from various studies. In a recent casecontrol study, dietary intake of vitamin C was inversely associated with PCa risk (OR =
0.60, 95% CI = 0.41 – 0.88), although the protective effect appeared to be confined only
to European Americans (OR = 0.56, 95% CI = 0.38 – 0.85) and not African Americans
(OR = 1.19, 95% CI = 0.34 – 4.24) [210]. In another case-control study, increased intake
of vitamin C was strongly and inversely associated with PCa (OR = 0.49, 95% CI = 0.33
– 0.74) [211]. Other studies have reported inverse associations between vitamin C and
PCa risk [166, 212].
However, two double-blinded, randomized, placebo-controlled trials have
investigated the role of vitamin C in PCa and have reported null effect [68, 74]. In the
Physicians’ Health Study II trial, Gaziano et al. found that daily supplementation of 500
mg of vitamin C did not have an effect on PCa incidence (HR; 1.02, 95% CI = 0.90 –
1.15), but rather appeared to increase the risk of death from PCa (HR; 1.46, 95% CI =
0.92 – 2.13) [74]. In the PLCO cancer screening trial, daily supplementation of 500 mg of
vitamin C was also found not to be associated with PCa incidence (RR = 1.01; 95% CI =
0.87 – 1.17, highest vs. lowest quartile, Ptrend = 0.98). A meta-analysis summarizing data
from these two trials also indicated that vitamin C has no effect on PCa risk (RR = 0.98,
95% CI = 0.91 – 1.06) [167]. In a case-control study conducted in Italy, prospective
assessment of dietary intake of vitamin C was not associated with the incidence of PCa
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(OR = 0.88, 95% CI = 0.78 – 1.07, Ptrend = 0.09). Stratified analysis by age, BMI, and
family history of PCa in that study also did not show any discernible associations
between vitamin C and PCa [162]. Hodge et al. [213] and Schuurman et al. [171] have
also investigated association between vitamin C intake and PCa incidence in a
population-based case-control study and a cohort study, respectively, and both studies
reported null associations. It is important to note that relative to the other antioxidants,
fewer studies have been conducted on associations between vitamin C and PCa.
Additionally, a thorough literature search did not show any study on vitamin C and PCa
aggressiveness within the last two decades. Thus, in the light of these conflicting
findings, research into vitamin C and PCa aggressiveness may offer much clearer
evidence on the nature of the relationship.

2.3

POLYMORPHISMS IN DNA REPAIR AND OXIDATIVE STRESS GENES AND THEIR
INTERACTION WITH ANTIOXIDANTS IN RELATION TO PROSTATE CANCER

Extensive research into prostate carcinogenesis has led to the discovery of several
deleterious molecular events such as oxidative stress, which allow the occurrence of
genetic aberrations including the formation of oxidized DNA base lesions, DNA strand
breaks, altered gene expression, deletions, and ultimately mutagenesis [6, 8, 70]. Several
lines of evidence suggest that oxidative DNA damage is causally linked to PCa, and the
extent of DNA damage correlates with the degree of PCa aggressiveness [117, 123].
Different DNA repair pathways are known to operate on different types of DNA damage.
For example, base excision repair (BER) pathway removes small lesions, such as
nonbulky adducts. Nucleotide excision repair (NER) removes bulky lesions and damaged
single-stranded fragments. Mismatch repair (MMR) corrects DNA replication errors such
37

as mispaired bases, and double-stranded breaks are repaired through complex pathways
involving homologous recombination and end-joining DNA repair mechanisms [124126]. It has been clearly demonstrated that genes involved in DNA repair harbor
polymorphisms that are functionally relevant to PCa because of their pro- or
anticarcinogenic properties [131, 214, 215]. Thus, individual variations in the capacity to
repair oxidative DNA damage, and by implication, the ability to inhibit the initiation and
progression of PCa may be due to polymorphisms in the DNA repair gene pathways.
However, these polymorphisms may act alone or in combination with environmental
factors, such as dietary antioxidants, to influence the occurrence and clinical behavior of
PCa.
Multiple polymorphisms in DNA repair genes have been investigated in relation
to PCa susceptibility and aggressiveness with equivocal results [131, 132, 214, 215].
Additionally, studies have shown that the expressions of natural antioxidant enzymes
such as glutathione peroxidase, catalase, and superoxide dismutase, which mitigate the
harmful effects of oxidative stress, are lower in PCa tissues than in healthy prostate
tissues [216, 217]. Hence, it is reasonable to speculate that increased intake of
antioxidants may help reduce oxidative DNA damage, and by extension, PCa risk and
aggressiveness. However, epidemiological data regarding the independent effect of
antioxidants on PCa also remains largely inconsistent [17]. Perhaps, investigations of the
joint effect of polymorphisms in DNA repair gene pathways and antioxidant intake may
provide better understanding of how these factors interact to influence PCa.
At least three recent case-control studies have examined joint effects of genetic
variants of the superoxide dismutase 2 (SOD2) gene (a member of the mitochondrial
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Fe/MnSOD family and an important component of the BER defense system) and plasma
antioxidant status in relation to PCa risk and aggressiveness [130, 133, 134]. First, Li et
al. [130] investigated associations between valine (Val)/alanine (Ala) polymorphism
(rs4880) in the SOD2 gene and prediagnostic plasma levels of selenium, lycopene, and αtocopherol on PCa risk and aggressiveness in a nested case-control study within the
Physicians’ Health Study. In this study, none of the SOD2 genotypes (Val/Val, Val/Ala,
and Ala/Ala) had independent associations with overall risk of PCa or PCa
aggressiveness. However, among men with Ala/Ala genotype, high prediagnostic plasma
selenium level was associated with a 67% lower risk of PCa (RR = 0.33; 95% CI = 0.160.68; P trend = 0.002) and an 82% reduced risk of aggressive PCa (RR = 0.18; 95% CI =
0.07-0.48; P trend <0.001) when compared to those with low levels. These inverse
associations were weaker in men with Val/Val + Val/Ala genotypes (P interaction = 0.01).
No evidence of effect modification by SOD2 genotype was observed for associations
between plasma lycopene and α-tocopherol status, and PCa risk or aggressiveness.
However, a combined antioxidant score computed based on quartile levels of plasma
concentrations of selenium, lycopene, and α-tocopherol showed significant interaction
between SOD2 genotype and prediagnostic antioxidant status on over risk of PCa (P
interaction

= 0.02) and PCa aggressiveness (P interaction = 0.01).
Subsequently, in a different population of PCa patients, using plasma selenium

levels measured at the time of the cancer diagnosis or shortly thereafter, Chan et al. [134]
observed a non-significant 40% lower risk of aggressive PCa in men with Ala/Ala
genotype of the SOD2 gene (rs 4880) and high plasma selenium levels (RR = 0.60, 95%
CI = 0.32 - 1.12; highest vs. lowest quintile, P trend = 0.06), which is consistent with the
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previous findings by Li et al. [130]. However, there is a major difference between the two
studies. Chan et al. observed that men with Val/Val + Val/Ala genotype and high plasma
selenium concentration had an 82% increased risk of aggressive PCa (RR = 1.82; 95%
CI = 1.27 - 2.61; highest vs. lowest quintile, P trend = 0.0003), while this population of
men had non-significant weak inverse association with aggressive PCa in the Li et al.
study. Possible explanations for this inconsistency is that Li et al. focused on
prediagnostic plasma selenium concentrations, and contrasted PCa cases with controls;
while Chan et al. utilized plasma selenium levels measured at the time of PCa diagnosis
or shortly thereafter, and contrasted low aggressive PCa with intermediate/high
aggressive PCa. Nonetheless, together, the evidence suggests that SOD2 variants
modulate associations between plasma antioxidant levels and PCa risk/aggressiveness.
More specifically, having Ala/Ala genotype of the SOD2 gene may be beneficial to men
with high intake of selenium and perhaps other antioxidants.
In a more recent study, Abe et al. [133] investigated the joint effect of SNPs in
DNA repair genes (i.e., GPX1, GPX4, PPARGC1A, PPARGC1B, SOD1, SOD2, SOD3
and XRCC1) and plasma selenium levels on PCa aggressiveness. Two SNPs in the SOD1
gene were independently associated with PCa aggressiveness. One of these SNPs
(rs17884057) was inversely associated with aggressive PCa (RR = 0.83; 95% CI = 0.700.99), while the other (rs4816407) was associated with an increased risk of aggressive
PCa (RR = 1.27; 95% CI = 1.02–1.57). No associations were found between SNPs in the
other genes and PCa aggressiveness. However, two additional SNPs; one in SOD1
(rs10432782) and another in SOD2 (rs2758330); were found to have modifying effects
on associations between plasma selenium status and PCa aggressiveness (P trend = 0.04
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and <.0001, respectively), which suggest that these SNPs act in combination with
antioxidants to influence PCa aggressiveness.
Goodman et al. [129] also examined whether an association between lycopene
and PCa can be modified by x-ray repair cross-complementing protein 1(XRCC1)
genotype, a gene involved with BER. These investigators observed a borderline
statistically significant inverse association between lycopene intake and PCa (OR = 0.49;
95% CI = 0.24-0.99; highest vs. lowest tertile, P trend = 0.05). However, a stronger and
statistically significant protective effect of lycopene was observed in men with Arg/Arg
genotype (OR = 0.21; 95% CI = 0.06-0.71; highest vs. lowest tertile, P trend < 0.01), but
not in those with Arg/Gln + Gln/Gln genotype (OR = 0.83; 95% CI = 0.33-2.01; highest
vs. lowest tertile; P trend = 0.79). A much stronger inverse association was observed for
combined antioxidant exposure (lycopene + α-tocopherol + β-carotene) and PCa among
men with Arg/Arg genotype (OR = 0.11; 95% CI = 0.02-0.65; above vs. below median;
Pinteraction= 0.01). However, the combined antioxidant exposure appeared to increase risk
of PCa in men with Arg/Gln + Gln/Gln genotype (OR = 2.08; 95% CI = 0.46-9.43; above
vs. below median); suggesting that the beneficial effect of antioxidant intake may be
limited to men with Arg/Arg genotype.
Van Gils et al. [218] also examined whether three common polymorphisms of the
XRCC1 gene at codon 194 (Arg/Trp), codon 280 (Arg/His), and codon 399 (Arg/Gln)
modify the effect of antioxidant intake on PCa risk. None of the polymorphisms
examined at each of the three codons had independent associations with PCa. However,
there was evidence of effect modification by XRCC1 genotype. Among men with
Arg/Arg genotype, low vitamin E intake was associated with a 2.4-fold increased risk of
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PCa (OR = 2.4; 95% CI = 1.0-5.6, p = 0.04); however, a much lesser and statistically
non-significant increased risk was observed in men with Arg/Gln + Gln/Gln genotype
with low vitamin E intake (OR = 1.2; 95% CI = 0.5-2.8, p = 0.65).
Similarly, Zhang et al. [128] examined joint associations between variants of
XRCC1 and hOGG1(two genes that are involved with BER ) in relation to PCa. In this
population based-study, Arg/Gln + Gln/Gln genotype of the XRCC1 gene were found to
increase risk of PCa by an estimated 56% (OR = 1.56; 95% CI = 1.01-2.45, p = 0.049),
while a non-significant inverse association was observed between Ser/Cys + Cys/Cys
genotype of the hOGG1gene and PCa risk (OR = 0.72; 95% CI = 0.46 - 1.10, p = 0.13).
When stratified by plasma antioxidant status, Arg/Gln + Gln/Gln genotype of the XRCC1
gene was associated with over 2-fold increased risk of PCa among men with lower than
median levels of lutein/zeaxanthin (OR = 2.15; 95% CI = 1.17- 4.01, p = 0.015), βcryptoxanthin (OR = 2.64; 95% CI = 1.40-5.07, p = 0.003), and lycopene (OR = 2.05;
95% CI = 1.07-3.98, P = 0.032) as compared to those with the Arg/Arg genotype. On the
other hand, having Ser/Cys + Cys/Cys genotype of the hOGG1gene and lower than
median levels of β-cryptoxanthin, lycopene, α-carotene, and α-tocopherol were
associated with statistically significant 48–62% reductions in PCa risk when compared
with the Ser/Ser genotype. Other studies have also reported similar effect modification
and/or interaction between DNA repair gene variants and antioxidants on PCa [135, 219,
220].
These findings suggest that potential etiologic associations between antioxidant
intake and PCa most likely depend on polymorphisms or genetic variants within DNA
repair gene pathways. Larger studies using biomarkers reflecting long-term antioxidant
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intake are required to provide supporting evidence and help better understand the
underlying mechanisms for targeted interventions. Nonetheless, data on joint associations
between antioxidant intake and polymorphisms in other genes that are involved in
oxidative stress and DNA repair in relations to PCa are lacking. Thus, additional studies
are also needed to examine the interplay between antioxidants and variants of these other
genes such as those involved in double-stranded DNA break repair (e.g., XRCC2,
XRCC4, and RAD51C); nucleotide excision repair (e.g., ERCC8, XPA, and XPC), and
oxidative stress (e.g., NQO1, NOX3, and PPARG) in relation to PCa, particularly
aggressive PCa, which is associated with high disease-specific mortality [5].
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Table 2.2 Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA repair genes in relation
to prostate cancer
Author

Gene & Dietary Agent

Subjects and Design

Results

Studies examining prostate cancer aggressiveness
Li et al.,
2005

Gene: polymorphism
(rs4880) in SOD2 gene:
valine (V) → alanine (A)

Nested case-control study within the
Physicians’ Health Study (PHS)
PCa cases, n = 567
Controls, n = 764

Diet: prediagnostic
plasma selenium,
lycopene, and αtocopherol

No data on race groups; however, the
PHS is 93% European American

Stratified analysis by genotype
AA genotype + high selenium: lower overall risk of PCa
(RR= 0.33; 95% CI, 0.16-0.68), and lower risk of
aggressive PCa (RR= 0.18; 95% CI, 0.07-0.48).
Weak, non-significant inverse association for men with (VV
+ VA), and high selenium in relation to overall risk of PCa
(RR = 0.6; 95% CI = 0.4 - 1.0), and PCa aggressiveness
(RR= 0.7; 95% CI = 0.4 -1.2).
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A significant interaction observed between combined
antioxidant score (selenium + lycopene + α-tocopherol) and
SOD2 in relation to PCa aggressiveness (P interaction = 0.01).
Chan et al.,
2009

Gene: polymorphism
(rs4880) in SOD2 gene:
valine (V) → alanine (A)

A nested case-control study Data from
Dana-Farber Cancer Institute: 489
locally advanced PCa cases.

Diet: plasma selenium
level (collect at, or
immediately after
diagnosis)

Aggressiveness: Low n = 276;
Intermediate n = 167;
High = 146.
Whites n = 468
Other n = 18
Unknown n = 3

AA genotype + high plasma selenium; 40% lower risk of
aggressive PCa (RR = 0.60, 95% CI = 0.32-1.12).
VV + VA genotype, and high selenium: increased risk of
aggressive PCa (RR = 1.82; 95% CI = 1.27 - 2.61).

Table 2.2 (continued) Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA repair
genes in relation to prostate cancer
Author

Gene & Dietary Agent

Subjects and Design

Results

Studies examining prostate cancer aggressiveness
Abe et al., 2011

Genes: GPX1, GPX4,
PARGC1A, PPARGC1B,
SOD1, SOD2, SOD3 and
XRCC

Same population as Chan et al. 2009

Diet: plasma selenium

Aggressiveness:
Low n = 394
Intermediate n = 259
High = 100

Design: nested case control study
(n = 753)
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Whites n = 719
Other n = 30
Unknown n = 4

Mikhak et al., 2008
Gene: SOD2 Ala16Val
polymorphism
Diet: Plasma carotenoids:
α-carotene; β-carotene;
lycopene; β-cryptoxanthin;
lutein/zeaxanthin

Nested case-control study within the Health
Professionals Follow-up Study (HPFS)
Controls (n = 612) matched to PCa cases (n = 612) on
year of birth, year of blood draw, history of PSA
screening.
No data on race groups; however, HPFS is 97%
European American.
Aggressive PCa: advanced stage (T3C, T4, N0M0, TN
(1-3), T M1 or Gleason sum ≥ 7. None aggressive
PCa: all others

SOD2 SNP (rs17884057) was
inversely associated with high
aggressive PCa (RR = 0.83; 95% CI
= 0.70-0.99).
SOD2 SNP (rs4816407) associated
with increased risk of aggressive
PCa (RR = 1.27; 95% CI = 1.02–
1.57).
Two additional SNPs; SOD1
(rs10432782) and SOD2
(rs2758330) had modifying effects
on associations between selenium
and PCa aggressiveness (P trend =
0.04 and <.0001, respectively).
No association between SOD2
genotype and risk of total or
aggressive PCa
No significant interaction between
SOD2 genotype and any of the
carotenoids

Table 2.2 (continued) Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA repair
genes in relation to prostate cancer
Author

Gene & Dietary Agent

Subjects and Design

Results

Studies examining prostate cancer risk
Goodman et al.,
2006

Gene: XRCC1 genotypes;
Arg/Arg, Arg/Gln, and Gln/Gln
Diet: lycopene from FFQ, αtocopherol and β-carotene from
plasma

Case-control study
conducted in North
Carolina.
Controls (n= 174) were
age-matched to cases (n =
77) [± 5 years].
Race groups:
Blacks, n = 20
Whites, n = 231

Protective effect of lycopene observed in men with
Arg/Arg genotype and high lycopene (OR = 0.21; 95% CI
= 0.06-0.71; P trend < 0.01), but not those with Arg/Gln +
Gln/Gln, and high lycopene (OR = 0.83; 95% CI = 0.332.01; P trend = 0.79).
Much stronger inverse association observed for combined
antioxidant exposure (lycopene + α-tocopherol + βcarotene) and PCa risk among men with Arg/Arg
genotype (OR = 0.11; 95% CI = 0.02-0.65; above vs.
below median; Pinteraction= 0.01).
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Combined antioxidant exposure appeared to increase risk
of PCa in men with Arg/Gln + Gln/Gln (OR = 2.08; 95%
CI = 0.46-9.43; above vs. below median).
Van Gils et al.,
2002

Gene: polymorphisms in XRCC1
gene at codon 194 (Arg/Trp),
codon 280 (Arg/His), and codon
399 (Arg/Gln)
Diet: vitamin A, C & E, β-carotene
and lycopene

Case-control study among
North Carolina residents

None of the polymorphisms had independent associations
with PCa risk.

Controls (n = 183) were
age-matched to cases (n =
77) [± 5 years].

Among men with Arg/Arg genotype, low vitamin E
intake was associated with an increased risk of PCa (OR
= 2.4; 95% CI = 1.0-5.6, p = 0.04).
A much lesser and non-significant increased risk
observed in men with Arg/Gln + Gln/Gln and low
vitamin E intake (OR = 1.2; 95% CI = 0.5-2.8, p = 0.65).
No effect modification by the other antioxidants

Table 2.2 (continued): Summary of findings on gene-diet studies; interactions between antioxidants and oxidative stress/DNA
relation to prostate cancer
Author
Gene & Dietary Agent
Subjects and Design
Results

repair genes in

Studies examining prostate cancer risk
Zhang et al.,
2010

Gene: XRCC1 (Arg399Gln
polymorphism), and
hOGG1 (Ser326Cys polymorphism)

A case-control study conducted
in Arkansas.

Diet: α-carotene, β-carotene, βcryptoxanthin, lycopene,

Cases, n = 193
Controls, n = 197

Arg/Gln + Gln/Gln genotype of the XRCC1 gene
associated with an increased risk of PCa among men
with lower than median levels of lutein/zeaxanthin (OR
= 2.15; 95% CI = 1.17- 4.01, p = 0.015),
β-cryptoxanthin (OR = 2.64; 95% CI = 1.40-5.07, p =
0.003), and lycopene (OR = 2.05; 95% CI = 1.07-3.98, p
= 0.032) compared to those with the Arg/Arg genotype.

Lutein/zeaxanthin and α-tocopherol
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Race groups:
Whites, n = 198
Blacks, n = 192

Men with Ser/Cys + Cys/Cys genotype of the
hOGG1gene and had lower than median levels of βcryptoxanthin, lycopene, α-carotene, and α-tocopherol
had 48–62% reductions in PCa risk when compared
with the Ser/Ser genotype.

2.4

DIETARY ASSESSMENT METHODS, ADVANTAGES AND DISADVANTAGES

Food Frequency Questionnaire
Epidemiological studies support hypotheses of associations between diet and
chronic diseases such as cancer [17, 63-66, 221]. To better understand these associations,
a measure of usual dietary intake is needed. Usual dietary intake is often measured by
different dietary assessment instruments including food records, multiple 24-hour recalls,
and food frequency questionnaires (FFQs) [222]. FFQs are the most suitable dietary
assessment method for measurement of usual intake in large nutritional epidemiological
studies due to issues of cost, time and feasibility [222-225]. FFQs are designed to
measure usual intake of specific foods, food groups and nutrients over an extended period
[222, 226, 227]. The rationale behind the FFQ approach is that long-term dietary intake,
such as usual eating patterns over weeks, months or years are conceptually more relevant
determinants of chronic diseases than intake on one or a few designated days [222]. The
FFQ is commonly used to rank individuals according to their intake of specific foods or
nutrients, and it has widespread applicability in case-control, cross-sectional and cohort
studies of diet and diet-disease associations [228-230].
There are several FFQ instruments in circulation, some of which have been
adapted and modified for different populations and purposes [231]. The most commonly
used FFQs are the Willett FFQ [232], the Block FFQ [233], the Fred Hutchinson Cancer
Research Center FFQ [234], and the National Cancer Institute Diet History Questionnaire
(NCI-DHQ), a cognitive-based FFQ designed to enhance respondents comprehension in
order to facilitate accurate reporting [235]. Despite continuous modification of existing
standard FFQs and development of new FFQs, the overall design and analytic methods
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remain the same. Typically, FFQ instruments contains a listed of predefined food groups
listed as line items. Respondents are asked to report frequency of consumption and
portion sizes over a designated period (e.g., usually the previous year) [222, 235].
Questions on food purchasing habits and preparation methods may also be asked [235].
FFQs require a robust and appropriate nutrient database for translation of reported dietary
intakes into nutrients, and for ranking individuals on specific foods and nutrients [236,
237]. Nutrient intake from a FFQ are generally estimated by summing the product of a
multiplication between the frequency of intake by nutrient density, and by portion size (if
asked) over all foods consumed (i.e., nutrient intake = frequency x portion size x nutrient
density) [222, 235, 238]. FFQs also require validation or calibration against other detailed
and more accurate dietary assessment tools such as 7-day food records or multiple 24hour dietary recalls [222, 238]. Several “validation” studies have found the FFQ approach
to be a reasonably accurate method for estimating food and nutrient intake when
compared to multiple 24-hour recalls or food records as reference instruments [223, 235,
238-244]. However, validation studies using recovery biomarkers as reference
instruments suggest that FFQs may have significant measurement errors [245, 246].

Advantages and disadvantages of food frequency questionnaires
The merits of the FFQ approach to dietary assessment are a subject of ongoing
debate [247-252]. It is important to note that FFQs differ widely, especially in terms of
food list and level of detail, and some FFQs may be better than others with regards to
food and nutrient assessment [235, 250, 253]. However, in general, FFQs are a
convenient and relatively inexpensive approach to dietary assessment [222, 235, 254].
Additionally, FFQ instruments are often designed to be self-administered with low
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respondent burden (require about 45 minutes to complete), and can be administered either
electronically or completed on scanner-readable forms which reduces the time, effort and
cost of data collection [254, 255]. Moreover, the use of standardized responses facilitates
quick data analysis [222]. Long-term exposures such as habitual eating patterns are
conceptually more relevant in studies of chronic disease, which makes FFQ more suitable
for investigating associations between diet and chronic diseases [222, 228, 233, 254].
Also, because FFQs solicit information about past dietary intake, they are able to
circumvent recent dietary changes which may have been motivated by a recent diagnosis
unrelated to the outcome of interest [255]. Statistically, FFQs are considered to be the
only dietary assessment tool that can minimize intra-person, day-to-day variations in
nutrient intake without the need for assessment of actual intake over several days [256,
257]. Furthermore, inclusion of open-ended questions allows reporting of foods that are
not listed on the FFQ [235]. In addition, standard FFQs are easy to modify to include
foods that are commonly consumed by specific ethnic minority groups or populations of
interest [258].
The limitations of FFQ have been discussed extensively, including substantial
measurement errors resulting from incomplete listing of foods consumed by study
participants, and inaccuracies in the estimation of portion size and frequency of intake
[225, 227]. Incompleteness of food listing in FFQ is particularly problematic when the
missing foods are major sources of nutrients in the study population, leading to
considerable inaccuracies in nutrient estimates for the group [225]. Quantitative studies
also suggest that portion size estimation by study participants are often influenced by the
type of food been considered, the role of the food item a meal (e.g., appetizer, main dish,
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or dissert) and personal food preferences, all of which can affect the accuracy of
reporting [259]. Also, portion sizes in FFQ are generally categorized into small, medium
and large, which may have different meaning for different respondents [260].
Additionally, when food is eaten as a mixed dish, it is often difficult to estimate portion
sizes for individual components of the dish [261]. Studies have also shown that
aggregation of food items in FFQs affects recall of food intake. For example, respondents
are more likely to recall intake of beef when it is separated from lamb, pork and ham,
than when they are all grouped together as a line item [253]. Reporting food intake can
also be affected by social desirability bias, which can result in under-reporting of
“unhealthy” foods and over-reporting of “healthy” foods [262]. Finally, given the
retrospective nature of FFQ, reporting of intake generally rely on long-term memory with
questionable accuracy, particularly among older adults. Despite these limitations,
carefully developed FFQs have a conceptual advantage over other dietary assessment
tools such 24-hour recalls and food records by providing estimates of usual intake over an
extended period. Additionally, FFQs are practically and economically more feasible for
large nutritional epidemiological studies, and impose lesser burden on participants
relative to the other assessment tools [248, 250, 263, 264].

Biochemical measures of dietary intake
Nutritional epidemiologists are acutely aware of the numerous methodological
issues and limitations of the traditional dietary assessment methods such as FFQs, food
records, and 24-hour dietary recall. The reality is that, a gold standard method of dietary
assessment is lacking [250]. However, the traditional methods are fraught with
considerable systematic and random measurement errors, which have increasingly
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motivated the use of nutritional biomarkers to complement the traditional methods [222,
265-267]. Nutritional biomarkers can be loosely defined as biochemical indicators of
dietary intake which reflects not only food and nutrient consumption, but also
metabolism and biological effects of dietary intake [268]. The underlying assumption for
the use of nutritional biomarkers is that, they are responsive to dietary intake, sensitive to
intake levels, and independent of some kinds of biases and measurement errors [245,
269]. An “ideal” nutritional biomarker will accurately reflect actual dietary intake levels,
and be applicable to different populations [270]. However, existing nutritional
biomarkers are not “ideal”, but are functional and have far-flung relevance in nutritional
epidemiology including their use as reference measurements for validation of the
traditional dietary assessment methods [268-271].
Nutritional biomarkers are generally categorized into four groups; recovery,
predictive, concentration and replacement biomarkers [269, 270, 272]. Recovery
biomarkers are thought to provide absolute estimates of intake based on the concept that
recovery of nutrient analytes from biologic samples are directly related to intake due to a
fixed metabolic balance between intake and output over a specific period of time [273].
In other words, recovery biomarkers are not subject to individual differences in
metabolism over a specified time window, hence considered as the gold standard of
biomarkers [222]. However, very few of these biomarkers actually exist, including
doubly labeled water (use to measure total energy expenditure and metabolic rate), and
urine nitrogen/potassium (for measuring total protein and total potassium intake,
respectively) [269, 270, 272]. Predictive biomarkers are similar to recovery biomarkers in
terms of responsiveness to intake, ability to reflect intake levels (dose-response relations),
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and time sensitivity. However, predictive biomarkers generally have lower recovery of
analytes from biological samples [270]. Predictive biomarkers have recently been used as
reference tool for correlation of sugars intake and recovery of sucrose and fructose from
24-hour urinary samples [271]. Concentration biomarkers generally do not reflect
absolute intake, but often correlate with the corresponding food or nutrient intake levels
[271, 274]. Examples of concentration biomarkers include serological markers (i.e.,
plasma and serum) and adipose tissue levels of nutrients, as well as urinary electrolytes
[269, 275]. Replacement biomarkers are also similar to concentration biomarkers. The
name “replacement” is generally used when food composition data are either unavailable
or unsatisfactory for specific nutrients such as aflatoxins [276], and some phytochemicals
[277]. Several studies have examined the efficacy of the various types of nutritional
biomarkers; however, this review will focus on concentration biomarkers in relation to
antioxidants recovery from blood, adipose tissue, and toenail clippings.

Advantages and disadvantages of biomarkers of antioxidant exposure
Epidemiological studies involving biomarkers of antioxidant intake often rely on
blood samples (i.e., plasma or serum), adipose tissue, and toenail clippings to measure
exposure level [278, 279]. Plasma/serum antioxidant levels are thought to reflect shortterm intake, while adipose tissue and toenail antioxidant concentrations reflect long-term
intake [280]. The use of these biomarkers in epidemiological research has several
advantages. First, nutritional biomarkers are known to improve the validity of exposure
estimates by eliminating information bias, particularly differential recall of intake in casecontrol studies [279]. Secondly, since the bioavailability of antioxidants is influenced by
individual differences in metabolism and absorption, nutritional biomarkers provide an
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assessment of the “biologically effective dose” of the nutrient of interest [279, 280].
Additionally, nutritional biomarkers are particularly advantageous for evaluating doseresponse associations as they are known to be responsive to intake, correlate with the
corresponding food or nutrient intake levels, and measure the bioactive dose of the
nutrient of interest [245, 271, 281]. Also, nutritional biomarkers are frequently used in
dietary intervention studies to assess compliance and individual response to the
intervention being studied [282]. Nonetheless, nutritional biomarkers are imperfect
measures of dietary intake.
Plasma/serum and adipose tissue antioxidant levels are often measured with high
performance liquid chromatography (HPLC) [283, 284]. A major concern with the use of
plasma/serum markers of antioxidant intake is that, they reflect recent rather than longterm dietary intake. Hence, plasma/serum biomarkers are not suitable for evaluating
etiological or temporal relationships between antioxidant intake and slow-progressing
diseases [222, 285]. Also, plasma/serum antioxidant levels may be altered by the disease
being studied, in which case some biomarkers would be inappropriate for use in casecontrol studies [222]. Several lines of evidence also suggest that plasma/serum
antioxidant levels are influenced by a variety of physiological and lifestyle factors
independent of dietary intake such smoking status, obesity, and alcohol use [286-289].
Studies also suggest that adipose tissue sampling with the needle biopsy can lower
participation rates in research studies [290]. Moreover, saponification of the adipose
tissue specimen is generally required before HPLC can be performed, which often
increases the cost of laboratory analysis [278]. Other limitations associated with
biomarkers of specific nutrients and nutrient groups are discussed below.
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Carotenoids such as β-carotene, α−carotene, β-cryptoxanthin, lycopene, and
lutein + zeaxanthine have been studied extensively in relation to PCa [67, 106, 175, 183].
Carotenoids levels in blood are influenced cooking methods (reviewed in [291]). For
example, mild heating (such as steaming) is known to promote the extraction of βcarotene from vegetables and increases its bioavailability in serological markers [292].
Similarly, processing of raw tomatoes into tomato paste or tomato sauce with mild heat
treatment has been shown to increase the bioavailability of lycopene in plasma [293,
294]. However, stir frying of green leafy vegetables has been found to reduce lutein
content by as much as 89%, while cooking these vegetables for 8 minutes has also been
found to reduce lutein content by up to 428% [295]. Carotenoids are known to
accumulate in adipose tissues because of their fat-soluble properties; however, their
turnover rates remain unknown [278, 296]. Hence, the actual or average exposure time
remains unclear. Studies have also shown that the distribution of carotenoids in adipose
tissue differ by body fat sites (e.g., abdomen, buttock, and thigh) due to differences in
carotenoid uptake and retention between the fat sites [280, 296]. Some researchers have
suggested that the differential distribution of carotenoids in adipose tissue sites accounts
for the poor reproducibility of carotenoid measurements from adipose tissue across
studies [280, 297, 298].
Vitamin E is primarily transported in the human blood by plasma lipoproteins,
and performs a biologic function of protecting lipids form oxidative degradation [299].
Due to its close association with lipids, plasma/serum lipids (especially total cholesterol)
must be measured and controlled for in multivariate models in studies involving plasma
vitamin E levels [278]. Relative to dietary questionnaires, plasma/serum levels of vitamin
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E may represent a more relevant biologic measure of systemic exposure; however, it
correlates poorly with estimates from dietary intake [278]. It has been suggested that
observed correlations between intake estimates and plasma levels of vitamin E are largely
due to vitamin E intake in supplement form, rather than from food intake [300, 301]. For
example, Ford and Sowell examined associations between plasma α-tocopherol levels
and dietary intake of α-tocopherol using 24-hour dietary recall in NHANES III and
observed that these two measures do not correlate [300]. Another study of vitamin E
supplementation showed that unlike dietary intake, the human blood responds well to
vitamin E intake in supplement form [302]. However, it is reasonable to speculate that the
poor correlation between dietary intake and plasma concentrations of vitamin E is likely
due to food handling and preparation methods. Studies have also suggested that adipose
tissue vitamin E concentrations have a low turnover rate [302]; however, findings from
studies attempting to verify this hypothesis remain inconclusive [297, 303].
Unlike carotenoids and vitamin E which are fat-soluble, vitamin C is a watersoluble micronutrient, thus easily destroyed by food handling practices such as cutting,
shredding, chopping or peeling of fruits and vegetables as well as cooking with excessive
water or excessive heat [304, 305]. Plasma/serum ascorbate (i.e., ascorbic acid) is often
used to measure vitamin C intake by HPLC methods. However, the use of plasma
ascorbate is problematic for a number of reasons. First, to avoid degradation of ascorbate
in serological markers, blood samples must be preserved in an acid stabilizer (e.g.,
metaphosphoric acid) immediately after collection of the samples. This makes many
archived plasma/serum samples that were not treated this way unsuitable for analysis of
ascorbate concentrations [278]. Secondly, the human body is unable to produce vitamin C
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naturally, and since vitamin C is often eliminated from the body through urine,
continuous dietary supply of vitamin C is required to maintain adequate levels in the
body [306]. Thus, ascorbic acid levels in the blood fluctuate in response to dietary intake
and renal clearance, which makes the use of fasting blood sample essential [278].
However, fasting blood samples usually estimate ascorbate at levels much lower than
actual dietary intake levels [278]. The fluctuation of ascorbic acid in serological markers
also implies that plasma/serum ascorbate is not a reliable measure of long-term intake
[278, 279, 307]. Additionally, because of the water-soluble properties of vitamin C, they
are not stored in adipose tissue [278, 307]. For these reasons, most researchers prefer the
used dietary questionnaires such as the FFQ to assessment of vitamin C.
Assessment of selenium intake with dietary questionnaires is also fraught with
problems. Selenium content in food vary considerably according to the levels of selenium
in the soil, and hence of crops and animal forage grown in the soil [308]. Selenium
content in the same foods from different geographic locations can vary by many folds, in
some cases by over 10-fold [309]. Thus, many researchers prefer biomarkers of selenium
intake such as selenium levels in plasma/serum, urine or toenail clippings [310].
However, these biologic markers are influenced by factors other than selenium intake,
such as general state of health, metabolism, past and present disease history, and smoking
status [286, 311]. The use of toenail clippings is relatively more attractive than the other
markers because it is easy to sample and store, and the sampling of toenail clippings
usually does not cause discomfort to subjects [147, 312]. Moreover, toenail clippings are
thought to reflect long-term intake. However, toenail levels of selenium are also
influenced by factors such as the size and thickness of the nail plate, rate of nail growth
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and metabolism of selenium in nail beds [313, 314] In addition, the average time of
selenium exposure reflected in toenail clippings remains unknown [314].
Despite these limitations, nutritional biomarkers are very appealing to most
researchers because of their ability to estimate internal dose of the nutrient of interest.
However, some researchers have suggested that it may be best to measure biomarkers of
dietary intake in target tissues of the disease of interest, rather than the use of surrogate
markers of systemic exposure [310]. All issues considered, use of multiple measures of
dietary intake such as plasma, adipose tissue and FFQ would provide complementary
information and perhaps offer a more robust dietary assessment than any single measure
of intake.
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CHAPTER 3
STUDY METHODS
3.1

OBJECTIVES AND HYPOTHESES

OBJECTIVE 1: To examine whether changes in dietary antioxidant intake (baseline to 3months) as measured by plasma concentrations of carotenoids and tocopherols are
associated with PCa progression (assessed by changes in serum PSA level as an
intermediate prognostic marker of disease progression) in African-American and
European-American men with biochemically defined PCa recurrence after
definitive therapy.
Hypotheses:
i.Higher levels of plasma carotenoids and tocopherols at baseline will be
associated with lower serum PSA levels at baseline.
ii. Higher post-intervention plasma carotenoids and tocopherol levels (at 3
months) will be associated with lower post-intervention PSA levels (at 3
months, and at 6 months), after adjusting for baseline PSA level.
iii. Change in plasma carotenoids and tocopherol levels (baseline to 3 months)
will inversely correlate with serum PSA levels at 3 months and at 6 months.

OBJECTIVE 2: To examine associations between antioxidant levels in adipose tissue,
plasma and diet, and PCa aggressiveness among African American and EuropeanAmerican men.
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Hypothesis: Lower levels of antioxidants in adipose tissue, plasma and diet are associated
with high aggressive PCa, and these associations do not vary by race.

OBJECTIVE 3: To examine whether SNPs in DNA repair and oxidative stress genes
modulate associations between antioxidants in adipose tissue, plasma and diet,
and PCa aggressiveness among African-American and European-American men.
Hypothesis: SNPs in DNA repair and oxidative stress genes modify associations between
antioxidants in adipose tissue, plasma and diet, and PCa aggressiveness, and the
degree of the effect modification vary by race.

3.2

STUDY DESIGN AND METHODS

OBJECTIVE 1
Design & Data Source
The first objective utilizes data from a previous study by Hébert et al. [13], which
is a 6-month intervention trial involving diet, exercise and stress reduction conducted in
South Carolina (the EASE Study). In brief, sixty men with histologically confirmed PCa
and serum PSA levels after primary therapy with radical prostatectomy or radiation were
recruited along with a partner of choice. Four participants were enrolled for the run-in
period of the intervention to ascertain feasibility and potential issues with compliance. Of
the remaining 54 participants, 29 (together with their partners) were randomized to
intervention (dietary modification, physical activity and meditation practice) and 25 were
randomized to usual care with an opportunity to receive the intervention at the end of the
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study. Full details of the randomization process and progression of the participants have
been provided in Figure-1.
Setting: The study participants were recruited from major urology practices
located in the Midlands Region of South Carolina, covering seven counties [Richland
county (67%),Lexington county (9%), Newberry (6%), Kershaw (6%), Orangeburg (6%),
Sumter (4%) and Fairfield (2%) counties]. The intervention was administered under the
supervision of the South Carolina Cancer Prevention and Control Program. Clinical data
on the study participants were collected in the facilities of the Cancer Prevention and
Control Program in Columbia.
Study Population: Eligible participants are men with histologically-confirmed,
adenocarcinoma of the prostate who: (1) have been treated by radical prostatectomy or
radiation therapy as primary treatment for PCa; (2) have had 3 successive rise in serum
PSA level of at least 1.5 ng/ml from post-treatment nadir (usually at or close to zero)
measured at 2- to 3-month intervals; (3) were free of other malignancy in the previous 5
years (except non-malignant skin cancer and primary PCa for which they were treated by
radical prostatectomy or radiation therapy); (4) had not been taking thyroid medication,
steroids, antibiotics or diuretics; (5) spoke English as first language; (6) were able to read
at sixth grade level; (7) were of sound mind, memory and understanding; (8) were
willing to be randomized to intervention or usual care. Prospective participants were
excluded from the study if they: (1) had received post-operative hormonal therapy for
PCa; (2) had a diagnosis or symptoms of cardiovascular disease, pulmonary disease,
Crohn's disease, active ulcerative colitis or metabolic disease; (3) had experienced
unexpected weight loss of 5 pounds or more within the previous 3 months; (4) plan to use
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hormone supplements, fish oil, or other ω-3 fatty acids based supplements; or (5) had a
diagnosis of post-traumatic stress disorder (PTSD).
Intervention: Participants were assigned to intervention or control group using
block randomization by age (± 5 years) and race (African American/European
American). The study spanned 6 months, which included a 3-month period of active
intervention followed by monthly booster session for the following 3 months. The
intervention consisted of dietary modifications, physical activity, and mindfulness-based
stress reduction training. The 3-month active phase of the intervention involved
individual diet and physical activity counseling and goal setting sessions, as well as
twelve weekly group meetings that included cooking classes and shared model meals. In
addition, participants were given weekly assignments on how to shop for and cook studycompliant meals, attain physical activity goals, and practice meditation for stress
reduction.
The diet aspect of the intervention emphasized increased intake of plant-based
foods such as whole grains, fruits, vegetables, and legumes (particularly soybeans and
soybean products) along with decreased intake of meat and dairy products. The physical
activity aspect involved working with participants to identify activities that they enjoyed
and reinforce those activities to promote physical fitness and overall well-being. The goal
of the exercise routine was to ensure that each participant attain the Centers for Disease
Control and American College of Sports Medicine (CDC/ACSM) recommendations of at
least 30 minutes of moderate intensity physical activity for 5 days or more per week
[315]. Because comprehensive dietary change can be difficult to maintain, participants
were taught to meditate in a way that inculcates mindfulness about decisions concerning
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food choices in order to promote their sense of control over the change in diet and
culinary habits [316]. Partner support was integrated to provide an encouraging
environment for the process of change. Following the 3-month active phase, monthly
booster sessions were held in a supportive group environment for another 3 months.
These included frequent telephone calls to each participant and his partner for wellness
checks and encouragement to sustain the intervention.
Control condition: Participants in the control group underwent the same general
assessment as those in the intervention group. There were no attempts made to restrict
their access to psychosocial support or educational resources available to PCa patients in
the community. These participants and partners were given the opportunity to take the
intervention at the end of the 6-month study period at no cost to them.
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Assessed for eligibility
(n =56)

Excluded (n = 2)
● Ineligible (n = 1)
● Dropped ( n= 1)

Randomized
(n = 54)

Control
(n = 25)

Intervention
(n = 29)

Dropout (n = 4)
● Medical Complication (n = 1)
● Time constraint ( n= 3)

Dropout (n = 3)
● Medical Complication (n = 2)
● Time constraint ( n= 1)

Analyzed
(n = 26)

Analyzed
(n = 21)

FIGURE 3.1 Consort diagram showing participants recruitment, screening, randomization,
and retention [13].
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Exposure and outcome variables: Plasma carotenoid and tocopherol levels at
baseline and at 3 months were the main exposure of interest. As part of the study
requirements, participants provided peripheral blood samples at baseline, 3 months and 6
months for analysis of biomarkers of food and nutrient intake as well as for analysis of
serum PSA levels. The blood samples were collected by a trained phlebotomist after
obtaining consent from the study participants. PSA was measured in serum at baseline, at
3 months and at 6 months. Carotenoids and tocopherols were measured in plasma using
high performance liquid chromatography (HPLC) by Craft Technologies [317]. Because
of limited availability of samples, data on carotenoids and tocopherols were only
measured at baseline and at 3 months. The following carotenoids and tocopherols were
measured: α- and γ-tocopherol, α-carotene, cis- and trans-β-carotene, lutein, zeaxanthin,
cis-lutein/zeaxanthin, α- and β-cryptoxanthin, cis- and all-trans-lycopene.
Other study measures: Data on clinical and pathologic attributes of PCa were
abstracted from participants’ medical records obtained from referring urologists. At
baseline, participants responded to questionnaires that solicited information on
demographics and health-related behaviors, including age, race, education, marital status,
employment, and smoking status. Data on diet, physical activity, and anthropometry were
obtained at each of the three study checkpoints: baseline, 3 months, and 6 months. Diet
assessments used 24-hour dietary recalls on three randomly selected days that included
two weekdays and one weekend day, as this method better captures daily variation in
intake [318, 319]. Physical activity was assessed using a questionnaire designed for older
adults that had been tested for reliability [320]. Physical activity was expressed as
metabolic equivalent (MET) value based on description of the activity using the
65

Compendium of Physical Activities [321], with one MET being equivalent to resting
metabolic rate. Total METs of physical activity were estimated for each participant’s sum
of METs from light, moderate, and vigorous physical activity per week. The
anthropometric measurements obtained were standing height (cm), weight (kg), waist and
hip circumference (cm) used to calculate waist-to-hip ratio, and bioelectric impedance
measures of percent body fat and lean body mass.

OBJECTIVE 2 & 3
Data Source & Design
Data from the North Carolina–Louisiana Prostate Cancer Project (PCaP) was used
to evaluate objectives 2 and 3. PCaP is a large, racially diverse, population-based,
multidisciplinary, cross-sectional, case-only, incident PCa study, designed to investigate
racial/ethnic differences in PCa outcomes among African Americans and European
Americans. The study population and methods have been published [4]. A total of 2,258
men (African-American, n = 1,130; European-American; n =1,128) with histologically
confirmed incident PCa were recruited through rapid case ascertainment in North
Carolina and Louisiana. In North Carolina, 1,031 men (African Americans, n = 505;
European Americans, n = 526) were recruited between July 2004 and October 2007. In
Louisiana, the study participants were recruited in two phases due to the devastation
caused by Hurricane Katrina. Pre-Hurricane Katrina cases were recruited between May
2004 and June 2005 (n = 213; African Americans, n = 119; European Americans, n = 94),
and Post-Hurricane Katrina cases were recruited between January 2006 and July 2009 (n
= 1,014; African Americans, n = 506; European Americans n = 508). Although PCaP is a
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case-only study, a case-control analysis was used to compare men with high aggressive
PCa (higher Gleason score, higher clinical stage, and higher PSA level) to those with
low/intermediate aggressive PCa.
Study population: Residents of the study catchment areas in North Carolina and
Louisiana were eligible to participate in PCaP if they: (1) had a first diagnosis of
histologically confirmed adenocarcinoma of the prostate; (2) were between the ages 4079 years at the time of diagnosis; (3) self-reported race/ethnicity as white/Caucasian
American or as black/African American; (4) Spoke English as a first language; and (5)
did not reside in an institution (e.g., nursing home). Prospective participants were
excluded if they: (1) were cognitively impaired or in a severely debilitated physical state;
(2) were under the influence of alcohol, severely medicated, or had apparent psychosis as
evaluated by recruiting staff.
Exposures: Three measures of antioxidant intake were assessed: (1) dietary
assessment of average daily nutrient intake using a modified National Cancer Institute
Diet History-Food Frequency Questionnaire (NCI-DHQ) [322]; (2) Supplemental
antioxidants intake assessed with a validated questions [323]; and (3) abdominal adipose
tissue antioxidant concentrations. The decision to use more than one measure of
antioxidant intake was based on the inherent limitations of each of these measures. First,
food frequency questionnaire (FFQ) is an imperfect dietary assessment tool because: (a)
reporting of food intake relies on respondent’s memory which may not accurately reflect
actual intake; (b) there is the possibility of over-reporting of “healthy” foods and underreporting of “unhealthy” foods which may contribute to random error; (c) FFQ’s are
generally less sensitive to absolute intake of specific nutrients due to the use of standard
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portion sizes; (d) categorization of foods in the FFQ limits reporting of details about
specific foods which may be relevant to nutrient estimation; (e) exclusion of foods that
are major contributors of certain nutrients may affect the validity of the nutrient estimates
[247, 261, 324, 325]. Reporting of supplement intake is also prone to recall bias [323].
Second, although adipose tissue concentrations of antioxidants are useful biomarker of
internal dose, individual variations in the absorption and metabolism of antioxidants can
affect bioavailability, bioconversion, and bioefficiency of these micronutrients [266, 326,
327]. Thus, concentration biomarkers do not reflect total antioxidant exposure. Therefore,
examining three separate measures of antioxidant exposure would provide more
comprehensive and perhaps more reliable data about the association between antioxidant
intake and PCa severity than would any one of these measures alone.
The NCI-DHQ was modified to include Southern foods, and had questions
pertaining to frequency of intake and portion sizes for 124 different food items as well as
questions about methods of food preparation. The questionnaire asked study participants
to recall food intake over the year prior to PCa diagnosis. Responses to the questions
were linked to an updated NCI nutrient database through which nutrient intake were
estimated using NCI Diet*Calc software [4]. Adipose tissue antioxidant concentrations
were measured from samples collected by PCaP study nurses during in-home visits after
obtaining written consent from the participants. Adipose tissue samples were collected
from the abdominal area. PCaP research nurses who were specifically trained for adipose
tissue sampling, followed a standardized procedure involving the insertion of a 15-gauge
needle into the subcutaneous fat and applying negative pressure by a 15 ml vacutainer
tube after prepping the overlying skin. The aspirated tissue was trapped in the needle and
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luer lock adapter, which was placed in a separate cryovial and transported on ice
immediately after collection to a designated storage facility where aliquots were prepared
and stored at -80oC until assayed. Individual carotenoids were measured by high
performance liquid chromatography at the Nutrition Analyses Laboratory of Craft
Technologies, Incorporated (Wilson, NC) using methods outlined by Craft et al. [328,
329]. The adipose tissue contents of α-, γ-, and δ-tocopherol, α-carotene, cis- and transβ-carotene, α-cryptoxanthin, β-cryptoxanthin, lutein, zeaxanthin, and cis- and translycopene were quantified at a minimum detection limit of 0.07 µg/g for tocopherols and
0.003 µg/g for carotenoids.
Outcome classification: The outcome of interest for objectives 2 and 3 was PCa
aggressiveness; defined by a combination of PSA level at diagnosis, clinical stage of PCa
at diagnosis and Gleason sum [4]. Information on these clinical attributes of PCa were
abstracted from participant’s medical records by trained personnel. To assess consistency
of abstractors and to ensure data quality, about 10% of the medical records were selected
at random and abstracted by a second staff member [330]. PCa aggressiveness was
categorized into three groups: high aggressive (Gleason sum ≥8 or PSA >20 ng/mL, or
Gleason sum ≥ 7 and clinical stage T3–T4); low aggressive (i.e., Gleason sum < 7 and
stage T1-T2 and PSA<10 ng/ml); and intermediate aggressive (all others).
SNP Selection: Candidate SNPs selected and genotyped by the PCaP consortiums
were used for executing objective 3. The SNPs were selected using the SNPinfo web
server (http://snpinfo.niehs.nih.gov) previously described in detail elsewhere [331]. In
brief, SNPinfo provides a platform that allows investigators to specify genes or linkage
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regions of interest and select SNPs based on results from genome-wide association
studies (GWAS), population-specific linkage disequilibrium (LD) structure, and detailed
functional predictions including coding, transcription factor binding, micro-ribonucleic
acid (miRNA) binding, and splicing [331]. The PCaP consortium used six separate SNP
selection procedures [131]. The first selection process was based on primary and
secondary data from GWAS and validation studies, which identified 286 SNPs that were
associated with PCa in published literature at the time of the SNP selection. The second
process involved a thorough review of literature on candidate genes associated with PCa
etiology or aggressiveness. Eight hundred and forty eight candidate genes were identified
through this process. Three hundred and six of these genes were retained for SNP
selection because: (a) they were listed in the CGEMS GWAS project as having p-values
< 0.05 (associated with PCa susceptibility or aggressiveness); or (b) had inadequate SNP
coverage in the 550K GWAS panel to sufficiently assess the gene. The SNPinfo’s
candidate gene SNP selection pipeline (GenePipe) was subsequently used to select 583
SNPs determined to be functionally significant to PCa based on p-values and multiple
population LD tag SNPs for both European Americans and African Americans from the
306 candidate genes. The third process utilized prioritized selection of SNPs in the
CGEMS GWAS 550K panel in conjunction with SNPinfo’s GWAS functional SNP
selection pipeline (GenomePipe). SNPs were selected from the CGEMS GWAS 550K
panel if they had small p-value (associated with PCa susceptibility or aggressiveness) and
were predicted to have functional effects, or had small p-value and were in high LD with
SNPs predicted to have functional effects. Six thousand and thirty four SNPs were
identified from the CGEMS GWAS 550K panel as having small p-values (p ≤ 0.01).
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SNPinfo’s GenomePipe was used to identify 41,755 SNPs that were in high LD (r2 ≥ 0.8)
with at least one of the SNPs from the CGEMS GWAS 550K panel. Of these, 379
common SNPs (minor allele frequency (MAF ≥ 0.05) predicted to have functional effects
by at least one of the biological function prediction methods were selected.
The fourth selection procedure was based on linkage regions. At the time of the
SNP selection, 43 non-overlapping linkage regions were reported to be associated with
PCa. The CGEMS GWAS 550K panel p-values (based on PCa susceptibility or
aggressiveness) were used together with SNPinfo's GWAS SNP selection in linkage loci
pipeline (LinkPipe) to select a maximum of seven SNPs from each of the 43 nonoverlapping linkage regions. The fifth involved overlap between small p-values for SNPs
that were reported in multiple PCa GWAS. Only the Framingham GWAS and the
CGEMS GWAS project had publicly available data on SNPs associated with PCa at the
time of the SNP selection. Thus, fifty-eight SNPs with p-values <0.01 in the CGEMS
project and the Framingham GWAS were included.
Finally, fifty ancestry informative markers (AIM) were selected using allele
frequency data in HapMap phase I + II (http://hapmap.ncbi.nlm.nih.gov) to control for
stratification in three populations: Utah residents with ancestry from Northern and
Western Europe (CEU) from the Centre d’Etude du Polymorphisme Humain (CEPH)
collection representing European ancestry; Yuroba individuals in Ibadan Nigeria (YRI)
representing African ancestry; and individuals from Han, China (CHB) and Tokyo, Japan
(JTP) collectively representing Asian ancestry (HapMap CHB plus JTP). Twenty-five of
these SNPs were monoallelic [variant allele frequency (VAF = 0)] in CEU, rare in Asians
(VAF < 0.01) but common YRI (VAF > 0.25). The other 25 SNPs were monoallelic in
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(YRI) (VAF = 0), rare in Asians (VAF <0.5) and but very common in CEU (VAF > 0.5).
The SNP selection process has been described in sufficient detail elsewhere [131].
Additional information on the ancestry informative markers for the PCaP study
participants is presented in Table 3.1.
Genotyping: Germline DNA was extracted from blood samples (n = 1,630) or
buccal cells (n = 118) by the University of North Carolina (UNC, Chapel Hill)
Biospecimen Processing Facility or from peripheral blood mononuclear cells
immortalized by the UNC Tissue Culture Facility (n = 216). Genotyping was done at the
National Institutes of Health (NIH) Center for Inherited Disease Research (CIDR) using a
custom designed Illumina GoldenGate array. There was an excellent genotyping call rate
(99.93%) and inter-assay agreement with blinded duplicates (99.99%). Further details of
the genotyping process and quality control measures have been published [332].

SNPs in DNA repair and oxidative stress genes
The PCaP consortium maintains a repository containing over 1,536 GWAS and
candidate SNPs among European Americans and African Americans. Data on SNPs in
DNA repair pathways (i.e., base excision repair, nucleotide excision repair, and doublestranded DNA break repair) and oxidative stress-related genes, which were considered
for analysis. A complete list of the SNPs that were evaluated is presented in Table 3.2.
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Table 3.1 Ancestry informative markers proportions by race and geographic region in the North
Carolina-Louisiana Prostate Cancer Project (PCaP) [333].
Self-Reported Race

African Americans
n = 1043

European Americans
n = 1063
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Non-ethnic African
Americans 1
n = 930
Non-ethnic European
Americans 1
n = 824

Study site

Mean YRI
(%)

Mean
CEU
(%)

Mean CHB plus JTP
(%)

Louisiana
n = 594
North Carolina
n = 449
Louisiana
n = 582
North Carolina
n = 481
Louisiana
n = 485
North Carolina
n = 445
Louisiana
n = 354
North Carolina
n = 470

86.9

11.9

1.2

p-value 2

0.03
89.5
1.8

9.3
96.9

1.2
1.3

0.8
89.2

98.4
9.5

0.8
1.3

0.001

0.78
89.4
1.5

9.4
97.3

1.2
1.2

0.8

98.6

0.6

0.002

Abbreviations: YRI- Yoruba individuals in Nigerians (represents African ancestry), CEU- Utah residents with
ancestry from Northern and Western Europe (represents European Americans), CHB plus JTP - individuals from
Han, China and Tokyo, Japan (representing Asian ancestry).
1

2

includes ONLY individuals reporting “no” ethnicity membership.

One-way multivariate analysis of variance (MANOVA) models comparing mean CEU and YRI ancestry estimates
between research subjects in North Carolina and Louisiana.

3.3

SAMPLE SIZE CALCULATION

OBJECTIVE 1
The data for Objective 1 (EASE study) has complete information on plasma
carotenoid and tocopherol levels for 39 participants at baseline and 35 participants at 3
months. No data on carotenoids or tocopherols are available for the 6-month time point;
thus, the 3–month data on tocopherols and carotenoids was analyzed in relation the 6month PSA levels. Calculation of statistical power for this Objective assumed unmatched
data. The outcomes for computing statistical power were mean PSA levels at baseline,
and at 3 months and 6 months comparing participants with high versus low plasma
carotenoid and tocopherol level. The null hypothesis was that mean PSA values are equal
in both groups (H0: µ1 = µ2). Based on findings from a previous study [11], a two-sided
test at level α = 0.05 and sample size of 39 and 35, a power of 86% and 81%,
respectively, were achieved to observe a difference as large as that observed in the
previous study (mean change PSA level of 0.09). The power calculation was performed
using the PASS software version 12.

OBJECTIVE 2
Complete data on dietary antioxidants intake and PCa aggressiveness were
available for 2102 PCaP study participants (African American, n = 1,023; European
Americans, n = 1,079). Analysis were performed separately for African Americans (high
aggressive PCa, n = 206; low/intermediate aggressive PCa, n = 817) and European
Americans (high aggressive PCa, n = 164; low/intermediate aggressive PCa, n = 915).
Previous studies have reported as much as 63–80% lower overall risk of PCa or lower
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risk high aggressive PCa among men with higher antioxidant intake [191, 334]. Thus,
assuming a 63% difference in odds of high aggressive PCa among men with low versus
high intake of antioxidants, based on a two-sided test at significance level α = 0.05 and
sample sizes of 1,023 and 1,079, a statistical power of 87% and 81% for African
Americans and European Americans respectively.

OBJECTIVE 3
Data on SNP genotypes and PCa aggressiveness also were available for 1,964
PCaP participants (African American, n = 948; European Americans, n = 1,016). Similar
to the analysis of main effect of the antioxidants, the gene-dietary analysis were
performed separately for African Americans (high aggressive PCa, n = 188;
low/intermediate aggressive PCa, n = 760) and European Americans (high aggressive
PCa, n = 153; low/intermediate aggressive PCa, n = 863). Calculation of statistical power
for gene-diet interaction was informed by findings from two recent studies. Li et al. [130]
observed a statistically significant 82% lower risk of aggressive PCa in men with Ala/Ala
genotype of the SOD2 gene polymorphism (rs4880) with high selenium intake. Goodman
et al. [129] also observed a statistically significant 89% lower risk of PCa in men with
Arg/Arg genotype of the XRCC1 gene and high antioxidant intake (lycopene + αtocopherol + β-carotene). Therefore assuming 89% difference in odds of high aggressive
PCa among men with low versus high intake of antioxidants by gene (dichotomous:
homozygous wild-type allele vs. homozygous + heterozygous variants), based on a twosided test at significance level α = 0.05 and sample sizes of 948 and 1,016, 42% and 43%
power was achieved for African Americans and European Americans respectively. The
analyses based on these data were underpowered and may have concealed some modest
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association. Thus, replication in larger studies is encouraged. The power calculations for
specific objectives 2 and 3 were performed using the NCI power and sample size
calculation software version 3.0.

3.4

STATISTICAL ANALYSES

OBJECTIVE 1
Differences in patient characteristics were compared between the intervention and
control groups using t-test for continuous variables and Fisher’s exact test for categorical
variables. Linear regression models were used to estimate least squares means and P
values for test of difference between group means, modeling PSA values as continuous
variable. Natural log transformation was performed on the positively skewed PSA data in
order to achieve normality; results were back transformed for presentation. Plasma
carotenoids and tocopherols were categorized into binary groups (< vs. ≥ median)
because of nonlinear distribution pattern assessed by the generalized additive model
procedure in SAS (PROC GAM). A total antioxidant score also was computed as a
measure of overall antioxidant status following the method described by Li et al. [335]. In
estimating the antioxidant score, the carotenoid and tocopherol variables (i.e., α- and γtocopherol, α-carotene, cis- and trans-β-carotene, α- and β-cryptoxanthin, lutein,
zeaxanthin, and cis- and trans-lycopene) were categorized into quartiles and scores were
assigned to each quartile in multiples of 3 (i.e., 3 to 12, from low to high). The scores
were summed for each participant across all carotenoids and tocopherols, and then
categorized into median groups (< vs. ≥ median).
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Analyses were performed in minimally adjusted (adjusting for age, race and
randomized group) and multivariable adjusted linear regression models. Covariates
selected for inclusion in the multivariable adjusted models were age (continuous); race
(African American, European American); education (high school graduate or less, high
school and some college, college graduate); marital status (Married or with partner,
Widowed, divorced, or single); employment (yes, full time; yes, part time; no); smoking
status (never, former, current); Gleason score (<5,5–6, ≥7); BMI (continuous); physical
activity (metabolic equivalent/week); energy intake (continuous); and randomized
condition (treatment, control). These variables were selected based on evaluation of
confounding effect (>10% change in effect estimates) in conjunction with the backward
elimination method. Additional variables considered but not included in the final analyses
were: type of PCa treatment received; body fat mass; fruit, vegetables, fiber and dairy
intake; and total dietary fat and omega-3 fatty acids intake., fiber and dairy intake; and
total dietary fat and ω-3 fatty acids intake.
Analysis for hypothesis-1 was based on baseline data, which compared mean PSA
values between participants with high versus low carotenoid or tocopherol using P values
as a for differences between group means. For hypothesis 2, mean PSA values levels at 3
months and at 6 months (modeled separately) were compared between participants with
high versus low carotenoid or tocopherol at 3 months, adjusting for baseline PSA values.
Hypothesis 3, examined percent change in carotenoid and tocopherol levels (from
baseline to 3 months) in relation to PSA levels at 3 months and at 6 months, adjusting for
baseline PSA values. The sign for the percent change values was reserved to ensure that a
positive value represented an increase in plasma carotenoid and tocopherol levels. The
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percent change variables were also categorized into binary (increase vs. decrease) as well
as tertile [decrease, minimal increase (1–20%), or substantial increase (>20 %)] groups
for evaluation of whether mean PSA level vary with substantial increase in plasma levels.

Statistical models for Objective 1:
Models-1: Y1 = β0 + β1 (antioxidanti) + ……....................................+ βk (Xk) + ε
Models-2: Y2 = β0 + β1 (antioxidantii) + β2 (baseline PSA level) ......+ βk (Xk) + ε
Model-3: Y2 = β0 + β1(antioxidant∆) + β2 (baseline PSA level) ......+ βk (Xk) + ε

𝜀𝜀

𝑖𝑖𝑖𝑖𝑖𝑖
~

N (0, σ2 )

Where Y1 = serum PSA level at baseline
Y2 = serum PSA level at 3 months and 6 months modeled separately
β0 = intercept, βj, j = 1…….....k, = slope
antioxidanti = plasma antioxidants at baseline (i.e., α- and γ-tocopherol, αcarotene, cis- and trans-β-carotene, lutein, zeaxanthin, cislutein/zeaxanthin, α- and β-cryptoxanthin, cis- and all-translycopene and antioxidant score).
antioxidantii = individual plasma antioxidants at 3 months, and antioxidant score
at 3 months
antioxidant∆ = percent change in antioxidants from baseline to month 3
Xj, j = 1...........k, = age, race, education, marital status, employment, smoking
status, Gleason score, BMI, physical activity, energy intake and randomized
group).

OBJECTIVE 2 & 3
All analyses were conducted separately for African Americans and African
European Americans because of significant interaction between race and lycopene intake.
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Distributions of research subjects’ characteristics by the levels of PCa aggressiveness
were examined using Students’ t-test and chi-square tests for continuous and categorical
variables, respectively. Objective 2: Associations between antioxidants intake and PCa
aggressiveness were examined using a case-control design by treating low/intermediate
aggressive PCa cases as “control” or comparison group, and high aggressive PCa as
“cases”. Unconditional logistic regression models were used to estimate odds ratios
(ORs) and corresponding 95% confidence intervals (CIs). Dietary and adipose tissue
tocopherol levels (i.e., α, β, γ and δ) as well as supplemental vitamin E intake (αtocopherol equivalent) were categorized into quartiles, while carotenoids (α-carotene, βcarotene, β-cryptoxanthin, lutein, zeaxanthin and lycopene) from diet, supplements and
adipose tissue were categorized into tertiles. These data were categorized based on
distribution among “controls” (i.e., low/intermediate aggressive PCa cases).
All analysis were performed in age-adjusted and multivariable models. The
following variables were evaluated for inclusion in multivariable models: age
(continuous), study site (NC, LA); BMI (in kg/m2); pre-diagnostic PSA screening history
(0, 1-7, >7 screenings); comorbidities (0, 1, 2, ≥3); family history of PCa in a first degree
relative (none vs. at least one); whether PCa treatment had started at the time of the
interview (yes, no); smoking status (never, former, current); education (less than high
school education, high school graduate/some college, college graduate); annual
household income (< $20,000, $20,001 - $40,000, $40,001 - $70,000, >$70,000);
NSAIDs use in the five years prior to diagnosis (yes, no); physical activity in the year
prior to diagnosis [total metabolic equivalents (METs) of light, moderate, and vigorous
exercise categorized as: ≤ 10.2, 10.3-29.0, > 29.0 METs/week]; total fat intake
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(grams/day); and alcohol intake (grams/day). As with objective 1 analysis, the
multivariable models were constructed first by evaluating the confounding effect of each
variable based on a 10% change in effect estimate of the main exposure variables with
the removal of the covariate from the model. Variables determined to be confounders and
those that are biologically relevant to PCa were then placed in an elaborate model for
final model selection. A combination of the backward elimination model selection
method and likelihood ratio tests were then used to select covariates for the final models
consisting of age, PSA screening history, BMI, smoking status, education, income,
NSAIDs use, total fat intake, and study site. Further adjustment for family history of PCa,
comorbidities, and PCa treatment status were done in models examining associations
between adipose carotenoid/tocopherol levels and PCa aggressiveness.

Statistical model for specific objective 2:
Model-1: ln(

π

1−π

) = β0 + β1 (antioxidanti) + ……………………………………+ βkXk

Where β0 = intercept,

βj, j = 1…….....k, = slope (coefficient)
antioxidanti = each antioxidant from diet, supplement and adipose tissue were
modeled separately
Xj, j = 1 ………k, covariates

Objective 3: Gene-nutrients analyses were performed for α-tocopherol, γtocopherol and lycopene only because of significant findings for these nutrients observed
in the analysis of the dietary data. Similar to specific objective 2, a case-control design
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was used to examine whether associations between dietary intakes of α-tocopherol, γtocopherol and lycopene, and PCa aggressiveness are modulated by SNPs in DNA repair
and oxidative stress genes, and whether the effect modification varies by race. A priori
SNPs selected and genotyped by the PCaP consortium were utilized (see Table 4). HardyWeinberg equilibrium (HWE) test was not performed in this analysis because of lack of a
disease-free control group. The “control group” as defined by this study is not an ideal
population for HWE test because of the possibility that some of the SNP allelic variants
may contribute to the expression of different PCa phenotypes [336, 337]. An a priori
decision was made to exclude SNPs with low minor allele frequency (MAF, < 0.05).
In order to maximize sample size, a dominant model was assumed by collapsing
the genotype variables into two groups [i.e., minor allele heterozygous + homozygous
versus homozygous common allele (referent group)]. Effect modification of associations
between α--tocopherol, γ-tocopherol, and lycopene with PCa aggressiveness, was
examined in series of stratified analyses by genotype (binary groups). This was done by
comparing high versus low levels of the nutrients intake in each stratum of genotype
groups. Likelihood ratio tests (LRTs) were used to examine interaction on the
multiplicative scale by comparing the difference in -2 log likelihood values of logistic
regression models with and without the interaction terms. Interaction p-values were
considered statistically significant at p < 0.10 to compensate for small sample size [336].
All results were adjusted for adjusted for multiple testing using the false discovery rate
(FDR) method [338]. All statistical analysis described in the document were performed
using SAS version 9.3 (SAS Inc., Cary, NC, USA) with statistical significance set at α =
0.05 (two-tailed).
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Statistical model for specific objective 3:
Model-1(stratified analysis by genotype groupings: wild-type versus variant genotype):

ln(

π

1−π

) = β0 + β1 (antioxidanti) +……………………………………………+ βkXk

Where β0 = intercept, βj, j = 1…….....k, = slope (coefficient)
antioxidanti = each dietary antioxidants (α- and γ-tocopherol, and lycopene)

Genotype groupings = homozygous wild-type allele (reference group) vs.
homozygous + heterozygous variant alleles
Xj = j…………..k, covariates
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CHAPTER 4
PLASMA CAROTENOIDS AND TOCOPHEROL LEVELS IN RELATION TO PROSTATE-SPECIFIC
ANTIGEN (PSA) LEVELS IN MEN WITH BIOCHEMICAL PROSTATE CANCER RECURRENCE
4.1

INTRODUCTION
Prostate cancer (PCa) is the most frequently diagnosed visceral tumor and the

second most lethal malignancy among American men [339]. Most patients diagnosed
with PCa in the United States present with clinically localized disease (about 94%), and
often are treated with radical prostatectomy or radiation with curative intent [340, 341].
Unfortunately, about 25–40% of these patients develop biochemical recurrence of the
disease within five years of definitive treatment [342-345]. Biochemical recurrence of
PCa is identified by rising serum prostate-specific antigen (PSA) level on three or more
successive tests after achieving post-treatment PSA nadir (lowest detectible level) [346].
PSA-defined PCa relapse following definitive therapy is often an early sign of metastasis,
and precedes pathological and radiographic evidence of metastasis by several years [347,
348]. Thus, the identification of PSA-defined PCa recurrence provides ample time for
intervention.
Although there is no known cure for biochemically recurrent PCa, it is often
managed with surgical or medical androgen ablation to delay the time to metastasis and
prolong survival [349, 350]. Androgen ablation is often ineffective in controlling the
disease progression as most patients become hormone-refractory within two years,
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resulting in continuous rise in PSA [351, 352]. Severe side effects are also associated
with the use of androgen ablation [349, 351]. Thus, there is continued interest in the
search for adjuvant and neoadjuvant therapies for biochemical PCa relapse [13].
Epidemiologic data from migrant studies indicate that in addition to age, race/ethnicity
and a positive family history, diet plays an important role in PCa [353, 354]. Greater
intake of cruciferous vegetables, fruits, and specific dietary nutrients such as lycopene,
soy isoflavones and polyhenols have been associated with modest reduction in PCa risk,
while energy imbalance and increased consumption of fat, meat, calcium and dairy
products have been associated with increased risk of PCa [17, 355, 356].
Few epidemiologic studies have investigated whether the progression of
biochemically recurrent PCa can be altered using plant-based, dietary intervention [11,
13, 357-361]. Most of these intervention trials incorporated supporting interventions such
as stress reduction [11, 358-360] and physical activity [13] to reinforce the dietary
modification. Five reported potential inhibitory effect of the intervention on PCa
progression [11, 357-360], while two reported null results [13, 361]. However, because
these trials involved different combinations of diet, stress reduction, and physical activity,
it is difficult to determine whether study diet or other factors were responsible for the
potential beneficial effects reported by some studies. Although others studies have
investigated effects of dietary modifications alone among men with biochemical
recurrence (reviewed in [355, 362, 363]), the diets used in these studies also had different
components, such as increasing fruits, vegetables, legumes, and whole grains intake
while decreasing meat and dairy intake, which also makes it difficult to examine the
independent effects of specific food components. Thus, additional work is needed to
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evaluate the role of specific foods and nutrients. Of particular interest are biomarkers of
antioxidant intake, which have been inversely associated with PCa risk in some studies
[364, 365] and therefore may be associated with reduction in progression of recurrent
PCa [362].
Our team previously reported results of a pilot intervention trial conducted in
South Carolina to investigate whether a plant-based dietary intervention integrated with
physical activity and stress reduction could alter the progression of PCa in men with
biochemical recurrence of PCa after definitive therapy [13]. The current report is an
expansion of that work. We investigated whether plasma carotenoids (including all major
carotenoids) and tocopherol (α− and γ−tocopherols) levels were associated with PSA
levels in these patients.
4.2

MATERIALS AND METHODS

Study Population
Participants of the intervention trial were men with histologically confirmed
localized adenocarcinoma of the prostate who had completed primary therapy (i.e.,
radical prostatectomy or radiation) and had experienced increasing serum PSA levels, a
minimum of three successive increases of 1.5 ng/mL above the post-treatment PSA
nadir, with each increase at 2- to 3-month intervals [13]. Participants were deemed
eligible if they were free of other malignancy in the previous 5 years (with the exception
of non-malignant skin cancer); spoke English as a first language; were able to read at a
sixth grade level; were of sound mind, memory, and understanding; had not been taking
thyroid medication, steroids, antibiotics, or diuretics; and were willing to be randomized
to intervention or control (with an option to obtain the intervention at the end of the
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study). The participants were required to enter the study with their spouse or partner of
choice to provide support for compliance with the study protocol. Prospective
participants were excluded if they had received post-operative hormonal therapy for
treatment of PCa; had a current diagnosis or symptoms of active ulcerative colitis or
cardiovascular, pulmonary, Crohn’s, or metabolic disease; had experienced weight loss of
5 pounds or more within the previous 3 months; planned to use hormone supplements,
fish oil, or other ω-3 fatty acids-based supplements; or had a diagnosis of post-traumatic
stress disorder (PTSD). All participants provided informed consent prior to enrollment.
The research protocol of the parent study was reviewed and approved by the Institutional
Review Boards (IRBs) of the University of South Carolina (USC) and Palmetto Health;
the current analysis also was approved by the USC IRB.
All participants were recruited from major urological practices of seven counties
in the Midlands region of SC (Richland, Lexington, Orangeburg, Kershaw, Sumer,
Fairfield, and Newberry). The majority of participants were from Richland (67%) and
Lexington (9%) counties, which are the two most densely populated counties in the
greater Columbia area. The intervention was conducted at locations close to the
recruitment sites under the auspices of the primary investigator (JRH). All clinical and
anthropometric data were collected at the facilities of the Cancer Prevention and Control
Program at USC.

Study Design
Details of the study design and methods have been published [13]. In brief,
participants were assigned to intervention or control group using block randomization by
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age (± 5 years) and race (African American/European American). The study spanned 6
months, which included a 3-month period of active intervention followed by monthly
booster session for the following 3 months. The intervention consisted of dietary
modifications, physical activity, and mindfulness-based stress reduction training. The 3month active phase of the intervention involved individual diet and physical activity
counseling and goal setting sessions, as well as twelve weekly group meetings that
included cooking classes and shared model meals. In addition, participants were given
weekly assignments on how to shop for and cook study-compliant meals, attain physical
activity goals, and practice meditation for stress reduction. The diet aspect of the
intervention emphasized increased intake of plant-based foods such as whole grains,
fruits, vegetables, and legumes (particularly soybeans and soybean products) along with
decreased intake of meat and dairy products. The physical activity aspect involved
working with participants to identify activities that they enjoyed and reinforce those
activities to promote physical fitness and overall well-being. The goal of the exercise
routine was to ensure that each participant attain the Centers for Disease Control and
American College of Sports Medicine (CDC/ACSM) recommendations of at least 30
minutes of moderate intensity physical activity for 5 days or more per week [315].
Because comprehensive dietary change can be difficult to maintain, participants were
taught to meditate in a way that inculcates mindfulness about decisions concerning food
choices in order to promote their sense of control over the change in diet and culinary
habits [316]. Partner support was integrated to provide an encouraging environment for
the process of change. Following the 3-month active phase, monthly booster sessions
were held in a supportive group environment for another 3 months. These included
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frequent telephone calls to each participant and his partner for wellness checks and
encouragement to sustain the intervention.
Participants in the control group underwent the same general assessment as those
in the intervention group. There were no attempts made to restrict their access to
psychosocial support or educational resources available to PCa patients in the
community. These participants and partners were given the opportunity to take the
intervention at the end of the 6-month study period at no cost to them.

Data Collection and Phlebotomy
Data on clinical and pathologic attributes of PCa were abstracted from
participants’ medical records obtained from referring urologists. At baseline, participants
responded to questionnaires that solicited information on demographics and healthrelated behaviors, including age, race, education, marital status, employment, and
smoking status. Data on diet, physical activity, and anthropometry were obtained at each
of the three study checkpoints: baseline, 3 months, and 6 months. Diet assessments used
24-hour dietary recalls on three randomly selected days that included two weekdays and
one weekend day, as this method has been found to be least prone to dietary measurement
error [318, 319]. Physical activity was assessed using a questionnaire designed for older
adults that had been tested for reliability [320]. Physical activity was expressed as
metabolic equivalent (MET) value based on description of the activity using the
Compendium of Physical Activities [321], with one MET being equivalent to resting
metabolic rate. Total METs of physical activity were estimated for each participant’s sum
of METs from light, moderate, and vigorous physical activity per week. The
anthropometric measurements obtained were standing height (cm), weight (kg), waist-to88

hip ratio, and bioelectric impedance measures of percent body fat and lean body mass
[13]. Body mass index (BMI) was subsequently calculated as weight (kg)/height (m2).
Each participant provided a 5 ml vial of blood from venipuncture obtained by a
trained phlebotomist at each of the three study timepoints. The samples were fractionated
by centrifuge, frozen at –80oc within 1 hour of collection, and transported on ice within
1week via overnight courier to Quest ® Laboratories for analysis. PSA was measured in
serum at baseline, at 3 months and at 6 months. Carotenoids and tocopherols were
measured in plasma using high performance liquid chromatography (HPLC). Because of
limited availability of samples, data on carotenoids and tocopherols were only measured
at baseline and at 3 months. The following carotenoids and tocopherols were measured:
α- and γ-tocopherol, α-carotene, cis- and trans-β-carotene, lutein, zeaxanthin, cislutein/zeaxanthin, α- and β-cryptoxanthin, cis- and trans-lycopene.

Statistical Methods
Differences in baseline characteristics were assessed using Student’s t-test to
compare means of continuous variables and Fisher’s exact test for categorical variables.
Means and standard deviations (SDs) of plasma carotenoids and tocopherols at baseline
and at 3 months also were calculated and compared by intervention group. Because
carotenoids and tocopherols are transported in the blood by lipoproteins [278], we
corrected for circulating lipid levels by dividing each carotenoid and tocopherol (µg/ml)
by total plasma cholesterol level (mg/dL). These variables were subsequently categorized
into binary groups (< vs. ≥ median) because of nonlinear distribution pattern; assessed by
the generalized additive model procedure in SAS (PROC GAM). A total antioxidant
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score was computed as a measure of overall antioxidant status following the method
described by Li et al. [335]. In estimating the antioxidant score, the carotenoid and
tocopherol variables (i.e., α- and γ-tocopherol, α-carotene, cis- and trans-β-carotene, αand β-cryptoxanthin, lutein, zeaxanthin, and cis- and trans-lycopene) were categorized
into quartiles and scores were assigned to each quartile in multiples of 3 (i.e., 3 to 12,
from low to high). The scores were summed for each participant across all carotenoids
and tocopherols, and then categorized into median groups (< vs. ≥ median).
The relations between serum PSA levels and plasma carotenoids and tocopherols
were examined in three sets of analyses. First, we considered how baseline carotenoid
and tocopherol levels are related to baseline PSA level. Second, we explored whether
carotenoid and tocopherol levels at 3 months are related to PSA levels at 3 months and at
6 months, adjusting for baseline PSA level, as baseline PSA is related to subsequent PSA
values [366]. Finally, we examined percent change in carotenoid and tocopherol levels
(from baseline to 3 months) in relation to PSA levels at 3 months and at 6 months,
adjusting for baseline PSA values. The sign for the percent change values was reserved to
ensure that a positive value represented an increase in plasma carotenoid and tocopherol
levels. The percent change variables also were categorized into binary (increase vs.
decrease) as well as tertile [decrease, minimal increase (1–20%), or substantial increase
(>20 %)] groups. Linear regression was used for all analyses to estimate least squares
means and P values for test of difference between group means, modeling PSA values as
continuous variable. Natural log transformation was performed on the positively skewed
PSA data in order to achieve normality; however, results were back transformed for
presentation.
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The analyses were performed in minimally adjusted (i.e., “crude model”,
adjusting for age, race and randomized group) and in multivariable adjusted models.
Covariates chosen for inclusion in the multivariable adjusted models were age, race,
education, marital status, employment, smoking status, Gleason score, BMI, physical
activity, energy intake and randomized group, and modeled as continuous or categorical
variables as presented in Table 4.1. These variables were selected based on evaluation of
confounding effect (>10% change in effect estimates) in conjunction with the backward
elimination method. Additional variables considered but not included in the final analyses
type of PCa treatment received; body fat mass; fruit, vegetables, fiber and dairy intake;
and total dietary fat and omega-3 fatty acids intake. All statistical tests were two sided;
statistical significance was set at α = 0.05, and all analyses performed using SAS version
9.3 (SAS Institute Inc., Cary, NC).

4.3

RESULTS
Full details of the randomization procedure have been reported [13]. Overall, 54

men with a history of localized PCa and rising PSA levels after definitive treatment with
radical prostatectomy, radiation or both were successfully randomized to intervention (n
= 29) and control (n = 25). Of these participants, seven were lost to follow-up
(intervention, n = 3; control, n = 4). Of the remaining 47 participants, data on plasma
carotenoid and tocopherol levels were available for 39 participants at baseline and 35
participants at 3 months.
Differences in the distribution of baseline characteristics and PSA levels at all
three timepoints are presented in Table 4.1. The mean age of the study sample was 70
years (SD = 8), with mean BMI of 29.75 kg/m2 (SD = 5.21), and included 28 (72%)
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European Americans and 11 (28%) African Americans. Fifteen percent of the participants
underwent radical prostatectomy, 39% had radiation only, and 46% had both radiation
and prostatectomy prior to enrollment in the study. Mean serum PSA levels were 3.91,
5.01, and 4.72 ng/mL at baseline, at 3 months, and at 6 months, respectively. None of the
baseline characteristics including education, marital status, employment, smoking status,
and tumor grade, differed significantly by intervention status.
The plasma carotenoid and tocopherol concentrations did not vary significantly
between the intervention and control groups at baseline or at 3 months (Table 4.2).
Analysis of baseline data also did not show any significant difference in mean PSA levels
between participants with high versus low carotenoid/tocopherol levels or total
antioxidant score (Table 4.3).
Tables 4.4 and 4.5 presents results for associations of plasma carotenoids and
tocopherols at 3 months in relation to serum PSA levels at 3 months and 6 months,
respectively, after adjusting for baseline PSA level in addition to age, race, education,
marital status, employment, smoking status, Gleason score, BMI, physical activity and
randomization status. Participants with higher carotenoid and tocopherol levels at 3
months, tended to have lower PSA levels at 3 months as compared to those with lower
carotenoid and tocopherol levels at 3 months, though the association with PSA levels at 3
months after adjustment was statistically significant only for cis-lutein/zeaxanthin (P =
0.008). The 3-month carotenoid and tocopherol levels appeared to be more strongly
associated with serum PSA levels at 6 months, as participants with high plasma levels of
α-tocopherol (P = 0.01), β-cryptoxanthin (P = 0.01), all-trans-lycopene (P = 0.004), and
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total antioxidant score (P = 0.003) showed significantly lower mean PSA levels than
those with low levels of these micronutrient antioxidants.
We further examined whether percent change in carotenoid and tocopherol levels
from baseline to month 3 was associated with PSA levels at 3 months and at 6 months,
adjusting for baseline PSA level (Table 4.6 and 4.7, respectively). These results show that
participants who experienced an increase in carotenoid and tocopherol levels generally
had lower mean PSA levels at 3 months compared to those who had a decrease in
carotenoid and tocopherol levels. The evidence of inverse relation with serum PSA at 3
months was particularly strong for α-tocopherol (P = 0.0007). Although significantly
lower mean PSA levels were observed for higher levels of all-trans-β-carotene and αcryptoxanthin in relation to PSA level at 3-months, significant findings in the tertile
categories was confined to participants who had a minimal increase in their plasma levels
(i.e., 1–20% increase). In the analysis of 6-month PSA values, percent increase in
carotenoid/tocopherol level was inversely related to mean PSA level for α-tocopherol,
trans-β-carotene, β-cryptoxanthin, cis-lutein/zeaxanthin, trans-lycopene, and total
antioxidant score.

4.4

DISCUSSION
In this study, we examined the relations between plasma carotenoid and

tocopherol levels, and serum PSA levels among men with biochemical recurrence of PCa
who were enrolled in a 6-month diet and lifestyle intervention trial in South Carolina. In
an analysis of baseline data, no significant differences in mean PSA levels were observed
between participants with high versus low carotenoid or tocopherol levels. We further
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explored whether carotenoid and tocopherol levels at 3 months (during the study period)
were associated with PSA levels at 3 months and at 6 months, adjusting for baseline PSA
values. Results from this analysis showed that participants with higher cislutein/zeaxanthin level at 3 months had statistically lower mean PSA level at 3 months.
Additionally, participants with higher plasma levels of α-tocopherol, β-cryptoxanthin,
all-trans-lycopene, and higher antioxidant score at 3 months, had significantly lower
mean PSA level at 6 months. Finally, we examined whether percent change in plasma
carotenoid and tocopherol levels from baseline to month 3 were inversely related to PSA
levels at 3 months and at 6 months, independent of baseline PSA values. These results
showed significantly lower mean PSA values at 3 months and at 6 months for participants
with an increase in α-tocopherol and trans-β-carotene levels compared to who had a
decrease in the levels of these nutrients. In addition, those with an increase in βcryptoxanthin, cis-lutein/zeaxanthin, trans-lycopene and antioxidant score had
significantly lower mean PSA values at 6 months. Overall, higher plasma levels of
certain carotenoids and tocopherols paralleled with lower PSA level at various time
points, with stronger findings for associations with the 6-month PSA values. This
suggests that it may take a few months before a clinical benefit on PSA is observed from
a dietary intervention.
The idea of using dietary agents as an alternate therapy or as a neoadjuvant to
delay the use of more traditional therapy such as androgen ablation is a prospect that
would be appealing to most patients because of the severe side effects associated with
traditional therapy [349, 350]. While it is plausible that intake of certain carotenoids and
tocopherols may influence serum PSA levels, it is possible that these nutrients could alter
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PSA levels without affecting cancer progression. Interestingly, declines in PSA have
been found to correlate with inhibition of the androgen-sensitive LNCaP prostate tumor
cell growth in animal and human studies [357, 367, 368]. Secretion of PSA and hormonedependent LNCaP activity are both modulated by androgens [369, 370]. Higher blood
levels of antioxidants such as lycopene and α-tocopherol have been found to downregulate serum androgen levels [371-373]. Thus, the suppression of androgens may be an
underlying mechanism for the potential effect of carotenoids and tocopherols on PSA,
and possibly, PCa progression. Other mechanisms involving antioxidative and antiinflammatory activities have also been proposed [374, 375].
Prior studies on men with biochemically recurrent PCa have focused primarily on
multiple interventions involving diet, exercise, and stress reduction [11, 13, 357-361].
There is very little published literature on associations of carotenoids and tocopherols
intake in relation to PSA levels among men with PCa relapse (reviewed in [355, 362,
363]). Data on carotenoids and tocopherols in relation to PSA progression among men
with PCa relapse are lacking. The vast majority of the available data are from studies
examining the potential benefits of supplemental or dietary lycopene. In a study
involving 71 men with biochemical recurrence who were randomized to intervention with
supplemental lycopene alone (15 mg) or together with soy isoflavones capsule (40 mg)
taken twice daily for 6 months, no decline in serum PSA level was observed in either
group [376]. In that same study, however, the rate of PSA rise decreased in 95% of
patients in the lycopene group and 67% of those in the lycopene and soy isoflavones
group [376]. In another study where 36 men with biochemical recurrence of PCa were
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given varying doses of lycopene (15, 30, 45, 60, 90 and 120 mg/day) for one year, no
change in serum PSA was observed across all the six dose groups [377].
In a related study, Chen et al. [374] investigated the effect of lycopene on cancer
progression among 32 patients with incident PCa treated tomato sauce-based diet
containing 30 mg of lycopene per day for 3 weeks before their scheduled prostatectomy.
The results showed significant reduction in serum PSA levels as well as declines in
markers of oxidative DNA damage measured in leukocytes and prostate tissue, when
comparing pre- and post-intervention measurements [374]. Ansari and Gupta [378]
evaluated the effect of lycopene and orchiectomy versus lycopene alone in 54 patients
with metastatic PCa, and found significantly lower PSA levels in the lycopene group after
6 months of follow-up. Others have reported that supplemental lycopene intake decreases
PSA velocity and may prolong PSA doubling time [379]. Among studies conducted in
disease-free men, one found an inverse association between serum α-carotene levels and
percent free PSA level (OR = 0.49, 95% CI = 0.32–0.76), but not total PSA, and no
inverse association was found for other carotenoids [380]. Another found no association
between tocopherol intake and serum PSA level or PSA velocity [381]. The variability is
these findings may be related to the source of the nutrients (e.g., supplement versus diet
for lycopene) or the possibility that these nutrients may have varying effect on different
disease states.
To our knowledge, this is the first study to examine biomarkers of carotenoids and
tocopherols in relation to PSA levels among men with biochemical recurrence of PCa.
The results show that after controlling for baseline PSA values, certain plasma
carotenoids and tocopherol were associated with low mean PSA values at various
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timepoints. Despite these findings, it is conceivable that these nutrients may have served
as surrogates for higher consumption of fruits and vegetables which contain other
beneficial dietary factors. Of note, the original EASE intervention study did not find a
beneficial effect of the diet and lifestyle intervention on PSA [13]. Challenges associated
with conducting clinical trials of lifestyle interventions, such as lack of large enough
contrast between the intervention and control group due to contamination or suboptimal
compliance [382], may partially explain this finding. The current study results suggest
that higher exposure to certain dietary antioxidants may have a beneficial effect on PSA
rise following prostatectomy and should be confirmed in other larger studies.
Both strengths and limitation of the study deserve mention. Given the small
sample size and the multiple comparisons made, there is a possibility that some of the
findings could be due to chance. Because humans consume foods containing multiple
nutrients, there is also the possibility that the study results may be reflecting interactions
between plasma nutrients, rather than the effect of a specific nutrient per se [383]. The
short duration of the study and lack of carotenoid and tocopherol data at 6 months
prohibited evaluation of temporal trends over long periods. Restricting the study to a
subgroup of PCa patients with strictly defined disease attributes precludes
generalizability of the findings to the larger population of men with PCa. However, since
the study participants had already undergone radical prostatectomy and/or radical
radiation for the treatment of organ-confined disease, continuous rise in serum PSA level
as defined in this study most likely reflect progressive disease (which was the intent of
the study), rather than residual normal tissue left from radiation or spared during
prostatectomy. Other strengths of the study include the use of biomarkers of nutrient
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intake, which are more reliable measures of nutritional status relative to self-reported
intake [384]. Several potential confounders including BMI, smoking, physical activity,
tumor grade and race were controlled for in the analysis. The study findings add to the
limited data on potentially beneficial dietary factors for men with biochemically recurrent
PCa.

4.5

CONCLUSIONS
Higher plasma levels of α-tocopherol, β-cryptoxanthin, trans-β-carotene, cis-

lutein/zeaxanthin, and trans-lycopene were associated with lower PSA levels among men
with biochemically defined PCa recurrence. A higher antioxidant score, used as a
measure of total antioxidant status, also was associated with lower PSA levels at various
timepoints. These findings suggest that increasing intake of these micronutrients, which
are found in many fruits and vegetables, may slow the progression of PSA in men with a
biochemical recurrence of PCa. Considering the small sample size and short duration,
additional work in larger cohorts with longer follow-up time is warranted.
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Table 4.1 Baseline characteristics of study subjects and changes in PSA levels
All subjects
Intervention
(n = 39)
(n = 22)

Age, years
BMI, kg/m2
Energy, kcal/day
Physical activity, total METs/week
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Race
White/European American
Black/African American
Education
High school graduate or less
High school and some college
College graduate
Marital status
Married or with partner
Widowed, divorced, or single
Employment
Yes, full time
Yes, part time
No
Smoking status
Never

Control
(n = 17)

P§

Mean ± SD

Mean ± SD

Mean ± SD

70 ± 8
29.75 ± 5.21
1683.90 ± 414.24
44.60 ± 35.51

69 ± 9
29.49 ± 4.86
1741.24 ± 367.52
52.02 ± 41.29

71 ± 7
30.09 ± 5.77
1609.68 ± 468.92
35.43 ± 24.96

n (%)

n (%)

n (%)

28 (72)
11 (28)

17 (77)
5 (23)

11 (65)
6 (32)

0.48

8 (20)
12 (31)
19 (49)

4 (18)
8 (36)
10 (45)

4 (23)
4 (23)
9 (53)

0.70

31 (79)
8 (21)

16 (73)
6 (27)

15 (88)
2 (12)

0.43

7 (18)
4 (10)
28 (72)

3 (14)
2 (9)
17 (77)

4 (23)
2 (12)
11 (65)

0.68

14 (37)

8 (36)

7 (41)

0.80

0.51
0.73
0.33
0.13
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Former
Current
Tumor grade (Gleason score)
Well differentiated (<5)
Moderately differentiated (5–6)
Poorly differentiated (≥7)
Missing
Type of treatment
Prostatectomy
Prostatectomy and radiation
Radiation only
PSA levels, mean (range) ng/mL a
Baseline
At 3-months
At 6-months

21 (53)
4 (10)

11 (50)
3 (14)

9 (53)
1 (6)

1 (3)
9 (23)
20 (51)
9 (23)

1 (5)
5 (23)
12 (54)
4 (18)

0 (0)
4 (24)
8 (47)
5 (29)

0.95

6 (15)
18 (46)
15 (39)

3 (14)
10 (45)
9 (41)

3 (18)
8 (47)
6 (35)

0.99

3.91 (0.10-52.00)
5.01 (0.10-68.30)
4.72 (0.10-67.20)

3.24 (0.10-37.90)
4.37 (0.10-44.70)
4.26 (0.10-54.40)

4.78 (0.10-52.00)
5.85 (0.10-68.30)
5.27 (0.10-67.20)

0.61
0.70
0.80

Abbreviations: PSA – prostate-specific antigen; SD – standard deviation; METs – metabolic equivalent task per week from physical
activity
a

Data represents actual PSA values, not logarithm transformed values.

§ P value comparing intervention and control groups using Student’s t-test for continuous variables and Fisher's exact test for
categorical variables

Table 4.2 Means and standard deviations of plasma carotenoid and tocopherol levels at baseline and at 3 months post-intervention
Baseline

Post-intervention (at 3 months)

Plasma carotenoids
and tocopherols
(µg/ml)

All subjects

Intervention

Control

(n = 39)

(n = 22)

(n = 17)

α-tocopherol

14.91 ± 5.15

15.23 ± 5.56

14.51 ± 4.71

γ-tocopherol

1.70 ± 1.01

1.67 ± 1.01

α-carotene

0.04 ± 0.03

cis-β-carotene

P

§

P§
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All subjects

Intervention

Control

(n = 35)

(n = 20)

(n = 15)

0.67

14.35 ± 5.17

14.64 ± 5.48

13.96 ±
4.87

0.71

1.73 ± 1.04

0.86

1.65 ± 0.99

1.60 ± 0.89

1.70 ± 1.13

0.78

0.04 ± 0.03

0.05 ± 0.03

0.60

0.05 ± 0.04

0.04 ± 0.03

0.05 ± 0.05

0.64

0.02 ± 0.01

0.02 ± 0.01

0.02 ± 0.01

0.07

0.02 ± 0.01

0.02 ± 0.01

0.02 ± 0.01

0.32

Trans-β-carotene

0.20 ± 0.13

0.18 ± 0.12

0.24 ± 0.15

0.17

0.20 ± 0.14

0.20 ± 0.16

0.21 ± 0.12

0.83

α-cryptoxanthin

0.02 ± 0.01

0.02 ± 0.01

0.02 ± 0.01

0.77

0.02 ± 0.01

0.02 ± 0.01

0.02 ± 0.01

0.86

β-cryptoxanthin

0.11 ± 0.08

0.11 ± 0.09

0.10 ± 0.07

0.71

0.10 ± 0.07

0.10 ± 0.08

0.09 ± 0.06

0.87

Lutein

0.11 ± 0.06

0.10 ± 0.06

0.12 ± 0.07

0.40

0.12 ± 0.07

0.12 ± 0.07

0.12 ± 0.08

0.92

Zeaxanthin

0.03 ± 0.01

0.03 ± 0.01

0.03 ± 0.02

0.30

0.03 ± 0.01

0.02 ± 0.01

0.03 ± 0.01

0.47

Cis-lutein/zeaxanthin

0.01 ± 0.01

0.01 ± 0.01

0.01 ± 0.01

0.59

0.02 ± 0.01

0.02 ± 0.01

0.01 ± 0.01

0.07

Cis-lycopene

0.18 ± 0.13

0.18 ± 0.11

0.18 ± 0.15

0.94

0.17 ± 0.11

0.19 ± 0.10

0.15 ± 0.13

0.26

Trans-lycopene

0.19 ± 0.12

0.20 ± 0.11

0.19 ± 0.14

0.81

0.19 ± 0.11

0.22 ± 0.10

0.16 ± 0.12

0.12

Abbreviation: SD, standard deviation
§
P value comparing intervention and control groups based on Student’s t-test

Table 4.3 Baseline PSA levels by baseline carotenoid and tocopherol levels
Crude model a

Adjusted model b

Plasma tocopherols and
carotenoids at baseline c
low
α-tocopherol
high

n

Mean (95% CI) d

P§

Mean (95% CI) d

P§

19
20

0.80 (0.39-1.62)
1.34 (0.57-3.14)

0.35

0.53 (0.25-1.16)
0.79 (0.30-2.07)

0.40

γ-tocopherol

low
high

20
19

1.40 (0.59-3.30)
0.78 (0.38-1.58)

0.30

0.71 (0.29-1.71)
0.52 (0.23-1.20)

0.50

α-carotene

low
high

19
20

1.10 (0.52-2.34)
0.88 (0.42-1.88)

0.67

0.49 (0.20-1.19)
0.70 (0.30-1.63)

0.45

Cis-β-carotene

low
high

20
19

0.77 (0.35-1.67)
1.27 (0.58-2.78)

0.37

0.67 (0.26-1.70)
0.55 (0.23-1.31)

0.71

Trans-βcarotene

low
high

20
19

0.91 (0.42-1.95)
1.07 (0.49-2.34)

0.75

0.50 (0.21-1.18)
0.72 (0.30-1.74)

0.44

α-cryptoxanthin

low
high

21
18

0.94 (0.44-2.00)
1.03 (0.48-2.22)

0.86

0.87 (0.35-2.19)
0.46 (0.20-1.05)

0.20

β-cryptoxanthin

low
high

20
19

0.92 (0.45-1.89)
1.08 (0.49-2.37)

0.76

0.56 (0.23-1.35)
0.66 (0.23-1.89)

0.80

Lutein

low
high

19
20

0.91 (0.40-2.06)
1.05 (0.51-2.14)

0.79

0.70 (0.29-1.68)
0.51 (0.22-1.22)

0.52

Zeaxanthin

low
high

18
21

0.96 (0.43-2.16)
1.01 (0.49-2.05)

0.93

0.53 (0.20-1.43)
0.63 (0.29-1.37)

0.74

Cislutein/zeaxanthin

low
high

21
18

0.94 (0.46-1.91)
1.05 (0.47-2.38)

0.82

0.61 (0.28-1.34)
0.58 (0.23-1.42)

0.90

Cis-lycopene

low
high

21
18

1.39 (0.60-3.22)
0.72 (0.28-1.87)

0.30

0.46 (0.14-1.54)
0.30 (0.11-0.85)

0.48

Trans-lycopene

low
high

20
19

1.27 (0.35-2.07)
0.85 (0.54-3.03)

0.50

0.42 (0.16-1.07)
0.22 (0.09-0.56)

0.14

Antioxidant
score e

low
high

19
20

1.16 (0.55-2.42)
0.82 (0.38-1.79)

0.51

0.77 (0.32-1.85)
0.45 (0.19-1.12)

0.31

Abbreviations: PSA – prostate-specific antigen, CI – confidence interval
a
Adjusted for age, race and randomized group.
b
Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score,
body mass index, total metabolic equivalent (MET) per week of physical activity, energy intake, and
randomized group.
c
Categorized by median splits as less than median (low) versus greater than or equal to median (high).
d
Data are reported as least square means.
e
Antioxidant score; low : 57 – 83, high: 84 –123.
§ P values from regression model comparing mean difference between low and high
tocopherol/carotenoid categories
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Table 4.4 Associations of carotenoid and tocopherol levels at 3 months in relation to PSA levels
at 3 months adjusting for baseline PSA level
PSA levels at 3 months a
Plasma tocopherols and
carotenoids at 3 months b

n

Crude model c

Adjusted model d

Means (95% CI)

P§

Means (95% CI)

P§

103

α-tocopherol

low
high

18
17

0.98 (0.74-1.29)
0.68 (0.49-0.94)

0.09

0.62 (0.45-0.85)
0.42 (0.27-0.65)

0.10

γ-tocopherol

low
high

17
18

0.70 (0.50-0.98)
0.97 (0.73-1.28)

0.16

0.56 (0.39-0.83)
0.53 (0.33-0.83)

0.82

α-carotene

low
high

18
17

1.00 (0.76-1.33)
0.69 (0.50-0.93)

0.07

0.65 (0.45-0.93)
0.44 (0.30-0.66)

0.13

Cis-β-carotene

low
high

17
18

1.04 (0.77-1.41)
0.69 (0.52-0.92)

0.05

0.66 (0.45-0.96)
0.49 (0.34-0.68)

0.16

Trans-β-carotene

low
high

18
17

1.03 (0.78-1.35)
0.66 (0.49-0.90)

0.03

0.63 (0.43-0.92)
0.50 (0.35-0.70)

0.25

α-cryptoxanthin

low
high

18
17

0.97 (0.73-1.30)
0.72 (0.54-0.97)

0.15

0.57 (0.41-0.80)
0.50 (0.30-0.83)

0.65

β-cryptoxanthin

low
high

18
17

0.99 (0.74-1.32)
0.72 (0.54-0.97)

0.13

0.56 (0.39-0.83)
0.53 (0.36-0.78)

0.82

Lutein

low
high

17
18

1.01 (0.75-1.36)
0.71 (0.54-0.95)

0.09

0.61 (0.41-0.93)
0.51 (0.35-0.73)

0.45

Zeaxanthin

low
high

17
18

0.92 (0.66-1.29)
0.79 (0.59-1.05)

0.48

0.60 (0.43-0.82)
0.44 (0.29-0.68)

0.17

Cis-lutein/zeaxanthin

low

18

1.02 (0.77-1.35)

0.05

0.75 (0.52-1.07)

0.008

high

17

0.67 (0.49-0.92)

0.45 (0.33-0.62)

Cis-lycopene

low
high

17
18

0.97 (0.72-1.30)
0.72 (0.52-0.99)

0.20

0.61 (0.43-0.88)
0.49 (0.34-0.71)

0.29

Trans-lycopene

low
high

17
18

0.90 (0.66-1.22)
0.78 (0.56-1.10)

0.57

0.58 (0.40-0.82)
0.51 (0.33-0.78)

0.60

Antioxidant score e

low
high

17
18

1.03 (0.77-1.37)
0.69 (0.52-0.92)

0.05

0.62 (0.44-0.87)
0.47 (0.32-0.68)

0.18

Abbreviation: PSA – prostate-specific antigen, CI – confidence interval
a

Data are reported as least square means
Categorized by median splits as less than median (low) versus greater than or equal to median (high).
c
Adjusted for age, race randomized group and baseline PSA level.
d
Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score,
body mass index, total metabolic equivalent (MET) per week of physical activity, energy intake,
randomized group and baseline PSA level.
e
Antioxidant score; low : 45 – 80, high: 81 –111.
b
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§ P values from regression model comparing mean difference between low and high
tocopherol/carotenoid categories

Table 4.5 Associations of carotenoid and tocopherol levels at 3 months in relation to PSA levels
at 6 months, adjusting for baseline PSA level
PSA levels at 6 months a
Plasma tocopherols and
carotenoids at 3 months b

n

Crude model c

Adjusted model d

Means (95% CI)

P§

Means (95% CI)

P§

105

α-tocopherol

low
high

18
17

1.00 (0.45-2.21)
0.38 (0.16-0.93)

0.11

0.76 (0.28-2.01)
0.13 (0.03-0.48)

0.01

γ-tocopherol

low
high

17
18

0.75 (0.32-1.72)
0.55 (0.21-1.39)

0.62

0.64 (0.16-2.59)
0.33 (0.10-1.08)

0.45

α-carotene

low
high

18
17

1.04 (0.45-2.40)
0.42 (0.19-0.95)

0.12

0.88 (0.26-2.95)
0.23 (0.07-0.73)

0.08

Cis-β-carotene

low
high

17
18

0.74 (0.32-1.68)
0.56 (0.23-1.39)

0.65

0.51 (0.18-1.50)
0.33 (0.10-1.15)

0.52

Trans-β-carotene

low
high

18
17

0.85 (0.37-1.95)
0.49 (0.21-1.17)

0.36

0.46 (0.12-1.70)
0.41 (0.14-1.23)

0.87

α-cryptoxanthin

low
high

18
17

0.67 (0.29-1.57)
0.63 (0.26-1.50)

0.90

0.69 (0.15-3.22)
0.36 (0.12-1.04)

0.46

β-cryptoxanthin

low
high

18
17

0.69 (0.27-1.44)
0.62 (0.29-1.63)

0.86

0.97 (0.33-2.86)
0.17 (0.05-0.53)

0.01

Lutein

low
high

17
18

0.80 (0.33-1.91)
0.55 (0.24-1.26)

0.53

0.77 (0.22-2.65)
0.28 (0.09-0.86)

0.17

Zeaxanthin

low
high

17
18

0.56 (0.23-1.37)
0.76 (0.32-1.78)

0.63

0.59 (0.15-2.30)
0.38 (0.13-1.08)

0.55

Cis-lutein/zeaxanthin

low

18

1.05 (0.46-2.35)

0.09

0.76 (0.23-2.50)

0.16

high

17

0.37 (0.15-0.91)

0.31 (0.11-0.86)

Cis-lycopene

low
high

17
18

0.77 (0.34-1.75)
0.52 (0.20-1.36)

0.54

0.73 (0.25-2.15)
0.43 (0.07-0.73)

0.08

Trans-lycopene

low
high

17
18

0.77 (0.34-1.75)
0.51 (0.18-1.42)

0.54

0.89 (0.33-2.37)
0.10 (0.03-0.37)

0.004

Antioxidant score e

low
high

17
18

0.84 (0.36-1.96)
0.51 (0.22-1.17)

0.38

0.86 (0.32-2.25)
0.14 (0.04-0.44)

0.003

Abbreviation: PSA – prostate-specific antigen, CI – confidence interval
a

Data are reported as least square means
Categorized by median splits as less than median (low) versus greater than or equal to median (high).
c
Adjusted for age, race randomized group and baseline PSA level.
d
Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass
index, total metabolic equivalent (MET) per week of physical activity, energy intake, randomized group and baseline
PSA level.
e
Antioxidant score; low : 45 – 80, high: 81 –111.
b
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§ P values from regression model comparing mean difference between low and high tocopherol/carotenoid categories

Table 4.6 Percent change in carotenoid and tocopherol levels from baseline to 3 months in relation to PSA levels at 3
months, adjusting for baseline PSA level
PSA level at 3 months a
Means (95% CI)
Change in plasma tocopherols and carotenoids from
baseline to 3 months

n

Crude model b

Adjusted model c
P§

α-tocopherol

107

γ-tocopherol

α-carotene

Cis-β-carotene

P§

Decrease
Increase

13
21

1.13 (0.80-1.59)
0.73 (0.56-0.95)

ref
0.04

0.84 (0.58-1.21)
0.47 (0.36-0.62)

ref
0.0007

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

13
14
7

1.13 (0.53-1.03)
0.74 (0.53-1.03)
0.71 (0.45-1.12)

ref
0.08
0.10

0.88 (0.61-1.26)
0.54 (0.37-0.77)
0.40 (0.26-0.61)

ref
0.008
0.004

Decrease
Increase

17
17

0.96 (0.69-1.32)
0.77 (0.56-1.05)

ref
0.34

0.56 (0.39-0.80)
0.52 (0.36-0.76)

ref
0.73

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

17
8
9

0.95 (0.69-1.31)
0.70 (0.45-1.08)
0.84 (0.56-1.28)

ref
0.25
0.66

0.56 (0.39-0.80)
0.50 (0.32-0.77)
0.55 (0.33-0.89)

ref
0.64
0.93

Decrease
Increase

29
5

0.85 (0.67-1.09)
0.88 (0.47-1.64)

ref
0.92

0.52 (0.38-0.71)
0.67 (0.33-1.36)

ref
0.50

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

29
3
2

0.85 (0.67-1.09)
0.91 (0.30-2.26)
0.83 (0.44-1.90)

ref
0.39
0.53

0.53 (0.38-0.73)
0.79 (0.32-1.90)
0.54 (0.19-1.51)

ref
0.38
0.98

Decrease

19

0.97 (0.75-1.03)

ref

0.92 (0.48-0.99)

ref

Trans-β-carotene

α-cryptoxanthin
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β-cryptoxanthin

Lutein

Increase

15

0.76 (0.50-0.96)

0.29

0.79(0.33-0.87)

0.52

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

19
7
8

0.97 (0.75-1.03)
0.67 (0.41-1.09)
0.81 (0.46-1.07)

ref
0.16
0.28

0.90 (0.51-0.93)
0.68 (0.15-0.86)
0.87(0.53-0.98)

ref
0.65
0.94

Decrease
Increase

19
15

1.08 (0.82-1.42)
0.63 (0.47-0.86)

ref
0.009

0.72 (0.51-1.04)
0.44 (0.32-0.60)

ref
0.01

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

19
9
6

1.08 (0.82-1.42)
0.63 (0.43-0.92)
0.65 (0.40-1.08)

ref
0.02
0.08

0.71 (0.51-0.99)
0.34 (0.23-0.49)
0.67 (0.42-1.06)

ref
0.0005
0.85

Decrease
Increase

10
24

1.00 (0.68-1.48)
0.79 (0.60-1.04)

ref
0.33

0.73 (0.44-1.20)
0.51 (0.38-0.69)

ref
0.16

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

10
5
19

1.01 (0.68-1.48)
0.64 (0.37-1.10)
0.84 (0.62-1.15)

ref
0.18
0.49

0.73 (0.45-1.18)
0.37 (0.23-0.61)
0.60 (0.42-0.85)

ref
0.03
0.45

Decrease
Increase

18
16

0.85 (0.63-1.16)
0.86 (0.61-1.20)

ref
0.97

0.62 (0.43-0.89)
0.47 (0.32-0.67)

ref
0.18

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

18
7
9

0.84 (0.62-1.14)
1.00 (0.61-1.64)
0.77 (0.50-1.18)

ref
0.57
0.71

0.62 (0.43-0.89)
0.45 (0.26-0.79)
0.47 (0.31-0.72)

ref
0.29
0.25

Decrease
Increase

15
19

0.81 (0.59-1.12)
0.90 (0.66-1.24)

ref
0.65

0.47 (0.32-0.69)
0.59 (0.42-0.83)

ref
0.29

Zeaxanthin

Cislutein/zeaxanthin
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Cis-lycopene

Trans-lycopene

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

15
6
13

0.82 (0.60-1.12)
0.65 (0.47-2.31)
0.77 (0.54-1.10)

ref
0.22
0.80

0.47 (0.32-0.69)
0.64 (0.35-1.18)
0.58 (0.40-0.83)

ref
0.37
0.33

Decrease
Increase

22
12

0.82 (0.62-1.08)
0.94 (0.64-1.37)

ref
0.55

0.48 (0.35-0.67)
0.53 (0.46-0.99)

ref
0.10

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

22
7
5

0.80 (0.61-1.05)
1.16 (0.71-1.87)
0.71 (0.41-1.23)

ref
0.20
0.68

0.47 (0.35-0.63)
0.54 (0.40-1.00)
0.48 (0.29-0.77)

ref
0.21
0.97

Decrease
Increase

11
23

0.81 (0.54-1.22)
0.88 (0.66-1.16)

ref
0.76

0.63 (0.39-1.00)
0.51 (0.38-0.71)

0.42

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

11
8
15

0.81 (0.54-1.22)
0.83 (0.53-1.29)
0.90 (0.64-1.28)

ref
0.94
0.68

0.63 (0.39-1.01)
0.51 (0.33-0.79)
0.52 (0.36-0.74)

ref
0.48
0.45

Decrease
Increase

14
19

0.77 (0.53-1.11)
0.93 (0.70-1.25)

ref
0.40

0.55 (0.37-0.81)
0.54 (0.37-0.79)

ref
0.97

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

14
8
11

0.76 (0.54-1.07)
0.73 (0.61-1.11)
0.70 (0.49-1.00)

ref
0.87
0.75

0.77 (0.44-1.36)
0.59 (0.40-0.87)
0.48 (0.33-0.71)

ref
0.40
0.34

Decrease
Increase

14
20

0.79 (0.55-1.11)
0.91 (0.68-1.21)

ref
0.52

0.55 (0.37-0.83)
0.53 (0.38-0.75)

ref
0.89

Decrease
Minimal increase (1-20%)

14
7

0.80 (0.57-1.12)
1.23 (0.76-1.99)

ref
0.14

0.56 (0.37-0.83)
0.64 (0.39-1.06)

ref
0.61

Antioxidant score d

Substantial increase (> 20%)

13

0.79 (0.56-1.10)

0.95

0.50 (0.34-0.72)

0.63

Decrease
Increase

14
19

0.87 (0.55-0.35)
0.85 (0.66-1.11)

ref
0.96

0.64 (0.40-1.02)
0.51 (0.37-0.70)

ref
0.37

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

14
8
11

0.85 (0.55-1.31)
1.07 (0.73-1.59)
0.71 (0.50-1.00)

ref
0.43
0.53

0.65 (0.42-1.01)
0.73 (0.47-1.14)
0.43 (0.30-0.60)

ref
0.69
0.10

Abbreviation: PSA – prostate-specific antigen, CI – confidence interval
a
Data are reported as least square means and confidence intervals
b
Adjusted for age, race, randomized group and baseline PSA level
c
Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass index, total
metabolic equivalent (MET) per week of physical activity, energy intake, randomized group and baseline PSA level
e
Antioxidant score; low : 45 – 80, high: 81 –111.
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§

P values from regression models comparing mean difference between decrease in tocopherol/carotenoid categories with an
increase, minimal increase or substantial increase respectively

Table 4.7 Percent change in carotenoid and tocopherol levels from baseline to 3 months in relation to PSA levels at 6 months,
adjusting for baseline PSA level
PSA level at 6 months a
Means (95% CI)
Change in plasma tocopherols and carotenoids from
baseline to 3 months

n

Crude model b

Adjusted model c
P§

α-tocopherol

111

γ-tocopherol

α-carotene

Cis-β-carotene

P§

Decrease
Increase

13
21

0.82 (0.63-1.06)
0.63 (0.52-0.77)

ref
0.11

0.89 (0.72-1.10)
0.51 (0.44-0.60)

ref
<0.0001

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

13
14
7

0.81 (0.63-1.05)
0.66 (0.52-0.84)
0.57 (0.40-0.80)

ref
0.25
0.09

0.92 (0.74-1.13)
0.55 (0.45-0.67)
0.45 (0.35-0.58)

ref
<0.0001
<0.0001

Decrease
Increase

17
17

0.70 (0.55-0.90)
0.68 (0.55-0.85)

ref
0.87

0.62 (0.48-0.79)
0.54 (0.42-0.71)

ref
0.38

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

17
8
9

0.70 (0.55-0.89)
0.61 (0.45-0.84)
0.75 (0.56-1.00)

ref
0.20
0.19

0.62 (0.48-0.79)
0.50 (0.37-0.68)
0.60 (0.44-0.84)

ref
0.20
0.91

Decrease
Increase

29
5

0.71 (0.60-0.84)
0.52 (0.32-0.85)

ref
0.23

0.59 (0.47-0.73)
0.55 (0.33-0.94)

ref
0.82

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

29
3
2

0.72 (0.61-0.85)
0.67 (0.37-1.24)
0.37 (0.19-0.74)

ref
0.32
0.36

0.62 (0.50-0.76)
0.82 (0.44-1.54)
0.34 (0.17-0.67)

ref
0.35
0.11

Decrease
Increase

19
15

0.84 (0.69-1.02)
0.73 (0.44-0.87)

ref
0.39

0.74 (0.61-0.88)
0.68 (0.34-0.82)

ref
0.84

Decrease

19

0.84 (0.70-1.02)

ref

0.75 (0.63-0.90)

ref

Trans-β-carotene

α-cryptoxanthin
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β-cryptoxanthin

Lutein

Zeaxanthin

Minimal increase (1-20%)
Substantial increase (> 20%)

7
8

0.79 (0.42-0.89)
0.66 (0.39-0.78)

0.56
0.15

0.71 (0.36-0.89)
0.63 (0.29-0.86)

0.28
0.63

Decrease
Increase

19
15

0.88 (0.74-1.04)
0.49 (0.41-0.60)

ref
<0.0001

0.84 (0.69-1.03)
0.45 (0.38-0.54)

ref
<0.0001

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

19
9
6

0.89 (0.75-1.04)
0.55 (0.43-0.72)
0.43 (0.32-0.58)

ref
0.002
<0.0001

0.84 (0.69-1.03)
0.46 (0.37-0.58)
0.44 (0.34-0.57)

ref
<0.0001
<0.0001

Decrease
Increase

10
24

0.76 (0.56-1.02)
0.67 (0.55-0.81)

ref
0.48

0.90 (0.64-1.27)
0.77 (0.46-0.67)

ref
0.39

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

10
5
19

0.76 (0.56-1.02)
0.66 (0.45-0.96)
0.67 (0.53-0.84)

ref
0.56
0.51

0.90 (0.65-1.26)
0.69 (0.48-0.92)
0.64 (0.41-0.64)

ref
0.43
0.18

Decrease
Increase

18
16

0.62 (0.50-0.79)
0.77 (0.61-0.97)

ref
0.21

0.66 (0.52-0.84)
0.49 (0.37-0.65)

ref
0.07

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

18
7
9

0.61 (0.49-0.76)
1.01 (0.74-1.38)
0.63 (0.48-0.82)

ref
0.21
0.89

0.67 (0.53-0.83)
0.70 (0.47-1.04)
0.44 (0.33-0.58)

ref
0.82
0.009

Decrease
Increase

15
19

0.76 (0.60-0.96)
0.63 (0.51-0.79)

ref
0.27

0.60 (0.46-0.80)
0.68 (0.45-0.73)

ref
0.74

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

15
6
13

0.76 (0.61-0.96)
0.78 (0.48-1.25)
0.60 (0.47-0.77)

ref
0.95
0.16

0.61 (0.45-0.81)
0.75 (0.35-0.98)
0.63 (0.44-0.86)

ref
0.75
0.77

Decrease
Increase

22
12

0.61 (0.50-0.74)
0.65 (0.49-1.09)

ref
0.33

0.57 (0.45-0.70)
0.63 (0.48-0.89)

ref
0.29

Decrease

22

0.61 (0.50-0.74)

ref

0.55 (0.44-0.68)

ref

Cislutein/zeaxanthin

Cis-lycopene
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Trans-lycopene

Antioxidant score d

Minimal increase (1-20%)
Substantial increase (> 20%)

7
5

0.66 (0.58-1.29)
0.64 (0.53-1.09)

0.25
0.29

0.77 (0.54-1.16)
0.54 (0.37-0.80)

0.65
0.86

Decrease
Increase

11
23

0.84 (0.63-1.11)
0.63 (0.52-0.77)

ref
0.11

0.80 (0.60-1.07)
0.52 (0.42-0.64)

0.003

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

11
8
15

0.84 (0.64-1.11)
0.72 (0.52-0.98)
0.59 (0.47-0.75)

ref
0.46
0.06

0.78 (0.60-1.02)
0.64 (0.49-0.83)
0.47 (0.38-0.57)

ref
0.26
0.0004

Decrease
Increase

14
19

0.77 (0.59-1.00)
0.68 (0.55-0.85)

ref
0.49

0.73 (0.57-0.94)
0.67 (0.39-0.86)

ref
0.19

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

14
8
11

0.76 (0.59-0.99)
0.83 (0.60-1.14)
0.59 (0.45-0.78)

ref
0.68
0.17

0.78 (0.65-0.98)
0.72 (0.56-1.01)
0.64 (0.34-0.82)

ref
0.69
0.28

Decrease
Increase

14
20

0.73 (0.57-0.93)
0.67 (0.54-0.83)

ref
0.59

0.69 (0.53-0.91)
0.53 (0.42-0.66)

ref
0.07

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

14
7
13

0.73 (0.57-0.93)
0.76 (0.53-1.10)
0.63 (0.49-0.81)

ref
0.85
0.39

0.69 (0.55-0.87)
0.73 (0.55-0.97)
0.45 (0.36-0.56)

ref
0.72
0.002

Decrease
Increase

14
19

0.81 (0.59-1.10)
0.65 (0.54-0.79)

ref
0.26

0.93 (0.72-1.21)
0.50 (0.42-0.60)

ref
<0.0001

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

14
8
11

0.81 (0.59-1.10)
0.64 (0.47-0.87)
0.66 (0.52-0.84)

ref
0.31
0.30

0.92 (0.72-1.16)
0.62 (0.50-0.78)
0.44 (0.37-0.53)

ref
0.01
<0.0001

Abbreviation: PSA – prostate-specific antigen, CI – confidence interval
a
Data are reported as least square means and confidence intervals
b
Adjusted for age, race, randomized group and baseline PSA level
c
Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass index, total

metabolic equivalent (MET) per week of physical activity, energy intake, randomized group and baseline PSA level
d
Antioxidant score; low : 45 – 80, high: 81 –111.
§
P values from regression models comparing mean difference between decrease in tocopherol/carotenoid categories with an
increase, minimal increase or substantial increase respectively
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Table 4.8 Percent change in carotenoid and tocopherol levels from baseline to 3 months in relation to postintervention PSA levels ( at 3 months and at 6 months), adjusting for baseline PSA level –– Mixed models
Means (95% CI) a
Change in plasma tocopherols and carotenoids from
baseline to 3 months

n

Crude model b

Adjusted model c
P§

α-tocopherol

γ-tocopherol
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α-carotene

Cis-β-carotene

P§

Decrease
Increase

13
21

0.91 (0.73-1.13)
0.72 (0.65-0.80)

ref
0.08

0.84 (0.59-1.19)
0.47 (0.36-0.63)

ref
0.003

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

13
14
7

0.91 (0.73-1.13)
0.74 (0.65-0.84)
0.67 (0.61-0.73)

ref
0.13
0.02

0.85 (0.60-1.21)
0.52 (0.40-0.69)
0.39 (0.23-0.64)

ref
0.004
0.01

Decrease
Increase

17
17

0.83 (0.69-1.01)
0.74 (0.66-0.84)

ref
0.35

0.56 (0.38-0.82)
0.52 (0.35-0.76)

ref
0.69

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

17
8
9

0.83 (0.68-1.01)
0.72 (0.59-0.87)
0.77 (0.69-0.86)

ref
0.29
0.57

0.56 (0.38-0.81)
0.50 (0.35-0.72)
0.54 (0.32-0.90)

ref
0.60
0.88

Decrease
Increase

29
5

0.85 (0.70-1.03)
0.72 (0.65-0.80)

ref
0.16

0.62 (0.44-0.89)
0.45 (0.30-0.69)

ref
0.10

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

29
3
2

0.84 (0.70-1.01)
0.77 (0.69-0.86)
0.64 (0.57-0.73)

ref
0.46
0.04

0.56 (0.37-0.84)
0.58 (0.39-0.87)
0.32 (0.18-0.60)

ref
0.88
0.01

Decrease
Increase

19
15

0.87 (0.75-1.00)
0.68 (0.61-0.76)

ref
0.28

0.67 (0.47-0.96)
0.65 (0.28-0.68)

ref
0.71

Decrease
Minimal increase (1-20%)

19
7

0.87 (0.75-1.00)
0.74 (0.66-0.84)

ref
0.22

0.67 (0.46-0.97)
0.66 (0.24-0.88)

ref
0.27

Trans-β-carotene

α-cryptoxanthin
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β-cryptoxanthin

Lutein

Zeaxanthin

Substantial increase (> 20%)

8

0.66 (0.58-0.75)

0.18

0.65 (0.34-0.76)

0.35

Decrease
Increase

19
15

0.90 (0.78-1.04)
0.65 (0.59-0.72)

ref
0.002

0.72 (0.50-1.05)
0.44 (0.32-0.61)

ref
0.01

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

19
9
6

0.90 (0.77-1.03)
0.69 (0.60-0.79)
0.57 (0.47-0.69)

ref
0.03
<0.0001

0.69 (0.50-0.95)
0.61 (0.41-0.91)
0.22 (0.09-0.53)

ref
0.56
0.02

Decrease
Increase

10
24

0.75 (0.68-0.83)
0.84 (0.70-1.03)

ref
0.26

0.50 (0.34-0.73)
0.60 (0.42-0.86)

ref
0.36

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

10
5
19

0.75 (0.68-0.83)
0.91 (0.68-1.22)
0.74 (0.64-0.86)

ref
0.22
0.19

0.54 (0.35-0.82)
0.72 (0.40-1.31)
0.48 (0.32-0.72)

ref
0.25
0.71

Decrease
Increase

18
16

0.78 (0.66-0.92)
0.79 (0.72-0.87)

ref
0.91

0.62 (0.40-0.96)
0.47 (0.31-0.70)

ref
0.24

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

18
7
9

0.78 (0.66-0.92)
0.85 (0.73-0.99)
0.74 (0.65-0.83)

ref
0.44
0.65

0.63 (0.41-0.97)
0.51 (0.29-0.89)
0.44 (0.29-0.66)

ref
0.44
0.21

Decrease
Increase

15
19

0.78 (0.70-0.86)
0.79 (0.67-0.93)

ref
0.83

0.47 (0.32-0.68)
0.59 (0.43-0.81)

ref
0.16

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

15
6
13

0.77 (0.70-0.85)
0.91 (0.64-1.28)
0.71 (0.60-0.84)

ref
0.38
0.32

0.46 (0.29-0.73)
0.62 (0.41-0.93)
0.55 (0.32-0.94)

ref
0.35
0.27

Decrease
Increase

22
12

0.84 (0.75-0.98)
0.76 (0.64-0.94)

ref
0.28

0.67 (0.46-0.97)
0.58 (0.42-0.88)

ref
0.25

Decrease

22

0.75 (0.66-0.86)

ref

0.64 (0.42-0.93)

ref

Cis-lutein/zeaxanthin

Cis-lycopene
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Trans-lycopene

Antioxidant score d

Minimal increase (1-20%)
Substantial increase (> 20%)

7
5

89 (0.77-1.04)
0.74 (0.65-0.84)

0.09
0.84

0.60 (0.33-0.78)
0.58 (0.43-0.99)

0.25
0.30

Decrease
Increase

11
23

0.79 (0.68-0.92)
0.78 (0.68-0.90)

ref
0.89

0.63 (0.42-0.94)
0.52 (0.36-0.75)

ref
0.32

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

11
8
15

0.79 (0.68-0.92)
0.84 (0.68-1.03)
0.76 (0.65-0.90)

ref
0.66
0.77

0.63 (0.42-0.97)
0.52 (0.36-0.74)
0.49 (0.25-0.94)

ref
0.52
0.32

Decrease
Increase

14
19

0.80 (0.68-0.94)
0.76 (0.67-0.85)

ref
0.56

0.54 (0.35-0.83)
0.54 (0.38-0.76)

ref
0.94

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

14
8
11

0.80 (0.67-0.94)
0.75 (0.67-0.84)
0.70 (0.62-0.79)

ref
0.30
0.15

0.58 (0.39-0.87)
0.74 (0.46-1.22)
0.47 (0.36-0.63)

ref
0.39
0.24

Decrease
Increase

14
20

0.78 (0.69-0.93)
0.76 (0.68-0.85)

ref
0.58

0.55 (0.35-0.86)
0.53 (0.38-0.75)

ref
0.87

Decrease
Minimal increase (1-20%)
Substantial increase (> 20%)

14
7
13

0.78 (0.69-0.93)
0.76 (0.68-1.85)
0.72 (0.55-1.09)

ref
0.26
0.91

0.59 (0.39-0.87)
0.66 (0.54-1.81)
0.46 (0.33-0.66)

ref
0.39
0.30

Decrease
Increase

14
19

0.85 (0.74-0.97)
0.65 (0.55-0.75)

ref
0.01

0.64 (0.46-0.91)
0.41 (0.30-0.58)

ref
0.004

Decrease
14 0.85 (0.74-0.97)
ref
0.67 (0.50-0.89)
ref
Minimal increase (1-20%)
8
0.62 (0.57-0.76)
0.06
0.62 (0.45-0.85)
0.29
Substantial increase (> 20%)
11 0.58 (0.66-0.80)
0.31 (0.21-0.47)
0.02
<0.0001
Abbreviation: PSA – prostate-specific antigen, CI – confidence interval
a
Data are reported as least square means and confidence intervals
b
Adjusted for age, race, randomized group and baseline PSA level
c
Adjusted for age, race, education, marital status, employment status, smoking status, Gleason score, body mass index, total

metabolic equivalent task (MET) per week of physical activity, energy intake, randomized group and baseline PSA level
d
Antioxidant score; low : 45 – 80, high: 81 –111.
§ P value comparing mean difference between decrease in tocopherol/carotenoid categories with an increase, minimal increase
or Substantial increase respectively
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CHAPTER 5
DIETARY, SUPPLEMENT, AND ADIPOSE TISSUE TOCOPHEROL LEVELS IN RELATION TO
PROSTATE CANCER AGGRESSIVENESS

5.1

INTRODUCTION
Prostate cancer (PCa) is the leading invasive malignancy and the second most

fatal cancer in American men [385]. International variations in PCa incidence as well as
changes in the disease risk patterns among migrant populations in Western countries
indicate the importance of environmental factors in PCa, particularly the role of dietary
factors [354, 386, 387]. Vitamin E, a fat-soluble antioxidant found in vegetable oils,
seeds, nuts, leafy green vegetables and whole grains, contributes to the body’s defenses
against reactive oxygen species (ROS), which may play a role in PCa by causing
oxidative DNA damage [117, 158, 388-390].
It has long been recognized that vitamin E, the collective name for eight naturally
occurring compounds consisting of four tocopherols (i.e., α-, β-, γ- and δ-tocopherol) and
corresponding four tocotrienols, has potent antioxidant properties that may inhibit
carcinogenesis [158, 388, 391]. Studies examining associations between vitamin E and
PCa have focused primarily on PCa incidence, but these yielded conflicting findings,
including results from randomized controlled trials (reviewed in [64, 392-394]).
Recently, there has been increasing awareness of the remarkable heterogeneity of PCa.
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Owing to the widespread use of prostate-specific antigen (PSA) blood test for
early detection, most newly diagnosed PCa cases are latent disease and often remain
indolent over a lifetime, similar to those observed at autopsy [395, 396]. Few of these
tumors progress aggressively (approximately 30%) and are associated with poorer
prognosis [5, 6]. There is the possibility that vitamin E may have differential effect on
aggressive PCa versus indolent disease, and thus, prior conflicting findings on PCa
incidence may be due to mixing of different disease states [397].
Distinguishing the modifiable factors of virulent PCa from that of indolent disease
is particularly important for addressing racial disparities in PCa as African Americans
(AAs) have greater burden of virulent PCa compared to European Americans (EAs)
[398]. Therefore, this study investigated whether higher intakes of tocopherols from diet
and supplements (α-tocopherol equivalent), and higher adipose tissue tocopherol levels
are inversely associated with PCa aggressiveness among AA and European American
(EA) men.
5.2

MATERIALS AND METHODS

Study Population
The North Carolina-Louisiana Prostate Cancer Project (PCaP) is a populationbased, cross-sectional, case-only, incident PCa study, designed to investigate racial and
geographical differences in PCa aggressiveness. The methods and design of PCaP have
been described [399]. Briefly, using a rapid case ascertainment system, men with a first
diagnosis of histologically confirmed adenocarcinoma of the prostate were recruited in
North Carolina (NC) and Louisiana (LA) between July 1, 2004 and August 31, 2009.
Residents of North Carolina and Louisiana were eligible if they resided within the study
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catchment areas, and were (1) between 40-79 years old at diagnosis; (2) self-identified
race as AA/Black or Caucasian/White (EA); (3) able to complete study interview in
English; (4) did not live in an institution (e.g., nursing home); and (5) were mentally and
physically able to complete the interview. Written informed consents were obtained from
all research subjects prior to participation. Approximately equal numbers of AAs and
EAs were enrolled from NC (AAs n = 505; EAs n = 527) and LA (AAs n = 632; EA n =
603), with participation rates of 62% for NC, 72% for pre- and 63% for post-Hurricane
Katrina Louisiana. The PCaP study protocols were approved by Institutional Review
Boards (IRB) of the University of North Carolina at Chapel Hill, Louisiana State
University Health Sciences Center, and the Department of Defense Prostate Cancer
Research Program. The current analyses also were approved by the University of South
Carolina IRB as exempt.
Data Collection
Consenting research subjects completed structured in-home interviews with
trained research nurses who administered study questionnaires covering various
information including demographics, pre-diagnostic PCa screening history,
comorbidities, family health history, healthcare access, and behavioral factors such as
physical activity and smoking status. The research nurses obtained anthropometric
measurements (height and weight) using standard protocols. Medical records were
obtained from diagnosing physicians and abstracted by trained personnel for information
including cancer stage at diagnosis, Gleason sum and prostate-specific antigen (PSA)
level at diagnosis. To ensure abstractor consistency, a random sample of the abstracted
medical records (approximately 10%) were abstracted a second time by another staff
121

member. In PCaP, PCa aggressiveness is defined by a combination of Gleason sum,
cancer stage and PSA level at diagnosis as (1) high aggressive (Gleason sum ≥8 or PSA
>20 ng/mL, or Gleason sum ≥ 7 and cancer stage T3–T4); (2) low aggressive (Gleason
sum < 7 and stage T1-T2 and PSA<10 ng/ml), and (3) intermediate aggressive PCa (all
others). For the present analyses, a case-control study design was used to contrast
research subjects with high aggressive PCa (“cases”) to those with low/intermediate
aggressive PCa (comparison group or “controls”).
Dietary Assessment
The food frequency questionnaire was based on the National Cancer Institute Diet
History Questionnaire (NCI-DHQ) modified to include Southern foods was used to
assess food intake in the year prior to PCa diagnosis and included questions pertaining to
frequency of intake, portion sizes and methods of food preparation for over 124 food
items [400]. Responses to the questions were linked to an updated NCI nutrient database
through which food compositions of α-, β-, γ-, and δ-tocopherol were estimated using the
NCI Diet*Calc software [401].
Assessment of Dietary Supplement Use
Information on dietary supplement use was solicited via a validated questionnaire
[323] administered by the research nurses during in-home visits. Data on supplemental
vitamin E intake were derived from response to questions about the use of multivitamins
containing vitamin E and use of single-nutrient vitamin E supplements. For
multivitamins, research subjects were asked whether they had taken multivitamin
supplements in the 12 months prior to PCa diagnosis (no, less than once a week, yes); and
if yes, the frequency of use (1-2, 3-4, 5-6, 7 days/week). Forty-five percent of the
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research subjects reported multivitamin supplement use in the previous 12 months, and
were asked to identify the most often used brand from a list of common multivitamin
brands in the U.S., which included an open-ended option for unlisted brands.
Subsequently, these research subjects were asked to provide the multivitamin supplement
bottle for recording of nutrient contents and dose. Research subjects who were unable to
provide the multivitamin bottle (about 5% of users) were assigned the vitamin E dose
listed on manufacturer label of the stated brand. When the manufacturer label could not
be found (less than 1%), research subjects were assigned the vitamin E dose of the most
commonly used brand among multivitamin supplement users; this value was 50 IU (i.e.,
from Centrum Silver). In subsequent questions, research subjects were asked about the
use of single nutrient supplements; and if yes (13% of subjects), the frequency of use
(same categories as above). Research subjects who were unable to provide the
supplement bottle were asked to indicate the usual dose taken; dose choices for singlenutrient vitamin E supplements were 30, 100, 200, 400, 600 or 800 IU/day, and an openended option for unlisted dose. Research subjects who reported using single-nutrient
vitamin E supplement but could not provide the supplement bottle or unable to report
usual dose (4% of users) were assigned the mode dose (i.e., 400 IU) among singlenutrient vitamin E supplement users. Total vitamin E supplement intake was estimated as
the sum of vitamin E from single-nutrient supplement and multivitamins, and converted
as 1 IU = 0.45 mg of α-tocopherol [402]. Total α-tocopherol exposure was subsequently
calculated as the sum of dietary α-tocopherol intake and total vitamin E supplement
intake (i.e., diet + supplement).
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Adipose Tissue Sampling and Analysis
Adipose tissue samples were obtained from the abdominal region of consenting
research subjects who were not allergic to the local anesthesia solution (2% lidocaine).
After the overlying skin was anesthetized, a 15-gauge needle was inserted into the
subcutaneous fat and suction was applied using 15 ml vacutainer tube. The aspirated
tissue was trapped in the needle and luer lock adapter, which was placed in separate
cryovials for transportation. The collected samples were transported on ice to the
assigned storage facility within 24 hours of collection and stored at -80oC. The samples
were later transported on ice to Craft Technologies, Incorporated in Wilson, NC for highperformance liquid chromatography (HPLC) analysis. The average time between sample
collection and storage was 24 hours, and average time from storage to analysis was 6
months. Adipose tissue concentrations of α-, γ- and δ-tocopherol were expressed as mcg
per gram of tissue at tocopherols detection limit of 0.07 mcg/g.
Statistical Methods
The analytic population was drawn from 2,173 PCaP research subjects with data
on PCa aggressiveness. Prior to data analysis, research subjects with implausibly low or
high daily caloric intake (< 500 or > 6,000 kcals, n = 71) were excluded, leaving a final
study sample of 2,102 (AAs n = 1,023, EAs n = 1,079). Of these research subjects, data
on adipose tissue tocopherol levels were available for 945 subjects (AA n = 361, EAs n =
584).
Descriptive statistics were compared by level of PCa aggressiveness as means
(continuous variables) and proportions (categorical variables) using t and χ2 tests,
respectively. All tocopherol exposure variables were categorized into quartiles, separately
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for AAs and EAs, based on distribution among low/intermediate aggressive cases in the
respective race group. Hence, analyses were conducted separately for AAs and EAs. The
decision to categorize the exposures separately by race was informed by preliminary
analysis indicating different dietary and supplement use patterns between AAs and EAs.
Unconditional logistic regression was used to estimate crude (age-adjusted) and
multivariable-adjusted odds ratios (ORs) and 95% confidence interval (CIs).
In selecting the multivariable-adjusted models, the following variables were
considered as potential confounders based on review of the literature: pre-diagnostic PSA
screening history (0, 1-7, >7 screenings); family history of PCa (number of affected first
degree relative: none vs. at least one); prevalence of comorbidities (Charlson
Comorbidity Index: 0, 1, 2, ≥3); whether PCa treatment had started at time of interview
(yes, no); smoking status (never, former, current); education (less than high school
education, high school graduate/vocational school, some college/college graduate,
graduate degree); annual household income (< $20,000, $20,001 - $40,000, $40,001 $60,000, $60,001 - $80,000, >$80,000, unknown); multivitamin use in the year prior to
diagnosis (yes, no); non-steroidal anti-inflammatory drug (NSAID) use in the five years
prior to diagnosis (yes, no); physical activity in the year prior to diagnosis [total
metabolic equivalents (METs) of light, moderate and vigorous exercise categorized as: ≤
10.2, 10.3-29.0, > 29.0 METs/week]; body mass index (BMI: kg/m2, continuous); study
site (NC, LA); energy intake (kcal/day); dairy intake (servings/day); and alcohol intake
(grams/day). These variables were first examined for confounding effect (i.e., ≥10%
change in effect estimates of each exposure variable with age in the model). Next,
variables determined to be confounders and those that are biologically relevant to PCa
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were placed in an elaborate model simultaneously for final model selection using a
combination of the backward elimination method and likelihood ratio tests to remove one
variable at a time. Through this process, the following variables were included in the final
adjusted model for analysis of dietary tocopherols and vitamin E supplement use
associations: age (continuous), pre-diagnostic PSA screening history, BMI, smoking
status, education, income, NSAIDs use, dietary fat intake, and study site. Additional
adjustment of family history of PCa, comorbidities and PCa treatment status were done
for associations of adipose tocopherol levels and PCa aggressiveness. Tests for linear
trend (Ptrend) were performed by modeling the median values of each tocopherol category
as continuous variable. Family history of PCa, pre-diagnostic PSA screening history,
BMI and NSAIDs use were examined for potential effect modification by assessing
stratum-specific ORs in stratified multivariable analyses, and including evaluation of
interaction terms between these factors and the main exposures using likelihood ratio
tests. All analyses were performed with SAS version 9.3 (Cary, NC, USA) with statistical
significance set at α = 0.05 (two-tailed).
5.3

RESULTS
Differences in distribution of research subject characteristics are presented by

level of PCa aggressiveness separately for AAs and EAs in Table 5.1. AA subjects with
high aggressive PCa were slightly older, had higher intakes of energy and dietary fat,
included a greater proportion of current smokers and lower incomes, more often reported
no PSA screening prior to diagnosis, but less often reported vitamin E supplement use
compared to those with low/intermediate aggressive disease. EA subjects with high
aggressive PCa were older, had slightly higher BMI, higher proportion had started PCa
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treatment by start of study and more often reported vitamin E supplement use compared
to those with low/intermediate aggressive PCa. In both AAs and EAs, research subjects
with high aggressive PCa had lower educational level than those with low/intermediate
aggressive PCa.
Table 5.2 presents mean difference in tocopherol levels and supplemental vitamin
E intake by race and by level of PCa aggressiveness. Overall, AA subjects tended to have
higher dietary intakes of γ- and δ-tocopherol but lower intakes of supplemental vitamin E
and total α-tocopherol compared to EAs. Mean adipose α-tocopherol level was 75%
higher in EAs than to AAs. While no differences in dietary, supplement or adipose
tocopherol levels were observed by the level of PCa aggressiveness among EAs, AA
subjects with low/intermediate aggressive PCa had higher intakes of supplemental
vitamin E and total α-tocopherol compared to their counterparts with high aggressive
PCa.
Multivariable-adjusted ORs for high aggressive PCa were estimated by quartiles
of dietary tocopherols and supplemental vitamin E intake with lower quartiles as the
referent group (Table 5.3). No significant associations were observed among AAs,
although there were some suggestive inverse associations, particularly in the highest
quartiles of dietary α-tocopherol and vitamin E supplement intake. Among EA subjects, a
dose-response inverse association was observed between dietary α-tocopherol intake and
PCa aggressiveness, showing 66% lower odds of high aggressive PCa in the highest
quartile. However, neither vitamin E supplement intake nor total α-tocopherol intake was
associated with PCa aggressiveness among EAs. Dietary δ-tocopherol intake also was
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inversely and linearly associated with PCa aggressiveness among EAs. A nearly
statistically significant inverse associations was observed in the highest quartile of βtocopherol intake (OR = 0.56, 95% CI = 0.30-1.02). There also was a nearly significant
trend for lower odds of high aggressive PCa with increasing consumption of γ-tocopherol
among EAs (Ptrend = 0.05).
Research subjects with and without data on adipose tocopherol levels did not
differ substantially. In sensitivity analyses, similar associations were observed between
dietary tocopherol intake and PCa aggressiveness among research subjects with and
without data on adipose tocopherols (Table 5.5 and 5.6). Adipose tissue tocopherol levels
also were categorized and analyzed separately for AAs and EAs (Table 5.4). While none
of the associations was statistically significant, higher adipose α-tocopherol level
appeared to be inversely associated with high aggressive PCa among AAs (OR = 0.66,
95% CI = 0.27-1.62, highest vs. lowest quartile), but positively associated among EAs
(OR = 1.43, 95% CI = 0.66-3.11, highest vs. lowest quartiles). Evaluations of potential
modifying effects of family history of PCa, pre-diagnostic PSA screening history,
smoking status, BMI and NSAIDs use did not show effect modification by these factors
(data not shown).
5.4

DISCUSSION
In this population-based, case-only, study of PCa aggressiveness, higher dietary

intake of α- and δ-tocopherol was inversely associated with high aggressive PCa among
EAs. Nearly statistically significant inverse associations also were observed between
higher dietary intake of γ- and β-tocopherol, and high aggressive PCa among EAs. None
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of the dietary tocopherols was associated with PCa aggressiveness among AAs.
Similarly, no significant association was observed for supplemental and total (diet and
supplement) α-tocopherol intake among AAs or EAs. Interestingly, there was a
suggestion that a higher adipose tissue α-tocopherol level was inversely associated with
high aggressive PCa among AAs, but positively associated among EAs.
Tocopherols are thought to have strong chemopreventive properties that may
protect against PCa by preventing or mitigating the deleterious effects of oxidative stress,
specifically oxidative damage to DNA, proteins and lipids [158, 388, 391, 394]. Many
reports indicate that tocopherols interact with a variety of ROS, notably peroxyl radicals,
to form relatively innocuous compounds, thereby mitigating oxidative stress [388, 403].
Other proposed anticarcinogenic properties of tocopherols include enhancing the immune
system’s surveillance and destruction of tumor cells, regulation of genes involved in
tumor cell growth, inhibition of protein kinase C, modulation of apoptosis and cell cycle
signaling pathways, and down-regulating inflammatory responses [158, 164, 403, 404].
However, clinical trials investigating the efficacy of supplemental α-tocopherol intake for
the prevention of PCa also have yielded contradictory results with some showing
beneficial effect [159], no benefits [74, 405], and even possible harm [164, 406]. In
particular, the Alpha Tocopherol Beta-Carotene (ATBC) Cancer Prevention Trial,
originally designed to investigate lung cancer incidence, reported a 32% reduced risk of
PCa and 41% decreased mortality from PCa among Finnish male smokers taking 50
mg/day of supplemental vitamin E (α-tocopherol) over 5-8 years compared to placebo
[159]. In contrast, the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
reported a 17% increased risk of PCa among healthy males taking 400 IU/day of α129

tocopherol over a 7-year median follow-up time compared to placebo [164]. Two other
clinical trials have reported null associations between vitamin E supplementation and
PCa incidence [74, 405]. The epidemiologic data relating to associations of tocopherols
intake and PCa incidence also are equivocal (reviewed in [64, 393, 394]).
Data on tocopherols from diet, supplements, and adipose tissue provide
complementary information about the role of tocopherols in PCa; however, as shown in
this analysis, they can yield mixed results because these data are different measures of
tocopherol status. While dietary and supplement use questionnaires can provide estimates
of usual intake patterns, typically in the recent past; they do not reflect day-to-day
variations or longer periods of intake [384]. On the other hand, fat-soluble antioxidants
are known to selectively accumulate in human adipose tissue and turn to turn over at a
low rate [407]. Thus, adipose tissue serves as an objective marker of tocopherol status
and can quantify systemic exposure over longer periods, although influenced by
individual differences in absorption and metabolism [290, 407].
The mean α-tocopherol intake level (10.5 mg/day) in this study population is
comparable to that of a study conducted among AAs and EAs in NC [408]. The inverse
association between increased dietary intake of α-tocopherol and PCa aggressiveness
also concurs with previous literature on PCa incidence [64, 393, 409]. It was somewhat
surprising that although AAs and EAs had similar dietary intakes of α-tocopherol (Tables
4.2.2 and 4.2.3); α-tocopherol was not associated with PCa aggressiveness among AAs.
This discrepancy may be explained, at least in part, by differences in food sources of αtocopherol between the two groups. Exploratory analysis showed that a greater
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proportion of EAs in the highest quartile of the dietary α-tocopherol had higher intake of
plant-based foods containing high amounts of α-tocopherol such as nuts, seeds, olive oils
and other healthy food sources of α-tocopherol. By contrast, AAs in this category tended
to consume higher amounts of foods from less healthy sources of α-tocopherol,
particularly processed foods containing high amounts of saturated fat including potato
and corn chips, and dark green vegetables prepared with fatback and lard. Besides racial
difference in dietary patterns, there is also the possibility of gene-nutrient interactions
involving polymorphisms in genes that regulate α-tocopherol activity [410], those
implicated in PCa aggressiveness [131, 411] or both, which may vary by race.
Despite the strong inverse association for dietary α-tocopherol among EAs,
supplemental vitamin E and total α-tocopherol intake from both diet and supplements
were not associated with PCa aggressiveness among EAs or AAs. Epidemiologic studies
regarding vitamin E supplement use and PCa incidence have often reported null results
[412-414]; few have reported protective associations but this has been limited to smokers
[68, 170] who may have greater need for vitamin E because of increased exposure to
ROS from tobacco smoke [415]. In the present study, however, subgroup analysis did not
show effect modification by smoking status, which may have been limited by small
sample size especially since analyses were stratified by race. The lack of significant
associations for total α-tocopherol may be because research subjects who consumed high
amounts of α-tocopherol from diet may have consumed low amounts from supplements
or vice versa, which would lead to classification differences into low and higher quartiles
when dietary and supplemental intakes were combined into one category.
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The nearly significant inverse association in the highest quartile of dietary βtocopherol and nearly significant inverse linear trend for γ-tocopherol among EAs
suggest a potential beneficial role for these tocopherols or food sources of these
tocopherols in PCa aggressiveness. Dietary intakes of γ-tocopherol were actually higher
than α-tocopherol; consistent with the general observation that the amounts of γtocopherol in American diet are higher than that of α-tocopherol [416]. Nonetheless,
blood concentrations of α-tocopherol are about ten times higher that γ-tocopherol, which
has been attributed to the preferential transfer of α-tocopherol to the blood by the hepatic
α-tocopherol transfer protein (α-TTP) [388, 417]. Thus, perhaps higher intakes of the
other tocopherols may be needed to increase their bioavailability and subsequent
antioxidant activity. Alternatively, α-tocopherol may have more potent anticarcinogenic
properties than the other tocopherols [391].
There was a suggestion that higher adipose α-tocopherol levels were inversely
associated with high aggressive PCa among AAs, but positively associated among EAs.
A possible explanation for these seemingly conflicting results is the significant difference
in adipose α-tocopherol levels among AAs and EAs. EAs had a 75% higher mean
adipose α-tocopherol level than AAs (Table 5.2). It is unclear what constitutes “normal”
adipose tocopherol levels. Mean α-tocopherol levels in EAs in PCaP were slightly
higher than those reported in breast tissue from Malaysian women in a previous study
[418] and lower than those reported in adipose tissue from European males in the
EURAMIC study [419]. It is reasonable to speculate that long-term use of dietary
supplements (the most common source of α-tocopherol) may have been the major
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contributor of the adipose α-tocopherol levels among EAs, especially since a much
greater proportion of EAs reported vitamin E supplement use compared to AAs. This
speculation could not be verified due to lack of data on long-term duration of supplement
use in PCaP.
Although the mechanisms by which higher physiological levels of α-tocopherol
may be influencing PCa aggressiveness have yet to be clarified, laboratory studies
suggest that α-tocopherol may have dual function as an antioxidant and as a pro-oxidant
such that at very high levels, α-tocopherol tends to exhibit pro-oxidant properties that
promote oxidative stress [420]. A recent study in mouse model suggest that α-tocopherol
supplementation in nutritionally replete organisms can promote cancer cell proliferation
by suppressing the expression of p53, a major tumor suppressor gene, which can lead to
cancer cell escape from apoptosis [421]. These reports suggest that a fine balance
between ROS and antioxidants is needed to maintain intracellular homeostasis, and
provide mechanistic support to the finding in SELECT where α-tocopherol
supplementation in healthy men was associated with increased risk of PCa [164, 406].
Notable strengths the present study includes its design to measure PCa
aggressiveness, which minimizes potential confounding by disease heterogeneity (i.e., the
mixing of indolent and aggressive disease). The evaluation of three complementary
measures of tocopherol intake allowed for a comprehensive assessment of tocopherol
status in PCa aggressiveness. Additionally, the assessment of individual tocopherols
rather than the mixing of tocopherols and tocotrienols helps delineate the role of each
tocopherol in PCa aggressiveness. The use of an ethnically diverse population with
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approximately equal numbers of AAs and EAs also made it possible to explore whether
associations between tocopherols and PCa aggressiveness differed by race. Moreover, the
potential for selection bias and selective survival were minimized because participation
rates were reasonably high at both study sites and research subjects were recruited shortly
after diagnosis via rapid case-ascertainment; an average of five months from the time of
diagnosis to time of interview.
The following limitations are also worth consideration. Imprecise measurements
of dietary tocopherols could have influenced the study results to some extent. Because
exposure assessment for tocopherols were done independent of the extent of PCa
aggressiveness, differential misclassification bias is unlikely; however, non-differential
exposure misclassification may have occurred, resulting in underestimation of ORs and
failure to show modest associations [422]. Diet was assessed using a food frequency
questionnaire. It is known that these structured instruments may be biased according to
response sets [423], which in turn, may be related to psychological traits that either may
exert a direct effect on cancer outcomes or indirectly affect other factors that may
influence carcinogenesis [424]. There is also the concern that adipose tocopherol levels
may be altered by the presence of a tumor; however, a study examining the effect of
breast tumor proximity on breast adipose tocopherol levels did not find significant
differences in adipose tocopherol levels at different quadrants of breast tissue, including
sites proximal and distal to the tumor [425]. Moreover, although adipose tocopherol
levels are good markers for internal dose, they may not reflect prostatic tocopherol levels.
Thus, results should be interpreted with this in mind. Other limitations include the failure
to control for cholesterol levels, in particularly, low density lipoprotein which function as
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transport vehicles for tocopherols [388] and abdominal adiposity which may influence
the adipose tocopherol levels. Nonetheless, this might have been indirectly considered by
adjusting for total dietary fat intake and BMI. The influence of individual differences in
metabolism and absorption, interactions between individual tocopherols compounds and
other micronutrients, as well as potential modifying effects of genetic variants acting via
similar mechanisms [383, 407, 426] were beyond the scope of this study. The possibility
exists that some of the findings may be spurious owing to the sample size and multiple
testing.
5.5

CONCLUSIONS
In summary, dietary intakes of α- and δ-tocopherol were inversely associated

with PCa aggressiveness among EAs. There was no evidence that vitamin E supplement
use protects against high aggressive PCa. However, higher adipose α-tocopherol levels
appear to be inversely associated with high aggressive PCa among AAs, but positively
associated among EA which may be due to a significantly higher adipose α-tocopherol
level among EAs. Future work with larger samples and involving evaluation of
interaction between measures of tocopherol intake and functional gene polymorphisms in
oxidative stress and DNA repair pathways may help to elucidate the etiologic relevance
of tocopherols on PCa aggressiveness.
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Table 5.1 Distribution of demographic and patient characteristics by race and prostate cancer aggressiveness among men in the North
Carolina – Louisiana Prostate Cancer Project (PCaP)
African Americans
n = 1,023

Characteristics

Age, years
Energy Intake, kcals/day
Dietary fat intake, grams/day
2

Body mass index (BMI), kg/m
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Study Site
NC
LA (pre & post Katrina)
Family History of Prostate Cancer
No affected 1st degree
relative
At least 1 affected 1st degree
relative
Prostate Cancer Screening History
0 screenings
1-7 screenings
> 7 screenings
Comorbidities
0

High
aggressive

Low/intermediate
aggressive

(n=206)

European Americans
n = 1,079
P‡

P‡

High
aggressive

Low/intermediate
aggressive

(n=817)

(n=164)

(n=915 )

Mean (SD)
63 (8)

Mean (SD)
62 (8)

0.004

Mean (SD)
67 (8)

Mean (SD)
64 (8)

<0.0001

2799.6 (1232.4)

2593.0 (1146.0)

0.02

2339.3 (952.0)

2320.5 (865.7)

0.80

103.9 (52.1)

94.8 (48.4)

0.02

94.5 (42.4)

91.1 (39.2)

0.31

29.9 (6.7)

29.2 (5.4)

0.16

30.5 (5.1)

29.0 (4.8)

0.0006

N

%

N

%

92
114

45
55

386
431

47
53

157

76

606

74

49

24

211

26

120
53
33

58
26
16

307
338
172

38
41
21

88

43

382

47

N

%

N

%

0.51

73
91

45
55

448
467

49
51

0.29

0.55

136

83

696

76

0.05

28

17

219

24

<0.0001

40
68
56

24
42
34

153
405
357

17
44
39

0.06

0.39

84

51

503

55

0.07
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1
2
≥3
Started PCa treatment at start of
study
No
Yes
Unknown
Education
Graduate/professional degree
Some college or college graduate
High school grad or voc/tech
school
Less than high school education
Income Level
≤ $20, 000
$20,001 - $40,000
$40,001 - $60,000
$60,001 - $80,000
>$80,000
Unknown
Smoking Status
Never
Former smokers
Current smokers
NSAID Use
No
Yes
Vitamin E Supplement Use a
No

53
36
29

26
17
14

216
106
113

26
13
14

31
29
20

19
18
12

214
98
100

23
11
11

20
163
23

10
79
11

112
599
106

14
73
13

0.20

11
146
7

7
89
4

99
720
96

11
79
10

0.007

6
50
65

3
24
32

59
239
275

7
29
34

0.004

29
71
37

18
43
23

197
377
260

22
41
28

0.01

85

42

243

30

27

16

81

9

82
52
20
12
14
26

40
25
10
6
7
13

234
212
132
70
99
70

29
26
16
8
12
8

0.001

24
33
24
20
47
16

15
20
15
12
29
9

78
184
154
124
298
77

9
20
17
13
33
8

0.22

40
107
59

19
52
29

276
390
151

34
48
18

<0.0001

59
87
18

36
53
11

330
501
84

36
55
9

0.76

84
120

41
59

364
446

45
55

0.33

56
108

34
66

305
608

33
67

0.85
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68

488

60

0.02

65

40

396

43

0.38

Yes

65

32

329

40

99

60

519

57

Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as follows:
High aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); Low /Intermediate aggressive: all other
cases.
a

Both single nutrient vitamin E supplements and multivitamins containing vitamin E.
Abbreviations: PCa – Prostate Cancer; SD – Standard deviation; NC –North Carolina LA – Louisiana; NSAIDs – Nonsteroidal antiinflammatory drugs.
‡

Test for differences between low/intermediate and high aggressive cancers were done using Student’s t-test for continuous variables and chisquare tests for categorical variables.

138

Table 5.2 Mean difference in tocopherol intake from diet and supplements, and adipose tissue tocopherol levels by race
and level of prostate cancer aggressiveness
African Americans
African
Americans

European
Americans

%
diff

n = 1,023

n = 1,079

Mean (SD)

Mean (SD)

α-tocopherol (mg/day)

10.6 (5.9)

10.5 (5.3)

1

β-tocopherol (mg/day)

0.4 (0.2)

0.4 (0.2)

0

European Americans

High
aggressive

Low/intermediate
Aggressive

n = 206

n = 817

n = 164

Mean (SD)

Mean (SD)

Mean (SD)

n = 915
Mean (SD)

10.9 (6.5)

10.5 (5.8)

0.43

10.1 (5.3)

10.6 (5.3)

0.29

P†

High
aggressive

Low/interme
diate
Aggressive

P†

Dietary intake

γ-tocopherol (mg/day)
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δ-tocopherol (mg/day)
a

21.0 (11.3)
3.0 (1.7)

18.6 (8.6)
2.7 (1.5)

0.4 (0.3)

0.4 (0.2)

0.13

0.4 (0.2)

0.4 (0.2)

0.35

11

‡

22.2 (11.7)

20.7 (11.2)

0.09

18.6 (9.1)

18.6 (8.5)

0.95

10

‡

3.2 (1.8)

2.9 (1.7)

0.05

2.7 (1.5)

2.7 (1.5)

0.58

‡

37.8 (54.2)

56.6 (86.6)

0.02

64.7 (94.2)

78.2 (101.4)

0.22

Supplemental vitamin E
(α-tocopherol, mg/day)
Total α-tocopherol
(diet + supplement) mg/day
Adipose tissue biomarkers b

53.5 (82.4)

76.0 (100.4)

- 42

31.2 (57.8)

54.1 (85.2)

- 73 ‡

22.8 (36.1)

33.3 (61.9)

0.00
2

49.2 (79.6)

55.0 (86.2)

0.42

α-tocopherol (mcg/g)

86.6 (144.9)

151.4 (198.0)

- 75 ‡

78.9 (138.0)

88.3 (146.6)

0.63

163.6 (221.3)

149.2 (193.7)

0.53

γ-tocopherol (mcg/g)

48.4 (74.1)

53.3 (54.5)

- 10

38.2 (38.2)

50.8 (79.9)

0.06

55.4 (56.5)

52.9 (54.1)

0.69

δ-tocopherol (mcg/g)

9.3 (10.2)

8.6 (7.8)

7

8.6 (9.9)

9.4 (10.3)

0.55

8.2 (6.6)

8.7 (8.0)

0.55

Among vitamin E supplement users only (African Americans, n = 394; European Americans, n = 618). Converted as 1 IU of Vitamin E = 0.45 mg α-tocopherol
[402].
b
Among research subjects with data on adipose tocopherol levels (African Americans, n = 361; European Americans, n = 584).
‡
Significant p-values (< 0.05) for test of difference between African Americans and European Americans
a

†

Chi-square test for difference by level of prostate cancer aggressiveness

Table 5.3 Associations between dietary and supplemental vitamin E intake and prostate cancer aggressiveness
among African Americans (n = 1,023) and European Americans (n = 1,079)
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Dietary α-tocopherol mg/day (median)
African Americans
Q1: 0.51 - 6.37 (4.82)
Q2: 6.38 - 9.25 (7.72)
Q3: 9.26 - 13.32 (10.85)
Q4: 13.33 - 44.62 (17.13)
European Americans
Q1: 1.67 - 7.02 (5.55)
Q2: 7.03 - 9.54 (8.35)
Q3: 9.55 - 12.79 (11.01)
Q4: 12.80 - 53.18 (16.28)
Vitamin E supplements d
α-tocopherol, mg/day (median)
African Americans
Q1: non-users
Q2: 1.13 – 11.25 (10.13)
Q3: 11.26 – 22.50 (22.50)
Q4: 22.51 – 472.50 (180.00)
European Americans
Q1: non-users
Q2: 0.96 – 20.25 (13.50)
Q3: 20.26 – 45.00 (22.50)
Q4: 45.01 – 540.00 (193.50)
Total α-tocopherol
Diet + supplement, mg/day (median)
African Americans
Q1: 0.52 – 9.14 (6.64)

Cases/
controls c

OR

Crude a
95% C.I.

P§

OR

Adjusted b
95% C.I.

51/205
42/204
59/204
54/204

1.00
0.86
1.21
1.13

(ref)
0.55-1.35
0.79-1.85
0.73-1.74

0.35

1.00
0.73
1.08
0.58

(ref)
0.43-1.22
0.62-1.86
0.28-1.19

0.20

54/229
35/229
39/229
36/228

1.00
0.66
0.77
0.68

(ref)
0.41-1.06
0.49-1.22
0.43-1.09

0.18

1.00
0.54
0.51
0.34

(ref)
0.32-0.91
0.29-0.88
0.17-0.69

0.006

141/488
24/91
27/136
14/102

1.00
0.95
0.69
0.48

(ref)
0.58-1.55
0.44-1.09
0.26-0.87

0.01

1.00
1.09
0.83
0.64

(ref)
0.65-1.84
0.51-1.34
0.34-1.21

0.15

65/396
37/178
37/172
25/169

1.00
1.24
1.25
0.83

(ref)
0.79-1.94
0.80-1.95
0.50-1.37

0.26

1.00
1.40
1.41
0.93

(ref)
0.87-2.24
0.88-2.27
0.55-1.58

0.38

51/205

1.00

(ref)

0.27

1.00

(ref)

0.36

P§

Q2: 9.15 – 15.83 (11.93)
Q3: 15.84 – 28.54 (20.71)
Q4: 28.55 – 482.37 (42.87)
European Americans
Q1: 2.40 – 11.40 (8.04)
Q2: 11.41 – 23.34 (15.56)
Q3:23.35 – 39.69 (31.55)
Q4:39.70 – 558.17 (190.37)
Dietary β-tocopherol mg/day (median)
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60/204
52/204
43/204

1.24
1.07
0.87

0.81-1.89
0.69-1.65
0.55-1.37

43/229
39/228
44/230
38/228

1.00
0.94
0.98
0.84

(ref)
0.58-1.51
0.62-1.56
0.52-1.36

African Americans
Q1: 0.03 - 0.25 (0.19)
Q2: 0.26 - 0.37 (0.31)
Q3: 0.38 - 0.52 (0.44)
Q4: 0.53 - 1.73 (0.69)

53/208
42/204
46/206
65/199

1.00
0.85
0.91
1.03

European Americans
Q1: 0.07 - 0.28 (0.22)
Q2: 0.29 - 0.38 (0.33)
Q3: 0.39 - 0.52 (0.45)

53/242
37/239
37/217

Q4: 0.53 - 1.62 (0.63)
Dietary γ-tocopherol mg/day (median)
African Americans
Q1: 0.03 - 12.37 (9.07)
Q2: 12.38 - 18.55 (15.48)
Q3: 18.56 - 27.04 (22.78)
Q4: 27.05 - 67.95 (33.75)
European Americans
Q1: 2.68 - 12.66 (9.83)
Q2: 12.67 - 17.35 (15.14)
Q3: 17.36 - 22.85 (19.57)
Q4: 22.86 - 55.13 (28.34)

1.27
0.88
0.89

0.78-2.06
0.50-1.52
0.51-1.58

0.47

1.00
0.85
0.99
0.83

(ref)
0.50-1.42
0.59-1.65
0.49-1.40

0.55

(ref)
0.54-1.33
0.58-1.41
0.92-2.12

0.05

1.00
0.92
1.04
1.08

(ref)
0.56-1.50
0.62-1.77
0.73-2.59

0.22

1.00
0.71
0.79

(ref)
0.44-1.12
0.50-1.26

0.44

1.00
0.64
0.65

(ref)
0.39-1.05
0.39-1.11

0.09

37/217

0.79

0.50-1.26

0.56

0.30-1.02

46/204
47/205
51/204
62/204

1.00
1.08
1.14
1.44

(ref)
0.68-1.70
0.73-1.78
0.94-2.22

0.08

1.00
1.02
0.94
0.83

(ref)
0.61-1.71
0.53-1.69
0.39-1.80

0.59

39/230
47/228
41/229
37/228

1.00
1.26
1.10
1.00

(ref)
0.79-2.01
0.68-1.78
0.61-1.64

0.82

1.00
1.14
0.77
0.52

(ref)
0.68-1.91
0.43-1.37
0.24-1.13

0.05

Dietary δ-tocopherol mg/day
(median)
African Americans
Q1: 0.08 - 1.63 (1.22)
Q2: 1.64 - 2.56 (2.11)
Q3: 2.57 - 3.71 (3.09)
Q4: 3.72 - 13.09 (4.92)
European Americans
Q1: 0.34 - 1.69 (1.31)
Q2: 1.70 - 2.37 (2.05)
Q3: 2.38 - 3.46 (2.84)
Q4: 3.47 - 10.92 (4.29)

41/206
52/204
48/204
65/203

1.00
1.33
1.21
1.64

(ref)
0.84-2.10
0.76-1.93
1.06-2.54

0.04

1.00
1.25
0.92
0.97

(ref)
0.75-2.08
0.52-1.65
0.47-1.98

0.69

36/231
56/229
43/228
29/227

1.00
1.64
1.24
0.89

(ref)
1.03-2.60
0.76-2.01
0.52-1.50

0.29

1.00
1.40
0.91
0.45

(ref)
0.85-2.30
0.52-1.60
0.21-0.95

0.007
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Cases: high aggressive prostate cancers; Controls: low and intermediate aggressive cancers
a
Adjusted for age
b
additional adjustment for PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake,
and study site
c
Some of the categories may not sum to the total sample size due to missing data
d
Converted as 1 IU of Vitamin E = 0.45 mg α-tocopherol [402].
§ Trend P value

Table 5.4 Associations between adipose tissue tocopherol levels and prostate cancer aggressiveness among African (n =
361) and European (n = 584) Americans.
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α-tocopherol mcg/g (median)
African Americans
Q1: 0.30 - 14.50 (6.45)
Q2: 14.51 - 36.30 (24.10)
Q3: 36.56 - 108.90 (61.12)
Q4: 108.91 - 1313.10 (183.27)
European Americans
Q1: 0.20 - 26.50 (12.50)
Q2: 26.51 - 78.80 (45.60)
Q3: 79.81 - 204.70 (125.70)
Q4: 204.71 - 1585.60 (328.90)
γ-tocopherol mcg/g (median)
African Americans
Q1: 0.10 - 10.4 0 (5.29)
Q2: 10.41- 28.90 (18.10)
Q3: 28.91- 64.10 (41.70)
Q4: 64.11 - 972.90 (92.42)
European Americans
Q1: 0.20 - 13.40 (6.20)
Q2: 13.41 - 37.90 (23.90)
Q3: 37.91 - 72.08 (52.10)
Q4: 72.34 - 318.70 (110.74)
δ-tocopherol mcg/g (median)
African Americans
Q1: 0.40 - 3.20 (2.00)

Cases/
Controls c

OR

Crude a
95% C.I.

p
(trend)

OR

Adjusted b
95% C.I.

18/74
13/73
22/74
13/73

1.00
0.74
1.18
0.68

(ref)
0.33-1.63
0.58-2.41
0.31-1.50

0.41

1.00
0.58
0.98
0.66

(ref)
0.24-1.39
0.44-2.16
0.27-1.62

0.60

16/123
26/123
26/123
21/123

1.00
1.54
1.39
1.12

(ref)
0.78-3.04
0.70-2.76
0.55-2.27

0.71

1.00
1.54
1.58
1.43

(ref)
0.74-3.23
0.75-3.33
0.66-3.11

0.68

17/73
19/72
15/72
15/72

1.00
1.21
0.86
0.90

(ref)
0.58-2.54
0.40-1.87
0.42-1.96

0.60

1.00
1.03
0.72
0.93

(ref)
0.45-2.35
0.31-1.69
0.40-2.16

0.77

16/122
28/122
27/122
19/122

1.00
1.70
1.59
1.14

(ref)
0.87-3.32
0.81-3.12
0.55-2.33

0.79

1.00
1.39
1.18
1.20

(ref)
0.68-2.83
0.57-2.46
0.56-2.55

0.91

14/68

1.00

(ref)

0.45

1.00

(ref)

0.73

p
(trend)

Q2: 3.21 - 6.43 (4.66)
20/67
1.39
0.64-2.99
1.46
0.63-3.36
Q3: 6.44 - 11.54 (8.71)
14/67
0.97
0.43-2.20
1.17
0.48-2.85
Q4: 11.55 - 101.40 (17.80)
12/67
0.86
0.37-2.01
1.01
0.40-2.55
European Americans
Q1: 0.30 - 2.99 (1.60)
17/117
1.00
(ref)
0.98
1.00
(ref)
0.81
Q2: 3.00 - 6.70 (4.60)
26/119
1.37
0.70-2.68
1.20
0.58-2.49
Q3: 6.71 - 11.60 (8.69)
23/115
1.28
0.64-2.55
1.10
0.52-2.32
Q4: 11.61- 54.11 (16.10)
19/116
1.12
0.55-2.29
0.99
0.46-2.13
a
Adjusted for age
b
Additional adjustment for education level, study site, BMI, smoking history, family history of PCa, PSA screening history, total fat intake,
whether treatment started at time of interview, and comorbidities.
c
Some of the categories may not sum to the total sample size due to missing data.
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Table 5.5 Comparison of demographic and clinical attributes of prostate cancer
between research subjects included and those excluded from the adipose tissue
tocopherol and prostate aggressiveness analysis
Included
Excluded
n = 945
n = 1157
Mean (SD)
Mean (SD)
Age, years
63.4 (7.9)
63.1 (7.8)
Energy Intake, kcals/day
2461.2 (1018.8)
2486.0 (1057.8)
Dietary fat intake, grams/day
94.9 (44.4)
93.4 (44.9)
2
Body mass index (BMI), kg/m
29.9 (5.2)
28.8 (5.3)
N
%
N
%
Race
African American
361
38
662
57
European American
584
62
495
43
Prostate cancer aggressiveness
Low aggressive
485
51
589
51
High aggressive
304
32
354
31
Intermediate aggressive
156
16
214
18
Study Site
NC
407
43
592
51
LA (pre & post Katrina)
538
57
565
49
Family History of Prostate Cancer
No affected 1st degree relative
696
74
899
78
At least 1 affected 1st degree relative
249
26
258
22
Prostate Cancer Screening History
0 screenings
248
26
372
32
1-7 screenings
375
40
489
42
> 7 screenings
322
34
296
26
Comorbidities
0
497
53
560
49
1
224
24
290
25
2
105
11
164
14
≥3
119
12
143
12
Started PCa treatment at start of study
No
95
10
147
13
Yes
749
79
879
76
Unknown
101
11
131
11
Education
Graduate/professional degree
155
17
136
12
Some college or college graduate
351
37
386
33
High school grad or voc/tech school
268
28
369
32
Less than high school education
171
18
265
23
Income Level
≤ $20, 000
156
16
262
23
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$20,001 - $40,000
$40,001 - $60,000
$60,001 - $80,000
>$80,000
Unknown
Smoking Status
Never
Former smokers
Current smokers
NSAID Use
No
Yes
Vitamin E Supplement Use a
No
Yes

188
148
124
233
96

20
16
13
25
10

293
182
102
225
93

25
16
9
19
8

355
471
119

37
50
13

350
614
193

30
53
17

361
584

38
62

448
698

39
61

474
471

50
50

616
541

53
47

Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical
stage, and PSA level at diagnosis and classified as follows: High aggressive
(Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4);
Low /Intermediate aggressive: all other cases.
a
Includes single nutrient vitamin E supplement and multivitamins containing
vitamin E.
Abbreviations: PCa – Prostate Cancer; SD – Standard deviation; NC –North
Carolina; LA – Louisiana; NSAIDs – Nonsteroidal anti-inflammatory drugs.
‡

Student’s t test for continuous variables and chi-square tests for categorical
variables
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Table 5.6 (Sensitivity Analysis) Associations between dietary vitamin E intake and
prostate cancer aggressiveness among African Americans (n = 361) and European
Americans (n = 584) with data on adipose tissue tocopherol levels.

Dietary α-tocopherol mg/day (median)
African Americans
Q1: 0.51 - 6.37 (4.82)
Q2: 6.38 - 9.25 (7.72)
Q3: 9.26 - 13.32 (10.85)
Q4: 13.33 - 44.62 (17.13)
European Americans
Q1: 1.67 - 7.02 (5.55)
Q2: 7.03 - 9.54 (8.35)
Q3: 9.55 - 12.79 (11.01)
Q4: 12.80 - 53.18 (16.28)
Vitamin E supplements d
α-tocopherol, mg/day (median)
African Americans
Q1: non-users
Q2: 1.13 – 11.25 (10.13)
Q3: 11.26 – 22.50 (22.50)
Q4: 22.51 – 472.50 (180.00)
European Americans
Q1: non-users
Q2: 0.96 – 20.25 (13.50)
Q3: 20.26 – 45.00 (22.50)
Q4: 45.01 – 540.00 (193.50)
Total α-tocopherol
Diet + supplement, mg/day (median)
African Americans
Q1: 0.52 – 9.14 (6.64)
Q2: 9.15 – 15.83 (11.93)
Q3: 15.84 – 28.54 (20.71)
Q4: 28.55 – 482.37 (42.87)
European Americans
Q1: 2.40 – 11.40 (8.04)
Q2: 11.41 – 23.34 (15.56)
Q3:23.35 – 39.69 (31.55)
Q4:39.70 – 558.17 (190.37)
Dietary β-tocopherol mg/day (median)
African Americans
Q1: 0.03 - 0.25 (0.19)
Q2: 0.26 - 0.37 (0.31)
Q3: 0.38 - 0.52 (0.44)
Q4: 0.53 - 1.73 (0.69)
European Americans
Q1: 0.07 - 0.28 (0.22)
Q2: 0.29 - 0.38 (0.33)
Q3: 0.39 - 0.52 (0.45)
Q4: 0.53 - 1.62 (0.63)
Dietary γ-tocopherol mg/day (median)
African Americans
Q1: 0.03 - 12.37 (9.07)

Cases/
controls c

OR

Crude a
95% C.I.

P§

OR

Adjusted b
95% C.I.

15/69
11/78
21/79
19/69

1.00
0.69
1.29
1.44

ref
0.29-1.61
0.61-2.73
0.67-3.11

0.15

1.00
0.50
0.76
0.43

ref
0.19-1.32
0.28-2.09
0.11-1.64

0.37

23/126
23/124
23/113
21/131

1.00
1.04
1.17
0.86

ref
0.55-1.96
0.62-2.22
0.45-1.64

0.65

1.00
0.86
0.84
0.46

ref
0.42-1.76
0.38-1.85
0.17-1.25

0.11

45/185
8/28
8/48
5/34

1.00
1.32
0.70
0.61

ref
0.55-3.12
0.31-1.60
0.22-1.66

0.31

1.00
1.04
0.76
0.79

ref
0.40-2.70
0.31-1.83
0.27-2.34

0.65

36/208
17/94
23/102
14/90

1.00
1.09
1.24
0.83

ref
0.58-2.06
0.69-2.22
0.42-1.63

0.45

1.00
1.22
1.46
0.89

ref
0.62-2.42
0.77-2.78
0.43-1.85

0.46

16/74
17/81
18/67
15/73

1.00
1.05
1.40
1.03

ref
0.49-2.25
0.65-3.01
0.47-2.25

0.93

1.00
0.81
0.85
0.71

ref
0.33-1.97
0.31-2.34
0.25-2.03

0.59

24/122
16/123
29/124
21/125

1.00
0.71
1.11
0.82

ref
0.36-1.41
0.61-2.04
0.43-1.57

0.65

1.00
0.57
1.11
0.74

ref
0.26-1.23
0.56-2.20
0.35-1.57

0.60

16/71
10/75
19/69
21/80

1.00
0.63
1.36
1.39

ref
0.27-1.50
0.64-2.90
0.66-2.92

0.16

1.00
0.61
1.25
1.02

ref
0.24-1.57
0.51-3.10
0.35-2.99

0.77

26/131
22/128
21/114
21/121

1.00
0.85
0.93
0.86

ref
0.45-1.59
0.49-1.76
0.45-1.62

0.71

1.00
0.67
0.72
0.50

ref
0.34-1.33
0.34-1.52
0.21-1.20

0.16

15/70

1.00

ref

0.14

1.00

ref

0.38
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P§

Q2: 12.38 - 18.55 (15.48)
Q3: 18.56 - 27.04 (22.78)
Q4: 27.05 - 67.95 (33.75)
European Americans
Q1: 2.68 - 12.66 (9.83)
Q2: 12.67 - 17.35 (15.14)
Q3: 17.36 - 22.85 (19.57)
Q4: 22.86 - 55.13 (28.34)
Dietary δ-tocopherol mg/day (median)
African Americans
Q1: 0.08 - 1.63 (1.22)
Q2: 1.64 - 2.56 (2.11)
Q3: 2.57 - 3.71 (3.09)
Q4: 3.72 - 13.09 (4.92)
European Americans
Q1: 0.34 - 1.69 (1.31)
Q2: 1.70 - 2.37 (2.05)
Q3: 2.38 - 3.46 (2.84)
Q4: 3.47 - 10.92 (4.29)

12/73
17/75
22/77

0.84
1.18
1.56

0.37-1.95
0.54-2.56
0.74-3.30

0.68
0.69
0.52

0.26-1.74
0.25-1.90
0.14-1.90

20/127
21/119
29/134
20/114

1.00
1.23
1.49
1.17

ref
0.63-2.40
0.79-2.79
0.59-2.31

0.62

1.00
1.12
0.98
0.58

ref
0.54-2.35
0.44-2.18
0.19-1.75

0.29

11/72
15/74
15/77
25/72

1.00
1.52
1.38
2.60

ref
0.64-3.57
0.59-3.23
1.17-5.77

0.02

1.00
1.25
0.95
1.39

ref
0.49-3.19
0.33-2.72
0.39-4.92

0.67

18/128
25/121
31/128
16/117

1.00
1.62
1.85
1.08

ref
0.83-3.15
0.97-3.50
0.52-2.24

0.95

1.00
1.37
1.57
0.57

ref
0.65-2.86
0.73-3.37
0.20-1.61

0.21

Cases: high aggressive prostate cancers; Controls: low and intermediate aggressive cancers
a
Adjusted for age
b
additional adjustment for PSA screening history, BMI, smoking status, education, income, NSAIDs
use, total dietary fat intake, and study site
c
Some of the categories may not sum to the total sample size due to missing data
d
Converted as 1 IU of Vitamin E = 0.45 mg α-tocopherol [402].
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CHAPTER 6
CAROTENOIDS INTAKE AND ADIPOSE TISSUE CAROTENOID LEVELS IN RELATION TO
PROSTATE CANCER AGGRESSIVENESS

6.1

INTRODUCTION
Prostate cancer (PCa) is the most frequently diagnosed non-dermatological

malignancy among men in Western countries [427]. Accumulated data on the relation
between diet and cancer indicates that about 30-40% of cancer cases are preventable
through healthy diet and weight control [428, 429]. Greater intake of fruits and
vegetables has been associated with reduced risk of various types of cancer, including
PCa [430-432]. Carotenoids are biologically active phytochemicals commonly found in
fruits and vegetables, and they are thought to contribute to the inverse associations
between fruits and vegetables intake and cancer incidence [433, 434]. However, findings
from case-control and cohort studies summarized in recent reviews [17, 434-436],
suggest that the pattern of association between carotenoids intake and PCa is largely
unclear.
β-carotene and lycopene are the most commonly studied carotenoids, with
lycopene, a carotenoid devoid of vitamin A activity, having the most favorable
association with PCa [437-440], although study results are not entirely consistent [413,
441, 442]. Early studies focused primarily on β-carotene, a pro-vitamin A carotenoid;
however, two large intervention trials failed to show a beneficial effect of β-carotene on
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PCa incidence in secondary data analyses [159, 188].however, two large intervention
trials failed to show a beneficial effect of β-carotene on PCa incidence in secondary data
analyses [159, 188]. One reported a 23% increased risk of PCa among β-carotene
intervention group versus placebo [159], and the other, which examined effects of βcarotene and retinol in tandem because of their close metabolic relationship, found a 52%
increased risk of aggressive PCa (Gleason ≥ 7 or stage III/IV) in the intervention group
compared with placebo [188]. The elevated risks associated with β-carotene
supplementation were not evident in follow-up studies [188, 443], and the majority of
observational studies have conflicted on β-carotene associations with PCa [17, 434-436,
444-447]. Carotenoids such as α-carotene, β-cryptoxanthin, lutein, and zeaxanthin have
been associated with modest reductions in PCa risk, but as with lycopene and β-carotene,
the study results are mixed [189, 448-451].
There is limited data regarding associations between carotenoids intake and PCa
aggressiveness. As suggested by Giovannucci et al. [437], the dietary risk factors for
aggressive PCa may differ from that of a non-aggressive disease, and thus, some
carotenoids may differentially influence aggressive versus non-aggressive PCa. Given the
growing interest in identifying modifiable risk factors for PCa, particularly among
African Americans (AAs), a population with a high incidence of aggressive PCa [452],
this study investigated associations of dietary, supplemental and adipose tissue carotenoid
levels in relation to PCa aggressiveness among AA and European-American (EA) men in
North Carolina and Louisiana.

150

6.2

MATERIALS AND METHODS

Study Population
A population-based, case-control study was conducted using data from the North
Carolina-Louisiana Prostate Cancer Project (PCaP). One of the primary aims of PCaP, a
multidisciplinary, cross-sectional, case-only, incident PCa study, was to investigate and
compare factors associated with PCa aggressiveness among AAs and EAs. Residents of
the study catchment areas in North Carolina and Louisiana were eligible to participate in
PCaP if they had a first, histologically confirmed, diagnosis of adenocarcinoma of the
prostate between July 1, 2004 and August 31, 2009, were 40-79 years of age at the time
of diagnosis, and self-identified their race as AA/Black or Caucasian American/White
(EA). The other eligibility criteria were having sufficient cognitive and physical functions
to consent and complete the study interview in English, and not residing in an institution
(e.g., nursing home). PCaP enrolled 2267 research subjects of whom approximately half
were EAs (n= 1130) and half were AAs (n = 1137). All research subjects provided
written informed consent before participating in the study. Participation rates were 62%
in North Carolina, 72% for pre-Hurricane Katrina Louisiana and 63% for post- Hurricane
Katrina Louisiana. Further details of the PCaP methods and design can be found
elsewhere [399]. The PCaP study protocols were approved by Institutional Review
Boards of all collaborating institutions, and the current study also received institutional
approval from the University of South Carolina.
Data Collection
Structured in-person interviews were conducted by trained research nurses,
usually in the home of the research subject or at a place of his choosing, soliciting various
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information that included demographic and socioeconomic factors, personal health
history, family history of PCa, pre-diagnostic PCa screening habits, smoking history,
physical activity, usual dietary intake, and use of dietary supplements and non-steroidal
anti-inflammatory drugs (NSAIDs). The research nurses measured each research
subject’s height, and weight at the end of each interview using a standardized protocol.
Information on the cancer stage, Gleason grade and prostate-specific antigen (PSA) level
at the time of diagnosis and other health data including comorbid conditions and diseasedirected treatments were extracted from the research subjects’ medical records which
were obtained from diagnosing physicians after receiving consent. The medical record
abstractions were performed by trained personnel and included a double abstraction of a
randomly selected sample (approximately 10%) to ensure consistency between
abstractors. PCa aggressiveness is defined in PCaP as high aggressive (Gleason sum ≥8
or PSA >20 ng/mL or Gleason sum ≥7 and cancer stage T3–T4), low aggressive (Gleason
sum < 7 and cancer stage T1-T2 and PSA<10 ng/ml), and intermediate aggressive (all
others). These categories were used in case-control analyses contrasting high aggressive
PCa “cases” with low/intermediate aggressive PCa as the comparison group or
“controls”.
Dietary Assessment
Dietary carotenoid intakes were assessed using the National Cancer Institute Diet
History-Food Frequency Questionnaire (NCI-DHQ) [453], which was modified to
include Southern foods. The modified, 124-item DHQ solicited information about usual
diet in the year before the diagnosis of PCa, including frequency of food intake, portion
size, and food preparation methods. Responses to the questions were linked to an updated
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NCI nutrient database through which the research subjects’ usual daily intakes of various
nutrients including α- and β-carotene, β-cryptoxanthin, lutein-zeaxanthin and lycopene
were estimated using the NCI Diet*Calc software [401].
Data on supplemental carotenoid intake were derived using a questionnaire that
has been tested for reliability [454]. The research subjects were asked about multivitamin
and single-nutrient supplement use in the year preceding their diagnosis of PCa (no, less
than once, yes) and those who answered “yes” were queried about the frequency of use
(1-2, 3-4, 5-6, 7 days/week). Responses to the questionnaire were recorded by the nurse
interviewers who also undertook an inventory of nutrient contents and listed dose
information from the manufacturer label of each supplement type. When the supplement
bottle was not available, subjects were asked to state the usual dose taken. Average daily
intakes of supplemental β-carotene, lutein and lycopene were subsequently estimated
based on contributions from multivitamin and single-nutrient supplements as frequency
(days per week) x dose (in µg) x number of pills taken at each time / 7 [454]. Total daily
intake of β-carotene, lutein and lycopene were estimated as the sum of intakes from diet
and supplement (diet + supplement).
Adipose Tissue Sampling and Analysis
Approximately two grams of subcutaneous abdominal adipose tissue samples
were obtained from consenting research subjects after anesthetizing the overlying skin
with 2% lidocaine solution. The PCaP research nurses, who were specifically trained for
adipose tissue sampling, followed a standardized procedure involving the insertion of a
15-gauge needle into the subcutaneous fat and applying negative pressure by a 15 ml
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vacutainer tube after prepping the overlying skin. The aspirated tissue was trapped in the
needle and luer lock adapter, which was placed in a separate cryovial and transported on
ice immediately after collection to a designated storage facility where aliquots were
prepared and stored at -80oC until assayed. Individual carotenoids were measured by high
performance liquid chromatography at the Nutrition Analyses Laboratory of Craft
Technologies, Incorporated (Wilson, NC) using methods outlined by Craft et al. [328,
329]. The adipose tissue contents of α-carotene, cis- and trans-β-carotene, αcryptoxanthin, β-cryptoxanthin, lutein, zeaxanthin, and cis- and trans-lycopene were
quantified at a minimum detection limit of 0.003 µg/g of tissue.

Statistical Methods
Before any analysis was performed, research subjects with incomplete data on
PCa aggressiveness (n = 94) and those with implausible values for energy intake (< 500
or ≥ 6000 kcal/day, n = 71) were excluded from the total PCaP sample of 2267. The
remaining 2,102 research subjects were included in the analyses; however, data on
adipose carotenoid levels were available for only 939 cases (EAs n = 581, AAs n = 358).
Descriptive statistics were expressed as means for continuous variables and
proportions for categorical variables using t-tests and chi-square tests, respectively. The
carotenoid variables were categorized into tertiles according to their distributions among
controls, and unconditional logistic regression was used to estimate odds ratios (ORs) and
corresponding 95% confidence intervals (95% CIs) for increasing tertiles with the lowest
tertiles as the referent group. Trend tests were performed by assigning each tertile its
median value expressed as a continuous variable in the logistic regression models. All
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associations were examined in crude (age-adjusted) and multivariable-adjusted models.
The following known or suspected risk factors for PCa were considered for inclusion in
the multivariable-adjusted models: age (continuous), study site (NC, LA); BMI (in
kg/m2); pre-diagnostic PSA screening history (0, 1-7, >7 screenings); comorbidities (0, 1,
2, ≥3); family history of PCa in a first degree relative (none vs. at least one); whether PCa
treatment had started at the time of the interview (yes, no); smoking status (never, former,
current); education (less than high school education, high school graduate/some college,
college graduate); annual household income (< $20,000, $20,001 - $40,000, $40,001 $70,000, >$70,000); NSAIDs use in the five years prior to diagnosis (yes, no); physical
activity in the year prior to diagnosis [total metabolic equivalents (METs) of light,
moderate, and vigorous exercise categorized as: ≤ 10.2, 10.3-29.0, > 29.0 METs/week];
total fat intake (grams/day); and alcohol intake (grams/day). The multivariable models
were constructed first by evaluating the confounding effect of each variable based on a
10% change in effect estimate of the main exposure variables with the removal of the
covariate from the model. Variables determined to be confounders and those that are
biologically relevant to PCa were then placed in an elaborate model for final model
selection. A combination of the backward elimination model selection method and
likelihood ratio tests were then used to select covariates for the final models consisting of
age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total
fat intake, and study site. Further adjustment for family history of PCa, comorbidities,
and PCa treatment status were done in models examining associations between adipose
carotenoid levels and PCa aggressiveness.
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Stratified analyses by BMI (< 24.9, 25-29.9, ≥ 30 kg/m2) and smoking status
were performed to evaluate whether the associations differed by these factors. In order to
retain enough sample size for the stratified analyses, the carotenoid variables were
categorized into two levels (< or ≥ median) with the lowest levels as the referent group.
The evaluation of effect modification included interaction terms between the BMI and
smoking status variables, and each of the carotenoids (median splits), which were
examined by likelihood ratio tests based on models with and without an interaction term.
All statistical tests were two-sided and a P value less than 0.05 was considered
statistically significant except for interaction p-values in the stratified analyses, which
were considered significant at a P value less than 0.10. All analyses were performed with
SAS version 9.3 (SAS Institute, Cary, NC).
6.3

RESULTS
Characteristics of the research subjects are presented for AAs and EAs in Table

6.1. In both AAs and EAs, the research subjects with high aggressive PCa were older and
less educated compared to those with low/intermediate aggressive PCa. EA research
subjects with high aggressive PCa had a slightly higher BMI and were more likely to
have started treatment for PCa compared to EAs with low/intermediate aggressive PCa.
The AA research subjects with high aggressive PCa tended to have a higher intake of
energy and total fat, were less likely to have had at least one pre-diagnostic PSA
screening, and included a greater proportion of current and former smokers and low
incomes compared to AAs with low/intermediate aggressive PCa.
Table 6.2 presents differences in carotenoid levels among AAs and EAs. In
general, the daily intake of carotenoids varied significantly between AAs and EAs, such
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that while EAs tended to have higher intakes of α-carotene, supplemental β-carotene and
lutein, and higher intake of lycopene from diet and supplements, AAs had a higher
dietary intake of β-carotene, β-cryptoxanthin and lutein + zeaxanthin. Adipose tissue
carotenoid levels were generally higher in EAs than AAs with significant differences in
the levels of zeaxanthin and lycopene (cis and trans). Few differences in carotenoid
intake or adipose levels were observed by the levels of PCa aggressiveness among EAs
and AAs.
Multivariable-adjusted ORs and corresponding 95% CIs for high aggressive PCa
in relation to dietary and supplemental carotenoids intake are reported in Table 6.3.
Because of the substantial differences in carotenoids intake between AAs and EAs,
different cut-points were used to categorize each carotenoid by race, based on
distributions among low/intermediate aggressive PCa research subjects in the respective
race group. Hence, results are presented separately for AAs and EAs. Among EAs,
dietary lycopene intake was associated with a 45% lower odds of high aggressive PCa in
the highest compared with the lowest tertile. Although supplemental lycopene use was
not independently associated with PCa aggressiveness among EAs, total lycopene intake
from both diet and supplements was inversely related to high aggressive PCa (OR = 0.56,
95% CI = 0.34-0.90, highest versus lowest tertile, Ptrend = 0.03). These significant
associations were not observed among AAs. However, dietary β-cryptoxanthin intake
was inversely associated with high aggressive PCa among AAs only (OR = 0.56, 95% CI
= 0.36-0.87, highest versus lowest tertile, Ptrend = 0.01). None of the other carotenoids
was significantly associated with PCa aggressiveness among AAs or EAs.
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Although data on adipose tissue carotenoid levels were available for a subgroup
of the study population, this group did not differ substantially from the total study sample
with regard to demographic and other variables (Table 6.5). Evaluation of associations
between adipose tissue carotenoid levels and PCa aggressiveness showed a marginally
significant linear trend toward lower odds of high aggressive PCa for the associations of
adipose α-carotene (Ptrend = 0.07) and lycopene (cis + trans, Ptrend = 0.11) (Table 6.4). No
apparent associations were observed between adipose carotenoid levels and PCa
aggressiveness among AAs. To examine the impact of missing data on the observed
associations, an alternative analysis of associations between dietary carotenoids intake
and PCa aggressiveness was conducted among subjects with data on adipose carotenoids
only. These results were very similar to those reported in Table 6.3 (see Table 6.6).
In the stratified analyses, the associations between all measured carotenoids and
PCa aggressiveness did not vary by smoking status (data not shown). However, there
were significant effect modifications by BMI for the associations of carotenoids intake
and PCa aggressiveness (Table 6.7). Notably, there was suggestion of reduced odds of
high aggressive PCa among EAs who were supplemental β-carotene users in the highest
BMI category (≥ 30 kg/m2) but increased odds for supplemental β-carotene use was
observed among EAs in the lowest BMI category (< 24.9 kg/m2). Among both AAs and
EAs, a similar interaction was observed for dietary and total lutein + zeaxanthin intake
and BMI(all P values for interaction, < 0.10). Among EAs, it appeared that the reduced
odds of high aggressive PCa with higher dietary lycopene was lowest among obese
research subjects (P value for interaction =0.01); whereas among AAs, a significant
interaction between BMI and dietary and total lycopene was observed such that increased
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intake of lycopene was associated with increased odds of high aggressive PCa among
research subjects in the normal weight BMI category but not in the other BMI categories.
6.4

DISCUSSION
This population-based, case-control study examined associations between

carotenoid intake and adipose tissue carotenoid levels in relation to PCa aggressiveness
among AAs and EAs in North Carolina and Louisiana. Inverse associations were
observed between intake of lycopene and PCa aggressiveness among EAs, and between
β-cryptoxanthin intake and PCa aggressiveness among AAs. Marginally significant linear
trends in the direction of reduced odds of high aggressive PCa were observed for higher
adipose levels of α-carotene and lycopene (cis + trans) among EAs only. Evaluation of
effect modification by BMI indicated that men with higher BMI (≥ 30 kg/m2) may have a
greater benefit from a higher intake of certain carotenoids, while higher lycopene intake
among AAs and use of β-carotene supplements among EAs was associated with
increased odds of high aggressive PCa among normal weight research subjects but not
overweight or obese subjects.
Carotenoids are broadly categorized as pro-vitamin A (i.e., α-carotene, βcarotene, and β-cryptoxanthin) or non-pro-vitamin A (i.e., lutein, zeaxanthin and
lycopene) depending on whether they are converted into retinol in the body [455]. These
carotenoids have been shown in in vitro and in vivo studies to have biological functions
that could prevent or suppress the progression of cancer [456]. Proposed mechanisms by
which carotenoids may influence PCa aggressiveness include induction of the apoptosis
of malignant cells, modulation of gene expression, up-regulation of gap-junctional
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communication, mitigation of oxidative stress, and enhancement of antitumor immune
responses [455-457]. Despite these mechanisms, the epidemiologic data relating to
carotenoid intake and PCa incidence are largely inconsistent [17, 434-436]. The
populations included in previous studies were predominantly of European decent, thus,
the results may not apply to AAs. It is worth noting that although the current study shows
some differences in carotenoid associations between AAs and EAs, comparisons were
made within each race. This analytic approach minimizes confounding by unmeasured
sociocultural factors, and possibly, biological factors that are inherently different between
AAs and EAs [452, 458].
The current finding on lycopene among EAs is consistent with previous studies
suggesting that lycopene may be beneficial in reducing the risk and aggressiveness of
PCa. In a prospective cohort study of male health professionals, higher lycopene intake
was associated a 21% lower risk of PCa and a high intake of tomato and tomato products,
which are primary sources of lycopene, also was association with a 53% reduced risk of
advance-staged PCa [449]. Gann et al. [438] found a lower risk of aggressive PCa in men
with high plasma lycopene levels. In another prospective study, Kirsh et al. [441]
reported an inverse association between lycopene intake and PCa incidence among men
with a family history of PCa. Reports from some case-control studies suggest that
lycopene may reduce the risk of PCa [450, 459], although others have failed to show an
association [413, 460-462]. Lycopene, which in addition to tomatoes and tomato products
can be obtained in modest amounts from watermelon, guava, and papaya, is considered
the most potent antioxidant carotenoid due to its exceptional singlet oxygen quenching
ability [463]. The bioavailability of lycopene increases with cooking, partly because
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thermal treatment of vegetables enhances the extractability of lycopene from the
vegetable fibers [464]. The act of processing tomatoes with oil and simultaneous
ingestion of lycopene-based foods with fat have also been shown to promote the
dissolution, absorption and subsequent bioavailability of lycopene [465]. Thus, the
potential benefits of lycopene are dependent on food processing methods and dietary
habits, which may explain the discrepancy in lycopene associations between AAs and
EAs. As indicated in Table 2, the consumption of lycopene from food and supplements,
as well as adipose lycopene concentrations were significantly higher in EAs than AAs.
Hence, it appears that the potential benefits of lycopene in relation to PCa aggressiveness
may be acquired only at higher levels of intake. Differences in lycopene associations
between AAs and EAs also may have been influenced by gene-diet interactions that may
vary by race. As demonstrated by Goodman et al. [466], polymorphic variants in XRCC1,
a gene involved in base excision repair of DNA damage, can alter the ability of lycopene
to decrease PCa risk. Evaluations of such gene-diet interactions between AAs and EAs
would help elucidate how lycopene may differentially influence PCa among different
population subgroups.
β-cryptoxanthin, which is commonly found in tangerines, oranges, grapefruit,
mangoes, fruit juices and red peppers [467], was inversely related to PCa aggressiveness,
but only among AAs. This discrepancy may be due to the greater intake of βcryptoxanthin among AAs relative to EAs (Table 2). Studies have reported inverse [189,
459] as well as positive [448, 468] associations between β-cryptoxanthin and PCa risk.
Reviews of the literature do not provide compelling evidence for or against a protective
association between β-cryptoxanthin and PCa incidence [17, 434-436]. Plasma β161

cryptoxanthin has been found to correlate inversely with markers of oxidative damage to
DNA and lipid peroxidation in humans [469]; factors that have been causally linked to
PCa [470]. Perhaps examining β-cryptoxanthin associations with different PCa
phenotypes, as done in this study, may help delineate the role of β-cryptoxanthin in
prostate carcinogenesis. The associations of α-carotene, β-carotene and lutein +
zeaxanthin, and PCa incidence have also varied across studies [17, 189, 434-436, 448451]. However, evaluations of these carotenoids in the context of PCa aggressiveness are
rare [413, 438, 440], but evolving, and may help clarify their role with PCa.
The use of adipose tissue biomarkers of nutrient intake in assessing disease risk
has been done in a few studies [284, 471] and continues to receive increased attention
because of the ability of adipose tissue to reflect long-term nutritional status [472].
Nonetheless, the uptake and turnover rates of carotenoids in adipose tissues remain
unclear [472]. This study suggests that higher adipose α-carotene and lycopene
concentrations are inversely related to PCa aggressiveness, which warrants further
investigation in larger studies. However, the possibility that adipose α-carotene and
lycopene may have acted as markers for increased consumption of fruits and vegetables
or as surrogates for a healthy lifestyle in general cannot be ruled out.
Cigarette smoking has been associated with depletion of circulating carotenoid
levels [473] and a high BMI also appear to increase the body’s carotenoids requirement
[474]; however, only BMI was found to have a modifying effect on associations between
carotenoids intake and PCa aggressiveness. The results suggest that men with a high BMI
may benefit from the intake of lycopene and lutein + zeaxanthin, while β-carotene
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supplement intake may increase odds of aggressive disease among EAs with normal BMI
and higher dietary lycopene may increase odds among normal BMI AAs. This is the first
study to examine effect modification of carotenoids by BMI in relation to PCa
aggressiveness, but of note, some studies suggest that β-carotene supplements may
increase the risk of PCa among smokers [159, 188]. It is unclear why β-carotene
supplements or dietary lycopene may be associated with increased odds of high
aggressive disease among normal weight men but not overweight or obese men. Given
the number of comparisons, the role of chance cannot be ruled out in these findings.
Diet was assessed using a food frequency questionnaire. It is known that these
structured instruments may be biased according to response sets [475], which in turn,
may be related to psychological traits that either may exert a direct effect on cancer
outcomes or indirectly affect other factors that may influence carcinogenesis [476]. Other
limitations of the current study include the fact that carotenoids likely do not act alone,
and thus, the results shown here may reflect interactions between individual carotenoids
or interactions with other food components or genetic variants [383, 466]. The recall of
dietary intakes over the year prior to diagnosis of PCa also may have been influenced by
changes in dietary patterns after the diagnosis with PCa. Such recall inaccuracies would
have resulted in non-differential misclassification because the research subjects were not
likely to consider the extent of their disease aggressiveness in answering questions
relating to food and supplements intake. Moreover, laboratory personnel involved in the
analyses of adipose carotenoid levels were blinded to the PCa attributes of the samples,
eliminating the possibility for differential misclassification of adipose measurements.
Therefore, non-differential, rather than differential, misclassification may have attenuated
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the ORs to some extent. Because it is possible that some carotenoids may exert their
beneficial effects in the early stages of carcinogenesis [456], the one-year reference
period for the dietary assessment may not be etiologically relevant to PCa, but can
provide an estimate of usual dietary patterns, [453], while adipose tissue concentrations
reflect longer-term exposure. It is conceivable that the adipose tissue carotenoid levels
can be altered through the metabolic processes of cancer; however, studies show that
adipose carotenoid levels are less susceptible to changes due to the presence of a tumor
[477]. Additionally, studies show that adipose carotenoid levels correlates inversely with
body fat percentage [296]; thus, it would have been desirable to control for body fat
mass. However, the potential confounding effect of body fat burden was partially
considered by adjusting for BMI (in the BMI unstratified analyses). The small sample
size may have reduced the statistical power of the study. Furthermore, since multiple
comparisons were made there is the possibility of chance findings. Despite these
limitations, the design of the study uniquely captures the complex pathological and
clinical attributes of PCa, and the findings of this analysis add to the limited knowledge
of the potential role of carotenoids in PCa aggressiveness within specific race groups.
6.5

CONCLUSIONS

In summary, this analysis shows a statistically significant inverse association between
lycopene intake and PCa aggressiveness among EAs, and between β-cryptoxanthin and
PCa aggressiveness among AAs. Higher adipose tissue α-carotene and lycopene (cis +
trans) levels also appear to be inversely related to PCa aggressiveness among EAs. In
addition, the results suggest that certain carotenoids may have greater beneficial impact
among obese individuals with the possibility of detrimental effects among normal weight
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men, findings that warrant further investigation in larger studies. Although some of the
findings vary by race, this was likely due to the variations in the levels of carotenoid
intake between AAs and EAs. Overall, the findings support suggestions that a higher
consumption of fruits and vegetables, which are the main sources of carotenoids, may be
inversely associated with CaP aggressiveness.
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Table 6.1 Characteristics of research subjects by race and prostate cancer aggressiveness
European Americans
n = 1,079
High
Low/intermediate
aggressive PCa
aggressive PCa

Characteristics

(n=164 )

(n=915 )

Mean (SD)

Mean (SD)

67 (8)

64 (8)

<0.0001

2339.3 (952.0)

2320.5 (865.7)

94.5 (42.4)
30.5 (5.1)

Age, years
Energy intake, kcals/day
Dietary fat intake, grams/day
Body mass index (BMI), kg/m

2

P‡

African Americans
n = 1,023
High
Low/intermediate
aggressive PCa
aggressive PCa

P‡

(n=206 )

(n=817)

Mean (SD)

Mean (SD)

64 (8)

62 (8)

0.004

0.80

2799.6 (1232.4)

2593.0 (1146.0)

0.02

91.1 (39.2)

0.31

103.9 (52.1)

94.8 (48.4)

0.02

29.0 (4.8)

0.0006

29.9 (6.7)

29.2 (5.4)

0.16
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N

%

N

%

N

%

N

%

Study Site
NC
LA (pre & post Katrina)

73
91

45
55

448
467

49
51

0.29

92
114

45
55

386
431

47
53

0.51

Family History of Prostate Cancer
No affected 1st degree relative
At least 1 affected 1st degree relative

136
28

83
17

696
219

76
24

0.05

157
49

76
24

606
211

74
26

0.55

PSA Screening History
0 screenings
1-7 screenings
> 7 screenings

40
68
56

24
42
34

153
405
357

17
44
39

0.06

120
53
33

58
26
16

307
338
172

38
41
21

<0.0001

Comorbidities
0
1
2
≥3

84
31
29
20

51
19
18
12

503
214
98
100

55
23
11
11

0.05

88
53
36
27

43
26
17
14

382
216
106
109

47
26
13
14

0.39

Started PCa treatment at start of study
No
Yes
Unknown
Education
Less than high school education
High school graduate/ some college
College graduate
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Income Level
≤ $20, 000
$20,001 - $40,000
$40,001 - $70,000
>$70,000
Unknown
Smoking Status
Never
Former smoker
Current smoker
NSAID Use
No
Yes

11
146
7

7
89
4

99
720
96

11
79
10

0.007

20
163
23

10
79
11

112
599
106

14
73
13

0.20

27
79
58

17
48
35

81
432
402

9
47
44

0.005

85
102
19

41
50
9

243
438
135

30
54
16

0.001

24
33
38
53
16

15
20
23
32
10

78
184
217
359
77

9
20
24
39
8

0.11

82
52
24
22
26

40
25
12
11
12

234
212
171
130
70

29
26
21
16
8

0.0005

59
87
18

36
53
11

330
501
84

36
55
9

0.76

40
107
59

19
52
29

276
390
151

34
48
18

<0.001

56
108

34
66

305
608

33
67

0.85

84
120

41
59

364
446

45
55

0.33

Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as follows:
high aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); low/intermediate aggressive: all other
cases.
Abbreviations: PCa – Prostate Cancer; LA – Louisiana; NC –North Carolina; NSAIDs – Nonsteroidal anti-inflammatory drugs; PSA – prostate
specific-antigen;
SD – Standard deviation
‡

Test for differences between high and low/intermediate PCa performed using t-test for continuous variables and chi-square tests for categorical
variables.

Table 6.2 Mean difference in carotenoids from diet, supplements, and adipose tissue by race and prostate cancer aggressiveness
European Americans

African Americans

%
diff
European
Americans

African
Americans

High aggressive
PCa

Low/intermediate
aggressive PCa

n = 1,079
Mean (SD)

n = 1,023
Mean (SD)

n = 164
Mean (SD)

n = 915
Mean (SD)

661.9 (741.7)

596.3 (730.2)

10 ‡

610.0 (874.3)

671.1 (715.5)

3914.5 (3028.0)

4788.6 (3898.9)

-22 ‡

3830.8 (3095.6)

3929.5 (3017.2)

300.9 (447.3)

467.4 (1734.2)

P†

P†

High aggressive
PCa

Low/intermediate
Aggressive PCa

n = 206
Mean (SD)

n = 817
Mean (SD)

597.6 (829.4)

595.9 (703.6)

4834.6 (3951.4)

4777.1 (3887.8)
245.6 (799.5)

0.50

α-carotene µg/day
dietary
β-carotene µg/day
dietary
supplement

a

diet + supplement

0.39

0.70

0.98

0.85

168

442.1 (1607.4)

235.0 (859.2)

47

0.01

192.8 (1064.9)

4356.5 (3477.9)

5023.6 (4028.0)

-15

4131.6 (3196.4)

4396.9 (3526.1)

0.37

5027.3 (4170.0)

5022.7 (3994.1)

0.99

162.9 (134.3)

223.5 (204.3)

-37 ‡

160.8 (117.8)

163.3 (137.1)

0.81

199.3 (171.8)

229.6 (211.4)

0.03

3230.5 (2708.2)

4231.4 (3533.4)

-31 ‡

3204.3 (2706.8)

3235.2 (2709.9)

0.89

4133.5 (3149.9)

4256.1 (3625.1)

0.63

84.0 (116.1)

81.3 (128.3)

48.8 (131.4)

0.03

‡

β-cryptoxanthin µg/day
dietary
Lutein + zeaxanthin µg/day
dietary
supplement (lutein) a

81.7 (126.5)

45.5 (123.4)

44

080

32.8 (83.1)

3312.2 (2736.6)

4277.0 (3550.0)

-29 ‡

3288.2 (2723.3)

3316.5 (2740.5)

0.90

4166.3 (3151.3)

4304.9 (3644.9)

0.62

6715.8 (7841.9)

5538.9 (7790.7)

17 ‡

5993.8 (5770.4)

6845.3 (8153.6)

0.10

5439.7 (8294.3)

5563.9 (7663.6)

0.84

85.3 (201.3)

66.7 (141.7)

22 ‡

85.0 (133.4)

85.3 (211.2)

0.97

60.5 (117.6)

68.3 (147.2)

0.42

6801.1 (7855.4)

5605.6 (7794.4)

18 ‡

6078.8 (5773.4)

6930.6 (8168.5)

0.10

5500.3 (8302.8)

5632.2 (7666.0)

0.83

N = 581
Mean (SD)

N = 358
Mean (SD)

N = 89
Mean (SD)

N = 492
Mean (SD)

N = 66
Mean (SD)

N = 292
Mean (SD)

0.04 (0.05)

0.03 (0.05)

25

0.03 (0.06)

0.04 (0.05)

0.26

0.03 (0.03)

0.03 (0.05)

0.33

cis-β-carotene

0.10 (0.14)

0.10 (0.15)

0

0.09 (0.16)

0.10 (0.14)

0.42

0.10 (0.17)

0.09 (0.14)

0.81

trans-β-carotene

0.19 (0.27)

0.16 (0.27)

16

0.16 (0.27)

0.19 (0.28)

0.32

0.17 (0.32)

0.16 (0.26)

0.79

0.02 (0.02)

0.03 (0.03)

0.16

0.02 (0.02)

0.02 (0.03)

0.49

0.08 (0.09)

0.09 (0.11)

0.28

0.07 (0.08)

0.08 (0.10)

0.84

diet + supplement
Lycopene µg/day
dietary
supplement

a

diet + supplement
Adipose tissue carotenoid levels
µg/day
α-carotene

‡

α-cryptoxanthin

0.03 (0.03)

0.02 (0.02)

33

β-cryptoxanthin

0.09 (0.11)

0.08 (0.10)

11

Lutein
Zeaxanthin
Lycopene
(cis + trans)
cis-lycopene
all-trans-lycopene

5
30 ‡

0.18 (0.17)
0.08 (0.07)

0.21 (0.23)
0.10 (0.17)

0.20
0.03

0.19 (0.23)
0.07 (0.08)

0.20 (0.24)
0.08 (0.09)

0.82
0.46

20 ‡

0.28 (0.32)

0.36 (0.42)

0.04

0.28 (0.32)

0.28 (0.35)

0.93

0.17 (0.21)

23

‡

0.17 (0.20)

0.22 (0.27)

0.05

0.17 (0.20)

0.17 (0.22)

0.96

0.10 (0.13)

23 ‡

0.10 (0.12)

0.13 (0.15)

0.05

0.11 (0.12)

0.10 (0.13)

0.84

0.21 (0.22)
0.10 (0.16)

0.20 (0.24)
0.07 (0.08)

0.35 (0.40)

0.28 (0.34)

0.22 (0.26)
0.13 (0.15)

Abbreviations: PCa – prostate cancer; SD – standard deviation
a
Among supplement users only
‡
Significant p-values (< 0.05) for test of difference between European Americans and African Americans
†

Chi-square test for difference by level of prostate cancer aggressiveness
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Table 6.3 Odds ratios (ORs) and 95% confidence intervals (CIs) for associations
between dietary and supplemental carotenoids intake and prostate cancer
aggressiveness among European-American ( n = 1,079) and African-American men
(1,023)
High aggressive/
lowintermediate
aggressive

OR (95% CI) a

OR (95% CI) b

Trend
p-value c

64/305
48/305
52/305

1.00 (ref)
0.74 (0.49-1.12)
0.80 (0.53-1.20)

1.00 (ref)
0.72 (0.47-1.11)
0.76 (0.49-1.18)

0.33

71/273
63/272
72/272

1.00 (ref)
0.89 (0.61-1.30)
1.05 (0.72-1.52)

1.00 (ref)
0.79 (0.52-1.21)
0.99 (0.64-1.52)

0.77

61/305
44/305
59/305

1.00 (ref)
0.68 (0.45-1.04)
0.91 (0.61-1.35)

1.00 (ref)
0.67 (0.43-1.05)
0.92 (0.60-1.43)

0.96

91/536
61/301
12/78

1.00 (ref)
1.20 (0.84-1.71)
0.88 (0.46-1.69)

1.00 (ref)
1.39 (0.96-2.02)
1.00 (0.50-1.97)

0.44

60/304
48/306
56/305

1.00 (ref)
0.76 (0.50-1.15)
0.87 (0.58-1.30)

1.00 (ref)
0.76 (0.49-1.18)
0.88 (0.56-1.37)

0.75

61/273
69/272
76/272

1.00 (ref)
1.16 (0.79-1.70)
1.22 (0.84-1.78)

1.00 (ref)
1.07 (0.70-1.62)
1.12 (0.72-1.73)

0.64

non-users
153/564
63.00 - 590.00
26/92
590.01 - 15600
27/161
Diet + supplement µg/day

1.00 (ref)
1.08 (0.67-1.74)
0.62 (0.40-0.98)

1.00 (ref)
1.22 (0.74-2.03)
0.76 (0.48-1.21)

0.37

1.00 (ref)
1.05 (0.72-1.53)

1.00 (ref)
0.98 (0.65-1.47)

0.88

Carotenoids
α-carotene
Dietary µg/day
European American
27.20 - 324.13
324.14 - 626.76
626.77 - 9812.26
African American
11.83 - 262.11
262.12 - 585.99
586.00 - 9558.28
β-carotene
European American
Dietary µg/day
194.86 - 2327.81
2327.82 - 4046.15
4046.16 - 25124.05
Supplement µg/day

non-users
63.00 - 600.00
600.01 - 16470.00
Diet + supplement µg/day
346 .80 - 2566.41
2566.42 - 4458.51
4458.52 - 25512.15
African American
Dietary µg/day
286.48 - 2544.86
2544.87 - 5156.05
5156.06 - 32901.26
Supplement µg/day

286.48 - 2773.39
2773.40 - 5405.28

67/273
69/272
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5405.29 - 32901.26

70/272

1.02 (0.70-1.49)

0.96 (0.62-1.49)

51/305
52/305
61/305

1.00 (ref)
1.00 (0.65-1.52)
1.18 (0.78-1.77)

1.00 (ref)
1.00 (0.64-1.55)
1.11 (0.71-1.72)

0.62

87/273
65/272
54/272

1.00 (ref)
0.75 (0.52-1.08)
0.63 (0.43-0.92)

1.00 (ref)
0.74 (0.50-1.11)
0.56 (0.36-0.87)

0.01

60/305
44/305
60/305

1.00 (ref)
0.71 (0.47-1.09)
1.01 (0.68-1.50)

1.00 (ref)
0.71 (0.45-1.12)
1.05 (0.67-1.63)

0.49

non-users
106/617
users
58/298
Diet + supplement µg/day

1.00 (ref)
0.90 (0.64-1.28)

1.00 (ref)
0.79 (0.55-1.14)

59/305
46/305
59/305

1.00 (ref)
0.75 (0.49-1.15)
1.01 (0.69-1.50)

1.00 (ref)
0.75 (0.48-1.18)
1.04 (0.69-1.63)

0.56

64/273
72/272
70/272

1.00 (ref)
1.15 (0.79-1.68)
1.10 (0.75-1.61)

1.00 (ref)
1.11 (0.74-1.68)
1.08 (0.70-1.65)

0.82

non-users
177/671
users
29/137
Diet + supplement µg/day

1.00 (ref)
1.34 (0.87-2.06)

1.00 (ref)
1.03(0.65-1.63)

63/273
74/272
69/272

1.00 (ref)
1.20 (0.82-1.75)
1.10 (0.75-1.61)

1.00 (ref)
1.19 (0.78-1.79)
1.09 (0.71-1.67)

0.85

70/305
48/305
46/305

1.00 (ref)
0.73 (0.48-1.09)
0.74 (0.49-1.12)

1.00 (ref)
0.67 (0.44-1.02)
0.55 (0.34-0.89)

0.02

β-cryptoxanthin
Dietary µg/day
European American
6.04 - 86.14
86.15 - 180.62
180.63 - 1082.55
African American
3.53 - 116.43
116.44 - 243.34
243.34 - 1594.39
Lutein + Zeaxanthin
European American
Dietary µg/day
289.67 - 1830.51
1830.52 - 3253.94
3253.95 - 30165.13
Supplement µg/day

289.67 - 1907.94
1907.95 - 3318.23
3318.23 - 31665.13
African American
Dietary µg/day
112.25 - 2299.78
2299.79 - 4408.18
408.19 - 36608.75
Supplement µg/day

112.25 - 2309.42
2309.43 - 4461.54
4461.55 - 37558.75
Lycopene
European American
Dietary µg/day
344.77 - 3605.57
3605.58 - 6299.34
6299.35 - 100250.76
Supplement µg/day
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non-users
114/664
64.28 - 250.00
17/126
250.01 - 5000.00
33/125
Diet + supplement µg/day

1.00 (ref)
1.91 (0.80-4.57)
1.09 (0.74-1.60)

1.00 (ref)
2.14 (0.87-5.24)
1.22 (0.82-1.83)

0.27

70/305
48/305
46/305

1.00 (ref)
0.72 (0.48-1.08)
0.74 (0.49-1.12)

1.00 (ref)
0.67 (0.44-1.02)
0.56 (0.34-0.90)

0.03

61/273
70/272
73/272

1.00 (ref)
1.23 (0.84-1.81)
1.29 (0.88-1.89)

1.00 (ref)
1.27 (0.83-1.94)
1.22 (0.77-1.93)

0.58

non-users
161/630
64.28 - 250.00
12/88
250.01 - 1000.00
33/99
Diet + supplement µg/day

1.00 (ref)
0.86 (0.39-1.89)
0.97 (0.65-1.45)

1.00 (ref)
0.97 (0.43-2.22)
1.14 (0.74-1.73)

0.57

1.00 (ref)
1.22 (0.83-1.79)
1.25 (0.85-1.84)

1.00 (ref)
1.21 (0.80-1.85)
1.16 (0.73-1.84)

0.70

344.77 - 3649.40
3649.41 - 6352.12
6352.13 - 100550.76
African American
Dietary µg/day
21.52 - 2390.06
2390.07 - 5003.81
5003.82 - 85677.94
Supplement µg/day

21.52 - 2448.39
2448.39 - 5064.89
5064.90 - 85677.94

62/273
70/272
72/272

Abbreviation: PCa – prostate cancer
a
Adjusted for age
b
Additional adjustment for PSA screening history, BMI, smoking status, education, income,
NSAIDs use, total dietary fat intake, and study site
c
Multivariable-adjusted trend p-value
d
Categorized into two levels because limited variability in dose did not allow for creation of
meaningful tertile categories
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Table 6.4 Associations between adipose tissue carotenoid levels and prostate cancer
aggressiveness among European Americans (n = 581) and African Americans ( n = 358)

Carotenoids
α-carotene µg/g

High
aggressive/
lowintermediate
aggressive

Trend
p-value c

OR (95% CI) a

OR (95% CI) b

26/128
30/116
12/112

1.00 (ref)
1.15 (0.63-2.08)
0.49 (0.24-1.03)

1.00 (ref)
1.52 (0.78-2.94)
0.58 (0.25-1.32)

0.07

16/54
7/53
13/49

1.00 (ref)
0.34 (0.11-1.09)
1.07 (0.39-2.92)

1.00 (ref)
0.45 (0.15-1.34)
1.13 (0.43-3.00)

0.70

28/138
27/134
27/135

1.00 (ref)
0.89 (0.49-1.61)
0.88 (0.49-1.59)

1.00 (ref)
1.06 (0.57-1.99)
1.16 (0.60-2.25)

0.65

23/71
7/71
24/71

1.00 (ref)
0.60 (0.12-1.74)
0.93 (0.47-1.83)

1.00 (ref)
0.74 (0.28-1.22)
1.13 (0.52-2.44)

0.71

33/154
34/152
21/151

1.00 (ref)
0.95 (0.56-1.64)
0.58 (0.32-1.06)

1.00 (ref)
1.11 (0.62-1.99)
0.75 (0.39-1.45)

0.31

21/88
17/88
22/88

1.00 (ref)
0.85 (0.42-1.73)
0.97 (0.49-1.91)

1.00 (ref)
0.70 (0.32-1.53)
1.12 (0.52-2.39)

0.57

23/113
18/112
20/115

1.00 (ref)
0.73 (0.37-1.45)
0.82 (0.42-1.60)

1.00 (ref)
0.84 (0.41-1.75)
0.97 (0.46-2.02)

0.99

15/62
14/62
12/61

1.00 (ref)
0.92 (0.41-2.07)
0.82 (0.35-1.90)

1.00 (ref)
0.94 (0.39-2.33)
1.03 (0.40-2.68)

0.93

30/151

1.00 (ref)

1.00 (ref)

European American
0.003 - 0.015
0.016 - 0.039
0.040 - 0.454
African American
0.003 - 0.012
0.013 - 0.025
0.026 - 0.450
cis-β-carotene µg/g
European American
0.003 - 0.032
0.033 - 0.088
0.089 - 1.233
African American
0.003 - 0.028
0.029 - 0.073
0.074 - 1.163
trans-β-carotene µg/g
European American
0.003 - 0.061
0.062 - 0.171
0.172 - 2.408
African American
0.003 - 0.045
0.046 - 0.126
0.127 - 2.322
α-cryptoxanthin µg/g
European American
0.003 - 0.013
0.014 - 0.025
0.026 - 0.219
African American
0.003 - 0.010
0.011 - 0.024
0.025 - 0.165
β-cryptoxanthin µg/g
European American
0.003 - 0.037

173

0.038 - 0.089
0.090 - 0.909
African American
0.003 - 0.030
0.031 - 0.070
0.071 - 0.638
Lutein µg/g

32/148
25/146

1.03 (0.59-1.79)
0.83 (0.46-1.49)

1.19 (0.64-2.19)
0.92 (0.48-1.76)

0.67

22/86
17/82
19/83

1.00 (ref)
0.82 (0.41-1.67)
0.90 (0.45-1.78)

1.00 (ref)
0.71 (0.32-1.61)
1.00 (0.46-2.19)

0.77

28/161
31/161
29/159

1.00 (ref)
1.22 (0.69-2.14)
1.01 (0.57-1.79)

1.00 (ref)
1.26 (0.69-2.31)
1.27 (0.68-2.35)

0.51

23/95
22/94
20/94

1.00 (ref)
0.96 (0.50-1.85)
0.89 (0.46-1.73)

1.00 (ref)
0.95 (0.47-1.95)
1.02 (0.49-2.12)

0.92

28/156
40/157
20/154

1.00 (ref)
1.42 (0.83-2.44)
0.76 (0.41-1.43)

1.00 (ref)
1.73 (0.96-3.09)
0.96 (0.49-1.88)

0.78

24/93
20/93
19/91

1.00 (ref)
0.83 (0.43-1.61)
0.83 (0.42-1.63)

1.00 (ref)
0.87 (0.42-1.83)
1.01 (0.47-2.17)

0.89

35/153
34/152
17/152

1.00 (ref)
1.02 (0.60-1.73)
0.51 (0.27-0.96)

1.00 (ref)
1.23 (0.69-2.18)
0.64 (0.34-1.31)

0.11

23/91
15/87
23/88

1.00 (ref)
0.74 (0.36-1.51)
1.08 (0.56-2.07)

1.00 (ref)
0.69 (0.31-1.56)
1.11 (0.53-2.35)

0.62

33/155
37/157
18/152

1.00 (ref)
1.14 (0.67-1.93)
0.57 (0.31-1.07)

1.00 (ref)
1.52 (0.85-2.71)
0.79 (0.40-1.54)

0.30

25/92
16/88
22/90

1.00 (ref)
0.74 (0.37-1.49)
0.94 (0.49-1.80)

1.00 (ref)
0.74 (0.34-1.63)
0.97 (0.46-2.02)

0.96

35/158
33/154
18/154

1.00 (ref)
0.99 (0.58-1.69)
0.54 (0.29-1.01)

1.00 (ref)
1.11 (0.63-1.99)
0.69 (0.36-1.36)

0.25

European American
0.004 - 0.078
0.079 - 0.219
0.220 - 1.457
African American
0.003 - 0.069
0.070 - 0.204
0.205 - 2.033
Zeaxanthin µg/g
European American
0.003 - 0.038
0.039 - 0.098
0.099 - 2.985
African American
0.003 - 0.028
0.029 - 0.073
0.074 - 0.713
Lycopene (cis + trans) µg/g
European American
0.004 - 0.137
0.138 - 0.371
0.372 - 3.164
African American
0.004 - 0.100
0.101 - 0.272
0.273 - 3.013
cis-lycopene µg/g
European American
0.003 - 0.080
0.081 - 0.234
0.235 - 2.049
African American
0.003 - 0.059
0.060 - 0.168
0.169 - 1.879
all-trans-lycopene µg/g
European American
0.003 - 0.050
0.051 - 0.137
0.138 – 1.115
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African American
0.003 - 0.037
0.038 - 0.102
0.103 - 1.134
a
b
c

d

22/95
17/90
22/92

1.00 (ref)
0.84 (0.42-1.70)
1.07 (0.55-2.07)

1.00 (ref)
0.85 (0.39-1.85)
1.10 (0.51-2.34)

0.72

Some categories may not sum to total number of subjects because of missing data
Adjusted for age
additional adjustment for PSA screening history, BMI, smoking status, education, income,
NSAIDs use, total dietary fat intake, study site, family history of prostate cancer, comorbidities,
and prostate cancer treatment status.
Multivariable-adjusted trend p-values
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Table 6.5 Characteristics of subsample with data on adipose carotenoids compared to
the total study sample
Total study
sample
Characteristics
Age, years
Energy intake, kcals/day
Dietary fat intake, grams/day
2

Body mass index (BMI), kg/m
Race
African American
European American

Prostate cancer aggressiveness
Low aggressive
High aggressive
Intermediate aggressive
Study Site
NC
LA (pre & post Katrina)
Family History of Prostate Cancer
No affected 1st degree relative
At least 1 affected 1st degree
relative
PSA Screening History
0 screenings
1-7 screenings
> 7 screenings
comorbidities
0
1
2
≥3
Started PCa treatment at start of
study
No
Yes
Unknown
Education
Less than high school education

n = 2,102
Mean (SD)
63.2 (7.9)
2474.8 (1040.3)

Subsample with
data on adipose
carotenoid levels
n = 939
Mean (SD)
63.3 (7.9)
2454.9 (1019.1)

p-value
0.66
0.62

94.0 (44.7)

94.7 (44.5)

0.68

29.7 (5.3)
n
%

29.9 (5.2)
n
%

0.29

<0.001

361

38

662

57

584

62

495

43

485

51

589

51

304

32

354

31

156

16

214

18

999
1103

48
52

408
531

43
57

0.04

1595
507

76
24

694
245

74
26

0.24

620
864
618

30
41
29

244
375
320

26
40
34

0.02

1057
514
269
255

50
25
13
12

497
220
107
115

53
24
11
12

0.53

242
1628
232

12
77
11

94
745
100

10
79
11

0.42

436

21

169

18

0.03
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0.48

High school graduate/ some
college
College graduate
Income Level
≤ $20, 000
$20,001 - $40,000
$40,001 - $70,000
>$70,000
Unknown
Smoking Status
Never
Former smoker
Current smoker
NSAID Use
No
Yes

1051

50

455

48

614

29

315

34

418
481
450
564
189

20
23
21
27
9

154
188
209
294
94

17
20
22
31
10

0.02

705
1085
312

33
52
15

353
470
116

38
50
12

0.04

809
1282

39
61

361
578

38
62

0.90

Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and
PSA level at diagnosis and classified as follows: high aggressive (Gleason sum ≥8 or PSA
>20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); low /intermediate aggressive: all
other cases.
Abbreviations: PCa – Prostate Cancer; LA – Louisiana; NC –North Carolina; NSAIDs –
Nonsteroidal anti-inflammatory drugs; PSA – prostate specific-antigen; SD – Standard
deviation
‡

Test for differences between two study populations were done using t-test for continuous
variables and chi-square tests for categorical variables.
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Table 6.6 (Sensitivity Analyses) Associations between dietary carotenoids and prostate
cancer aggressiveness among European Americans and African Americans with data on
adipose tissue carotenoid level only (n = 939)

Carotenoids
α-carotene

High
aggressive/
lowintermediate
aggressive

OR (95% CI) a

OR (95% CI) b

Trend
p-value
c

Dietary µg/day
European American
27.20 - 324.13
324.14 – 626.76
626.77– 9812.26
African American
11.83 – 262.11
262.12 – 585.99
586.00 – 9558.28

35/173
23/157
31/162

1.00 (ref)
0.71 (0.40-1.27)
0.89 (0.52-1.52)

1.00 (ref) 0.33
0.75 (0.41-1.41)
0.88 (0.48-1.64)

24/94
17/107
25/91

1.00 (ref)
0.60 (0.30-1.20)
1.07 (0.57-2.01)

1.00 (ref) 0.92
0.40 (0.18-1.16)
0.76 (0.36-1.62)

34/163
19/179
36/150

1.00 (ref)
0.48 (0.26-1.06)
1.05 (0.62-1.78)

1.00 (ref) 0.44
0.50 (0.26-1.04)
1.07 (0.58-1.96)

48/277
33/181
8/34

1.00 (ref)
1.09 (0.67-1.77)
1.36 (0.59-3.15)

1.00 (ref) 0.15
1.35 (0.80-2.28)
1.73 (0.70-4.24)

31/162
24/179
34/151

1.00 (ref)
0.86 (0.38-1.21)
1.08 (0.62-1.85)

1.00 (ref) 0.50
0.71 (0.38-1.33)
1.10 (0.60-2.04)

12/95
27/95
27/102

1.00 (ref)
2.27 (0.93-4.77)
2.03 (0.97-4.24)

1.00 (ref) 0.25
1.64 (0.74-3.64)
1.81 (0.77-4.23)

50/211
7/25
9/56

1.00 (ref)
1.35 (0.55-3.35)
0.69 (0.32-1.50)

1.00 (ref) 0.83
1.24 (0.46-3.38)
0.87 (0.38-1.97)

β-carotene
European American
Dietary µg/day
194.86 - 2327.81
2327.82 - 4046.15
4046.16 - 25124.05
Supplement µg/day
non-users
63.00 - 600.00
600.01 - 16470.00
Diet + supplement µg/day
346 .80 - 2566.41
2566.42 - 4458.51
4458.52 - 25512.15
African American
Dietary µg/day
286.48 - 2544.86
2544.87 - 5156.05
5156.06 - 32901.26
Supplement µg/day
non-users
63.00 - 590.00
590.01 - 15600
Diet + supplement µg/day
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286.48 - 2773.39
2773.40 - 5405.28
5405.29 - 32901.26

16/94
25/95
25/103

1.00 (ref)
1.54 (0.77-3.09)
1.39 (0.70-2.77)

1.00 (ref) 0.69
1.15 (0.54-2.43)
1.20 (0.54-2.68)

19/170
38/159
32/163

1.00 (ref)
2.10 (0.89-3.82)
1.70 (0.92-3.15)

1.00 (ref) 0.38
1.94 (0.64-3.64)
1.57 (0.80-3.07)

25/101
22/102
19/89

1.00 (ref)
0.88 (0.46-1.66)
0.87 (0.45-1.70)

1.00 (ref) 0.19
0.75 (0.37-1.53)
0.59 (0.27-1.28)

30/166
24/166
35/160

1.00 (ref)
0.72 (0.40-1.30)
1.20 (0.70-2.07)

1.00 (ref) 0.21
0.82 (0.43-1.56)
1.34 (0.71-2.50)

59/325
30/167

1.00 (ref)
1.04 (0.64-1.69)

1.00 (ref)
0.90 (0.54-1.52)

28/168
28/164
33/160

1.00 (ref)
0.91 (0.51-1.63)
1.23 (0.70-2.15)

1.00 (ref) 0.26
1.06 (0.57-1.99)
1.40 (0.73-2.66)

1.00 (ref)
1.57 (0.79-3.12)
1.53 (0.78-3.02)

1.00 (ref) 0.42
1.11 (0.52-2.37)
1.35 (0.63-2.90)

1.00 (ref)
0.89 (0.43-1.83)

1.00 (ref)
0.69 (0.32-1.51)

1.00 (ref)
1.53 (0.77-3.04)
1.52 (0.77-2.99)

1.00 (ref) 0.42
1.10 (0.51-2.35)
1.35 (0.63-2.88)

β-cryptoxanthin
Dietary µg/day
European American
6.04 - 86.14
86.15 - 180.62
180.63 - 1082.55
African American
3.53 - 116.43
116.44 - 243.34
243.34 - 1594.39
Lutein + Zeaxanthin
European American
Dietary µg/day
289.67 - 1830.51
1830.52 - 3253.94
3253.95 - 30165.13
Supplement µg/day
non-users
users
Diet + supplement µg/day
289.67 - 1907.94
1907.95 - 3318.23
3318.23 -31665.13
African American

Dietary µg/day
112.25 - 2299.78
17/103
2299.79 - 4408.18
24/90
4408.19 - 36608.75
25/99
Supplement µg/day
non-users
55/248
users
11/44
Diet + supplement µg/day
112.25 - 2309.42
17/102
2309.43 - 4461.54
24/91
4461.55 - 37558.75
25/99
Lycopene
European American
Dietary µg/day

179

344.77 - 3605.57
3605.58 - 6299.34
6299.35 -100250.76
Supplement µg/day
non-users
64.28 - 250.00
250.01 - 5000.00
Diet + supplement µg/day
344.77 - 3649.40
3649.41 - 6352.12
6352.13 - 100550.76
African American
Dietary µg/day
21.52 - 2390.06
2390.07 - 5003.81
5003.82 - 85677.94
Supplement µg/day
non-users
64.28 - 250.00
250.01 - 1000.00
Diet + supplement µg/day
21.52 - 2448.39
2448.39 - 5064.89
5064.90 - 85677.94

34/162

1.00 (ref)

1.00 (ref) 0.18

28/154
27/176

0.87 (0.50-1.52)
0.81 (0.46-1.41)

0.83 (0.46-1.51)
0.63 (0.32-1.23)

54/243
13/114
22/135

1.00 (ref)
1.40 (0.38-5.15)
0.86 (0.51-1.47)

1.00 (ref) 0.95
1.46 (0.38-5.63)
1.00 (0.57-1.76)

33/165
29/150
27/177

1.00 (ref)
0.98 (0.56-1.70)
0.85 (0.49-1.49)

1.00 (ref) 0.26
0.96 (0.53-1.74)
0.69 (0.35-1.37)

15/97
23/87
26/108

1.00 (ref)
1.82 (0.89-3.74)
1.72 (0.85-3.48)

1.00 (ref) 0.79
1.69 (0.76-3.75)
1.36 (0.59-3.01)

42/205
14/40
10/47

1.00 (ref)
1.78 (0.60-4.76)
0.99 (0.46-2.10)

1.00 (ref) 0.70
1.94 (0.52-6.32)
1.10 (0.49-2.45)

16/98
22/87
26/107

1.00 (ref)
1.72 (0.84-3.51)
1.67 (0.84-3.34)

1.00 (ref) 0.79
1.56 (0.71-3.44)
1.31 (0.58-2.96)

a

Adjusted for age
Additional adjustment for PSA screening history, BMI, smoking status, education, income, NSAIDs
use, total dietary fat intake, and study site
c
First value represents age-adjusted trend p-values and the second is the multivariable adjusted trend
p-value
d
Multivariable-adjusted trend p-value
e
Categorized into two levels because limited variability in dose did not allow for creation of
meaningful tertile categories
b
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Table 6.7 Stratified analyses of associations between dietary carotenoids and prostate cancer
aggressiveness by BMI among European Americans (n = 1,079) and African Americans (n =
1,023).
European Americans
High
aggressive/
lowOR (95% CI) ‡
intermediate
aggressive
PCa
Dietary α-carotene (µg/day) a
< median
≤ 24.9
kg/m2
≥ median
< median
25 – 29.9
kg/m2
≥ median
BMI
< median
2
≥ 30 kg/m
≥ median

9/79
11/80
32/ 201
32/ 224
45.174
32/153

1.00 (ref)
0.73 (0.24-2.21)
1.00 (ref)
0.97 (0.55-1.72)
1.00 (ref)
0.76 (0.44-1.34)

interaction (BMI by α-carotene)
= 0.32
Dietary β-carotene (µg/day) b
< median
≤ 24.9
kg/m2
≥ median
< median
25 – 29.9
kg/m2
≥ median
BMI
<
median
≥ 30 kg/m2
≥ median

5/83
15/76
30/193
34/232
45/178
32/149

1.00 (ref)
1.86 (0.55-6.32)
1.00 (ref)
0.92 (0.51-1.64)
1.00 (ref)
0.93 (0.54-1.63)

interaction (BMI by β-carotene) =
0.06
Supplemental β-carotene (µg/day) c
non-users
≤ 24.9
kg/m2
users
non-users
25 – 29.9
kg/m2
users
BMI
non-users
≥ 30 kg/m2
users

6/88
14/71
32/249
32/176
50/196
27/131

1.00 (ref)
3.50 (1.04-11.84)
1.00 (ref)
1.54 (0.87-2.73)
1.00 (ref)
0.81 (0.47-1.41)

interaction (BMI by
supplemental β-carotene) = 0.007
Total β-carotene (diet + supplement, µg/day) d
< median
6/78
≤ 24.9
kg/m2
≥ median
14/81
< median
28/198
25 – 29.9
kg/m2
≥ median
36/227
BMI
<
median
44/178
≥ 30 kg/m2
≥ median
33/149

1.00 (ref)
1.33 (0.41-4.31)
1.00 (ref)
1.11 (0.61-2.00)
1.00 (ref)
0.93 (0.54-1.62)

interaction (BMI by total βcarotene) = 0.10
Dietary β-cryptoxanthin (µg/day) e
≤ 24.9
< median
BMI
kg/m2
6/77

1.00 (ref)
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African Americans
High
aggressive/
lowOR (95% CI) ‡
intermediate
aggressive
PCa
19/92
1.00 (ref)
21/79
0.92 (0.41-2.08)
36/176
1.00 (ref)
39/149
1.22 (0.67-2.17)
41/135
1.00 (ref)
43/179
0.88 (0.51-1.52)
interaction (BMI by α-carotene)
= 0.25
19/99
1.00 (ref)
21/72
1.10 (0.49-2.48)
37/167
1.00 (ref)
38/158
0.91 (0.51-1.63)
38/138
1.00 (ref)
46/176
0.90 (0.53-1.55)
interaction (BMI by β-carotene)
= 0.35
32/116
8/55
52/231
23/94
62/213
22/101

1.00 (ref)
0.45 (0.17-1.20)
1.00 (ref)
1.08 (0.59-1.97)
1.00 (ref)
0.85 (0.47-1.53)
interaction (BMI by
supplemental β-carotene) = 0.42
19/96
1.00 (ref)
21/75
0.99 (0.43-2.28)
37/166
1.00 (ref)
38/159
0.89 (0.50-1.59)
38/143
1.00 (ref)
46/171
0.94 (0.55-1.62)
interaction (BMI by total βcarotene) = 0.50

23/91

1.00 (ref)

25 – 29.9
kg/m2
≥ 30 kg/m2

≥ median
< median
≥ median
< median
≥ median

14/82
32/208
32/217
39/171
38/156

1.21 (0.37-4.00)
1.00 (ref)
0.82 (0.46-1.46)
1.00 (ref)
1.22 (0.72-2.06)

interaction (BMI by dietary βcryptoxanthin) = 0.51
Dietary lutein + zeaxanthin (µg/day)
< median
≤ 24.9
kg/m2
≥ median
<
median
25 – 29.9
2
kg/m
≥ median
BMI
<
median
≥ 30 kg/m2
≥ median

f

6/82
14/77
31/205
33/220
45/168
32/159

1.00 (ref)
1.79 (0.51-6.35)
1.00 (ref)
1.06 (0.60-1.87)
1.00 (ref)
0.80 (0.46-1.39)

interaction (BMI by dietary lutein
+ zeaxanthin) = 0.03
Supplemental lutein (µg/day) c
non-users
≤ 24.9
kg/m2
users
non-users
25 – 29.9
kg/m2
users
BMI
non-users
≥ 30 kg/m2
users

9/100
11/59
36/287
28/138
59/227
18/100

1.00 (ref)
1.67 (0.53-5.26)
1.00 (ref)
1.74 (0.98-3.11)
1.00 (ref)
0.76 (0.42-1.39)

interaction (BMI by supplemental
lutein) = 0.02
g
Total Lutein + Zeaxanthin (diet + supplement, µg/day)
< median
6/77
1.00 (ref)
≤ 24.9
2
kg/m
≥ median
14/82
1.40 (0.40-4.93)
< median
34/207
1.00 (ref)
25 – 29.9
kg/m2
≥ median
30/218
0.92 (0.52-1.62)
BMI
< median
45/171
1.00 (ref)
≥ 30 kg/m2
≥ median
32/156
0.81 (0.47-1.42)
interaction (BMI by total lutein +
zeaxanthin) = 0.08
Dietary lycopene (µg/day) h
< median
≤ 24.9
kg/m2
≥ median
< median
25 – 29.9
kg/m2
≥ median
BMI
< median
2
≥ 30 kg/m
≥ median

9/86
11/73
37/211
27/214
45/158
32/169

1.00 (ref)
0.86 (0.26-2.80)
1.00 (ref)
0.83 (0.46-1.50)
1.00 (ref)
0.68 (0.38-1.21)

interaction (BMI by dietary
lycopene) = 0.01
Supplemental lycopene (µg/day) c
non-users
≤ 24.9
kg/m2
users
BMI
non-users
25 – 29.9
kg/m2
users
≥ 30 kg/m2
non-users

17/80
0.79 (0.34-1.84)
51/153
1.00 (ref)
24/172
0.32 (0.18-1.61)
39/161
1.00 (ref)
45/153
1.34 (0.77-2.23)
interaction (BMI by dietary βcryptoxanthin) = 0.19

12/109
8/50
39/309
25/116
60/242

1.00 (ref)
1.51 (0.45-5.02)
1.00 (ref)
1.64 (0.90-2.99)
1.00 (ref)
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15/99
1.00 (ref)
25/72
1.50 (0.66-3.39)
35/163
1.00 (ref)
40/162
0.99 (0.56-1.74)
40/142
1.00 (ref)
44/172
0.93 (0.54-1.60)
interaction (BMI by dietary
lutein + zeaxanthin) = 0.13
34/138
6/33
63/274
12/51
73/253
11/61

1.00 (ref)
0.84 (0.28-2.54)
1.00 (ref)
1.29 (0.60-2.78)
1.00 (ref)
0.68 (0.33-1.41)
interaction (BMI by
supplemental lutein) = 0.64

15/101
1.00 (ref)
25/70
1.66 (0.74-3.74)
35/162
1.00 (ref)
40/163
1.00 (0.57-1.75)
41/141
1.00 (ref)
43/173
0.88 (0.51-1.50)
interaction (BMI by total lutein
+ zeaxanthin) = 0.07
11/90
1.00 (ref)
29/81
2.90 (1.15-7.31)
32/168
1.00 (ref)
43/157
1.31 (0.72-2.40)
41/146
1.00 (ref)
43/168
1.03 (0.57-1.85)
interaction (BMI by dietary
lycopene) = 0.02
32/126
8/45
58/261
17/64
64/237

1.00 (ref)
0.70 (0.25-1.93)
1.00 (ref)
1.24 (0.64-2.42)
1.00 (ref)

users

17/85

0.91 (0.49-1.70)

interaction (BMI by supplemental
lycopene) = 0.16
i
Total Lycopene (diet + supplement, µg/day)
< median
9/84
1.00 (ref)
≤ 24.9
kg/m2
≥ median
11/75
0.85 (0.26-2.75)
< median
37/212
1.00 (ref)
25 – 29.9
kg/m2
≥ median
27/213
0.85 (0.47-1.53)
BMI
< median
44/160
1.00 (ref)
≥ 30 kg/m2
≥ median
33/167
0.75 (0.43-1.33)
interaction (BMI by total
lycopene) = 0.25

20/77

1.01 (0.55-1.86)
interaction (BMI by
supplemental lycopene) = 0.62
12/91
1.00 (ref)
28/80
2.46 (0.99-6.07)
32/168
1.00 (ref)
43/157
1.34 (0.74-2.44)
40/146
1.00 (ref)
44/168
1.10 (0.62-1.97)
interaction (BMI by total
lycopene) = 0.05

‡

Adjusted for age, PSA screening history, smoking status, education, income, NSAIDs use, total dietary
fat intake, and study site

Dietary α-carotene: European Americans (range: 27.20-9812.26, median = 453.42 µg/day); African
Americans (range: 11.83-9558.28, median = 396.03 µg/day)
a

Dietary β-carotene: European Americans (range: 194.86-25124.05, median =3016.49 µg/day); African
Americans (range: 286.48-32901.26, median = 3727.51 µg/day)
b

c

Supplements: compared users to non-users because limited variability in dose did not allow for creation
of meaningful categories

Total β-carotene: European Americans (range: 346.80-25512.15, median = 3356.11 µg/day); African
Americans (range: 286.48-32901.26, median = 3872.02 µg/day)
d

Dietary β-cryptoxanthin: European Americans (range: 6.04-1082.55, median = 125.73 µg/day); African
Americans (range: 3.53-1594.39, median = 179.15 µg/day)
e

Dietary Lutein + Zeaxanthin: European Americans (range: 289.67-30165.13 , median = 2423.60 µg/day);
African Americans (range: 112.25-36608.75, median = 3140.16 µg/day)
f

Total Lutein + Zeaxanthin: European Americans (range: 289.6-31665.13 , median = 2535.48 µg/day);
African Americans (range: 112.25-37558.75, median = 3185.08 µg/day)
g

Dietary lycopene: European Americans (range: 344.77-100250.76, median = 4646.27 µg/day); African
Americans (range: 4.90-106071.98, median = 3305.31 µg/day)
h

Total Lycopene: European Americans (range: 344.77-100550.76 , median = 4708.89 µg/day); African
Americans (range: 4.90-106071.98, median = 3336.95 µg/day)
i
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CHAPTER 7
POLYMORPHISMS IN DNA REPAIR AND OXIDATIVE STRESS-RELATED GENES, DIETARY
ALPHA- AND GAMMA-TOCOPHEROL INTAKE, AND PROSTATE CANCER AGGRESSIVENESS
7.1

INTRODUCTION
Among American men, prostate cancer (PCa) continues to have the highest

incidence and second highest mortality of any other cancer [339]. Although the etiology
of PCa remains largely unclear, considerable evidence indicates that oxidative stress may
play a role in the disease initiation and progression [470, 478, 479]. Oxidative stress is a
state of elevated intracellular levels of reactive oxygen and nitrogen species beyond
antioxidant defense capacity, which can lead to the malignant transformation of normal
epithelial cells [480, 481].
Several studies have shown parallels between oxidative stress and the known and
potential risk factors of PCa. For example, exposure to reactive oxygen species (ROS),
whether endogenously or exogenously generated, and accumulation of oxidative DNA
damage are known to increase with age, which is the strongest risk factor for PCa [482].
Chronic inflammation, particularly chronic prostatitis, is thought to promote oxidative
stress by activating inflammatory cells that increase the up-take of oxygen resulting in
excessive production of ROS [483, 484]. Epidemiologic data regarding diet and PCa
suggest that energy imbalance as well as high-fat and high-calorie diets promote PCa
incidence and aggressiveness [17]. These factors also have been shown to increase
oxidative stress through various metabolic pathways [470]. Studies show that the
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expression of oxidative stress defense enzymes, such as superoxide dismutase (SOD),
glutathione peroxidase (GPx), and catalase (CAT), are lower in malignant prostate tissues
than in health prostate tissues [485-487]. Furthermore, high aggressive CaPs are found to
have a greater degree of oxidative stress than less aggressive CaPs [479]. Together, these
observations suggest that oxidative stress may be an underlying mechanism through
which several risk factors influence PCa incidence and aggressiveness.
Sustained oxidative stress resulting from impaired antioxidant defense or
excessive exposure to ROS causes damage to DNA and other important cellular
components [481]. Oxidative DNA damage is repaired through complex DNA repair
pathways involving base excision repair (BER) which repairs non-bulky adducts and
single-strand breaks, nucleotide excision repair (NER) removes bulky and helixdistorting adducts, mismatch repair (MMR) corrects mispaired DNA bases, and
homologous recombination and end-joining DNA repair mechanisms are involved in the
repair of double-stranded breaks [488, 489]. There is ample evidence that genes involved
in oxidative stress, antioxidant defense, and DNA repair mechanisms harbor
polymorphisms that may have functional significance to PCa due to their pro- or anticarcinogenic properties [490-492]. These polymorphisms may act in tandem with
environmental factors to influence prostate carcinogenesis.
Habitually low antioxidant intake may promote oxidative stress and susceptibility
to PCa, whereas greater intakes of antioxidants can boost antioxidant defense against
oxidative stress [470]. There has been particular interest in the cancer prevention
potential of alpha (α) and gamma (γ) tocopherol, which have strong antioxidant
properties and are the major forms of vitamin E [391]; however, study results are varied
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(reviewed in [17, 493-496]). It is possible that these nutrients offer protection only for
men with certain genetic profiles, and are perhaps detrimental to others. Therefore, this
study examined whether associations between α- and γ-tocopherol intake and PCa
aggressiveness are modulated by single nucleotide polymorphisms (SNPs) in DNA repair
and oxidative stress-related genes among African-American (AA) and EuropeanAmerican (EA) men in North Carolina and Louisiana.
7.2

METHODS

Study Population
This work was performed with data from the North Carolina-Louisiana Prostate
Cancer Project (PCaP), which is a population-based, case-only, cross-sectional study of
PCa aggressiveness. North Carolina (NC) and Louisiana (LA) residents with pathologistconfirmed, first diagnosis of adenocarcinoma of the prostate between July 2004 and
August 2009, who were 40-79 years old at diagnosis and self-identified their race to be
Black/AA or Caucasian American/White/EA were recruited via rapid case-ascertainment.
Other eligibility criteria included the ability to complete study interview in English and
being mentally and physically competent to give consent and participate in the study. A
detailed description of the PCaP research protocol has been published [399]. All research
subjects provided written informed consent, including consent for genetic studies, prior to
enrollment. PCaP enrolled a total of 2258 research subjects with approximately equal
numbers of AAs (n = 1,130) and EAs (n = 1,128). Analyses were restricted to the
research subjects with genotyped data on the polymorphisms of interest (AA, n = 948;
EA, n = 1,016). The study protocols were approved by Institutional Review Boards
(IRBs) of the University of North Carolina at Chapel Hill (UNC-CH), the Louisiana State
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University Health Sciences Center, and the Department of Defense Prostate Cancer
Research Program. For the current analyses, additional IRB approval was obtained from
the University of South Carolina.

Data Collection
Trained research nurses conducted structured, in-person interviews soliciting
information on prostate-related health factors, including demographics, family history of
PCa, pre-diagnostic PCa screening habits, personal and family health history, physical
activity, smoking status, and use of vitamins and supplements, non-steroidal antiinflammatory drugs (NSAIDs), and alcohol. The research nurses obtained anthropometric
measurements (i.e., weight and height) using standardized protocol during in-person
interviews and collected biological specimens that included peripheral blood and buccal
cell samples for DNA analyses. The research subjects provided consent for review of
their medical records, which were obtained from diagnosing physicians and abstracted by
trained personnel to yield information relating to prostate-specific antigen (PSA) tests,
Gleason scores and cancer stage at diagnosis as well as other health status information.
Approximately 10% of the abstracted medical records were selected at random and
abstracted a second time by a different staff member to ensure consistency between
abstractors. In PCaP, a research subject is considered to have high aggressive PCa if he
had a Gleason sum ≥8, PSA >20 ng/mL or a Gleason sum ≥7 and cancer stage T3–T4 at
diagnosis. Low aggressive PCa was defined as research subjects with Gleason sum < 7
and cancer stage T1-T2 or PSA<10 ng/ml. All other cases are classified as intermediate
aggressive PCa. The current analyses utilized a case-control design to compare high
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aggressive PCa (cases) to low/intermediate aggressive disease (comparison group or
controls).
Dietary Assessment
Dietary nutrient intake in the 12 months prior to PCa diagnosis was assessed
using a modified version of the National Cancer Institute Diet History, Food-frequency
Questionnaire (NCI-DHQ) [400]. The NCI-DHQ was modified to include Southern foods
and assesses frequency of intake and usual portion sizes for 144 food items/groups.
Nutrient values were assigned to various foods by linking the questionnaire responses to
an updated NCI nutrient database. Usual daily intakes of various nutrients were estimate
by the NCI Diet*Calc software [401], including intakes of α- and γ-tocopherol. None of
the research subjects included in this analysis had implausible energy intake values (i.e.,
< 500 or > 6000 kcal/day).

SNP Selection
A set of 34 SNPs across 18 candidate genes involved in oxidative stress,
antioxidant defense, and DNA repair with known or suspected functional significance in
cancer based on previous association studies [2, 134, 466, 490-492, 497-499] were
selected from the PCaP GWAS data bank [500]. These included four SNPs implicated in
oxidative stress: NOS3 (rs1799983, rs3918201, rs3918226), NOX3||ARID1B
(rs9372014); and six SNPs involved in antioxidant defense: GPX2 (rs4902346), NQO1
(rs689453), PPARG (rs1801282), SOD2 (rs10370, rs4880), and USP4||GPX1
(rs8179172). SNPs in different DNA repair pathways were included, with nine in the
BER pathway: APEX1 (rs1048945, rs1130409), APEX2 (rs28382675), MUTYH
(rs3219489), OGG1 (rs1805373), and XRCC1 (rs1799778, rs1799782, rs2854508,
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rs3213247); and seven in the NER pathway: ERCC8 (rs4647100, rs4647102, rs976631),
XPA (rs1800975, rs3176644), and XPC (rs2227998, rs2733537). Three are involved in
homologous recombination repair: RAD51C (rs304269, rs6503874), and XRCC2
(rs3218522). Five are in the non-homologous end-joining repair pathway: XRCC4
(rs10474079, rs28360135, rs28360248, rs35268, rs3777018 ) [488, 489]. The selected
SNPs were eliminated from further analysis if they had less than 5% minor allele
frequency (MAF). Based on this criterion, the following SNPs were removed from
analyses among AAs and EAs: APEX1 (rs1048945), NOS3 (rs3918201), and XRCC4
(rs28360135, rs28360248). Additionally, NOS3 (rs3918226), PPARG (rs1801282), and
XRCC1 (rs3213247, rs10474079, rs3777018) were eliminated among AAs only and
APEX2 (rs28382675), OGG1 (rs1805373), USP4||GPX1 (rs8179172), and XPA
(rs3176644) were eliminated among EAs only.
Genotyping
DNA was extracted from each research subject’s peripheral blood samples (n =
1,630) or buccal cells (n = 118) by the UNC-CH Biospecimen Processing Facility, or
from immortalized lymphocytes by the UNC-CH Tissue Culture Facility (n = 216).
Genotyping was done by the Johns Hopkins University’s Center for Inherited Disease
Research using a custom 1,536-SNP Illumina GoldenGate array. The genotyping data
included 22 blinded duplicates and HapMap control samples consisting of a set of 11 YRI
and 8 CEU trios for quality checks. Full details of the genotyping and quality control
procedures has been described by Bensen et al. [500].
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Statistical Methods
Differences in the distributions of research subjects’ characteristics by their levels
of PCa aggressiveness were assessed using t and χ2 tests for continuous and categorical
variables, respectively. Unconditional logistic regression was use to estimate odds ratios
(ORs) and 95% confidence intervals (CIs) in models examining main effects of SNP
genotypes and dietary α- and γ-tocopherol. Because the frequency of minor alleles of the
SNPs were too low to allow for meaningful analysis, the genotypes were categorized into
two groups assuming a dominant model, by combining the heterozygous and
homozygous variants into one group and compared to the homozygous common
genotype (referent group).
Associations between dietary α- and γ-tocopherol intake and PCa aggressiveness
were examined by categorizing research subjects into “high” or “low” levels of intake
based on median cutpoints among the low/intermediate aggressive research subjects in
each race group. These variables were categorized separately for AAs and EAs because
of an indication of different dietary patterns between these race groups. Accordingly,
analyses were performed separately by race. A priori variables determined to be
confounders in a previous PCaP study of associations between tocopherols intake and
PCa aggressiveness were included in the multivariable-adjusted regression models. These
include age (continuous), PSA screening history (0, 1-7, >7 screenings), body mass index
(BMI, kg/m2), smoking status (never, former, current), education (less than high school
education, high school graduate, some college/college graduate, graduate degree),
household income (<$20,000, $20,001-$40,000, $40,001-$60,000, $60,001-$80,000,
>$80,000, unknown), use of NSADs in the five years before diagnosis (no, yes), total
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dietary fat intake (grams/day), and study site (NC, LA). Other variables examined for
confounding effects but not included in the final analyses were: number of first degree
relatives with PCa (none, at least one), comorbidities (0, 1, 2, ≥3), PCa treatment status
(started treatment, not started) and total metabolic equivalents (METs) of light, moderate
and vigorous exercise in the year prior to diagnosis (≤ 10.2, 10.3-29.0, >29.0 METhours/week).
To examine effect modification of associations between α- and γ-tocopherol and
PCa aggressiveness, a series of stratified analyses by genotype (categorized into two
groups) were performed comparing high to low levels of tocopherol intake. Likelihood
ratio tests (LRTs) were used to examine interaction on the multiplicative scale between
the binary genotype variable for each SNP and binary tocopherol variables. In evaluating
interaction, the difference in -2 log likelihood values of logistic regression models with
and without the interaction terms was evaluated by χ2 test with one degree of freedom.
Interaction p-values were considered statistically significant at p < 0.10 to compensate for
small sample size, which limits statistical power to detect significant interaction [336].
Results were adjusted for multiple testing by controlling for false discovery rate at 0.05
[338]. All statistical analyses were performed with SAS® (version 9.3, SAS Institute,
Cary, NC).

7.3

RESULTS
Table 7.1 presents research subject characteristics by level of PCa aggressiveness

among AAs and EAs. AA research subjects with high aggressive PCa were somewhat
older, had higher dietary fat intake, were less educated, less likely to have had at least one
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PSA screening test prior to diagnosis, and included a greater percentage of lower incomes
and current smokers as compared to AAs with low/intermediate aggressive PCa. EAs
with high aggressive PCa also were older and less educated, and had slightly higher BMI
than EAs with low/intermediate aggressive disease.
Analysis of the main effect of the SNPs showed a nearly significant increased
odds of high aggressive PCa among EAs with the heterozygous or homozygous variants
of XRCC4 (rs377018) (OR = 1.63, 95% CI = 1.00-2.64, AG+GG versus AA), but no
other association was observed (Table 7.2). Similarly, dietary α-tocopherol intake was
not associated with PCa aggressiveness among AAs (OR = 1.23, 95% CI = 0.79-1.93) or
EAs (OR = 0.70, 95% CI = 0.44-1.11) when comparing high with low intake (Table 7.3).
In analysis stratified by genotype, statistically significant interactions were observed
between α-tocopherol intake and certain SNP genotypes, with some variations in genenutrient interaction by race (Table 7.3).
Effect modification by NOS3 (rs1799983, G > T) was observed among EA
research subjects, such that among the minor allele carriers, high α-tocopherol intake was
associated with a 54% lower odds of high aggressive PCa compared to low intake, while
no association was observed among those homozygous for the common allele (Pinteraction =
0.08), and no evidence of effect modification among AAs. XPA (rs3176644) was
examined among AAs only because of less variability in genotype distribution among
EAs (i.e., MAF < 0.05). The AA research subjects who harbor the homozygous common
allele of XPA (rs3176644, G > T) and had high α-tocopherol intake as compared to lower
intake, had an over two-fold increased odds of high aggressive PCa, whereas no
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association was observed among those with one or two copies of the minor allele
(Pinteraction = 0.08).
Statistically significant effect modification by XRCC1 (rs2854508, T > A) was
observed among both AAs and EAs (Pinteraction = 0.01 and 0.04, respectively). In the
stratified analysis by XRCC1 (rs2854508) genotype, α-tocopherol intake was inversely
related to high aggressive PCa among EA research subjects who were homozygous for
the common allele (OR = 0.46, 95% CI = 0.22-0.85; high versus low intake), while no
association was observed among AAs with this genotype (OR = 0.95, 95% CI = 0.541.64; high versus low intake). In contrast, higher α-tocopherol intake appeared to be
positively associated with high aggressive PCa among AA research subjects
heterozygous or homozygous for the XRCC1 (rs2854508) minor allele, with no
association among EA research subjects with these genotypes. The other notable
associations were observed among EAs only, wherein higher α-tocopherol intake was
inversely associated with PCa aggressiveness among EA research subjects homozygous
for the common allele of APEX (rs1130409, T > G), PPARG (rs1801282, C > G), XPC
(rs2733537, A > G), and XRCC1 (rs1799782, G > A). There were no associations among
EA carriers of the minor alleles of these SNPs, and no evidence of interaction (all
interaction P values > 0.10).
ORs for high versus low γ-tocopherol intake did not show significant associations
with PCa aggressiveness among AAs or EAs (Table 7.4). However, among EA research
subjects, higher γ-tocopherol intake was inversely related to PCa aggressiveness among
carriers of the minor allele of XRCC1 (rs1799782, G > A) and XRCC2 (rs3218522, C >
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T), but not those homozygous for the common allele of these SNPs (Pinteraction = 0.04 and
0.02, respectively). Among AAs, higher γ-tocopherol intake appears to be inversely
related to high aggressive PCa among those who possess the minor allele of OGG1
(rs1805373, G > A), but not the homozygous common allele carriers (Pinteraction = 0.08).
Similar to the findings for α-tocopherol, a suggestion of positive association between
higher γ-tocopherol intake and PCa aggressiveness was observed among AA research
subjects with one or two copies of the minor allele for XRCC1 (rs2854508, T > A)
(Pinteraction = 0.03). In two instances among EAs, no interaction was observed, but higher
γ-tocopherol intake was significantly and inversely associated with PCa aggressiveness
among carriers of the minor allele of ERCC8 (rs4647102, T > C) and RAD51C
(rs6503874, C > G), while no associations were observed among EAs homozygous for
the common allele. However, neither these associations nor those reported for αtocopherol retained statistical significance after adjusting for multiple testing using false
discovery rate of 0.05.

7.4

DISCUSSION
This population-based, case-only study of incident PCa showed that associations

between dietary intakes of α- and γ-tocopherol and PCa aggressiveness may be modified
by certain genotypes of SNPs in oxidative stress and DNA repair genes. The strongest
evidence of effect modification for an association between α-tocopherol and PCa
aggressiveness was observed among genotypes of NOS3 (rs1799983), XPA (rs3176644),
and XRCC1 (rs2854508). The results indicate that higher α-tocopherol intake is
associated with significantly lower odds of high aggressive among EAs who are
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heterozygous or homozygous for the minor allele of NOS3 (rs1799983, G > T), but not
EA homozygous common allele, and there was no evidence of effect modification among
AAs. Higher α-tocopherol intake also was associated with an increased odds of high
aggressive PCa among AAs who harbor the homozygous common allele of XPA
(rs3176644, G > T), with no associations observed among AAs who possess the at least
one copy of the minor allele. Interaction by XRCC1 (rs2854508, T > A) pointed towards
an inverse association between higher α-tocopherol intake and PCa aggressiveness
among EAs who were homozygous for the common allele, while a suggestion of an
increased odds of high aggressive PCa was associated with higher intake of α- and γtocopherol among AAs who were heterozygous or homozygous for the minor allele of
this SNP. Additional evidence of effect modification by variants in OGG1 (rs1805373),
XRCC1 (rs1799782) and XRCC2 (rs3218522) was observed for associations between γtocopherol intake and PCa aggressiveness.
Although there is compelling evidence that oxidative stress, ineffective DNA
repair, and habitually low antioxidant intake may act synergistically to promote PCa
[470, 491, 494, 495], few studies have investigated interactions between genetic variants
in oxidative stress or DNA repair genes, and antioxidants intake in relation to PCa [2,
128, 219, 220, 466, 497]. Even fewer studies have evaluated such interactions within the
context of PCa aggressiveness [133, 134, 335]. This is the first study to examine SNPs
such as XPA (rs3176644), XRCC1 (rs1799782, rs2854508), and XRCC2 (rs3218522) for
their potential modifying effect of associations between dietary tocopherols and PCa.
Other polymorphisms in these genes have been examined in gene-nutrient interaction
studies in relation to PCa [2, 128, 466].
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In one study, van Gils et al. [2] observed that XRCC1 (rs25487, Arg399Gln)
genotype modulates the association between dietary vitamin E intake (α-tocopherol
equivalent) and PCa incidence, such that lower vitamin E intake was associated with an
increased risk of PCa among carriers of Arg/Arg (OR= 2.4, 95%CI = 1.0-5.6, < versus ≥
median), and not those with Arg/Gln or Gln/Gln. In contrast, Goodman et al. [466] did
not observe a modifying effect by the XRCC1 Arg399Gln genotype on association
between α-tocopherol intake and PCa risk. However, in an evaluation of combined
antioxidant exposure (α-tocopherol + lycopene + β-carotene), higher antioxidant
exposure was associated with lower risk of PCa among men with Arg/Arg genotype
(OR= 0.11, 95%CI = 0.02-0.65, < versus ≥ median), while no association was observed
among those with Arg/Gln or Gln/Gln genotype (Pinteraction = 0.01) [466]. However, it
remains unclear if α-tocopherol acts differently depending on the biological activity of
XRCC1 variants. In vitro studies suggest that the allele substitution Gln → Arg at codon
399 appear to decrease the BER capacity of XRCC1 (rs25487) [501, 502]. Evidence from
animal studies indicate that adequate intake of α-tocopherol as well as other antioxidants
can boost antioxidant defense and promote DNA repair functions [503]. Thus, αtocopherol may compensate for defective DNA repair associated with the Arg allele
[466]. Information on the functional effects of other XRCC1 polymorphism such as
(rs1799782, rs2854508) are lacking. Possibly, the DNA repair functionality of allelic
variants of other XRCC1 polymorphism also vary, and thus may differentially influence
tocopherol associations with PCa aggressiveness.
Genetic variations in the NOS3, an oxidative stress-related gene, have been
associated with several malignancies including breast and prostate cancer [499, 504-506].
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The results from the main effect of NOS3 (rs1799983, G > T) in the current study was
suggestive of an increased odds of high aggressive PCa among EA who carry the minor
allele; however, higher α-tocopherol intake in this population was associated with
significantly lower odds of high aggressive PCa. Similar observation was made by Li et
al. [499], where a positive relation between the NOS3 (rs1799983) T allele and breast
cancer risk in analysis of the main effect of genotype reversed towards a lower risk of
breast cancer in the presence of higher fruit and vegetable intake (Pinteraction = 0.005).
Although the biological mechanisms are not clearly elucidated, a functional
polymorphism in NOS3 (894 G → T) at exon 7 has been shown to reduce pro-oxidant
enzyme activity [507, 508]. Thus, it appears that the T allele may be sensitive to
antioxidant intervention, and as suggested by the current findings, EAs who possess the
NOS3 (rs1799983) T allele may benefit from dietary α-tocopherol intake with respect to
PCa aggressiveness.
The main effect of XRCC4 (rs3777018, G > A) was suggestive of an increased
odds of high aggressive PCa among EA carriers of the minor allele; however, there was
no evidence of interaction with α- or γ-tocopherol intake. Perhaps XRCC4 (rs3777018)
may modulate associations of other dietary factors in relation PCa. It is also worth noting
that while no interaction was observed between α-tocopherol intake and the genotypes of
APEX1 (rs1130409, T > G), PPARG (rs1801282, C > G), XPC (rs2733537, A > G) or
XRCC1 (rs1799782, G > A), higher α-tocopherol intake was associated with a
significantly lower odds of high aggressive PCa among EA who possess the homozygous
common alleles of these SNPs. This supports suggestions that the potential benefits of αtocopherol and other antioxidants may be limited to men with certain genetic variants,
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and may explain some of the inconsistencies in the epidemiologic literature when diet is
examined in isolation of genetic factors [509].
Among the major findings for γ-tocopherol were significant interactions with
XRCC1 (rs1799782, G > A) and XRCC2 (rs3218522, C > T) wherein higher γ-tocopherol
intake was inversely associated with PCa aggressiveness among EA carriers of the
heterozygous and homozygous minor alleles. The minor alleles of ERCC8 (rs4647102, T
> C), RAD51C (rs6503874, C > G), XRCC4 (rs35268, T > C) among EAs, and OGG1
(rs1805373, G > A) among AAs also were inversely related to PCa aggressiveness with
higher intake of γ-tocopherol. Nonetheless, results should be interpreted cautiously as
some of the effect estimates are unstable due to the small sample size. Additionally, the
observed associations did not retain statistical significance after correction for multiple
comparisons.
Other limitations that are worth consideration include the use of a food frequency
questionnaire to measure tocopherol intake, which in addition to identified response set
biases [510-512] does not account for the bioavailability or bioefficiency of these
nutrients because of inter-individual variability in absorption and metabolism [278]. The
use of a single dietary assessment interview also could have introduced some
misclassification of tocopherol exposure. However, because this is a case-only study,
such misclassification would likely be non-differential, resulting in conservative OR
estimates [513]. Because this analysis was limited to research subjects with data on the
SNPs of interest, there is the possibility of selection bias, though included versus
excluded research subjects did not vary substantially in their demographic characteristics
suggesting selection bias due to lack of genotyping data is likely minimal (Supplemental
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Table 1). Strengths of the study include its evaluation of PCa aggressiveness as opposed
to overall risk of PCa. Aggressive PCa tends to have a strong genetic influence, and thus,
aggressive and non-aggressive forms of PCa may differ in their etiology [458]. Hence,
examining PCa aggressiveness reduces confounding by different disease states. The use
of a multiethnic population spanning two states also increases the generalizability of the
study findings. Although genotyping errors cannot be completely ruled out in any genetic
study, the genotyped data had over 99% concordance with blinded duplicates [411],
which adds to the strengths of the study.

7.5

CONCLUSIONS

This study provides evidence of effect modification of the association between αtocopherol and PCa aggressiveness by XRCC1 (rs2854508), NOS3 (rs1799983) and XPA
(rs3176644) genotypes. The results further suggest that an association between γtocopherol and PCa aggressiveness may be modified OGG1 (rs1805373), XRCC1
(rs2854508) and XRCC2 (rs3218522) genotypes. Although the general applicability of
these findings awaits verification in larger studies, they illustrate the complex interaction
between α- and γ-tocopherol intake, and polymorphisms in oxidative stress and DNA
repair genes in relation to PCa aggressiveness. The findings also underscore the
importance of considering one’s genetic makeup in dietary intervention to identify those
mostly likely to benefit from such interventions.
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Table 7.1 Characteristics of prostate cancer patients by level of the disease aggressiveness among African and European
American men
African Americans
N = 948

Characteristics
High
aggressive

Low/intermediate
aggressive

High
aggressive

Low/intermediate
aggressive

(n=188 )

(n= 760)

(n=153)

(n= 863 )

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

63 (7.6)

62 (7.6)

0.007

67 (7.5)

64 (7.7)

<0.0001

2792.8 (1200.8)

2614.7 (1153.1)

0.06

2360.1 (963.4)

2322.1 (878.2)

0.63

103.8 (51.6)

95.5 (48.2)

0.04

95.7 (43.2)

91.2 (39.7)

0.20

30.0 (6.7)

29.2 (5.4)

0.10

30.3 (5.1)

29.0 (4.8)

0.002

Age, years
Energy Intake, kcals/day
Dietary fat intake, grams/day

200

2

Body mass index (BMI), kg/m

Study Site
NC
LA
PSA Screening History
0 screenings
1-7 screenings
> 7 screenings
Education
Graduate/professional degree
Some college or college graduate
High school grad or voc/tech
school
Less than high school education
Income Level

European Americans
N = 1,016

N

%

N

%

80
108

43
57

347
413

46
54

111
46
31

59
24
17

278
321
161

4
49
57

2
26
30

78

42

P‡

P‡

N

%

N

%

0.44

64
89

42
58

413
450

48
52

0.17

37
42
21

<0.0001

35
63
55

23
41
36

140
385
338

16
45
39

0.13

54
227
258

7
30
34

0.002

28
65
33

18
42
22

184
361
244

21
42
28

0.004

220

29

27

18

74

9

≤ $20, 000
$20,001 - $40,000
$40,001 - $60,000
$60,001 - $80,000
>$80,000
Unknown
Smoking Status
Never
Former smokers
Current smokers
NSAID Use
No
Yes

75
47
18
11
14
23

40
25
10
6
7
12

217
199
120
65
94
65

29
26
16
8
12
8

0.004

22
30
24
19
44
14

14
20
16
12
29
9

71
171
149
120
278
74

8
20
17
14
32
9

0.28

37
99
52

20
52
28

258
358
144

34
47
19

0.0003

54
82
17

35
54
11

314
472
77

36
55
9

0.69

76
110

41
59

336
420

44
56

0.38

52
101

34
66

289
572

34
66

0.92

Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as follows: High
aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); Low /Intermediate aggressive: all other cases.
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Abbreviations: LA – Louisiana; NC –North Carolina; NSAIDs – nonsteroidal anti-inflammatory drugs; PSA – prostate-specific antigen; SD – standard
deviation
‡

Test for differences between low/intermediate and high aggressive cancers were done using t-test for continuous variables and chi-square tests for
categorical variables.

Table 7.2 Associations of single nucleotide polymorphisms (SNPs) in oxidative stress and DNA repair genes in relation to
prostate cancer aggressiveness by race
African Americans
Gene (SNP ID)

Genotype

Case/
Controls b

OR (95% CI)

European Americans
Case/
Controls b

c

P

188/760
APEX1 (rs1130409)

ERCC8 (rs4647100)
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ERCC8 (rs4647102)

ERCC8 (rs976631)

GPX2 (rs4902346)

MUTYH (rs3219489)

NOS3 (rs1799983)

OR (95% CI) c

P

153/863

TT

81/305

1.00 (ref)

GT+GG

107/455

0.88 (0.64-1.22)

AA

156/625

1.00 (ref)

AG+GG

32/135

0.97 (0.64-1.49)

TT

75/315

1.00 (ref)

CT+CC

113/443

1.10 (0.79-1.53)

TT

101/434

1.00 (ref)

CT+CC

85/325

1.09 (0.79-1.51)

AA

70/266

1.00 (ref)

AG+GG

118/494

0.90 (0.64-1.25)

CC

107/434

1.00 (ref)

CC+GG

81/326

1.02 (0.74-1.41)

GG

152/598

1.00 (ref)

GT+TT

36/160

0.89 (0.59-1.33)

0.44

0.91

0.57

0.58

0.53

0.89

0.56

38/230

1.00 (ref)

115/633

1.10 (0.74-1.64)

87/481

1.00 (ref)

66/382

0.96 (0.67-1.36)

61/324

1.00 (ref)

92/539

0.90 (0.63-1.29)

46/275

1.00 (ref)

107/585

1.12 (0.77-1.63)

86/553

1.00 (ref)

67/310

1.39 (0.98-1.97)

92/459

1.00 (ref)

61/404

0.76 (0.53-1.08)

59/382

1.00 (ref)

94/475

1.31 (0.92-1.87)

0.63

0.81

0.57

0.56

0.07

0.12

0.13

NOS3 (rs3918226)

d

NOX3||ARID1B
(rs9372014)

d

NQO1 (rs689453)

OGG1 (rs1805373)

d

PPARG (rs1801282)

d
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RAD51C (rs304269)

RAD51C (rs6503874)

SOD2 (rs10370)

SOD2 (rs4880)

USP4||GPX1
(rs8179172)

d

CC

-

-

-

126/725

1.00 (ref)

CT+TT

-

-

-

27/138

1.09 (0.69-1.73)

GG

-

-

-

77/403

1.00 (ref)

GT+TT

-

-

-

76/459

0.86 (0.60-1.21)

CC

171/673

138/731

1.00 (ref)

CT+TT

17/87

15/132

0.62 (0.35-1.10)

GG

151/648

1.00 (ref)

AG+AA

37/112

1.45 (0.96-2.20)

CC

-

CG+GG

-

GG

104/400

1.00 (ref)

AG+AA

84/360

0.92 (0.67-1.27)

CC

89/388

1.00 (ref)

CG+GG

99/371

1.20 (0.87-1.65)

TT

145/549

1.00 (ref)

GT+GG

43/209

0.79 (0.54-1.15)

AA

69/254

1.00 (ref)

AG+GG

118/505

0.88 (0.63-1.23)

AA

153/640

1.00 (ref)

AT+TT

35/120

1.22 (0.81-1.86)

1.00 (ref)
0.75 (0.44-1.31)

0.31

0.70

0.38

0.10

-

-

-

0.08

-

-

-

-

-

122/670

1.00 (ref)

-

-

30/193

0.84 (0.54-1.29)

57/360

1.00 (ref)

96/503

1.21 (0.85-1.73)

136/767

1.00 (ref)

0.61

0.27

0.21

0.45

0.34

17/96

1.00 (0.57-1.73)

94/515

1.00 (ref)

59/348

0.96 (0.67-1.37)

42/197

1.00 (ref)

111/665

0.77 (0.52-1.14)

0.42

0.30

0.99

0.83

0.19

-

-

-

-

-

-

XPA (rs1800975)

XPA (rs3176644)

d

XPC (rs2227998)

XPC (rs2733537)

XRCC1 (rs1799778)
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XRCC1 (rs1799782)

XRCC1 (rs2854508)

XRCC1 (rs3213247)

d

XRCC2 (rs3218522)

XRCC4 (rs10474079

d

CC

121/470

1.00 (ref)

CT+TT

67/289

0.90 (0.64-1.25)

GG

69/322

1.00 (ref)

GT+TT

118/437

1.28 (0.92-1.79)

CC

94/366

1.00 (ref)

CT+TT

94/394

0.92 (0.67-1.27)

AA

131/527

1.00 (ref)

AG+GG

57/233

0.96 (0.68-1.37)

GG

102/462

1.00 (ref)

GT+TT

85/294

1.31 (0.95-1.81)

GG

165/660

1.00 (ref)

AG+AA

23/100

0.93 (0.57-1.52)

TT

123/478

1.00 (ref)

AT+AA

65/281

0.90 (0.64-1.26)

CC

-

AC+AA

-

CC

122/529

CT+TT

66231

1.25 (0.89-1.75)

GG

-

AG+AA

-

0.52

0.14

69/366

1.00 (ref)

84/497

0.90 (0.64-1.28)

-

-

-

-

-

-

78/480

1.00 (ref)

75/378

1.17 (0.83-1.66)

86/401

1.00 (ref)

67/462

0.71 (0.50-1.01)

66/353

1.00 (ref)

87/509

0.91 (0.64-1.29)

131/735

1.00 (ref)

22/128

0.98 (0.60-1.60)

98/508

1.00 (ref)

0.54

55/355

0.80 (0.56-1.14)

-

-

136/772

1.00 (ref)

-

-

17/91

1.06 (0.61-1.84)

38/248

1.00 (ref)

0.20

115/615

1.20 (0.80-1.78)

-

-

115/665

1.00 (ref)

-

-

38/197

1.07 (0.71-1.60)

0.62

0.84

0.10

0.79

1.00 (ref)

0.56

0.36

0.05

0.58

0.93

0.22

0.84

0.38

0.74

XRCC4 (rs28360135 d

XRCC4 (rs35268)

XRCC4 (rs3777018)

a

d

TT

-

-

-

144/792

CT+CC

-

-

-

9/71

TT

100/417

1.00 (ref)

CT+CC

87/343

1.08 (0.78-1.49)

AA

-

AG+GG

-

1.00 (ref)
0.77 (0.37-1.59)

116/670

1.00 (ref)

0.63

37/193

1.05 (0.70-1.59)

-

-

128/769

1.00 (ref)

-

-

25/94

1.63 (1.00-2.64)

The most common genotype used as the reference category
Some categories may not sum to total sample because of missing data
c
Adjusted for age
d
Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group
b

0.48

0.80

0.05
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Table 7.3 Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary α-tocopherol
intake and prostate cancer aggressiveness, and stratified by genotype of SNP in oxidative stress and DNA repair gene
pathways

Dietary α-tocopherol mg/day a

low
high
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Cases/
Controls

Gene (SNP ID),
major/minor allele

ERCC8 (rs4647100)
ERCC8 (rs4647102)
ERCC8 (rs976631)
GPX2 (rs4902346)

1.00 (ref)
1.23 (0.79-1.93)

Homozygous Common Allele

Stratified analysis by SNP

APEX1(rs1130409)

Cases/
Controls
84/379
104/381

African Americans
(n = 948)
b
OR (95% CI)

T/G
A/G
T/C
T/C
A/G

OR (95% CI) b

Heterozygous or Homozygous
Minor Allele
Cases/
Controls

OR (95% CI) b

P‡

low

34/158

1.00 (ref)

50/221

1.00 (ref)

high

47/147

1.58 (0.79-3.14)

57/234

1.06 (0.58-1.94) 0.44

low

74/316

1.00 (ref)

10/63

1.00 (ref)

high

82/309

1.22 (0.74-1.99)

22/72

1.29 (0.41-4.09) 0.57

low

39/159

1.00 (ref)

45/220

1.00 (ref)

high

36/156

0.80 (0.37-1.71)

68/223

low

46/212

1.00 (ref)

37/167

1.00 (ref)

high

55/222

1.08 (0.58-1.99)

48/158

1.39 (0.70-2.75) 0.63

low

32/125

1.00 (ref)

52/254

1.00 (ref)

1.52 (0.86-2.69)

0.60

MUTYH (rs3219489)

C/G

NOS3 (rs1799983)
NOS3 (rs3918226)

G /T
c

C/T

NOX3||ARID1B (rs9372014) c
G/T
NQO1 (rs689453)

C/T
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OGG1 (rs1805373)

c

PPARG (rs1801282)
RAD51C (rs304269)
RAD51C (rs6503874)
SOD2 (rs10370)

G/A
c

C/G
G/A
C/G
T/G

high

38/141

1.17 (0.54-2.52)

66/240

1.32 (0.75-2.33) 0.80

low

44/218

1.00 (ref)

40/161

1.00 (ref)

high

63/216

1.50 (0.82-2.72)

41/165

1.03 (0.51-2.05) 0.35

low

69/308

1.00 (ref)

15/70

1.00 (ref)

high

83/290

1.38 (0.84-2.28)

21/90

0.61 (0.20-1.85) 0.66

low

-

-

-

high

-

-

-

low

-

-

-

high

-

-

-

low

75/340

1.00 (ref)

9/39

1.00 (ref)

high

96/333

1.26 (0.79-2.00)

8/48

2.20 (0.26-18.27) 0.22

low

65/329

1.00 (ref)

19/50

1.00 (ref)

high

86/319

1.33(0.81-2.18)

18/62

1.06 (0.30-3.77) 0.15

low

-

-

-

high

-

-

-

low

48/201

1.00 (ref)

36/178

1.00 (ref)

high

56/199

1.65 (0.89-3.05)

48/182

0.82 (0.41-1.64) 0.68

low

40/210

1.00 (ref)

44/169

1.00 (ref)

high

49/178

1.56 (0.78-3.12)

55/202

0.95 (0.52-1.74) 0.44

low

61/270

1.00 (ref)

21/107

1.00 (ref)

SOD2 (rs4880)

A/G

USP4||GPX1 (rs8179172)

c

A/T
XPA (rs1800975)
XPA (rs3176644)

.C / T
c

G/T

XPC (rs2227998)

C/T
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XPC (rs2733537)

A/G

XRCC1 (rs1799778)

G/T

XRCC1 (rs1799782)

G/A

XRCC1 (rs2854508)
XRCC1 (rs3213247)

T/A
c

C/A

high

84/279

1.24 (0.74-2.07)

22/102

1.14 (0.41-3.18) 0.75

low

27/116

1.00 (ref)

56/262

1.00 (ref)

high

42/138

1.18 (0.54-2.56)

62/243

1.33 (0.76-2.34) 0.81

low

68/318

1.00 (ref)

16/61

1.00 (ref)

high

85/322

1.17 (0.72-1.92)

19/59

1.66 (0.46-6.06) 0.74

low

54/236

1.00 (ref)

30/142

1.00 (ref)

high

67/234

1.10 (0.63-1.95)

37/147

1.41 (0.67-2.99) 0.74

low

27/163

1.00 (ref)

56/213

1.00 (ref)

high

42/159

2.19 (1.05-4.57)

62/224

0.80 (0.45-1.44) 0.08

low

43/182

1.00 (ref)

41/197

1.00 (ref)

high

51/184

0.95 (0.49-1.83)

53/197

1.47 (0.78-2.76) 0.84

low

58/267

1.00 (ref)

26/112

1.00 (ref)

high

73/260

1.19 (0.69-2.05)

31/121

1.55 (0.64-3.78) 0.75

low

47/227

1.00 (ref)

37/151

1.00 (ref)

high

55/235

1.23 (0.68-2.20)

48/143

1.15 (0.55-2.39) 0.74

low

72/336

1.00 (ref)

12/43

1.00 (ref)

high

93/324

1.33 (0.83-2.15)

112/57

0.43 (0.07-2.73) 0.19

low

61/229

1.00 (ref)

23/150

1.00 (ref)

high

62/249

0.95 (0.54-1.67)

42/131

2.04 (0.94-4.42) 0.01

low

-

-

-

high

-

-

-

XRCC2 (rs3218522)

C/T

XRCC4 (rs10474079)

c

XRCC4 (rs28360135)

c

XRCC4 (rs35268)

c

XRCC4 (rs3777018 )

G/A
T/C
T/C

c

A/G

low

52/274

1.00 (ref)

32/105

1.00 (ref)

high

70/255

1.54 (0.88-2.71)

34/126

0.77 (0.35-1.70) 0.11

low

-

-

-

high

-

-

-

low

-

-

-

high

-

-

-

low

47/204

1.00 (ref)

36/175

1.00 (ref)

high

53/213

1.08 (0.59-1.99)

51/168

1.63 (0.83-3.21) 0.16

low

-

-

-

high

-

-

-
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Categorized based on median split (< vs. ≥ median) among controls for African Americans as low: 1.54 – 9.30 mg/day
and high: 9.31 – 44.62 mg/day; and for European Americans: 1.67 – 9.50 and 9.51 – 53.18 mg/day, respectively.
a

b

Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake,
and study site
c

Results not presented for SNPs with deviation from Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less
than 5% minor allele frequency among controls in the respective race group.

‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype
(homozygous common allele vs. homozygous variant + heterozygous) and dietary α-tocopherol level (< vs. ≥ median) in
multivariable adjusted models.

Table 7.3 (continued) Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary αtocopherol intake and prostate cancer aggressiveness, and stratified by genotype of SNP in oxidative stress and DNA repair
gene pathways

Dietary α-tocopherol mg/day a

low
high

210

Cases/
Controls

Gene (SNP ID),
major/minor allele

ERCC8 (rs4647100)
ERCC8 (rs4647102)
ERCC8 (rs976631)
GPX2 (rs4902346)

1.00 (ref)
0.70 (0.44-1.11)

Homozygous Common Allele

Stratified analysis by SNP

APEX1(rs1130409)

Cases/
Controls
81/430
72/433

European Americans
(n = 1,016)
b
OR (95% CI)

T/G
A/G
T/C
T/C
A/G

OR (95% CI) b

Heterozygous or Homozygous
Minor Allele
Cases/
Controls

OR (95% CI) b

low

20/102

1.00 (ref)

61/328

1.00 (ref)

high

18/128

0.31 (0.12-0.81)

54/305

0.90 (0.53-1.54)

low

46/244

1.00 (ref)

35/486

1.00 (ref)

high

41/237

0.62 (0.33-1.15)

31/196

0.71 (0.35-1.44)

low

34/158

1.00 (ref)

47/272

1.00 (ref)

high

27/166

0.55 (0.26-1.16)

45/267

0.82 (0.46-1.49)

low

25/135

1.00 (ref)

56/294

1.00 (ref)

high

21/140

0.61 (0.26-1.40)

51/291

0.75 (0.43-1.33)

low

46/269

1.00 (ref)

35/161

1.00 (ref)

high

40/284

0.60 (0.32-1.09)

32/149

0.82 (0.39-1.72)

P‡

0.50
0.99
0.31
0.94
0.41

MUTYH (rs3219489)

C/G

NOS3 (rs1799983)
NOS3 (rs3918226)

G /T
c

C/T
c

NOX3||ARID1B (rs9372014)
G/T
NQO1 (rs689453)
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OGG1 (rs1805373)

C/T
c

PPARG (rs1801282)
RAD51C (rs304269)
RAD51C (rs6503874)
SOD2 (rs10370)
SOD2 (rs4880)

G/A
c

C/G
G/A
C/G
T/G
A/G

low

50/228

1.00 (ref)

31/202

1.00 (ref)

high

42/231

0.57 (0.31-1.06)

30/202

0.90 (0.44-1.82)

low

29/205

1.00 (ref)

52/222

1.00 (ref)

high

30/177

1.09 (0.51-2.30)

42/253

0.46 (0.25-0.84)

low

63/363

1.00 (ref)

18/67

1.00 (ref)

high

63/362

0.80 (0.48-1.32)

9/71

0.39(0.11-1.37)

low

39/200

1.00 (ref)

42/230

1.00 (ref)

high

38/203

0.93 (0.48-1.81)

34/229

0.52 (0.27-1.02)

low

73/369

1.00 (ref)

8/61

1.00 (ref)

high

65/362

0.72 (0.44-1.17)

7/71

0.87 (0.17-4.40)

low

-

-

-

high

-

-

-

low

67/329

1.00 (ref)

14/101

1.00 (ref)

high

55/341

0.59 (0.35-0.99)

16/92

0.86 (0.26-2.80)

low

28/181

1.00 (ref)

53/249

1.00 (ref)

high

29/179

0.86 (0.41-1.81)

43/254

0.64 (0.35-1.17)

low

70/381

1.00 (ref)

11/49

1.00 (ref)

high

66/386

0.74 (0.46-1.21)

6/47

0.39 (0.05-3.15) 0.53

low

52/253

1.00 (ref)

29/177

1.00 (ref)

high

42/262

0.56 (0.31-1.03)

30/171

0.88 (0.42-1.84)

low

23/114

1.00 (ref)

58/316

1.00 (ref)

0.77

0.08
0.12
0.74
65

0.24
0.42

0.54

USP4||GPX1 (rs8179172)

c

A/T
XPA (rs1800975)
XPA (rs3176644)

C/T
c

G/T

XPC (rs2227998)

C/T

XPC (rs2733537)

A/G
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XRCC1 (rs1799778)

G/T

XRCC1 (rs1799782)

G/A

XRCC1 (rs2854508)

XRCC1 (rs3213247)
XRCC2 (rs3218522)

T/A
c

C/A
C/T

high

19/83

1.29 (0.52-3.21)

53/349

0.59 (0.34-1.05)

low

-

-

-

high

-

-

-

low

36/187

1.00 (ref)

45/243

1.00 (ref)

high

33/179

0.65 (0.32-1.32)

39/254

0.73 (0.39-1.35)

low

-

-

-

high

-

-

-

low

41/247

1.00 (ref)

40/181

1.00 (ref)

high

37/233

0.78 (0.42-1.47)

35/197

0.58 (0.29-1.16)

low

50/194

1.00 (ref)

31/236

1.00 (ref)

high

36/207

0.46 (0.24-0.88)

36/226

1.19 (0.61-2.33)

low

31/178

1.00 (ref)

50/251

1.00 (ref)

high

35/175

1.04 (0.50-2.15)

37/258

0.55 (0.30-1.03)

low

69/357

1.00 (ref)

12/73

1.00 (ref)

high

62/378

0.60 (0.37-0.99)

10/55

3.90 (0.68-22.32)

low

58/248

1.00 (ref)

23/182

1.00 (ref)

high

40/260

0.46 (0.22-0.85)

32/173

1.11 (0.51-2.41)

low

72/386

1.00 (ref)

9/44

1.00 (ref)

high

64/386

0.70 (0.43-1.14)

8/47

0.80 (0.14-4.41)

low

16/130

1.00 (ref)

65/300

1.00 (ref)

high

22/118

0.87 (0.32-2.42)

50/315

0.63 (0.38-1.07)

0.49

0.63

0.57
0.12
0.19
0.71

0.04
0.61

0.11

XRCC4 (rs10474079)

XRCC4 (rs28360135)
XRCC4 (rs35268)

c

XRCC4 (rs3777018 )

c

c

G/A

T/C
T/C

c

A/G

low

60/330

1.00 (ref)

21/99

1.00 (ref)

high

55/335

0.68 (0.40-1.15)

17/98

0.80 (0.28-2.26)

low

77/399

1.00 (ref)

4/31

1.00 (ref)

high

67/393

0.67 (0.42-1.09)

5/40

2.57 (0.20-32.89)

low

61/331

1.00 (ref)

20/99

1.00 (ref)

high

55/339

0.80 (0.47-1.36)

17/94

0.40 (0.14-1.14)

low

67/382

1.00 (ref)

14/48

1.00 (ref)

high

61/387

0.76 (0.46-1.24)

11/46

0.89 (0.20-4.02)

0.95
0.81
0.99
0.98

Categorized based on median split (< vs. ≥ median) among controls for African Americans as low: 1.54 – 9.30 mg/day
and high: 9.31 – 44.62 mg/day; and for European Americans: 1.67 – 9.50 and 9.51 – 53.18 mg/day, respectively.
a
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b

Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake,
and study site
c

Results not presented for SNPs with deviation form Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less
than 5% minor allele frequency among controls in the respective race group.

‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype
(homozygous common allele vs. homozygous variant + heterozygous) and dietary α-tocopherol level (< vs. ≥ median) in
multivariable adjusted models.

Table 7.4 Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary γ-tocopherol
intake and prostate cancer aggressiveness, and stratified by genotype among African Americans
African Americans

low
high

Dietary γ-tocopherol mg/day a

Cases/
Controls
85/379
103/381

OR (95% CI) b
1.00 (ref)
0.89 (0.56-1.44)

Stratified analysis by SNP

Homozygous Common Allele

Heterozygous or Homozygous
Minor Allele

Gene (SNP ID),
major/minor allele

Cases/
Controls

Cases/
Controls
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APEX1(rs1130409)
ERCC8 (rs4647100)
ERCC8 (rs4647102)

ERCC8 (rs976631)
GPX2 (rs4902346)
MUTYH (rs3219489)

T/G
A/G
T/C

T/C
A/G
C/G

OR (95% CI) b

OR (95% CI) b

P‡

low

39/152

1.00 (ref)

46/227

1.00 (ref)

high

42/153

0.78 (0.37-1.63)

61/228

1.01 (0.54-1.92) 0.62

low

75/310

1.00 (ref)

10/69

1.00 (ref)

high

81/315

0.82 (0.48-1.39)

22/66

1.51 (0.46-4.94) 0.26

low

34/153

1.00 (ref)

51/226

1.00 (ref)

high

41/162

0.76 (0.34-1.70

62/217

1.05 (0.57-1.94) 0.73

low

45/214

1.00 (ref)

38/165

1.00 (ref)

high

56/220

0.93 (0.48-1..82)

47/160

0.98 (0.48-1.97) 0.92

low

32/128

1.00 (ref)

53/251

1.00 (ref)

high

38/138

0.71 (0.31-1.64)

65/243

0.99 (0.54-1.80) 0.72

low

46/219

1.00 (ref)

39/160

1.00 (ref)

NOS3 (rs1799983)
NOS3 (rs3918226)

G /T
c

C/T

NOX3||ARID1B (rs9372014)

c

G/T
NQO1 (rs689453)
OGG1 (rs1805373)

C/T
c
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PPARG (rs1801282)

G/A
c

RAD51C (rs304269)
RAD51C (rs6503874)

SOD2 (rs10370)
SOD2 (rs4880)

C/G
G/A
C/G

T/G
A/G

high

61/215

0.91 (0.49-1.71)

42/166

0.87 (0.42-1.80) 0.68

low

69/303

1.00 (ref)

16/76

1.00 (ref)

high

83/295

1.05 (0.62-1.77)

20/84

0.42 (0.11-1.56) 0.55

low

-

-

-

high

-

-

-

low

-

-

-

high

-

-

-

low

78/341

1.00 (ref)

7/38

1.00 (ref)

high

93/332

0.85 (0.52-1.40)

10/49

1.69 (0.17-16.36) 0.69

low

65/328

1.00 (ref)

20/51

1.00 (ref)

high

86/320

1.05 (0.63-1.79)

17/61

0.30 (0.08-1.17) 0.08

low

-

-

-

high

-

-

-

low

49/201

1.00 (ref)

36/178

1.00 (ref)

high

55/199

1.26 (0.66-2.43)

48/182

0.54 (0.25-1.14) 0.70

low

44/204

1.00 (ref)

41/175

1.00 (ref)

high

45/184

0.63 (0.30-1.34)

58/196

1.13 (0.60-2.13) 0.61

low

66/268

1.00 (ref)

19/111

1.00 (ref)

high

79/281

0.77 (0.44-1.33)

24/98

1.43 (0.51-3.97) 0.59

low

29/133

1.00 (ref)

55/245

1.00 (ref)

high

40/121

1.39 (0.62-3.14)

63/260

0.72 (0.39-1.31) 0.25

USP4||GPX1 (rs8179172) c
A/T
XPA (rs1800975)
XPA (rs3176644)

C /T
c

G/T

XPC (rs2227998)

C/T

XPC (rs2733537)

A/G
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XRCC1 (rs1799778)

G/T

XRCC1 (rs1799782)

G/A

XRCC1 (rs2854508)
XRCC1 (rs3213247)

T/A
c

C/A

XRCC2 (rs3218522)
XRCC4 (rs10474079)

C/T
c

G/A

low

69/321

1.00 (ref)

16/58

1.00 (ref)

high

84/319

0.83 (0.49-1.41)

19/62

1.24 (0.32-4.85) 0.65

low

53/237

1.00 (ref)

32/141

1.00 (ref)

high

68/233

0.97 (0.53-1.76)

35/148

0.76 (0.34-1.71) 0.64

low

29/157

1.00 (ref)

55/222

1.00 (ref)

high

40/165

1.24 (0.57-2.70)

63/215

0.76 (0.40-1.42) 0.57

low

40/186

1.00 (ref)

45/193

1.00 (ref)

high

54/180

0.98 (0.48-1.98)

49/201

0.82 (0.42-1.59) 0.21

low

60/267

1.00 (ref)

25/112

1.00 (ref)

high

71/260

0.82 (0.46-1.46)

32/121

1.10 (0.42-2.86) 0.72

low

47/226

1.00 (ref)

38/153

1.00 (ref)

high

55/236

0.98 (0.53-1.82)

47/141

0.77 (0.35-1.71) 0.69

low

73/331

1.00 (ref)

12/48

1.00 (ref)

high

92/329

0.92 (0.56-1.53)

11/52

0.86 (0.15-4.93) 0.49

low

64/237

1.00 (ref)

21/142

1.00 (ref)

high

59/241

0.71 (0.39-1.29)

44/139

1.60 (0.71-3.63) 0.03

low

-

-

-

-

high

-

-

-

-

low

53/266

1.00 (ref)

32/113

1.00 (ref)

high

69/263

0.97 (0.53-1.75)

34/118

0.78 (0.34-1.81) 0.30

low

-

-

-

-

XRCC4 (rs28360135)
XRCC4 (rs35268)

c

XRCC4 (rs3777018 )

c

T/C
T/C

c

A/G

high

-

-

-

-

low

-

-

-

-

high

-

-

-

-

low

46/206

1.00 (ref)

39/173

1.00 (ref)

high

54/211

0.87 (0.46-1.65)

48/170

0.84 (0.40-1.75) 0.51

low

-

-

-

-

high

-

-

-

-

Categorized based on median split (< vs. ≥ median) among controls for African Americans as low: 0.78 – 18.54 mg/day
and high: 18.55 – 67.95 mg/day; and for European Americans: 2.68 – 17.22 and 17.23 – 55.13 mg/day, respectively.
a

b

217

Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake,
and study site
c

Results not presented for SNPs with deviation form Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less
than 5% minor allele frequency among controls in the respective race group.

‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype
(homozygous common allele vs. homozygous variant + heterozygous) and dietary γ-tocopherol level (< vs. ≥ median) in
multivariable adjusted models.

Table 7.4 (continued) Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between dietary γtocopherol intake and prostate cancer aggressiveness, and stratified by genotype among European Americans
European Americans

Dietary γ-tocopherol mg/day a

low
high

Cases/
Controls

Gene (SNP ID),
major/minor allele
218

ERCC8 (rs4647100)
ERCC8 (rs4647102)
ERCC8 (rs976631)
GPX2 (rs4902346)
MUTYH (rs3219489)

T/G
A/G
T/C
T/C
A/G
C/G

OR (95% CI) b
1.00 (ref)
0.77 (0.48-1.24)

Homozygous Common Allele

Stratified analysis by SNP

APEX1(rs1130409)

Cases/
Controls
75/431
78/432

OR (95% CI) b

Heterozygous or Homozygous
Minor Allele
Cases/
Controls

OR (95% CI) b

low

17/108

1.00 (ref)

58/323

1.00 (ref)

high

21/122

0.69 (0.25-1.92)

57/310

0.77 (0.44-1.33)

low

39/243

1.00 (ref)

36/188

1.00 (ref)

high

48/238

1.06 (0.56-2.01)

30/194

0.48 (0.23-1.03)

low

24/152

1.00 (ref)

51/279

1.00 (ref)

high

37/172

1.54 (0.71-3.32)

41/260

0.48 (0.25-0.91)

low

23/133

1.00 (ref)

52/296

1.00 (ref)

high

23/142

0.60 (0.25-1.42)

55/289

0.85 (0.48-1.52)

low

42/273

1.00 (ref)

33/158

1.00 (ref)

high

44/280

0.73 (0.39-1.37)

34/152

0.85 (0.39-1.82)

low

47/232

1.00 (ref)

28/199

1.00 (ref)

P‡

0.77
0.20
0.16
0.95
0.54

NOS3 (rs1799983)
NOS3 (rs3918226)

G /T
c

C/T
c

NOX3||ARID1B (rs9372014)
G/T
NQO1 (rs689453)
OGG1 (rs1805373)

C/T
c
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PPARG (rs1801282)

G/A
c

RAD51C (rs304269)
RAD51C (rs6503874)

SOD2 (rs10370)
SOD2 (rs4880)

C/G
G/A
C/G

T/G
A/G

high

45/227

0.58 (0.31-1.11)

33/205

1.15 (0.55-2.40)

low

26/184

1.00 (ref)

49/244

1.00 (ref)

high

33/198

0.78 (0.36-1.69)

45/231

0.72 (0.39-1.34)

low

57/361

1.00 (ref)

18/70

1.00 (ref)

high

69/364

0.88 (0.52-1.50)

9/68

0.37(0.11-1.22)

low

41/201

1.00 (ref)

34/229

1.00 (ref)

high

36/202

0.58 (0.28-1.18)

42/230

0.97 (0.50-1.88)

low

69/363

1.00 (ref)

6/68

1.00 (ref)

high

69/368

0.69 (0.41-1.14)

9/64

3.34 (0.70-15.84)

low

-

-

-

high

-

-

-

low

63/330

1.00 (ref)

12/101

1.00 (ref)

high

59/340

0.58 (0.34-1.00)

18/92

2.02 (0.63-6.53)

low

24/179

1.00 (ref)

51/252

1.00 (ref)

high

33/181

0.98 (0.47-2.08)

45/251

0.67 (0.35-1.26)

low

65/388

1.00 (ref)

10/43

1.00 (ref)

high

71/379

0.90 (0.55-1.48)

7/53

0.15 (0.03-0.90)

low

48/249

1.00 (ref)

27/182

1.00 (ref)

high

46/266

0.62 (0.33-1.15)

32/166

1.04 (0.47-2.27)

low

21/111

1.00 (ref)

54/320

1.00 (ref)

high

21/86

1.66 (0.62-4.43)

57/345

0.65 (0.37-1.13)

0.60

0.75
0.12
0.17
0.32

0.10
0.27
0.30
0.41

0.59

USP4||GPX1 (rs8179172) c
A/T
XPA (rs1800975)
XPA (rs3176644)

C/T
c

G/T

XPC (rs2227998)

C/T

XPC (rs2733537)

A/G
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XRCC1 (rs1799778)

G/T

XRCC1 (rs1799782)

G/A

XRCC1 (rs2854508)
XRCC1 (rs3213247)

T/A
c

C/A

XRCC2 (rs3218522)
XRCC4 (rs10474079)

C/T
c

G/A

low

-

-

-

high

-

-

-

low

33/184

1.00 (ref)

42/247

1.00 (ref)

high

36/182

0.51 (0.23-1.11)

42/250

0.96 (0.51-1.79)

low

-

-

-

high

-

-

-

low

39/236

1.00 (ref)

36/193

1.00 (ref)

high

39/244

0.66 (0.34-1.29)

39/185

0.92 (0.45-1.86)

low

42/186

1.00 (ref)

33/245

1.00 (ref)

high

44/215

0.64 (0.33-1.26)

34/217

0.90 (0.45-1.80)

low

28/178

1.00 (ref)

47/253

1.00 (ref)

high

38/175

0.91 (0.42-1.95)

40/256

0.67 (0.36-1.26)

low

59/362

1.00 (ref)

16/69

1.00 (ref)

high

72/373

1.06 (0.52-1.43)

6/59

0.23 (0.04-1.38)

low

51/250

1.00 (ref)

24/181

1.00 (ref)

high

47/258

0.76 (0.42-1.36)

31/174

0.73 (0.32-1.70)

low

66/387

1.00 (ref)

9/44

1.00 (ref)

high

70/385

0.76 (0.46-1.25)

8/47

1.39 (0.23-8.30)

low

13/139

1.00 (ref)

62/292

1.00 (ref)

high

25/109

1.20 (0.42-3.42)

53/323

0.66 (0.39-1.14)

low

55/326

1.00 (ref)

20/105

1.00 (ref)

0.80

0.53
0.32
0.26

0.04
0.35
0.81

0.02

XRCC4 (rs28360135)
XRCC4 (rs35268)

c

XRCC4 (rs3777018 )

c

T/C
T/C

c

A/G

high

60/339

0.71 (0.41-1.24)

187/92

1.11 (0.40-3.06)

low

72/402

1.00 (ref)

3/29

1.00 (ref)

high

72/390

0.72 (0.44-1.18)

6/42

2.48 (0.21-28.62)

low

54/335

1.00 (ref)

21/97

1.00 (ref)

high

62/335

1.04 (0.60-1.79)

16/96

0.27 (0.08-0.83)

low

62/375

1.00 (ref)

13/56

1.00 (ref)

high

66/394

0.75 (0.45-1.24)

12/38

1.96 (0.37-10.28)

0.72

0.66
0.19
0.72

Categorized based on median split (< vs. ≥ median) among controls for African Americans as low: 0.78 – 18.54 mg/day
and high: 18.55 – 67.95 mg/day; and for European Americans: 2.68 – 17.22 and 17.23 – 55.13 mg/day, respectively.
a

b
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Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total dietary fat intake,
and study site
c

Results not presented for SNPs with deviation form Hardy-Weinberg equilibrium (p-value <0.05) and for SNPs with less
than 5% minor allele frequency among controls in the respective race group.

‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype
(homozygous common allele vs. homozygous variant + heterozygous) and dietary γ-tocopherol level (< vs. ≥ median) in
multivariable adjusted models.

CHAPTER 8
LYCOPENE INTAKE AND PROSTATE CANCER AGGRESSIVENESS: EFFECT MODIFICATION BY
POLYMORPHISMS IN DNA REPAIR AND OXIDATIVE STRESS RELATED GENES

8.1

INTRODUCTION
Prostate cancer (PCa) is the most common invasive cancer and a leading cause of

cancer death among men in North America and Western Europe [514]. The aggressive
forms of PCa occur most frequently in men of African ancestry, and these are often
diagnosed at an early age [515, 516]. Epidemiologic studies suggest that the etiology of
aggressive PCa may be different from that of non-aggressive PCa, including differences
in genetic susceptibility [517, 518] and potential differences in dietary risk factors [17,
437]. Lycopene, an antioxidant carotenoid, is among the potentially beneficial dietary
factors associated with a reduced risk of PCa [179, 440, 519]. Some studies show that
lycopene may have a stronger inverse association with the aggressive forms of PCa
compared with more indolent PCa [520, 521]. Genetic variants (i.e., single nucleotide
polymorphisms, SNPs) in oxidative stress and DNA repair genes have also been
associated with PCa risk and aggressiveness [332, 491, 492, 522]. However, lycopene
intake and genetic risk variants, when examined in isolation, may explain only a small
portion of the factors contributing to PCa aggressiveness. There is some evidence that the
association between lycopene and PCa are modulated by polymorphic variants of genes
involved in the biological processes of PCa, such as those in the oxidative stress and
DNA repair pathways [2, 128, 466, 470].
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Several reports indicate that oxidative stress-related genes may confer greater risk
of PCa [478, 522]. Indeed, oxidative stress has been implicated in prostate tumorigenesis
[470, 478] and is thought to promote PCa initiation and aggressiveness by causing
damage to DNA [479]. Cellular response to oxidative DNA damage involves the
activation of oxidative stress-mediating genes, including those involved in base excision
repair, nucleotide excision repair, homologous re-combination repair, and nonhomologous end-joining DNA repair genes to correct the damaged parts and restore
genomic stability [125, 523]. The ability to recognize and repair oxidatively modified
DNA is an important determinant of an individual’s susceptibility to PCa [523]. Thus,
individual differences in polymorphic variants of genes encoding oxidative stress and
DNA repair functions may influence the incidence and aggressiveness of PCa [125, 478].
Lycopene, which is obtained mainly from tomatoes and tomato-based products,
has been shown in laboratory studies to have many anticancer properties, including acting
as an antioxidant and inhibitor of oxidative DNA damage [371, 524]. However,
associations between lycopene and PCa overall are inconsistent (reviewed in [179, 393,
440, 519]). Of five prospective dietary studies [180, 437, 449, 525, 526], three [180, 437,
449] reported an inverse association between lycopene intake and PCa incidence, while
two [525, 526] were not supportive of a beneficial role of lycopene in PCa. Among casecontrol studies, three [450, 527, 528] reported inverse associations with higher lycopene
intake, while several others have reported null association ([461, 462, 529], also reviewed
in [179, 393, 440, 519]). Similarly, some [520, 521], but not all [442, 530, 531], plasmaand serum-based studies have reported inverse associations between lycopene levels and
PCa incidence. These somewhat inconsistent findings might be because these studies
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consisted of a heterogeneous group of PCa cases, which can confound associations. It
might also reflect the genetic risk variability of the studied populations. Examining genenutrient interaction in relation to PCa phenotype may therefore help clarify the
association between lycopene and PCa.
The purpose of this study was to investigate whether polymorphisms in oxidative
stress and DNA repair genes interact with lycopene to modulate PCa aggressiveness
among African-American (AA) and European-American (EA) men in North Carolina and
Louisiana. The hypothesis was that associations between lycopene intake and PCa
aggressiveness are modified by SNPs in oxidative stress and DNA repair genes.
8.2

METHODS

Study Population
This study was conducted using data from the North Carolina-Louisiana Prostate
Cancer Project (PCaP) [399]. PCaP is a large, population-based, cross-sectional, caseonly study designed to examine biological, lifestyle, and socio-demographic factors
associated with PCa aggressiveness among AAs and EAs. Between July 2004 and August
2009, PCaP enrolled 2,258incident PCa cases (AAs, n = 1,130; EAs, n = 1,128) from
North Carolina (NC) and Louisiana (LA), with a median time between diagnosis and
recruitment of 3.9 months. The inclusion criteria for PCaP were having a first diagnosis
of histologically confirmed adenocarcinoma of the prostate, being of age 40–79 years at
diagnosis, and self-identification of race as Black/AA or Caucasian American/White/EA.
The eligible participants were also required to be able to complete the study interview in
English; have sufficient physical and cognitive ability to participate; and not reside in an
institution (e.g., nursing home). Institutional Review Board (IRB) approval was obtained
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from all collaborating institutions, and all of the research subjects provided consent
before enrollment [399]. The current analysis also was approved by the IRB of the
University of South Carolina. The PCa cases included in this analysis were drawn from
PCaP research subjects with available data on the SNPs of interest (n = 1,964; AAs n =
948; EAs n = 1,016).
Data Collection
Data on demographic, lifestyle, and health-related factors were obtained by
trained research nurses using structured questionnaires during in-home visits [399]. The
research nurses also obtained anthropometric measures and peripheral blood samples
during each interview following a standardized protocol. Research subjects who could
not provide blood samples were given the option to complete a buccal rinse for DNA
analysis (approximately 5%). Information on the cancer stage at diagnosis, Gleason sum,
and prostate-specific antigen (PSA) level at diagnosis were abstracted from the medical
records obtained from diagnosing physicians. The medical records abstraction was
standardized and performed by trained personnel, and included a duplicate abstraction of
a random sample (about 10%) to ensure consistency between abstractors. PCa
aggressiveness was classified as previously described [399] to be high aggressive
(Gleason sum ≥8; PSA >20 ng/ml; or Gleason sum = 7 and stage T3–T4), low aggressive
(Gleason sum <7 and stage T1–T2 and PSA<10 ng/ml), or intermediate aggressive (all
other cases). These categories were used in a case-control study design to compare high
aggressive PCa “cases” with low or intermediate aggressive PCa “controls,” as has been
done in previous studies [532, 533].
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Dietary Assessment
Dietary data were obtained using the National Cancer Institute Dietary History,
Food-frequency Questionnaire (NCI-DHQ) [453], which was modified to include
Southern foods. The modified 144-item questionnaire queried on frequency of food
intake, usual portion size, and food preparation methods in the 12 months prior to
diagnosis with PCa. Usual daily nutrient intake was estimated using the Diet*Calc
software, which utilizes the NCI’s nutrient database [399]. In addition, a validated
questionnaire [454] was used to solicit information on multivitamins and single-nutrient
supplement use in the 12 months prior to diagnosis. This information was used to
calculate total lycopene intake by combining lycopene intake from food and supplements.
None of the subjects included in this analysis had implausible values for calorie intake
(i.e., < 500 or > 6000 kcal/day).
SNP Selection
Details of the methods used for SNP selection in PCaP has been reported [332].
For the current analysis, 34 candidate SNPs across 18 genes were selected from the PCaP
genotype data repository for analyses. These include NOS3 (rs1799983, rs3918201,
rs3918226) and NOX3||ARID1B (rs9372014), which are implicated in oxidative stress,
and GPX2 (rs4902346), NQO1 (rs689453), PPARG (rs1801282), SOD2 (rs10370,
rs4880), and USP4||GPX1 (rs8179172), which are involved in antioxidant defense. Also
included were APEX1 (rs1048945, rs1130409), APEX2 (rs28382675), MUTYH
(rs3219489), OGG1 (rs1805373), and XRCC1 (rs1799778, rs1799782, rs2854508,
rs3213247), which are located in the base excision repair pathway, and ERCC8
(rs4647100, rs4647102, rs976631), XPA (rs1800975, rs3176644), and XPC (rs2227998,
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rs2733537), which are located in the nucleotide excision DNA repair pathway. RAD51C
(rs304269, rs6503874) and XRCC2 (rs3218522), which are involved in homologous
recombination, and XRCC4 (rs10474079, rs28360135, rs28360248, rs35268,
rs3777018), which is involved in non-homologous end-joining DNA repair, were also
analyzed [489, 534]. These SNPs were selected because of known or suspected functional
significance in oxidative stress or DNA repair in relation to cancer based on published
literature [491, 492, 522, 535]. An a priori decision was made to exclude SNPs with low
minor allele frequency (MAF, < 0.05). Based on this criterion, four out of the 34 SNPs
were removed from the analyses for both AAs and EAs: APEX1 (rs1048945), APEX2
(rs28382675), NOS3 (rs3918201), and XRCC4 (rs28360248). Of the remaining SNPs,
OGG1 (rs1805373), USP4||GPX1 (rs8179172), and XPA (rs3176644) were excluded
from analyses among EAs only, while NOS3 (rs3918226), NOX3||ARID1B (rs9372014),
PPARG (rs1801282), XRCC1 (rs3213247), and XRCC4 (rs10474079, rs28360135,
rs3777018) were excluded among AAs only.
Genotyping
DNA was extracted from blood samples (n = 1,630) or buccal cells (n = 118) by
the University of North Carolina (UNC, Chapel Hill) Biospecimen Processing Facility or
from peripheral blood mononuclear cells immortalized by the UNC Tissue Culture
Facility (n = 216). Genotyping was done at the National Institutes of Health (NIH) Center
for Inherited Disease Research (CIDR) using a custom designed Illumina GoldenGate
array. There was an excellent genotyping call rate (99.93%) and inter-assay agreement
with blinded duplicates (99.99%). Further details of the genotyping process and quality
control measures have been published [332].
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Statistical Methods
All analyses were conducted separately for AAs and EAs because of significant
interaction that was observed between race and lycopene intake. Distributions of research
subjects’ characteristics by the levels of PCa aggressiveness were examined using
Students’ t-test and chi-square tests for continuous and categorical variables, respectively.
Unconditional logistic regression was used to calculate odds ratios (ORs) and
corresponding 95% confidence intervals (CIs). In order to maximize sample size, a
dominant model of inheritance was adopted to evaluate the effect of genotype on PCa
aggressiveness by collapsing the three-level genotype variables into two groups. This was
done by taking the most frequent genotype (i.e., homozygous common allele) as the
reference category to estimate ORs for the homozygous and heterozygous variant
genotypes (combined in one group), adjusting for age at diagnosis. The lycopene
variables also were categorized into two groups (< versus ≥ median) to conserve sample
size. Cutpoints for categorizing the dietary and total (diet + supplement) lycopene
variables were based on race-specific distribution among low/intermediate aggressive
cases.
All multivariable logistic regression models simultaneously adjusted for the
following variables: age (continuous), study site (NC, LA), BMI (in kg/m2), prediagnostic PSA screening history (0, 1–7, >7 screenings), smoking status (never, former,
current), education (less than high school education, high school graduate/some college,
college graduate), annual household income (< $20,000, $20,001–$40,000, $40,001–
$70,000, >$70,000), regular NSAIDs use in the five years prior to diagnosis (yes, no),
and total fat intake (grams/day). Other factors that were evaluated as potential
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confounders but not included in the final adjusted models are: comorbidities (0, 1, 2, ≥3),
a first degree family history of PCa (none, at least one), PCa treatment status (started
treatment, not started), and physical activity (i.e., metabolic equivalents (METs) of light,
moderate, and vigorous exercise in the year prior to diagnosis, ≤ 10.2, 10.3–29.0, >29.0
MET-hours/week).
To examine potential modification of associations between lycopene intake and
PCa aggressiveness, stratified analyses were performed comparing greater than or equal
to median (i.e. high) with less than median (i.e., low) intake within each stratum of the
genotype groups (homozygous common allele versus heterozygous or homozygous minor
allele). Interaction effects were assessed on the multiplicative scale using likelihood ratio
tests to compare models with and without interaction terms of the dichotomous genotype
and lycopene variables following the hierarchical principle. The threshold for a
statistically significant interaction was set at P value < 0.10 to compensate for the small
sample size in the stratified groups [336]. All other tests were considered statistically
significant at the 0.05 level. Results were corrected for multiple testing using the false
discovery rate (FDR) method [338]. All statistical tests were two-sided and performed
using SAS® version 9.3 (SAS, Inc.).
8.3

RESULTS
In both race groups, research subjects with high aggressive PCa were older and

less educated as compared to those with low or intermediate aggressive PCa (Table 8.1).
EA research subjects with high aggressive PCa had a marginally higher BMI than EAs
with low or intermediate aggressive PCa. AA research subjects with high aggressive PCa
tended to have higher dietary fat intake and included greater proportions of current
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smokers, low incomes, and those who have never had a PSA screening test prior to
diagnosis with PCa as compared with AAs with low or intermediate aggressive PCa.
As shown in Table 8.2, evaluation of the main effect of the SNP variants in
relation to PCa aggressiveness did not show a statistically significant beneficial or
harmful effect for any of the SNPs, except for a marginally significant association for the
XRCC4 (rs3777018) SNP among EAs. The EA carriers of the minor allele of XRCC4
(rs3777018, A > G) appeared to have greater odds of high aggressive PCa than those
homozygous for the common allele (OR = 1.63, 95% CI = 1.00-2.64).
Dietary lycopene intake expressed as the median split variable was not
significantly associated with PCa aggressiveness among EAs (OR = 0.77, 95% CI =
0.53–1.16, high versus low intake) or AAs (OR = 1.41, 95% CI = 0.96-2.07, high versus
low intake) (Table 8.3). However, evidence existed of gene-nutrient interaction, which
was particularly noticeable for the XRCC1 (rs2854508, T > A) (P values for interaction =
0.01 and 0.06 for AAs and EAs, respectively). The pattern of the interaction was such
that, in both AAs and EAs, high (compared to low) dietary lycopene intake tended to be
associated with increased odds of high aggressive PCa among those heterozygous or
homozygous for the minor allele, while higher lycopene intake was inversely related to
high aggressive PCa among those homozygous for the common allele. XPA (rs1800975,
C > T) also appeared to have a modifying effect on associations between dietary lycopene
and PCa aggressiveness in that lycopene intake was associated with reduced odds of high
aggressive PCa among EAs with one or two copies of the minor allele (OR = 0.56, 95%
CI = 0.32–0.98, high versus low intake), but not those homozygous for the common
allele (OR = 1.02, 95% CI = 0.56–1.87, high versus low intake; P value for interaction =
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0.07). Analogous findings were observed among AAs, although statistical interaction was
non-significant in this group. A similar pattern of lower odds of high aggressive PCa was
observed among EAs who harbor the minor allele of NQO1 (rs689453, C > T) and
XRCC2 (rs3218522, C > T) and had higher lycopene intake, which was not observed
among EAs who were homozygous for the common allele (P values for interaction =
0.05 and 0.08, respectively). Among AAs only, higher dietary lycopene intake was
associated with increased odds of high aggressive PCa among those homozygous for the
common alleles of ERCC8 (rs4647102, T > C), RAD51C (rs6503874, C > G), and
XRCC1 (rs1799778, G >T), but not those who were heterozygous or homozygous for the
minor alleles of these SNPs. Among AAs heterozygous or homozygous for the minor
alleles of XPA (rs3176644, G >T), XPC (rs2227998, C >T), and XPC (rs2733537, A > G)
higher lycopene intake was associated with increased odds of high aggressive PCa.
Table 8.4 presents associations of total lycopene intake from diet, supplements,
and PCa aggressiveness by genotype. Similar to dietary lycopene, there were no
significant associations between total lycopene intake and PCa aggressiveness among
EAs or AAs. Interactions observed with total lycopene were fewer, but largely mirror
those observed with dietary lycopene. In particular, the genetic variants in XRCC1
(rs2854508), XPA (rs1800975), and NQO1 (rs689453) demonstrated identical interaction
with total lycopene intake as observed with dietary lycopene. Similarly, the associations
observed for RAD51C (rs6503874), XPA (rs3176644), and XPC (rs2733537) with dietary
lycopene among AAs were consistent with the findings for total lycopene intake among
AAs.
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8.4

DISCUSSION
In this population-based, case-only study, there was evidence that an association

between lycopene and PCa aggressiveness can be modified by genotype of SNPs in
oxidative stress and DNA repair genes. The evidence was strongest for the XRCC1
(rs2854508) SNP, whereby among research subjects with the variant genotypes (AT or
AA), higher lycopene intake was associated with an increased odds of high aggressive
PCa, while high lycopene intake was associated with lower odds of high aggressive PCa
among those with the homozygous common genotype (TT). In addition to XRCC1
(rs2854508), other SNPs that did not have independent association with high aggressive
PCa appeared to interact with lycopene to influence PCa aggressiveness. Notably, XPA
(rs1800975) and NQO1 (rs689453), demonstrated statistical interaction with dietary and
total lycopene intake, with similar patterns of association in both AAs and EAs. It is,
however, worth noting that no study has yet examined these SNPs in gene-diet interaction
studies. Hence, confirmatory studies are warranted.
Few data exist for interaction between lycopene and other polymorphisms in
DNA repair and oxidative stress-related genes [2, 128, 335, 466, 497]. Goodman and
colleagues [466] demonstrated that the XRCC1 A399G polymorphism modifies
association between lycopene and PCa risk such that the beneficial effect of lycopene
was only evident in men with the AA genotype, not those with the AG or GG genotype.
Li et al. [335] examined interaction between pre-diagnostic plasma lycopene level and
genotype of the manganese superoxide dismutase (MnSOD, also referred to as SOD2)
gene, but did not find independent association of MnSOD genotype or interaction with
plasma lycopene level in relation to overall risk of PCa and risk for aggressive PCa. This
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finding concurs with the current results for the SOD2 SNPs (rs10370 and rs4880).
However, in an analysis of combined plasma antioxidant status (sum of lycopene,
selenium and α-tocopherol), the highest quartile of plasma antioxidant status (compared
to lowest) was associated with a five-fold lower risk of PCa and ten-fold lower risk of
aggressive PCa among men with the AA genotype, but no significant association was
observed among those with AV or VV genotype [335]. Similar findings have been
reported by Mikhak et al. [497]. Although different candidate SNPs have been examined
in various studies, together, these data provide support for the gene-nutrient interactions
observed in the current analyses, indicating that the association between lycopene and
PCa can be modified by genotype of polymorphisms in relevant genes.
A nearly significant positive association with PCa aggressiveness was observed
for the XRCC4 (rs3777018) G allele though it did not modify the association of lycopene
intake with PCa aggressiveness. While some of the SNPs did not show evidence of
statistical interaction with lycopene, certain variants of the SNPs appear to work in
tandem with lycopene to influence PCa aggressiveness. As suggested by Savas et al.
[502] and Rebbeck [536], it is possible that some of these variants confer low-tomoderate risk or protection against cancer that becomes evident only under certain
physiological conditions or environmental exposures.
Limitations of the study include the use of a food frequency questionnaire to
measure lycopene intake, which in addition to identified response set biases [510-512],
does not account for the bioavailability or bioefficiency of carotenoids because of interindividual variability in absorption and metabolism [278]. The use of a single dietary
assessment also might have introduced some misclassification of lycopene exposure.
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However, because this is a case-only study, such misclassification would likely be nondifferential, resulting in conservative OR estimates [384]. Another limitation includes the
use of median cutpoints to categorized lycopene in an effort to conserve sample size;
however, this may have resulted in too small contrast between high and low lycopene
intake categories to observe a substantial effect of lycopene. Other limitations include the
observational nature of the study, which precludes causal inferences. Because of the
small sample size and multiple comparisons, chance findings cannot be excluded,
considering that none of the P values retained statistical significance after FDR correction
for multiple testing (data not shown). Therefore, replication of the findings in larger
studies would be useful. Even though analyses were stratified by self-reported race,
residual confounding by ethnicity due to genetic admixture cannot be completely ruled
out [537, 538]. Additionally, post hoc analysis involving adjustment for African ancestry
proportions did not materially change the study results (Supplementary Tables 3 and 4).
8.5

CONCLUSIONS

In summary, the results of the analysis suggest that EA men with AG or GG genotype of
the XRCC4 (rs3777018) SNP may be at a higher risk of developing high aggressive PCa
compared to those with the AA genotype. The results also show that an association
between lycopene and PCa aggressiveness can be modified by genotype of SNPs in
oxidative stress and DNA repair genes, including XRCC1 (rs2854508), XPA (rs1800975)
and NQO1 (rs689453). Additional work is needed to verify these findings and help
determine their potential for targeted PCa interventions.
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Table 8.1 Demographic and health-related characteristics of the research subjects by level of prostate cancer aggressiveness
Characteristics

Age, years
Energy Intake, kcals/day
Dietary fat intake,
grams/day
Body mass index (BMI),
kg/m2
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Study Site
NC
LA
PSA Screening History
0 screenings
1-7 screenings
> 7 screenings
Education
Less than high school
education
High school graduate/
some college
College graduate
Income Level
≤ $20, 000
$20,001- $40,000

European Americans
N = 1016
High
Low/intermediate
aggressive
aggressive
(n=153 )
(n= 863)
Mean (SD)
Mean (SD)
67 (7.5)
64 (7.7)

P‡

<0.0001

African Americans
N = 948
High
Low/intermediate
aggressive
aggressive
(n=188)
(n= 760)
Mean (SD)
Mean (SD)
63 (7.6)
62 (7.6)

P‡

0.007

2360.1 (963.4)
95.7 (43.2)

2322.1 (878.2)
91.2 (39.7)

0.63
0.20

2792.8 (1200.8)
103.8 (51.6)

2614.7 (1153.1)
95.5 (48.2)

0.06
0.04

30.3 (5.1)

29.0 (4.8)

0.002

30.0 (6.7)

29.2 (5.4)

0.10

N

%

N

%

N

%

N

%

64
89

42
58

413
450

48
52

0.17

80
108

43
57

347
413

46
54

0.44

35
63
55

23
41
36

140
385
338

16
45
39

0.13

111
46
31

59
24
17

278
321
161

37
42
21

<0.0001

27

18

74

8

0.002

78

42

220

29

0.001

70

46

412

48

93

49

413

54

56

37

377

44

17

9

126

17

22
30

14
20

71
171

8
20

75
47

40
25

217
199

29
26

0.15

0.002

$40,001- $70,000
>$70,000
Unknown
Smoking Status
Never
Former smokers
Current smokers
NSAID Use
No
Yes

37
50
14

24
33
9

211
336
74

24
40
8

54
82
17

35
54
11

314
472
77

36
55
9

52
101

34
66

289
572

34
66

22
21
23

12
11
12

158
121
65

21
16
8

0.69

37
99
52

20
52
28

258
358
144

34
47
19

0.0003

0.92

76
110

41
59

336
420

44
56

0.38

236

Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as
follows: High aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); Low /Intermediate
aggressive: all other cases.
Abbreviations: PCa – prostate cancer; LA – Louisiana; NC –North Carolina; NSAIDs – nonsteroidal anti-inflammatory drugs; PSA
– prostate-specific antigen; SD – standard deviation
‡
Test for differences between high aggressive and low/intermediate aggressive prostate cancers performed using Student’s t-test for
continuous variables and chi-square tests for categorical variables.

Table 8.2 Associations of polymorphisms in DNA repair and oxidative stress-related genes in relation to prostate cancer
aggressiveness among European Americans and African Americans
African Americans
Gene (SNP ID)

Genotype

Case/
Controls b

OR (95% CI)

European Americans
Case/
Controls b

c

P

188/760
APEX1
(rs1130409)
ERCC8
(rs4647100)
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ERCC8
(rs4647102)
ERCC8 (rs976631)

GPX2 (rs4902346)

MUTYH
(rs3219489)
NOS3 (rs1799983)

NOS3 (rs3918226)
d

OR (95% CI) c

P

153/863

TT

81/305

1.00 (ref)

GT+GG

107/455

0.88 (0.64-1.22)

AA

156/625

1.00 (ref)

AG+GG

32/135

0.97 (0.64-1.49)

TT

75/315

1.00 (ref)

CT+CC

113/443

1.10 (0.79-1.53)

TT

101/434

1.00 (ref)

CT+CC

85/325

1.09 (0.79-1.51)

AA

70/266

1.00 (ref)

AG+GG

118/494

0.90 (0.64-1.25)

CC

107/434

1.00 (ref)

CC+GG

81/326

1.02 (0.74-1.41)

GG

152/598

1.00 (ref)

GT+TT

36/160

0.89 (0.59-1.33)

CC

-

CT+TT

-

38/230

1.00 (ref)

115/633

1.10 (0.74-1.64)

87/481

1.00 (ref)

66/382

0.96 (0.67-1.36)

61/324

1.00 (ref)

92/539

0.90 (0.63-1.29)

46/275

1.00 (ref)

107/585

1.12 (0.77-1.63)

86/553

1.00 (ref)

67/310

1.39 (0.98-1.97)

92/459

1.00 (ref)

61/404

0.76 (0.53-1.08)

59/382

1.00 (ref)

0.56

94/475

1.31 (0.92-1.87)

-

-

126/725

1.00 (ref)

-

-

27/138

1.09 (0.69-1.73)

0.44

0.91

0.57

0.58

0.53

0.89

0.63

0.81

0.57

0.56

0.07

0.12

0.13

0.70

NOX3||ARID1B
(rs9372014)

d

NQO1 (rs689453)

OGG1 (rs1805373)
d

PPARG
(rs1801282)

d

RAD51C
(rs304269)
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RAD51C
(rs6503874)
SOD2 (rs10370)

SOD2 (rs4880)

USP4||GPX1
(rs8179172)

d

XPA (rs1800975)

XPA (rs3176644)

d

GG

-

-

-

77/403

1.00 (ref)

GT+TT

-

-

-

76/459

0.86 (0.60-1.21)

CC

171/673

138/731

1.00 (ref)

CT+TT

17/87

15/132

0.62 (0.35-1.10)

GG

151/648

1.00 (ref)

AG+AA

37/112

1.45 (0.96-2.20)

CC

-

CG+GG

-

GG

104/400

1.00 (ref)

AG+AA

84/360

0.92 (0.67-1.27)

CC

89/388

1.00 (ref)

CG+GG

99/371

1.20 (0.87-1.65)

TT

145/549

1.00 (ref)

GT+GG

43/209

0.79 (0.54-1.15)

AA

69/254

1.00 (ref)

AG+GG

118/505

0.88 (0.63-1.23)

AA

153/640

1.00 (ref)

AT+TT

35/120

1.22 (0.81-1.86)

CC

121/470

1.00 (ref)

CT+TT

67/289

0.90 (0.64-1.25)

GG

69/322

1.00 (ref)

GT+TT

118/437

1.28 (0.92-1.79)

1.00 (ref)
0.75 (0.44-1.31)

0.31

0.38

0.10

-

-

-

0.08

-

-

-

-

-

122/670

1.00 (ref)

-

-

30/193

0.84 (0.54-1.29)

57/360

1.00 (ref)

96/503

1.21 (0.85-1.73)

136/767

1.00 (ref)

0.61

0.27

0.21

0.45

0.34

0.52

0.14

17/96

1.00 (0.57-1.73)

94/515

1.00 (ref)

59/348

0.96 (0.67-1.37)

42/197

1.00 (ref)

111/665

0.77 (0.52-1.14)

0.42

0.30

0.99

0.83

0.19

-

-

-

-

-

-

69/366

1.00 (ref)

84/497

0.90 (0.64-1.28)

0.56

-

-

-

-

-

-

XPC (rs2227998)

XPC (rs2733537)

XRCC1
(rs1799778)
XRCC1
(rs1799782)
XRCC1
(rs2854508)
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XRCC1
(rs3213247)

d

XRCC2
(rs3218522)
XRCC4
(rs10474079)

d

XRCC4
(rs28360135)

d

XRCC4 (rs35268)

XRCC4
(rs3777018)

d

CC

94/366

1.00 (ref)

CT+TT

94/394

0.92 (0.67-1.27)

AA

131/527

1.00 (ref)

AG+GG

57/233

0.96 (0.68-1.37)

GG

102/462

1.00 (ref)

GT+TT

85/294

1.31 (0.95-1.81)

GG

165/660

1.00 (ref)

AG+AA

23/100

0.93 (0.57-1.52)

TT

123/478

1.00 (ref)

AT+AA

65/281

0.90 (0.64-1.26)

CC

-

AC+AA

-

CC

122/529

CT+TT

66231

GG

-

AG+AA

78/480

1.00 (ref)

75/378

1.17 (0.83-1.66)

86/401

1.00 (ref)

67/462

0.71 (0.50-1.01)

66/353

1.00 (ref)

87/509

0.91 (0.64-1.29)

131/735

1.00 (ref)

22/128

0.98 (0.60-1.60)

98/508

1.00 (ref)

0.54

55/355

0.80 (0.56-1.14)

-

-

136/772

1.00 (ref)

-

-

17/91

1.06 (0.61-1.84)

38/248

1.00 (ref)

0.20

115/615

1.20 (0.80-1.78)

-

-

115/665

1.00 (ref)

-

-

-

38/197

1.07 (0.71-1.60)

TT

-

-

-

144/792

1.00 (ref)

CT+CC

-

-

-

9/71

TT

100/417

1.00 (ref)

CT+CC

87/343

1.08 (0.78-1.49)

AA

-

AG+GG

-

0.62

0.84

0.10

0.79

1.00 (ref)
1.25 (0.89-1.75)

0.77 (0.37-1.59)

116/670

1.00 (ref)

0.63

37/193

1.05 (0.70-1.59)

-

-

128/769

1.00 (ref)

-

-

25/94

1.63 (1.00-2.64)

0.36

0.05

0.58

0.93

0.22

0.84

0.38

0.74

0.48

0.80

0.05

a

The most common genotype used as the reference category
Some categories may not sum to total sample because of missing data
c
Adjusted for age
d
Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group
b
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Table 8.3 Associations between dietary lycopene and prostate cancer aggressiveness stratified by genotype of SNPs in
DNA repair and oxidative stress-related genes
European Americans
(n = 1,016)
b
OR (95% CI)

Dietary lycopene mg/day a

low
high

Stratified analysis by SNP
Gene (SNP ID),
major/minor allele
241

APEX1(rs1130409)
ERCC8 (rs4647100)

T/G
A/G

ERCC8 (rs4647102)

T/C

ERCC8 (rs976631)

T/C

GPX2 (rs4902346)
MUTYH (rs3219489)

A/G
C/G

low
high
low
high
low
high
low
high
low
high
low
high

Cases/
Controls
85/431
1.00 (ref)
68/432
0.77 (0.53-1.16)
Homozygous Common
Allele

Heterozygous or Homozygous
Minor Allele

Cases/
Controls

OR (95% CI) b

Cases/
Controls

20/110
18/120
51/240
36/241
34/155
27/169
26/144
20/131
47/278
39/275
55/229
37/230

1.00 (ref)
0.51 (0.22-1.18)
1.00 (ref)
0.62 (0.37-1.07)
1.00 (ref)
0.68 (0.36-1.29)
1.00 (ref)
0.81 (0.38-1.72)
1.00 (ref)
0.83 (0.49-1.42)
1.00 (ref)
0.64 (0.38-1.08)

65/321
50/312
34/191
32/191
51/276
41/263
59/286
48/299
38/153
29/157
30/202
31/202

OR (95% CI) b

1.00 (ref)
0.85 (0.54-1.35)
1.00 (ref)
0.94 (0.51-1.73)
1.00 (ref)
0.85 (0.51-1.42)
1.00 (ref)
0.76 (0.47-1.21)
1.00 (ref)
0.65 (0.36-1.19)
1.00 (ref)
1.04 (0.56-1.92)

P‡

0.71
0.43
0.56
0.57
0.62
0.39

NOS3 (rs1799983)

G /T

NOS3 (rs3918226) c

C/T

NOX3||ARID1B (rs9372014) c
G/T
NQO1 (rs689453)

C/T
c

G/A

PPARG (rs1801282) c

C/G

RAD51C (rs304269)

G/A

RAD51C (rs6503874)

C/G

SOD2 (rs10370)

T/G

SOD2 (rs4880)

A/G

OGG1 (rs1805373)
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USP4||GPX1 (rs8179172)

c

A/T
XPA (rs1800975)

C/T

low
high
low
high

31/188
28/194
72/371
54/354

1.00 (ref)
0.99 (0.52-1.88)
1.00 (ref)
0.76 (0.49-1.18)

54/240
40/235
13/60
14/78

1.00 (ref)
0.65 (0.39-1.08) 0.45
1.00 (ref)
0.89 (0.33-2.41) 0.96

low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high

41/191
36/212
75/378
63/353
67/336
55/334
31/180
26/180
76/382
60/385
53/258
41/257
25/91
17/106
-

1.00 (ref)
0.81 (0.47-1.41)
1.00 (ref)
0.89 (0.59-1.35)
1.00 (ref)
0.79 (0.51-1.23)
1.00 (ref)
0.90 (0.46-1.76)
1.00 (ref)
0.76 (0.50-1.15)
1.00 (ref)
0.77 (0.46-1.26)
1.00 (ref)
0.56 (0.25-1.26)
-

44/240
32/219
10/53
5/79
18/95
12/98
54/251
42/252
9/49
8/47
32/173
27/175
60/339
51/326
-

1.00 (ref)
0.71 (0.40-1.27) 0.84
1.00 (ref)
0.19 (0.03-1.14) 0.05
1.00 (ref)
0.69 (0.26-1.86) 0.83
1.00 (ref)
0.71 (0.43-1.17) 0.57
1.00 (ref)
1.33 (0.26-6.79) 0.91
1.00 (ref)
0.77 (0.40-1.48) 0.97
1.00 (ref)
0.84 (0.53-1.33) 0.27
-

low
high

33/185
36/181

1.00 (ref)
1.02 (0.56-1.87)

52/246
32/251

1.00 (ref)
0.56 (0.32-0.98)

0.07

XPA (rs3176644) c

G/T

XPC (rs2227998)

C/T

XPC (rs2733537)

A/G

XRCC1 (rs1799778)

G/T

XRCC1 (rs1799782)

G/A

XRCC1 (rs2854508)
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XRCC1 (rs3213247)

T/A
c

C/A

XRCC2 (rs3218522)

C/T

XRCC4 (rs10474079)

c

XRCC4 (rs28360135)
XRCC4 (rs35268)

c

XRCC4 (rs3777018 )

G/A
c

T/C
T/C

c

A/G

low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high

48/239
30/241
51/202
35/199
37/181
29/172
74/365
57/370
63/266
35/242
77/390
59/382
16/126
22/122
65/333
50/332
79/404
65/388
68/327
48/343
74/382
54/387

1.00 (ref)
0.65 (0.38-1.12)
1.00 (ref)
0.65 (0.37-1.14)
1.00 (ref)
0.74 (0.39-1.39)
1.00 (ref)
0.71 (0.46-1.09)
1.00 (ref)
0.57 (0.34-0.95)
1.00 (ref)
0.73 (0.48-1.12)
1.00 (ref)
1.22 (0.53-2.80)
1.00 (ref)
0.74 (0.47-1.16)
1.00 (ref)
0.81 (0.54-1.21)
1.00 (ref)
0.95 (0.41-1.22)
1.00 (ref)
0.68 (0.44-1.04)

37/190
38/188
34/229
33/233
48/249
39/260
11/66
11/62
22/165
33/190
8/41
9/50
69/305
46/310
20/97
18/100
6/27
3/44
17/104
20/89
11/49
14/45

1.00 (ref)
0.90 (0.49-1.65)
1.00 (ref)
0.96 (0.55-1.69)
1.00 (ref)
0.75 (0.45-1.27)
1.00 (ref)
1.15 (0.34-3.66)
1.00 (ref)
1.22 (0.63-2.39)
1.00 (ref)
1.02 (0.30-3.40)
1.00 (ref)
0.66 (0.42-1.05)
1.00 (ref)
0.80 (0.34-1.87)
1.00 (ref)
0.44 (0.04-4.56)
1.00 (ref)
1.31 (0.71-4.10)
1.00 (ref)
1.31 (0.39-4.39)

0.37
0.47
0.82
0.47
0.06
0.69
0.08
0.71
0.34
0.27
0.23

Categorized based on median split (< versus ≥ median) among controls for European Americans as low: 344.77 – 4626.17
mcg/day and high: 4626.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3319.69 and 3319.70 – 106071.98 mcg/day,
respectively.
a

b
c

Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and study site
Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group

‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype
(homozygous common allele vs. homozygous variant + heterozygous) and dietary lycopene intake (<versus ≥ median) in
multivariable adjusted models.
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Table 8.3 (continued) Associations between dietary lycopene and prostate cancer aggressiveness stratified by genotype of
SNPs in DNA repair and oxidative stress-related genes
African Americans
(n = 948)
Dietary lycopene mg/day a

low
high

Stratified analysis by SNP
Gene (SNP ID),
major/minor allele
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APEX1(rs1130409)
ERCC8 (rs4647100)

Cases/
Controls
T/ G
A/G

ERCC8 (rs4647102)

T/C

ERCC8 (rs976631)

T/C

GPX2 (rs4902346)
MUTYH (rs3219489)
NOS3 (rs1799983)

Cases/
OR (95% CI) b
Controls
80/380
1.00 (ref)
108/380
1.41 (0.96-2.07)
Homozygous Common
Allele

A/G
C/G
G /T

OR (95% CI) b

Heterozygous or Homozygous
Minor Allele
Cases/
Controls

OR (95% CI) b

low

32/153

1.00 (ref)

48/227

1.00 (ref)

high
low
high
low
high
low
high
low
high
low
high
low

49/152
66/312
90/313
28/161
47/154
45/211
56/223
29/127
41/139
40/212
67/222
68/297

1.71 (0.95-3.07)
1.00 (ref)
1.47 (0.97-2.25)
1.00 (ref)
1.94 (1.01-3.73)
1.00 (ref)
1.28 (0.76-2.17)
1.00 (ref)
1.49 (0.76-2.94)
1.00 (ref)
1.65 (0.98-2.78)
1.00 (ref)

59/228
14/68
18/67
52/219
61/224
35/169
50/156
51/253
67/241
40/168
41/158
12/82

1.25 (0.74-2.10)
1.00 (ref)
0.91 (0.33-2.49)
1.00 (ref)
1.13 (0.70-1.82)
1.00 (ref)
1.45 (0.80-2.60)
1.00 (ref)
1.39 (0.86-2.24)
1.00 (ref)
1.19 (0.67-2.13)
1.00 (ref)

P‡

0.50
0.79
0.08
0.64
0.95
0.31

NOS3 (rs3918226)

c

C/T

NOX3||ARID1B (rs9372014)

c

G/T
NQO1 (rs689453)
OGG1 (rs1805373)

C/T
c

G/A
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PPARG (rs1801282) c

C/G

RAD51C (rs304269)

G/A

RAD51C (rs6503874)

C/G

SOD2 (rs10370)

T/G

SOD2 (rs4880)
USP4||GPX1 (rs8179172)

A/G
c

A/T
XPA (rs1800975)

C/T

XPA (rs3176644) c

G/T

high
low
high

84/301
-

1.25 (0.82-1.90)
-

low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high
low
high

71/336
100/337
62/33
89/315
49/207
55/193
38/203
51/185
61/263
84/286
32/137
37/117
66/321
87/319

1.00 (ref)
1.42 (0.95-2.13)
1.00 (ref)
1.56 (1.00-2.39)
1.00 (ref)
1.27 (0.75-2.14)
1.00 (ref)
1.86 (1.03-3.35)
1.00 (ref)
1.32 (0.85-2.06)
1.00 (ref)
1.28 (0.68-2.41)
1.00 (ref)
1.30 (0.86-1.99)

low
high
low

49/247
72/223
36/161

1.00 (ref)
1.28 (0.88-2.06)
1.00 (ref)

-

24/78
-

1.90 (0.71-5.12)
-

9/44
8/43
18/47
19/65
31/173
53/187
42/177
57/194
19/116
24/93
47/242
71/263
14/59
21/61

1.00 (ref)
0.16 (0.25-5.37)
1.00 (ref)
0.83 (0.31-2.26)
1.00 (ref)
1.50 (0.82-2.74)
1.00 (ref)
1.11 (0.65-1.89)
1.00 (ref)
1.47 (0.63-3.43)
1.00 (ref)
1.57 (0.96-2.59)
1.00 (ref)
1.28 (0.43-3.79)

31/133
36/156
44/218

1.00 (ref)
0.73 (0.53-1.84) 0.14
1.00 (ref)

-

0.20
0.35
0.11
0.50
0.37
0.81
0.83
0.89
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high
33/161
0.91 (0.49-1.69)
74/219
1.92 (1.16-3.20) 0.10
XPC (rs2227998)
C/T
low
40/179
1.00 (ref)
40/201
1.00 (ref)
high
54/187
1.12 (0.64-1.96)
54/193
1.74 (1.01-3.01) 0.84
XPC (rs2733537)
A/G
low
59/276
1.00 (ref)
21/104
1.00 (ref)
high
72/251
1.22 (0.77-1.94)
36/129
2.26 (1.03-4.92) 0.56
XRCC1 (rs1799778)
G/T
low
40/226
1.00 (ref)
40/152
1.00 (ref)
high
62/236
45/142
1.00 (0.55-1.84) 0.42
1.77 (1.05-2.98)
XRCC1 (rs1799782)
G/A
low
72/332
1.00 (ref)
8/48
1.00 (ref)
high
93/328
1.37 (0.91-2.05)
15/52
1.88 (0.42-8.37) 0.93
XRCC1 (rs2854508)
T/A
low
60/232
1.00 (ref)
20/148
1.00 (ref)
high
63/246
0.79 (0.63-1.66)
45/133
2.50 (1.27-4.89) 0.010
XRCC1 (rs3213247) c
C/A
low
high
XRCC2 (rs3218522)
C/T
low
50/265
1.00 (ref)
30/115
1.00 (ref)
high
72/264
1.38 (0.93-2.49)
36/116
0.89 (0.53-1.48) 0.39
c
XRCC4 (rs10474079)
G/A
low
high
XRCC4 (rs28360135) c
T/C
low
high
c
XRCC4 (rs35268)
T/C
low
41/211
1.00 (ref)
39/169
1.00 (ref)
high
59/206
0.99 (0.55-1.78)
48/174
1.33 (0.97-2.97) 0.38
c
XRCC4 (rs3777018 )
A/G
low
high
a
Categorized based on median split (< versus ≥ median) among controls for European Americans as low: 344.77 –
4626.17 mcg/day and high: 4626.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3319.69 and 3319.70 –

106071.98 mcg/day, respectively.
b
Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and
study site
c
Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype
(homozygous common allele vs. homozygous variant + heterozygous) and dietary lycopene intake (<versus ≥ median) in
multivariable adjusted models.
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Table 8.4 Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between total lycopene intake
(diet + supplements) and prostate cancer aggressiveness, stratified by polymorphisms in DNA repair and oxidative stressrelated genes
European Americans
(n = 1,016)
OR (95% CI) b

Total lycopene mg/day a

low
high

Stratified analysis by SNP
Gene (SNP ID),
major/minor allele

Cases/
Controls
84/431
1.00 (ref)
69/432
0.81 (0.55-1.20)
Homozygous Common Allele
Cases/
Controls

OR (95% CI) b

Heterozygous or Homozygous
Minor Allele
Cases/
OR (95% CI) b
Controls

P‡
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APEX1(rs1130409)
ERCC8 (rs4647100)
ERCC8 (rs4647102)
ERCC8 (rs976631)
GPX2 (rs4902346)
MUTYH (rs3219489)

T/G
A/G
T/C
T/C
A/G
C/G

low

20/109

1.00 (ref)

64/322

1.00 (ref)

high

18/121

0.46 (0.20-1.06)

51/311

0.90 (0.57-1.42) 0.59

low

51/239

1.00 (ref)

33/192

1.00 (ref)

high

36/242

0.61 (0.36-1.05)

33/190

1.05 (0.57-1.91) 0.29

low

34/156

1.00 (ref)

50/275

1.00 (ref)

high

27/168

0.68 (0.36-1.28)

42/264

0.91 (0.55-1.51) 0.47

low

25/143

1.00 (ref)

59/287

1.00 (ref)

high

21/132

0.87 (0.41-1.83)

48/298

0.78 (0.49-1.25) 0.52

low

47/278

1.00 (ref)

37/153

1.00 (ref)

high

39/275

0.82 (0.48-1.41)

30/157

0.70 (0.38-1.27) 0.76

low

55/229

1.00 (ref)

29/202

1.00 (ref)

NOS3 (rs1799983)
NOS3 (rs3918226)

G /T
c

C/T
c

NOX3||ARID1B (rs9372014)
G/T
NQO1 (rs689453)
OGG1 (rs1805373)

C/T
c
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PPARG (rs1801282)
RAD51C (rs304269)
RAD51C (rs6503874)
SOD2 (rs10370)
SOD2 (rs4880)

G/A
c

C/G
G/A
C/G
T/G
A/G

USP4||GPX1 (rs8179172) c A / T

high

37/230

0.65 (0.39-1.10)

32/202

1.11 (0.60-2.07) 0.32

low

30/187

1.00 (ref)

54/241

1.00 (ref)

high

29/195

1.12 (0.59-2.12)

40/234

0.64 (0.38-1.06) 0.30

low

71/371

1.00 (ref)

13/60

1.00 (ref)

high

55/354

0.80 (0.51-1.24)

14/78

0.90 (0.33-2.47)

low

41/193

1.00 (ref)

43/238

1.00 (ref)

high

36/210

0.83 (0.48-1.44)

33/221

0.74 (0.41-1.31)

low

74/378

1.00 (ref)

10/53

1.00 (ref)

high

64/353

0.92 (0.61-1.39)

5/79

0.20 (0.03-1.22)

low

-

-

-

-

-

high

-

-

-

-

-

low

66/335

1.00 (ref)

18/96

1.00 (ref)

high

56/335

0.82 (0.53-1.27)

12/97

0.73 (0.27-1.97)

low

30/183

1.00 (ref)

54/248

1.00 (ref)

high

27/177

1.04 (0.53-2.03)

42/255

0.69 (0.41-1.13)

low

78/382

1.00 (ref)

8/49

1.00 (ref)

high

58/385

0.76 (0.50-1.16)

9/47

1.81 (0.38-8.72) 0.59

low

52/260

1.00 (ref)

32/171

1.00 (ref)

high

42/255

0.82 (0.50-1.35)

27/177

0.75 (0.39-1.43)

0.84

low
high
low

25/91
17/106
-

1.00 (ref)
0.58 (0.26-1.29)
-

59/339
52/326
-

1.00 (ref)
0.87 (0.55-1.38)
-

0.26
-

high

-

-

-

-

0.81
0.82
0.06

0.82
0.34

-

XPA (rs1800975)
XPA (rs3176644)

C/T
c

G/T

XPC (rs2227998)

C/T

XPC (rs2733537)

A/G

XRCC1 (rs1799778)

G/T

XRCC1 (rs1799782)

G/A
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XRCC1 (rs2854508)
XRCC1 (rs3213247)

T/A
c

C/A

XRCC2 (rs3218522)

C/T

XRCC4 (rs10474079)

c

XRCC4 (rs28360135)

c

XRCC4 (rs35268)

c

G/A
T/C
T/C

low

32/187

1.00 (ref)

52/244

1.00 (ref)

high

37/179

1.15 (0.63-2.09)

32/253

low

-

-

-

0.56 (0.32-0.97)
-

high

-

-

low

48/238

1.00 (ref)

36/190

1.00 (ref)

high

30/242

0.64 (0.37-1.11)

39/188

0.98 (0.54-1.79)

low

50/205

1.00 (ref)

34/226

1.00 (ref)

high

36/196

0.75 (0.43-1.31)

33/236

0.93 (0.52-1.63)

low

37/183

1.00 (ref)

47/247

1.00 (ref)

high

29/170

0.76 (0.40-1.43)

40/262

0.79 (0.47-1.32)

low

73/364

1.00 (ref)

11/67

1.00 (ref)

high

58/371

0.73 (0.48-1.12)

11/61

1.30 (0.39-4.33)

low

62/264

1.00 (ref)

62/264

1.00 (ref)

high

36/244

36/244

1.24 (0.64-2.41)

low

77/390

0.59 (0.36-0.99)
1.00 (ref)

7/41

1.00 (ref)

high

59/382

0.73 (0.48-1.120

10/50

1.21 (0.36-4.07)

low

16/125

1.00 (ref)

68/306

1.00 (ref)

high

22/123

1.20 (0.52-2.76)

47/309

0.70 (0.45-1.11)

low

64/333

1.00 (ref)

20/97

1.00 (ref)

high

51/332

0.77 (0.49-1.21)

18/100

0.82 (0.35-1.90)

low

78/404

1.00 (ref)

6/27

1.00 (ref)

high

66/388

0.84 (0.56-1.26)

3/44

0.44 (0.04-4.56)

low

67/327

1.00 (ref)

17/104

1.00 (ref)

0.04
0.26
0.73
0.89
0.42
0.07
0.41
0.11
0.76
0.32

XRCC4 (rs3777018 )

c

A/G

high

49/343

0.67 (0.42-1.05)

20/89

1.46 (0.74-3.21)

low

73/382

1.00 (ref)

11/49

1.00 (ref)

high

55/387

0.70 (0.46-1.08)

14/45

1.31 (0.39-4.39)

0.21
0.36

Categorized based on median split (< vs. ≥ median) among controls for European Americans as low: 344.77 – 4698.17 mcg/day and
high: 4698.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3358.85 and 3358.86 – 106071.98 mcg/day, respectively.

a

b

Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and study site

c

Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group

‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype (homozygous
common allele vs. homozygous variant + heterozygous) and total lycopene intake (<versus ≥ median) in multivariable adjusted models.
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Table 8.4 (continued) Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between total
lycopene intake (diet + supplements) and prostate cancer aggressiveness, stratified by polymorphisms in DNA repair and
oxidative stress-related genes
African Americans
(n = 948)
Total lycopene mg/day a

low
high

Stratified analysis by SNP
Gene (SNP ID),
major/minor allele
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APEX1(rs1130409)
ERCC8 (rs4647100)
ERCC8 (rs4647102)
ERCC8 (rs976631)
GPX2 (rs4902346)
MUTYH (rs3219489)

Cases/
OR (95% CI) b
Controls
81/380
1.00 (ref)
107/380
1.36 (0.92-1.99)
Homozygous Common Allele
Cases/
Controls

T/G
A/G
T/C
T/C
A/G
C/G

OR (95% CI) b

Heterozygous or Homozygous
Minor Allele
Cases/
OR (95% CI) b
Controls

low

32/153

1.00 (ref)

49/227

1.00 (ref)

high

49/152

1.69 (0.94-3.04)

58/228

1.15 (0.69-1.94)

low

67/312

1.00 (ref)

14/68

1.00 (ref)

high

89/313

1.41 (0.92-2.14)

18/67

0.91 (0.33-2.49)

low

29/161

1.00 (ref)

52/219

1.00 (ref)

high

46/154

1.77 (0.93-3.40)

61/224

1.11 (0.69-1.80)

low

45/211

1.00 (ref)

36/169

1.00 (ref)

high

56/223

1.25 (0.74-2.12)

49/156

1.34 (0.74-2.40)

low

29/126

1.00 (ref)

52/254

1.00 (ref)

high

41/140

1.48 (0.75-2.92)

66/240

1.31 (0.82-2.11)

low

41/211

1.00 (ref)

40/169

1.00 (ref)

high

66/223

1.53 (0.91-2.55)

41/157

1.20 (0.67-2.14)

P‡

0.42
0.86
0.11
0.74
0.87
0.42

NOS3 (rs1799983)
NOS3 (rs3918226)

G /T
c

C/T
c

NOX3||ARID1B (rs9372014)
G/T
NQO1 (rs689453)
OGG1 (rs1805373)

C/T
c

PPARG (rs1801282)

G/A
c

C/G
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RAD51C (rs304269)
RAD51C (rs6503874)
SOD2 (rs10370)

G/A
C/G
T/G

SOD2 (rs4880)

A/G

USP4||GPX1 (rs8179172)

c

A/T
XPA (rs1800975)

C/T

low

69/296

1.00 (ref)

12/83

1.00 (ref)

high

83/302

1.18 (0.78-1.80)

24/77

1.94 (0.72-5.23)

low

-

-

-

high

-

-

low

-

-

high

-

-

low

72/337

1.00 (ref)

9/43

1.00 (ref)

high

99/336

1.38 (0.92-2.07)

8/44

0.79 (0.16-3.75) 0.29

low

62/332

1.00 (ref)

19/48

1.00 (ref)

high

89/316

1.53 (0.99-2.34)

18/64

low

-

-

-

0.76 (0.28-2.09) 0.07
-

high

-

-

-

low

49/205

1.00 (ref)

32/175

1.00 (ref)

high

55/195

1.23 (0.73-2.07)

52/185

1.42 (0.78-2.58) 0.53

low

38/204

1.00 (ref)

43/176

1.00 (ref)

high

51/184

1.81 (1.02-3.34)

56/195

1.03 (0.61-1.75) 0.27

low

62/263

1.00 (ref)

19/116

1.00 (ref)

high

83/286

1.25 (0.81-1.94)

24/93

1.47 (0.63-3.44) 0.73

low
high
low

32/137
37/117
67/319

1.00 (ref)
1.27 (0.67-2.39)
1.00 (ref)

48/242
70/263
14/61

1.00 (ref)
1.46 (0.89-2.39) 0.95
1.00 (ref)

high

86/321

1.23 (0.81-1.87)

21/59

1.43 (0.48-4.29) 0.74

low

50/249

1.00 (ref)

31/131

1.00 (ref)

0.16

-

-

-

-

-

-

-

-

-

-

-

-

XPA (rs3176644)

c

G/T

XPC (rs2227998)

C/T

XPC (rs2733537)

A/G

XRCC1 (rs1799778)

G/T

XRCC1 (rs1799782)

G/A
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XRCC1 (rs2854508)
XRCC1 (rs3213247)

T/A
c

C/A

XRCC2 (rs3218522)

C/T

XRCC4 (rs10474079)

c

XRCC4 (rs28360135)

c

XRCC4 (rs35268)

c

G/A
T/C
T/C

high

71/221

1.79 (1.09-2.95)

36/158

0.85 (0.51-1.76) 0.13

low

36/161

1.00 (ref)

45/218

1.00 (ref)

high

33/161

0.91 (0.49-1.70)

73/219

1.79 (1.08-2.96) 0.13

low

40/180

1.00 (ref)

41/200

1.00 (ref)

high

54/186

1.11 (0.64-1.94)

53/194

1.63 (0.95-2.81) 0.94

low

60/274

1.00 (ref)

21/106

1.00 (ref)

high

71/253

1.14 (0.72-1.80)

36/127

2.33 (1.06-5.10) 0.43

low

41/225

1.00 (ref)

40/153

1.00 (ref)

high

61/237

1.63 (0.97-2.73)

45/141

1.01 (0.55-1.85) 0.56

low

73/331

1.00 (ref)

8/49

1.00 (ref)

high

92/329

1.29 (0.86-1.94)

15/51

2.24 (0.48-10.48)

low

61/230

1.00 (ref)

20/150

1.00 (ref)

high

62/248

0.95 (0.59-1.53)

45/131

2.56 (1.30-5.02)

low

-

-

-

-

-

high

-

-

-

-

-

low

50/264

1.00 (ref)

31/116

1.00 (ref)

high

72/265

1.48 (0.90-2.42)

35/115

1.06 (0.56-2.00)

low

-

-

-

-

-

high

-

low

-

-

-

-

-

high

-

-

42/210

39/170

-

low

1.00 (ref)

high

58/207

1.00 (0.56-1.80)

48/173

0.83
0.005

0.34

1.00 (ref)
1.61 (0.95-2.71)

0.62

XRCC4 (rs3777018 ) c
a

A/G

low

-

-

-

-

-

high

-

-

-

-

-

Categorized based on median split (< vs. ≥ median) among controls for European Americans as low: 344.77 – 4698.17 mcg/day and high:
4698.18 – 100250.76 mcg/day; and for African Americans: 4.90 – 3358.85 and 3358.86 – 106071.98 mcg/day, respectively.
b
Adjusted for age, PSA screening history, BMI, smoking status, education, income, NSAIDs use, total fat intake, and study site
c
Results are not presented for SNPs with less than 5% minor allele frequency in the respective race group
‡ Interaction p-value based likelihood ratio tests with and without multiplicative interaction term between SNP genotype (homozygous common
allele vs. homozygous variant + heterozygous) and total lycopene intake (<versus ≥ median) in multivariable adjusted models.
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CHAPTER 9
SYNTHESIS
9.1

ANTIOXIDANT INTAKE AND PROSTATE SPECIFIC ANTIGEN IN MEN WITH BIOCHEMICAL
RECURRENCE OF PROSTATE CANCER

It is estimated that about 94% of American men with prostate cancer present with
clinically localized disease and often are treated with radical prostatectomy or radical
radiation with curative intent [340, 341]. However, about 25–40% of these men develop
biochemical recurrence of PCa within 5 years of treatment [342-345]. Biochemical
recurrence of PCa, which is generally defined by continuous rise in serum PSA level on
three or more successive tests, is often an early sign of metastasis and precedes metastasis
by an average of eight years [348]. Unfortunately, there is no known cure for biochemical
recurrence of PCa, but it is usually managed with surgical or medical androgen ablation
with the hope of delaying the time to metastasis. Androgen ablation has been associated
with severe and life-altering side effects [351, 539], which makes its use unappealing to
both patients and clinics. Thus, the idea of using dietary agents as alternate therapy or a
first line treatment to delay the use of androgen ablation is a prospect that would be
attractive to most patients. Results from this study show that men with higher plasma
levels of α-tocopherol, β-cryptoxanthin, trans-β-carotene, cis-lutein/zeaxanthin and
trans-lycopene had lower PSA levels at follow-up timepoints compared to men with
lower plasma levels of these nutrients. This suggests that greater intake of foods
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containing these micronutrients might be beneficial to men with biochemical recurrence
of PCa.
These micronutrients are abundantly available in many fruits and vegetables (food
sources reviewed in [291, 540]), which raises the question of whether these
micronutrients may have acted as surrogates for greater intake of fruits and vegetables,
which contain other beneficial micronutrients and phytochemicals. Thus, replication of
the findings in larger studies with longer follow-up would be useful. Other caveats that
should be considered are noted below.

9.2

ASSOCIATIONS OF ANTIOXIDANTS AND PROSTATE CANCER AGGRESSIVENESS
Although the epidemiologic literature is replete with reports on associations

between antioxidants intake and PCa incidence, much less is known about antioxidants
effect on PCa aggressiveness. Antioxidants are thought to mitigate oxidative stress,
thereby averting oxidative DNA damage and the potential for malignant transformation
of normal prostate cells. Recent published data indicates that oxidative stress correlates
with the extent of PCa aggressiveness, such that the highly aggressive forms of PCa tends
to display markedly higher degree of oxidative stress than do the less aggressive forms
PCa [123]. Thus, increasing antioxidant intake may boost the body’s defenses against
oxidative stress, and by extension, protect against PCa and its aggressiveness [394, 541].
Results from analysis of associations between antioxidants intake, supplemental
antioxidant use, and adipose tissue antioxidants levels in relation to PCa aggressiveness
revealed some important findings. While there were no significant findings for
supplemental antioxidant use, higher dietary intake of α-, γ- and δ-tocopherol were
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inversely associated with PCa aggressiveness among European American, but not
African Americans. These racial differences in associations are likely due to variations in
dietary patterns and the possibility of gene-diet interaction that may vary by race. For
example, European Americans in this study were more likely to obtained α-tocopherols
from healthy foods sources such as olive oils, nuts, seeds and vegetables, while African
Americans often obtained α-tocopherol from less healthy foods such as potato and corn
chips, and dark green vegetables prepared with fatback and lard. Thus, the source of
tocopherol intake may explain some of these differences in associations by race. Higher
adipose tissue concentration of α-tocopherol appeared to be associated with increased
odds of high aggressive PCa among European Americans only, albeit statistically nonsignificant. It is worth noting that European Americans in this study had a 75% higher
adipose α-tocopherol concentration than African Americans. It is, however, unclear what
constitutes “normal” adipose α-tocopherol levels, although the mean α-tocopherol levels
among European Americans in this study were slightly higher than those reported in
breast tissue from Malaysian women [418] and lower than those reported in adipose
tissue from European males in the EURAMIC study [419]. Nonetheless, it is reasonable
to speculate that long-term use of dietary supplements (the most common source of αtocopherol) may have been the major contributor of the adipose α-tocopherol levels
among European Americans, especially since a much greater proportion of European
Americans reported vitamin E supplement use compared to African Americans.
Carotenoids intake varied significantly between African Americans and European
Americans, including higher intake of lycopene among European Americans and higher
β-cryptoxanthin intake among African Americans. Dietary lycopene was associated with
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lower odds of high aggressive PCa among European Americans, and β-cryptoxanthin was
associated with lower odds of high aggressive PCa among African Americans. Adipose
tissue α-carotene and lycopene (cis + trans) levels were higher among European
Americans than African Americans, and marginally significant inverse linear trends were
observed for adipose α-carotene and lycopene in relation to PCa aggressiveness among
European Americans only. Given that inverse associations were only observed in the race
group with higher dietary intake or adipose concentration of these nutrients, it stands to
reason that the potential benefits of lycopene, β-cryptoxanthin and α-carotene may be
acquired only at higher levels of intake. However, potential interactions with genetic
variants in relevant genes cannot be ruled out and is described in section 5.3.

9.3

GENE-DIET INTERACTION
Associations between antioxidant intake and PCa incidence have varied across

studies [17]. There is some evidence that polymorphic variants in oxidative stress and
DNA repair genes modulate associations between antioxidant intake and PCa incidence
[128, 466]. Therefore, the inconsistency in prior studies may be reflecting genetic risk
variability of the studied populations. In this study, we investigated whether associations
of α-tocopherol, γ-tocopherol and lycopene in relation to PCa aggressiveness are
modulated by single nucleotide polymorphisms (SNPs) in oxidative stress and DNA
repair genes, and whether effect modification varies by race.
There was evidence of effect modification by certain SNPs with some variations
by race. XRCC1 (rs2854508) genotype significantly modified association between αtocopherol intake and PCa aggressiveness among African Americans and European
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Americans, such that among those who possess the TT genotype, higher α-tocopherol
intake was inversely related to PCa aggressiveness, while the opposite was observed
among those with AA or AT genotypes. A similar pattern of effect modification by
XRCC1 (rs2854508) was observed for association between γ-tocopherol and PCa
aggressiveness, but only among African Americans. XRCC1 (rs2854508) genotype also
demonstrated interaction with lycopene, in that higher lycopene intake was associated
with increased odds of high aggressive PCa among African Americans who harbor the
AT or AA genotype, but not African Americans with the TT genotype. By contrast,
higher lycopene intake was inversely related to high aggressive PCa among European
Americans with the TT genotype, and no association was observed among European
Americans with the AT or AA genotype. Lower odds of high aggressive prostate cancer
was observed among European Americans who had higher lycopene intake and possessed
the CT or TT genotype of NQO1 (rs689453), but not European Americans with the CC
genotype, and there was no evidence of effect modification among African Americans.
Even though some of the SNPs did not show evidence of statistical interaction
with antioxidants intake, certain variants of the SNPs appear to work in tandem with
antioxidants to influence PCa aggressiveness. Notably, higher α-tocopherol intake was
associated with significantly lower odds of high aggressive PCa among European
Americans who were homozygous for the common allele of APEX1 (rs1130409, T > G),
PPARG (rs1801282, C > G), XPC (rs2733537, A > G) or XRCC1 (rs1799782, G > A).
This supports suggestions that the potential benefits of α-tocopherol as well as other
antioxidants may be limited to men with certain genetic variants, and this may explain
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some of the inconsistencies in the epidemiologic literature when diet is examined in
isolation of genetic factors.
This study provides evidence of interactions between α-tocopherol, γ-tocopherol
and lycopene intake and SNPs in oxidative stress and DNA repair genes in relation to
PCa aggressiveness. The findings indicate that not all men may benefit equally from
dietary interventions involving these nutrients. Thus, targeted interventions for a
subgroup of men with certain genetic variants may be a future strategy for
chemoprevention of aggressive PCa.

9.4

STRENGTHS AND LIMITATIONS

Biochemical Recurrence of Prostate Cancer
The examination of the potential benefits of exposure to carotenoids and
tocopherols in relation PSA rise following radical prostatectomy is appealing because
diet interventions provide a non-invasive, relatively inexpensive, and safe treatment
alternative for management of the disease progression in a population with limited
treatment options. Since the study participants had already undergone radical
prostatectomy or radical radiation for the treatment of organ-confined disease, continuous
rise in serum PSA level as defined in this study most likely reflects progressive disease,
rather than residual normal tissue left from radiation or spared during prostatectomy. The
use of biomarkers of nutrient intake provides more reliable measures of nutritional status
relative to self-reported intake [384]. Additionally, several potential risk factors of PCa
including BMI, smoking, physical activity, tumor grade and race also were controlled for
in the analysis, which limits potential confounding of the observed associations.
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Limitations of the study include the small study and the multiple comparisons
made, thus some of the findings could be due to chance alone. There is also the
possibility that the study results may be reflecting interactions between plasma nutrients,
rather than the effect of a single nutrient per se [383]. Blood antioxidant levels reflect
short-term intake rather than average intake over long periods, which may be more
relevant to PCa progression. The short duration of the study and lack of carotenoid and
tocopherol data at 6 months prohibited evaluation of temporal trends over long periods.
Additionally, restricting the study to a subgroup of PCa patients with strictly defined
disease attributes precludes generalizability of the findings to the larger population of
men with PCa.

Antioxidants and Prostate Cancer Aggressiveness
Notable strengths the analysis of associations between antioxidants intake and
PCa aggressiveness include the design to measure PCa aggressiveness, which minimizes
potential confounding by disease heterogeneity (i.e., the mixing of different disease
states). The evaluation of three complementary measures of antioxidant intake allowed
for a more comprehensive assessment of antioxidant status in PCa aggressiveness.
Additionally, the assessment of individual antioxidants helps delineate the role of
different antioxidants in PCa aggressiveness. The use of an ethnically diverse population
with approximately equal numbers of African Americans and European Americans also
made it possible to explore whether associations between antioxidants and PCa
aggressiveness differed by race. Moreover, the potential for selection bias and selective
survival were minimized because participation rates were reasonably high at both study
sites (62% for North Carolina, 72% for pre- and 63% for post-Hurricane Katrina
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Louisiana) and research subjects were recruited shortly after diagnosis via rapid caseascertainment; an average of five months from the time of diagnosis to time of interview.
However, imprecise measurements of dietary antioxidants could have influenced
the study results to some extent. Because exposure assessment for antioxidants were done
independent of the extent of PCa aggressiveness, differential misclassification bias is
unlikely; however, non-differential exposure misclassification may have occurred,
resulting in underestimation of ORs and failure to detect modest associations [422]. Diet
was assessed using a food frequency questionnaire. It is known that these structured
instruments may be biased according to response sets [423], which in turn, may be related
to psychological traits that either may exert a direct effect on cancer outcomes or
indirectly affect other factors that may influence carcinogenesis [424]. There is also the
concern that adipose antioxidant levels may be altered by the presence of a tumor;
however, a study examining the effect of breast tumor proximity on breast adipose
antioxidant levels did not find significant differences in adipose antioxidant levels at
different quadrants of breast tissue, including sites proximal and distal to the tumor [425].
Moreover, although adipose antioxidant levels are good markers for internal dose, they
may not reflect prostatic antioxidant levels; thus, results should be interpreted with this in
mind. Other limitations include the failure to control for cholesterol levels, in particular,
low density lipoprotein which function as transport vehicles for antioxidants [388], and
abdominal adiposity which may influence the adipose antioxidant levels. The influence of
individual differences in metabolism and absorption, interactions between individual
antioxidants compounds and other micronutrients, as well as potential modifying effects
of genetic variants acting via similar mechanisms [383, 407, 426] were beyond the scope
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of this study. In addition, the possibility exists that some of the findings may be spurious
owing to the sample size and multiple testing.
Gene-Diet Interaction
Very few studies have examined gene-diet interaction in relation to PCa
aggressiveness, thus this study contributes important information to the limited data. The
aggressive forms of PCa tend to have a strong genetic influence, and thus, aggressive and
non-aggressive forms of PCa may differ in their etiology [458]. Thus, examining PCa
aggressiveness reduces confounding by disease heterogeneity. Considering the
controversy over the use of antioxidant nutrients for the prevention and control of PCa,
this study provides evidence that indicates cautious use of such interventions, with
suggestions that it may be beneficial only to a subgroup of men dependent on genotype of
certain polymorphisms. Although genotyping errors cannot be completely ruled out in
any genetic study, the genotyped data had over 99% concordance with blinded duplicates
[411], which adds to the strengths of the study.
Limitations include the use of median cutpoints to categorize antioxidant in an
effort to conserve sample size; however, this may have resulted in too small contrast
between high and low antioxidant intake categories to observe a substantial effect of
antioxidant by genotype. The observational nature of the study also precludes causal
inferences. Because of the small sample size and multiple comparisons, chance findings
cannot be excluded, especially considering that none of the P values retained statistical
significance after FDR correction for multiple testing. Single dietary assessment in the
year prior to PCa diagnosis may have resulted in misclassification of dietary intake and
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overall dietary pattern to some extent. However, such misclassification is not likely to
differ by the extent of PCa aggressiveness, as it is improbable that the research subjects
considered their disease severity in responding to questions about dietary patterns. Thus,
nondifferential misclassification may have attenuated some of the effect estimates. Even
though analyses were stratified by self-reported race, residual confounding by ethnicity
due to genetic admixture cannot be completely ruled out [537, 538]. Additionally, post
hoc analysis involving adjustment for African ancestry proportions did not materially
change the study results.

9.5 Public Health Significance
The study findings have important public health implications. First, we observed
that certain antioxidant micronutrients (i.e., α-tocopherol, β-cryptoxanthin, trans-βcarotene, cis-lutein/zeaxanthin, and trans-lycopene) might slow the progression of PCa in
men with biochemical recurrence of the disease. This was evidence by lower serum PSA
levels among men with higher plasma concentrations of these nutrients at various
timepoints over a 6-month period. If confirmed by other studies, dietary interventions that
emphasize greater intake of these nutrients could serve as an alternate therapy or
neoadjuvant to delay the use of androgen ablation in these patients. This is particularly
encouraging because of the severe side effects associated with the use of androgen
ablation [14-16].
The epidemiologic data relating to the role of antioxidants in PCa aggressiveness
is very limited. Although the majority of PCa patients are diagnosed with indolent disease
owing to the widespread use of PSA blood test for early detection, an estimated 30% of
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prostate tumors progress aggressively [6]. Men with highly aggressive PCa have about a
14-fold increased risk of dying from the disease as compared to those with less
aggressive disease [3]. Therefore, distinguishing the modifiable risk factors of virulent
PCa from that of indolent disease is of particular interest. This study showed that greater
intake of β-cryptoxanthin was inversely associated with PCa aggressiveness among
African Americans, while greater intake of α-, γ- and δ-tocopherol as well as lycopene
were associated with lower odds of PCa among European Americans. Given that the
biology of PCa may be different between African Americans and European Americans,
and the fact that populations included in previous studies were predominantly of
European decent and thus findings may not apply to African Americans, this study
uniquely provides information on the potentially beneficial dietary factors for the
prevention/control of aggressive PCa in specific race groups.
The combined work of Objective 1 & 2 also advances our understanding on how
antioxidants may be influencing PCa aggressiveness in general, and in men with certain
genetic profiles. The evaluation of gene-diet interaction clearly demonstrated that not all
men would benefit from antioxidant intervention in relation to PCa aggressiveness.
Indeed, there were suggestions of increased odds of aggressive PCa with higher intake of
some antioxidants in men with certain genetic profiles. Although preliminary, these
findings have much translational potential as it could help clinician in designing
structured and monitored dietary intervention programs aimed at reducing the occurrence
of aggressive PCa, particularly among African Americans, an underserved population
who suffer a greater burden of virulent PCa.
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